

HIDE ON THE BOSTEAN BOOK OF THE COMPANY OF THE COMP

<u> TO AUL TO WHOM THOSE; PRESENTS SHAVU COME;</u>

UNITED STATES DEPARTMENT OF COMMERCE

**United States Patent and Trademark Office** 

November 09, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/538,799

FILING DATE: January 23, 2004

# **PRIORITY DOCUMENT**

By Authority of the

COMMISSIONER OF PATENTS AND TRADEMARKS

**Certifying Officer** 

## PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).


154 U.S. PTC 10/538799

DOCKET NUMBER ITR0048PV INVENTOR(S) Given Name (first and middle [if any]) Family Name or Surname Residence (City and either State or Foreign Country) Stefano Colloca Rome, Italy 00153 Alfredo Nicosia Rome, Italy 00144 Elisabetta Sporeno Rome, Italy 00153 Agostino Cirillo Lanuvio, Italy 00040 Bruno Bruni Ercole Pomezia, Italy 00040 Annalisa Meola Ariccia, Italy 00040 Additional inventors are being named on the separately numbered sheets attached hereto TITLE OF THE INVENTION (500 characters max) CHIMPANZEE ADENOVIRUS VACCINE CARRIERS CORRESPONDENCE ADDRESS Direct all Correspondence to: Merck & Co., Inc. Patent Department - RY60-30 X Customer Number 000210 P.O. Box 2000 Rahway STATE New Jersey ZIP CODE 07065 COUNTRY U.S.A. ENCLOSED APPLICATION PARTS (check all that apply) Specification CD(s), Number 64 Number of Pages ➤ Drawing(s) 153 Number of Sheets Other (specify) Application Data Sheet. See 37 CFR 1.76 METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one) A check or money order is enclosed to cover the filing fees FILING FEE The Director is hereby authorized \$160.00 AMOUNT (\$) to charge filing fees or credit any 13-2755 overpayment to Deposit Account Number: The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government. Yes, the name of the U.S. Government agency and the Government contract number are: Respectfully submitted, SIGNATURE 01/23/2004 Date TYPED or PRINTED NAME Patricia Chisholm REGISTRATION NO. 45,822 TELEPHONE <u>732-594-5738</u> (if appropriate)

NOTE: Mail to Mail Stop Provisional Application

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT Sancary 23, 2004
EXPRESS MAIL NO. EV 3231 53515US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE
UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE PATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS.
P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.
MAILED BY AND ACIONAL DATE AND ACIONAL

In Duplicate



10

15

20

25

30

35

#### CHIMPANZEE ADENOVIRAL VACCINE CARRIERS

#### FIELD OF THE INVENTION

The present invention relates to the field of recombinant vectors and more specifically to the production and use of recombinant replication-defective chimpanzee adenoviral vectors to elicit immune responses in mammalian hosts.

#### **BACKGROUND OF THE INVENTION**

The adenoviruses (Ads) comprise a large family of double-stranded DNA viruses found in amphibians, avians, and mammals which have genome organization and a nonenveloped icosahedral capsid structure (Straus, Adenovirus infections in humans. In *The Adenoviruses.* 451-498, 1984; Hierholzer *et al.*, *J. Infect. Dis.*, 158: 804-813, 1988; Schnurr and Dondero, *Intervirology.*, 36: 79-83, 1993; Jong *et al.*, *J Clin Microbiol.*, 37:3940-3945:1999). In contrast to retroviruses, adenoviruses can transduce numerous cell types of several mammalian species, including both dividing and nondividing cells, without integrating into the genome of the host cell.

Generally speaking, adenoviral DNA is typically very stable and remains episomal (e.g., extrachromosomal), unless transformation or tumorigenesis has occurred. In addition, adenoviral vectors can be propagated to high yields in well-defined production systems which are readily amenable to pharmaceutical scale production of clinical grade compositions. These characteristics and their well-characterized molecular genetics make recombinant adenoviral vectors good candidates for use as vaccine carriers. Typically, the production of recombinant adenoviral vectors relies on the use of a packaging cell line which is capable of complementing the functions of adenoviral gene products that have been either deleted or engineered to be nonfunctional.

Presently, two well-characterized human subgroup C adenovirus serotypes (i.e., hAd2 and hAd5) are widely used as the sources of the viral backbone for most of the adenoviral vectors that are used for gene therapy. Replication-defective human adenoviral vectors have also been tested as vaccine carriers for the delivery of a variety of immunogens derived from a variety of infectious agents (e.g., viruses, parasites, or bacterial pathogens) and tumor cells, including tumor-associated antigens (TAAs). Studies conducted in experimental animals (e.g., rodents, canines and nonhuman primates) indicate that recombinant replication-defective human adenoviral vectors carrying transgenes encoding immunogens derived from the E6 and E7 oncoproteins of human papillomavirus (HPV-16) (He, Z et al., (2001) Virology, 270:3583-3590,

10

15

20

25

30

the rabies virus glycoprotein (Xiang, Z. et al (1996) Virolgy, 219:220-227), the circumsporozoite protein of Plasmodium falciparum Rodriguez, E. et al. (1997) J. Immunol. 158:1268-1274) as well as other heterologous antigens elicit both humoral and cell-mediated immune responses against the transgene product. Generally speaking, investigators have reported success using human adenoviral vectors as vaccine carriers in nonhuman experimental systems by either using an immunization protocols that utilizes high doses of recombinant adenoviral vectors that are predicted to elicit immune responses; or by using immunization protocols which employ the sequential administration of adenoviral vectors that are derived from different serotypes but which carry the same transgene product as boosting immunizations (Mastrangeli, et al., Human Gene Therapy, 7: 79-87 (1996).

However, it is predicted that vaccine carriers derived from ubiquitous human serotypes, such as types 2 and 5, will encounter preexisting humoral and cellular immunity in the human population. Thus, although replication-defective recombinant human adenoviruses have been successfully employed as vaccine carriers in experimental systems employing rodent, canine, and nonhuman primate hosts; human innate and adaptive immunity is expected to significantly limit the utility of these serotypes as vaccine carriers. This expectation is based on the fact that subgroup C, which includes type 2 and type 5, adenoviral infection is endemic in the human population. As a consequence, the majority of humans seroconvert within the first five years of life as the result of a natural infection. Thus, vectors derived from viruses that naturally infect and replicate in humans may not be optimal candidates for use as vaccine carriers.

Another problem associated with the use of human adenoviral-derived vectors is the risk that the production method used to propagate the recombinant viruses will give rise to vector stocks that are contaminated with replication competent adenovirus (RCA). This is caused by homologous recombination between overlapping sequences from the recombinant vector and the adenoviral genes that are present in the E1-complementing helper cell lines such as human 293 (Graham, F.L. et al, (1977) J. Gen. Virol. 36:59-72.) cells. The presence of RCA in vector stocks prepared for use in clinical trials constitutes a safety risk because it can promote the mobilization and spread of the replication defective virus. Spread of the defective virus can aggravate the host immune response and cause other adverse immunopathological consequences (Fallux, F. J., et al. Human Gene Therapy 9: 1909-1917 (1998). Accordingly, the Food and Drug Administration (FDA) and other regulatory bodies have promulgated guidelines which establish limits on the levels of RCA that can be present in vector preparations intended for clinical use. The intent of imposing RCA limits is to ensure limited exposure of patients to replicating adenovirus in compositions that are used in clinical trials.

10

15

20

25

30

Thus, there continues to be a need for the development of adenoviral vaccine carriers that are suitable for use in mammalian hosts which are: easy to manipulate, amenable to pharmaceutical scale production and long term storage, capable of high-level replication in human complementation cell lines, highly immunogenic, devoid of neutralizing B cell epitopes that cross-react with the common serotypes of human adenoviruses, comply with the safety RCA standards promulgated by regulatory agencies, and which are amenable for use in prime/boost protocols that are suitable for use in humans.

### SUMMARY OF THE INVENTION

The present invention relates to recombinant replication-defective adenovirus vectors derived from chimpanzee adenoviruses and methods for generating chimpanzee adenoviral vectors in human E1-expressing cell lines. The invention also provides methods for generating clinical grade vector stocks suitable for use in humans and means for using the disclosed vectors as vaccine carriers to elicit protective and/or therapeutic immune responses. The invention further provides methods for using the recombinant adenoviruses of the invention to prepare vaccine compositions designed to delivery, and direct the expression of, transgenes encoding immunogens. In one embodiment, the invention contemplates the use of the disclosed vectors as vaccine carriers for the administration of vaccines comprising transgenes encoding immunogens derived from an infectious agent. In a second embodiment, the invention contemplates the use of the disclosed vectors to prepare and administer cancer vaccines. In a particular embodiment, the invention contemplates the preparation and administration of a cancer vaccine comprising a transgene encoding a TAA.

In one aspect, the invention discloses the complete genomic sequence of five chimpanzee adenoviruses (ChAds), referred to herein as ChAd3 (SEQ ID NO: 1) (Figures 5A-5V), ChAd6 (SEQ ID NO: 2) (Figures 6A-6V, CV32 (SEQ ID NO:3) (Figures 7A-7K), CV33 (SEQ ID NO: 4) (Figures 8A-8K), and CV23 (SEQ ID NO:5) (Figures 9A-9J). ChAd3 and ChAd6 represent novel adenoviruses isolated according to the methods disclosed herein. The genomes of the ChAd3 and ChAd6 are 37741 and 36648 base pairs in length, respectively. ChAd3 hexon gene is comprised between nt 19086-21968(SEQ ID NO: 41) while fiber gene is comprised between nt 32805-34490 (SEQ ID NO: 42). ChAd6 hexon gene is comprised between nt 18266-21127 (SEQ ID NO: 43) while fiber gene is comprised between nt 32218-33555 (SEQ ID NO: 44). Based on sequence homology deduced from a multiple sequence alignment of full-length hexon peptides, ChAd3 has been classified into human subgroup C and ChAd6 has been classified into human subgroup E.

10

15

20

25

30

35

The genomes of the CV32, CV33 and CV23 adenoviruses are 36,606, 36,535, and 32,020 base pairs in length, respectively. CV32 (Pan 6, ATCC N. VR-592), CV33 (Pan 7, ATCC N. VR-593) and CV23 (Pan 5) (Esoterix Inc.,) have all been determined to be related to human Ad4 (hAd4) (subgroup E) (Wigand, R *et al. Intervirology* 1989, 30:1-9). However, based on hexon sequence alignment CV32 has subsequently characterized as being more closely analogous to human subgroup D members than to hAd4.

In a second aspect, the invention provides nucleotide sequences for the fiber and hexon genes of ten additional chimpanzee adenoviruses (ChAd20, ChAd4, ChAd5, ChAd7, ChAd9, ChAd10, ChAd11, ChAd16, ChAd17 and ChAd19) isolated according to the methods disclosed herein. The fiber gene sequences are set forth in Figures 10-19 and SEQ ID NOS: 6-15: (SEQ ID NO: 6, ChAd20); (SEQ ID NO: 7, ChAd4); (SEQ ID NO: 8, ChAd5); (SEQ ID NO: 9, ChAd7); (SEQ ID NO: 10, ChAd9); (SEQ ID NO: 11, ChAd10); (SEQ ID NO: 12, ChAd11); (SEQ ID NO: 13, ChAd16) (SEQ ID NO: 14, ChAd17) and (SEQ ID NO: 15, ChAd19). Figures 20A-20D provides a comparison of the amino acid sequences of the fiber proteins disclosed and claimed herein.

The hexon gene sequences are set forth in Figures 21-30 and SEQ ID NOS: 16-25: (SEQ ID NO: 16, ChAd20); (SEQ ID NO: 17, ChAd4); (SEQ ID NO: 18, ChAd5); (SEQ ID NO: 19, ChAd7); (SEQ ID NO: 20, ChAd9); (SEQ ID NO: 21, ChAd10); (SEQ ID NO: 22, ChAd11); (SEQ ID NO: 23, ChAd16); (SEQ ID NO: 24, ChAd17) and (SEQ ID NO: 25, ChAd19). Figures 31A-31M provide a comparison of the amino acid sequences of the hexon proteins disclosed and claimed herein. A multiple sequence alignment of hexon proteins allows an artisan to perform a phylogenetic analysis of that is consistent with the proposed classification of human adenoviral serotypes (Rux, J.J., et al (2003) J. Virol. 77:9553-9566).

In an alternative aspect, the invention further provides ten additional chimpanzee adenovirus isolates. Samples comprising ChAd20, ChAd4, ChAd5, ChAd7, ChAd9, ChAd10, ChAd11, ChAd16, ChAd17 and ChAd19 were deposited on December 12, 2003 with the European Collection of Cell Cultures (ECACC, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom) as an original deposit under the Budapest Treaty. The deposits were assigned accession numbers: 03121201 (ChAd4), 03121202 (ChAd5), 03121203 (ChAd7), 03121204 (ChAd9), 03121205 (ChAd10), 03121206 (ChAd11), 03121207 (ChAd16), 03121208 (ChAd17), 03121209 (ChAd19) and 03121210 (ChAd20). These deposits will be maintained under the terms of the *Budapest Treaty* on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. These deposits were made merely as a convenience for those of skill in the art and are not an admission that a deposit is required under 35 U.S.C. §112. All restrictions on the availability to the public of the deposited material will be

10

15

20

25

30

35

irrevocably removed, except for the requirements specified in 37 C.F.R. §1.808(b), upon the granting of a patent.

In a third aspect, the invention provides replication-defective recombinant adenoviral vectors which are capable of infecting mammalian cells, preferably human cells, and directing expression of encoded transgene product(s). As demonstrated herein, the disclosed vectors are suitable for use as vaccine carriers for the delivery of transgenes comprising immunogens against which an immune response is desired. In particular embodiments, the invention provides recombinant replication-defective chimpanzee adenoviral vectors that are capable of high-level replication in human E1-expressing (i.e., packaging) cell lines. In one embodiment, the invention provides recombinant adenoviruses that are capable of replicating in PER.C6<sup>TM</sup> cells.

Generally speaking, the recombinant vectors encompassed by the invention provide vaccine carriers that will evade pre-existing immunity to the adenovirus serotypes that are typically encountered in the human population. More specifically, the recombinant vectors of the invention comprise vector backbone sequences which are shown herein to be devoid of neutralizing B epitopes that cross-react with the common serotypes of human adenoviral derived vectors.

The invention further provides group-specific shuttle vectors that include an adenoviral portion and a plasmid portion, wherein said adenoviral portion generally comprises:

a) viral left end (ITR and packaging signal), part of the pIX gene and viral genome right end; and b) a gene expression cassette. The group-specific shuttle vectors are designed to exploit the nucleotide sequence homology which is observed between adenoviruses that are assigned to the same serotype subgroup (i.e., subgroups A, B, C, D or E), and can be used to manipulate the nucleotide sequences disclosed herein and/or to clone other chimpanzee adenoviruses belonging to the same subgroup generating an adenovirus pre-plasmid containing a chimp adenoviral genome deleted of E1 region.

Other aspects of this invention include host cells comprising the adenoviral vaccine vectors and/or the adenovirus pre-plasmid vectors, methods of producing the vectors comprising introducing the adenoviral vaccine vector into a host cell which expresses adenoviral E1 protein, and harvesting the resultant adenoviral vaccine vectors. In a particular embodiment, the invention provides a method of producing a replication-defective chimpanzee adenoviral vector comprising introducing one of the disclosed adenoviral vectors into an adenoviral E-1 expressing human cell, and harvesting the resulting recombinant adenoviruses.

Another aspect of the invention also provides vaccine compositions which comprise an adenoviral vector of the invention. Compositions comprising recombinant

10

15

20

30

chimpanzee adenoviral vectors may be administered alone or in combination with other viral- or non-viral-based DNA/protein vaccines. They also may be administered as part of a broader treatment regimen. These compositions can be administered to mammalian hosts, preferably human hosts, in either a prophylactic or therapeutic setting. As shown herein, administration of the disclosed vaccine compositions, either alone or in a combined modality, such as a prime boost regimen or multiple injections of serologically distinct Ad vectors results in the induction of an immune response in a mammal that is capable of specifically recognizing the immunogen encoded by the transgene.

One of the methods disclosed and claimed herein, comprises administering to a mammal (that is either naïve or primed to be immunoreactive to a target antigen), a sufficient amount of a recombinant chimpanzee adenoviral vector, containing at least a functional deletion of its wild-type E1 gene, carrying a sequence comprising a promoter capable of directing expression of a nucleotide sequence encoding the least one target antigen, wherein administration of the recombinant vector elicits (or primes) an antigen-specific immune response.

In one embodiment, the invention provide a method designed to induce an immune response (prophylactic or therapeutic) against an infectious agent (e.g., a viral or bacterial pathogen or a mammalian parasite). In a second embodiment, the invention provides a method designed to induce an immune response in a mammal that will break tolerance to a self-antigen, such as a TAA. This aspect of the invention contemplates the use of the disclosed vectors as a vaccine carrier for the preparation and administration of cancer vaccines.

Yet other embodiments and advantages of the present invention will be readily apparent from the following detailed description of the invention.

### 25 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic drawing which summarizes the cloning strategy used to construct a ChAd6 shuttle vector (pARS ChAd6-3).

Figure 2 is a schematic drawing which illustrates the cloning strategy used to clone the ChAd6 viral genome by homologous recombination in *E.coli* strain BJ5183.

Figure 3 is a schematic drawing illustrating the elements of various ChAd6 shuttle plasmids including: pARS ChAd6-3 GAG; pARS ChAd6-3 SEAP; pARS ChAd6-3 EGFP; and pARS ChAd6-3 NS MUT.

Figure 4 is a schematic drawing which illustrates the homologous recombination scheme utilized to clone the ChAd6  $\Delta$ E1expression vectors.

10

15

20

25

30

35

(SEQ ID NO: 16).

Figures 5A-5V provides the genomic nucleotide sequence of ChAd3 (SEQ ID NO: 1). Figures 6A-6V provides the genomic nucleotide sequence of ChAd6 (SEQ ID NO: 2). Figures 7A-7K provides the genomic nucelotide sequence of CV32 (SEQ ID NO: 3). Figures 8A-8K provides the genomic nucleotide sequence of CV33 (SEQ ID NO: 4). Figures 9A-9J provides the genomic nucleotide sequence of CV23 (SEQ ID NO: 5). FigureS 10 A and B provides the nucleotide sequence of the fiber gene of ChAd20 (SEQ ID NO: 6). Figures 11 A and B provides the nucleotide sequence of the fiber gene of ChAd4 (SEQ ID NO: 7). Figures 12 A and B provides the nucleotide sequence of the fiber gene of ChAd5 (SEQ ID NO: 8). Figures 13 A and B provides the nucleotide sequence of the fiber gene of ChAd7 (SEQ ID NO: 9). Figures 14 A and B provides the nucleotide sequence of the fiber gene of ChAd9 (SEQ ID NO: 10). Figures 15 A and B provides the nucleotide sequence of the fiber gene of ChAd10 (SEQ ID NO: 11). Figures 16 A and B provides the nucleotide sequence of the fiber gene of ChAd11 (SEQ ID NO: 12). Figures 17 A and B provides the nucleotide sequence of the fiber gene of ChAd16 (SEQ ID-NO: 13). Figures 18 A and B provides the nucleotide sequence of the fiber gene of ChAd17 (SEQ ID NO: 14). Figures 19 A and B provides the nucleotide sequence of the fiber gene of ChAd19 (SEQ ID NO: 15). Figures 20A-20D provides a comparison of the amino acid sequences of the fiber proteins of C1, ChAd11, ChAd20, ChAd17, ChAd3, ChAd19, PAN6, ChAd5, ChAd6, ChAd7, PAN5, PAN7, ChAd9, ChAd10, ChAd4, CV68 and ChAd16. Figures 21A-21C provides the nucleotide sequence of the hexon gene of ChAd20

10

**15** ,

20

25

30

Figures 22A-22C provides the nucleotide sequence of the hexon gene of ChAd4 (SEQ ID NO: 17).

Figures 23A-23C provides the nucleotide sequence of the hexon gene of ChAd5 (SEQ ID NO: 18).

Figures 24A-24C provides the nucleotide sequence of the hexon gene of ChAd7 (SEQ ID NO: 19).

Figures 25A-25C provides the nucleotide sequence of the hexon gene of ChAd9 (SEQ ID NO: 20).

Figures 26A-26C provides the nucleotide sequence of the hexon gene of ChAd10 (SEQ ID NO: 21).

Figures 27A-27C provides the nucleotide sequence of the hexon gene of ChAd11 (SEQ ID NO: 22).

Figures 28A-28C provides the nucleotide sequence of the hexon gene of ChAd16 (SEQ ID NO: 23).

Figures 29A-29C provides the nucleotide sequence of the hexon gene of ChAd17 (SEQ ID NO: 24).

Figures 30A-30C provides the nucleotide sequence of the hexon gene of ChAd19 (SEQ ID NO: 25).

Figures 31A-31M provides a comparison of the amino acid sequences of the hexon proteins of: hAd12, hAd3, hAd7, hAd11, hAd21, hAd34, hAd35, C1, hAd1, hAd2, hAd5, ChAd3, ChAd11, ChAd17, ChAd19, ChAd20, hAd48, ChAd4, ChAd5 ChAd7, ChAd16, Pan6, hAd4, hAd16, ChAd6, ChAd9, ChAd10, C68, Pan5, Pan7, hAd41 and hAd40.

Figure 32 provides a listing of the oligonucleotide sequences (SEQ ID NOS: 26-46) disclosed herein.

Figure 33 is a graphic representation of the immunization break-point of ChAd vectors belonging to different serotype subgroups (i.e., subgroups C, E and D). The lowest dose eliciting a measurable immune response was determined by performing titration experiments in mice immunized with gag-expressing ChAd3, ChAd11, ChAd20, CV33, CV68, ChAd6, ChAd9, ChAd10, CV32, ChAd4, ChAd7 and ChAd16 vectors.

Figure 34 provides a graphic representation of a CEA-specific T cell response elicited in rhesus macaques immunized sequentially with a human adenoviral vector (MRKAd5 RhCEA) followed by a chimpanzee adenoviral vector (CV33 RhCEA) after 12 week interval. The immune responses were evaluated by IFN-γ ELISPOT assay, and the data illustrate the number of spot-forming cells (SFC) per million peripheral blood mononuclear cells (PBMC)

10

15

20

25

30

following incubuation in the absence (DMSO) and presence of rhesus CEA C and D peptide pools.

Figure 35 provides a phylogenetic tree of human and chimpanzee adenoviruses of deduced from a multiple sequence alignment of full-length hexon peptide sequences using PAUPSEARCH (Wisconsin Package Version 10.3, Accelrys Inc.) and visualized and manipulated with TREEVIEW.

Figure 36 is a graphic representation of immunization results obtained in response to the administration of ChAd3 and hAd5 gag vectors to mice which were pre-exposed to hAd5. Cell-mediated immunity was evaluated 3 weeks post-immunization by IFN-γ ELISPOT using purified splenocytes.

Figure 37 is a graphic representation of kinetics of anti-CEA CMI elicited in human CEA transgenic mice immunized with ChAd3hCEA and Ad5hCEA. CMI was evaluated by ICS of PBMC stimulated with CEA peptide pool. The results are expressed as % of IFN $\gamma^+$  CD8 $^+$ /total PBMC.

## DETAILED DESCRIPTION OF THE INVENTION

As used throughout the specification and appended claims, the following definitions and abbreviations apply:

The term "cassette" refers to a nucleic acid molecule which comprises at least one nucleic acid sequence that is to be expressed, along with its transcription and translational control sequences. Changing the cassette, will cause the vector into which is incorporated to direct the expression of different sequence or combination of sequences. In the context of the present invention, the nucleic acid sequences present in the cassette will usually encode an immunogen. Because of the restriction sites engineered to be present at the 5' and 3' ends, the cassette can be easily inserted, removed or replaced with another cassette.

The term "cis-acting element" refers to nucleotide sequences which regulate genes to which they are attached. Cis-acting elements present in DNA regulate transcription, and those transcribed into mRNA can regulate RNA processing, turnover and protein synthesis.

The term "vector" refers to some means by which DNA fragments can be introduced into a host organism or host tissue. There are various types of vectors including plasmid, virus (including adenovirus), bacteriophages and cosmids.

The term "promoter" refers to a recognition site on a DNA strand to which an RNA polymerase binds. The promoter forms an initiation complex with RNA polymerase to

10

15

20

25

30

35

initiate and drive transcriptional activity. The complex can be modified by activating sequences such as enhancers, or inhibiting sequences such as silencers.

The term "pharmaceutically effective amount" refers to an amount of recombinant adenovirus that is effective in a particular route of administration to transduce host cells and provide sufficient levels of transgene expression to elicit an immune response.

The term "replication-competent" recombinant adenovirus (AdV) refers to an adenovirus with intact or functional essential early genes (i.e., E1A, E1B, E2A, E2B and E4). Wild type adenoviruses are replication competent.

The term "replication-defective" recombinant AdV refers to an adenovirus that has been rendered to be incapable of replication because it has been engineered to have at least a functional deletion, or a complete removal of, a gene product that is essential for viral replication. The recombinant chimpanzee adenoviral vectors of the invention are replication-defective.

The term "mammalian" refers to any mammal, including a human being.

The term "percent sequence identity" or "identical" in the context of nucleic acid sequences refers to the residues in the two sequences that are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over the full-length of the genome. (e.g., about 36 kbp), the full-length of an open reading frame of a gene, protein, subunit, or enzyme [see, e.g., the tables providing the adenoviral coding regions], or a fragment of at least about 500 to 5000 nucleotides, is desired. However, identity among smaller fragments, e.g. of at least about nine nucleotides, usually at least about 20 to 24 nucleotides, at least about 28 to 32 nucleotides, at least about 36 or more nucleotides, may also be desired. Similarly, "percent sequence identity" may be readily determined for amino acid sequences, over the full-length of a protein, or a fragment thereof. Suitably, a fragment is at least about 8 amino acids in length, and may be up to about 700 amino acids. Examples of suitable fragments are described herein.

Identity is readily determined using such algorithms and computer programs as are defined herein at default settings. Preferably, such identity is over the full length of the protein, enzyme, subunit, or over a fragment of at least about 8 amino acids in length. However, identity may be based upon shorter regions, where suited to the use to which the identical gene product is being put.

In general, adenoviral constructs, gene constructs are named by reference to the genes contained therein. For example, "pChAd3  $\Delta$ E1gag" refers to a plasmid construct which comprises a ChAd3 chimpanzee adenoviral genome deleted of the E1 region. In this plasmid, the E1 region is replaced by an immunogen expression cassette comprising an HIV gag gene

10

15

20

25

30

35

under the control of a human CMV promoter followed by a bovine growth hormone polyadenylation signal. Similarly, pCV33DE1-E3 NSmut, refers to a second plasmid construct disclosed herein which comprises a CV33 chimpanzee adenoviral genome, deleted of the E1 and E3 regions, which is replaced by an immunogen expression cassette comprising HCV non-structural genes under the control a human CMV promoter followed by a bovine growth hormone polyadenylation signal.

The abbreviation "Ag" refers to an antigen.

As used throughout the specification and in the appended claims, the singular forms "a," "an," and "the" include the plural reference unless the context clearly dictates otherwise.

Adenoviruses (Ads) are noneveloped, icosahedral viruses that have been identified in several avian and mammalian hosts. Human Ads (hAd) belong to the Mastadenovirus genus which includes all known human and many Ads of animal (e.g., bovine, porcine, canine, murine, equine, simian and ovine) origin. Human adenoviruses are divided into six subgroups (A-F) based on a number of biological, chemical, immunological and structural criteria which include hemagglutination properties of rat and rhesus monkey erythrocytes, DNA homology, restriction enzyme cleavage patterns, percentage G+C content and oncogenicity (Straus, 1984, In *The Adenoviruses*, ed. H. Ginsberg, pps. 451-498, New York: Plenus Press, and Horwitz, 1990 In *Virology*, eds. B.N. Fields and D.M. Knipe, pps. 1679-1721). To date, 51 distinct serotypes have been recognized and grouped into subgroups on the basis of their hemagglutination properties and biophysical and biochemical criteria.

The adenoviral virion has an icosahedral symmetry and, depending on the serotype, a diameter of 60-90 nm. The icosahedral capsid consists three major proteins, hexon (II), penton base (III) and a knobbed fibre (IV) as well as a number of minor proteins (i.e., VI, VIII, IX, IIIa and IVa2) (W.C. Russel, *J. Gen. Virol.*, 81: 2573-2604 (2000). One aspect of the preexisting immunity that is observed in humans is humoral immunity, which can result in the production and persistence of antibodies that are specific for viral proteins. The humoral response elicited by adenovirus is mainly directed against the major structural proteins: hexon, penton and fiber.

Published reports have established that titers comprising antibodies against multiple serotypes are common (Dambrosio, E. (1982) J. Hyg. (London) 89: 209-219) and that a substantial portion of the preexisting titers have neutralizing activity. Neutralizing immunity to adenovirus is type specific, and infection with a particular serotype of adenovirus confers immunity only to that serotype. Several reports have suggested that antibodies directed towards the hexon are the strongest and the most neutralizing (Toogood, C.I.A., Crompton, J. and Hay

10

15

20

25

30

35

R.T. (1992) *J.Gen. Virol.* 73, 1429-1435). Therefore, it is reasonable to assume that the epitopes responsible for type-specific neutralization are located within seven hypervariable regions identified by alignment of the hexon sequences deriving from different serotypes. (Crawford-Miksza, L and D.P.Schnurr. (1996) *J.Virol.* 70:1836-1844).

A direct correlation between the presence of type-specific neutralizing antibodies and the inability to elicit an immune response with a vector based on the same serotype has been established by different methods including the passive transfer of immune sera from treated to naïve animals. Generally speaking, preexisting humoral immunity for a specific viral serotype reduces the therapeutic efficacy of the vector administration. Moreover, the administration of a vector based on a specific viral serotype elicits an immune-response against the vector that prevents the re-administration of the same serotype.

In a particular embodiment, the invention provides a method of circumventing the adverse effects associated with the consequences of preexisting immunity to common serotypes of hAds. More specifically, the invention contemplates the use of chimpanzee adenoviral vectors characterized by a serotype that does not circulate in humans. Accordingly, the invention provides adenoviral (Chad) vectors which lack neutralizing B-cell epitopes that cross react with those of common human serotypes as a vaccine carrier.

Although it has been reported that adenoviral-specific cell mediated immunity (CMI) can be cross-reactive, vaccination studies based on repeated injections of multiple serotypes demonstrated a higher efficiency than immunization schedules based on a single vector. These experiments further demonstrate that the main limitation of a vector administration for vaccine purposes is the humoral pre-existing immunity against the vector. Potential solutions to the problems associated with the use of a human adenovirus as a vaccine carrier include the administration of a higher dose of an adenovirus (e.g., a subgroup C serotype) that is predicted to encounter a preexisting immune response, and the use of vectors based on rare human serotypes. However, the use of higher doses of vaccine increases the cost of the vaccine and risk of undesirable side effects and the results of preclinical testing suggest that human alternate serotypes are less immunogenic than hAd5 and hAd6.

In an attempt to avoid the problems of host humoral and cellular immune responses against the adenoviral backbone elements of the vector, and to minimize the risk of using human adenovirus-derived vector stocks that may be contaminated with replication-competent adenoviruses (RCA), several nonhuman adenoviruses have been characterized and developed as vaccine carriers (Soudois, C. et al (2000) J. Virology, 74:10639-10649; Farina, S.F. et al (2001) J. Virology, 75:11603-11613; Cohen, C.J. et al (2002) J. Gen. Virology, 83:151-155.) The premise underlying the use of nonhuman adenoviral sequences to circumvent the

10

15

20

25

30

35

problems associated with preexisting immunity is based on the observation that neutralizing antibodies to common human adeonvirus serotypes are unlikely to cross-neutralize nonhuman viruses. However, the incompatibility of viral and cellular factors imposes a practical limitation on the vast majority of alternative vector systems (bovine, ovine, canine) which are characterized by the disadvantage of having to be propagated in non-human cell lines.

Wilson et al. have published a report describing the characterization of a replication-defective vector based on chimpanzee adenovirus type 68 (CV68) C68, which was originally isolated from a mesenteric lymph node of a chimpanzee (Basnight, M., et. al. (1971) Am. J. Epidemiol. 94:166-171.), CV68 was fully sequenced and found to be similar in overall structure to human adenoviruses (Farina, S. F. et al., J. Virol. 75(23): 11603-11613 (2001). The genome of the virus is 36,521 base pairs in length and has been described as being most similar to subgroup E of human adenoviruses, with 90% identity to most human Ad4 open reading frames that have been sequenced. The CV68 ITRs are 130 base pairs in length, and all of the major adenoviral early and late genes are present. CV68 is characterized by a serotype that does not circulate in humans and which lacks neutralizing B cell epitopes that cross-react with those of common human serotypes. Although Chimpanzee adeonviruses are similar to human adenoviruses crossreactive neutralizing immunity against chimpanzee serotypes has not been documented in humans (Farina, S. F. et al. J. Virol. (2001) 75(23):11603-13).

The recombinant vectors derived from CV68 are described as being sufficiently similar to human serotypes to support transduction of cells expressing the coxasckievirus and adenovirus receptor (Cohen, C. et al., J. Gen. Virol. 83: 151-155 (2002). Significantly, CV68 is characterized by a sufficient level of similarity to human adenoviruses to support its replication 293 cells which harbor E1 from human adenovirus type 5 (Farina, S. F. et al., J. Virol. 75(23): 11603-11613 (2001). Furthermore, based on the observation that the flanking sequences of the human serotype 5 E1 are nonhomologous with those of the CV68-derived vector sequences, it is predicted that homologous recombination will not occur. Thus, it has been predicted that there is a low likelihood that CV68-derived vaccine stocks will be contaminated with RCA.

The same group of investigators subsequently reported the use of CV68-derived adenoviral sequences as a vaccine carrier for induction of antibodies to the rabies virus glycoprotein in mice. A replication-defective version of CV68 was created by replacing the E1A and E1B genes with a minigene cassette. Mice immunized with an E1-deletion-containing adenoviral recombinant (AdC68rab.gp) comprising a transgene product encoding the rabies virus glycoprotein developed protective immunity to rabies virus and remained resistant to challenge with an otherwise lethal dose of rabies virus (Xiang, Z et al., J. Virol. 76(5): 2667-2675 (2002). A second CV68 construct expressing a codon-optimized, truncated form of gag of

10

15

20

25

30

35

HIV-1 was recently reported to induce a vigorous gag-specific CD8<sup>+</sup> T cell response in mice. The vaccine-induced response was shown to provide protection to challenge with a vaccinia gag recombinant virus (Fitzgerald, J. C. et al., J. Immunol. 170: 1416-1422 (2003). Experimental vaccination of mice preimmunized to human adenovirus serotype 5 with CV68gag or Ad5gag vectors demonstrated a more pronounced reduction of gag-specific T cells and protection against viral challenge elicited by Ad5 than by CV68 vaccine. The reduction in efficacy of C68gag vaccine was attributed to a cross-reactivity of Ad5-specific CD8+ T cells (Id.).

Considered together this data suggests that simian-derived replication-defective adenoviral vectors may be more suitable for use as human vaccine carriers than vectors based on common human serotypes. As shown herein, the results of experiments in which mice that were strongly immunized against human Ad5 (Figure 36) can be immunized with ChAd3-gag adenoviral vectors indicate the preexisiting anti-human Ad5 immunity did not reduce the gag-specific CMI response elicited by the ChAd vectors. These results are consistent with the conclusion that human Ad5 cross-reactive B and T-cell epitopes are not present in ChAd3- or ChAd6 vectors.

Generally speaking, the adenoviral genome is very well characterized and despite the existence of several distinct serotypes, there is some general conservation in the overall organization of the adenoviral genome with specific functions being similarly positioned. The nucleotide sequences of the chimpanzee adenoviruses C1 and CV68 disclosed by Wilson *et al.*, and the location of the E1A, E1B, E2A, E2B, E3, E4, L1, L2, L3, L4 and L5 genes of each virus are provided in U.S. Patent No. 6,083,716 (Chimpanzee Adenovirus Vectors), and PCT published application WO 03/000851 (Methods for Rapid Screening of Bacterial Transformants and Novel Simion Adenoviral Proteins), the teachings of which are incorporated herein by reference.

Each extremity of the adenoviral genome comprises a sequence known as an inverted terminal repeat (ITRs), which is necessary for viral replication. The virus also comprises a virus-encoded protease, which is necessary for processing some of the structural proteins required to produce infectious virions. The structure of the adenoviral genome is described on the basis of the order in which the viral genes are expressed following host cell transduction. More specifically, the viral genes are referred to as early (E) or late (L) genes according to whether transcription occurs prior to or after onset of DNA replication. In the early phase of transduction, the E1, E2, E3 and E4 genes of adenovirus are expressed to prepare the host cell for viral replication. The virus can be rendered replication defective by deletion of the essential early-region 1(El) of the viral genome. Brody et al, 1994 Ann N Y Acad Sci., 716:90-101. During the late phase, expression of the late genes L1-L5, which encode the structural

10

15

20

25

30

35

components of the virus particles is switched on. All of the late genes are under the control of a single promoter and encode proteins including the penton (L2), the hexon (L3), the 100 kDa scaffolding protein (L4), and the fiber protein (L5), which form the new virus particle into which the adenoviral DNA becomes encapsidated. Depending on the serotype of the virus, 10,000-100,000 progeny adenovirus particles can be generated in a single host cell. Ultimately, the adenoviral replication process causes lysis of the cells.

The replication-defective adenoviral vectors disclosed herein were constructed by deletion of specific nucleotide sequences from the disclosed chimpanzee nucleic acid sequences and insertion of sequences derived other DNA sequences that are useful for transgene insertion, expression or other genetic manipulations. Accordingly, the recombinant chimpanzee adenoviruses described herein may contain adenoviral sequences derived from one or more chimpanzee adenoviruses, or sequences from a chimpanzee adenovirus and from a human adenovirus. Suitable polynucleotide sequences can be produced recombinantly, synthetically or isolated from natural sources. Adenoviral sequences suitable for use in particular aspects of the invention include sequences which lack neutralizing B-cell epitopes that are cross-reactive with common human serotypes.

At a minimum, the recombinant chimpanzee adenovirus (e.g., vector) of the invention contain the chimpanzee adenovirus *cis*-acting elements necessary for replication and virion encapsidation, in combination with at least one immunogen expression cassette. Typically, the *cis*-acting elements flank the expression cassette which comprises a transgene that encodes at least one antigen. More specifically, the vectors of the invention contain the requisite *cis*-acting 5' inverted terminal repeat (ITR) sequences of the adenoviruses (which function as origins of replication), 3' ITR sequences, packaging/enhancer domains, and a nucleotide sequence encoding a heterologous molecule. Regardless of whether the recombinant vector comprises only the minimal adenoviral sequences or an entire adenoviral genome with only functional deletions in particular genes (e.g., the E1 and/or E3 or E4 regions), the vectors of the invention comprise a chimpanzee adenovirus capsid.

Generally, speaking the adenoviral vectors disclosed herein comprise a replication-defective adenoviral genome, wherein the adenoviral genome does not have a functional E1 gene, and an immunogen expression cassette which comprises: a) a nucleic acid encoding at least one immunogen against which an immune response is desired; and b) a heterologous (i.e., with respect to the adenoviral sequence) promoter operatively linked to the nucleic acid sequence encoding the immunogen(s); and a transcription terminator.

More specifically, the invention provides replication-defective vectors that consist of a recombinant adenoviral genome that is devoid of at least one early gene selected from the

group consisting of E1, E2, E3, and E4. In one embodiment, a replication-defective vector is prepared by replacing, or disrupting, the E1 gene of one of the adenoviral isolates disclosed herein (e.g., ChAd3, ChAd6, ChAd4, ChAd5, ChAd7, ChAd9, ChAd10, ChAd11, ChAd16, ChAd17, ChAd19 or ChAd20) with an immunogen expression cassette. For example, a vector can be prepared by deleting/disrupting the E1 gene of ChAd 3 (SEQ ID NO:1) or ChA6 (SEQ ID NOS: 2). Alternatively, a replication-defective vector can be prepared from any one of the other adenovirus isolates disclosed herein, including ChAd3, ChAd6, ChAd4, ChAd5, ChAd7, ChAd9, ChAd10, ChAd11, Chad16, Chad17, ChAd19 or ChAd20. In other embodiments, replication-defective vectors of the invention comprises an adenoviral genome derived from one of the ChAds disclosed herein that has been optionally engineered to lack a functional E3 gene. It is to be understood that the chimpanzee adenoviral sequences disclosed herein can be rendered replication-defective by either completely removing an early gene or by rendering the gene inoperative or nonfunctional.

It is to be understood that the invention encompasses vectors that are characterized as having modifications, such as a "functional deletion" which destroys the ability of the adenovirus to express one or more selected gene products. The phrase "functional deletion" as used herein broadly encompasses modifications that have the effect of rendering a particular gene product nonfunctional. Generally speaking, functional deletions take the form of a partial or total deletion of an adenoviral gene. However, one of skill in the art will readily acknowledge that other manipulations, including but not limited to making a modification which introduces a frame shift mutation, will also achieve a functional deletion. For example, the recombinant chimpanzee adeonviral vectors of the invention can be rendered replication-defective by introducing a modification that is designed to interfere with, or to functionally delete, the ability of the virus to express adenoviral E1A and/or E1B.

It is well-known that replication-defective adenoviral vectors can be obtained by introducing a modification that is designed to interfere with, or to functionally delete the expression of one o more genes from the group of E2 genes. More in detail, a replication-defective vector can be constructed by inactivating the polymerase gene, or the pre-terminal protein gene or the DNA binding protein gene. Moreover deletion or inactivation of genes expressed by E4 region is an alternative strategy to construct replication-defective chimp Ad vectors. Early gene deletion or inactivation can be combined in order to produce more attenuated vectors. Alternatively, replication-defective ChAd vectors can also comprise additional modifications in other viral genes, such as the late genes L1 through L5. In addition, novel adenoviral vaccine carriers can be generated by combining hexon and fiber genes obtained from different serotypes. The utilization of a hexon and fiber gene shuffling strategy will also allow an

10

15

20

25

30

35

investigator to change the biological properties of a ChAd and facilitate the production of vectors with a different tropism or with new serological characteristics.

It is to be understood that the present invention encompasses recombinant adenoviral vectors comprising deletions of entire genes or portions thereof which effectively destroy the biological activity of the modified gene either alone or in any combination. For example, recombinant simian adenoviruses can be constructed which have a functional deletion of the genes expressed by E4 region, although as shown herein it may be desirable to introduce the heterologous Ad5 E4 sequence into the vector in combination with the functional deletion of an E1 gene. Alternatively, the function of the adenoviral delayed early E3 gene may be eliminated; however because the function of E3 is not necessary for the production of a recombinant adenoviral particle it is not necessary to replace this gene product in order to produce a recombinant that is capable of packaging a virus useful in the invention.

In one embodiment of this invention, the replication- defective adenoviral vector used is a chimpanzee subgroup C adenovirus containing deletions in E1 and optionally in E3. For example, for ChAd3, a suitable E1 deletion/disruption can be introduced in the region from bp 460 to bp 3542 (with reference to SEQ ID NO: 1). For ChAd6, a suitable E1 deletion/disruption can be introduced in the region from bp 457 to bp 3425 (with reference to SEQ ID NO: 2). For CV32, the E1 deletion is preferably from bp 456 to bp 3416 (with reference to SEQ ID NO: 3); for CV33, the E1 deletion is preferably from bp 456 to bp 3425 (with reference to SEQ ID NO: 4) and for CV23, the E1 deletion is preferably from bp 456 to bp 3415 (with reference to SEQ ID NO: 5). E3 deletions for CV32 and CV33 are preferably from bp 27446 to bp 31911 (with reference to SEQ ID NO: 3); from bp 27146 to bp 31609 (with reference to SEQ ID NO: 4) respectively. Those of skill in the art can easily determine the equivalent sequences for other chimpanzee isolates based on sequence homologies and multiple sequence alignments.

One of skill in the art will readily acknowledge that in order to construct an E1-deleted adenoviral vector a number of decisions must be made regarding the structure of the vector backbone and the composition of the nucleic acid sequence comprising the transgene. For example, an investigator must determine if the size of the E1 deletion will accommodate the size of the transgene. If not, then additional deletions will have to be introduced into the backbone of the vector.

The nucleic acid sequence embodying the transgene can be a gene, or a functional part of a gene and will typically exist in the form of an expression cassette. Typically a gene expression cassette includes: (a) nucleic acid encoding a protein or antigen of interest; (b) a heterologous promoter operatively linked to the nucleic acid encoding the protein; and (c) a

10

25

30

35

transcription termination signal. The nucleic acid can be DNA and/or RNA, can be double or single stranded. The nucleic acid can be codon-optimized for expression in the desired host (e.g., a mammalian host).

Decisions must also be made regarding the site within the backbone where the transgene will be introduced and the orientation of the transgene. More specifically, the transgene can be inserted in an E1 parallel (transcribed 5' to 3') or anti-parallel (transcribed in a 3' to 5' direction relative to the vector backbone) orientation. In addition, appropriate transcriptional regulatory elements that are capable of directing expression of the transgene in the mammalian host cells that the vector is being prepared for use as a vaccine carrier in need to be identified and operatively linked to the transgene. "Operatively linked" sequences include both expression control sequences that are contiguous with the nucleic acid sequences that they regulate and regulatory sequences that act in *trans*, or at a distance to control the regulated nucleic acid sequence.

Regulatory sequences include: appropriate expression control sequences, such as transcription inititation, termination, enhancer and promoter sequences; efficient RNA processing signals, such as splicing and polyadenylation signals; sequences that enhance translation efficiency (e.g., Kozak consensus sequences); sequences that enhance protein stability, and optionally sequences that promote protein secretion. Selection of these and other common vector elements are conventional and many suitable sequences are well known to those of skill in the art (see, e.g., Sambrook *et al.*, and references cited therein at, for example, pages 3.18-3.26 and 16.17-16.27 and Ausubel *et al.*, Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989).

In specific embodiments, the promoter is a heterologous promoter (i.e., with respect to the adenovirus sequences) which is recognized by an eukaryotic RNA polymerase. In a preferred embodiment, the promoter is a "strong" or "efficient" promoter. An example of a strong promoter is the immediate early human cytomegalovirus promoter (Chapman *et al*, 1991 *Nucl. Acids Res* 19:3979-3986, which is incorporated by reference). The human CMV promoter can be used without (CMV) or with the intron A sequence (CMV-intA), although those skilled in the art will recognize that any of a number of other known promoters, such as the strong immunoglobulin, or other eukaryotic gene promoters may be used, including the EF1 alpha promoter, the murine CMV promoter, Rous sarcoma virus (RSV) promoter, SV40 early/late promoters and the beta-actin promoter.

Further examples of promoters that can be used in the present invention are the strong immunoglobulin promoter, the EF1 alpha promoter, the murine CMV promoter, the Rous Sarcoma Virus promoter, the SV40 early/late promoters and the beta actin promoter, albeit those

10

15

20

25

30

35

of skill in the art can appreciate that any promoter capable of effecting expression in the intended host can be used in accordance with the methods of the present invention. The promoter may comprise a regulatable sequence such as the Tet operator sequence. Sequences such as these that offer the potential for regulation of transcription and expression are useful in instances where repression of gene transcription is sought.

Suitable gene expression cassettes will also comprise a transcription termination sequence. A preferred transcriptional terminator is the bovine growth hormone terminator. The promoter/transcription termination combination of CMVintA-BGH terminator is particularly preferred although other promoter/terminator combinations may also be used. As shown herein, the bovine growth hormone termination/polyadenylation signal (bGHpA) or short synthetic polyA signal (SPA) of 50 nucleotides in length defined as follows:

AATAAAAGATCTTTATTTTCATTAGATCTGTGTGTT-GGTTTTTTGTGTG (SEQ ID NO:26). Generally speaking, exemplify suitable termination sequences. The polyA signal is inserted following the nucleic acid sequence which comprises the transgene and before the 3' adenovirus ITR sequence.

The recombinant adenoviral vectors described herein may contain adenoviral sequences derived from one or more strain of adeonvirus. Suitable sequences may be obtained from natural sources, produced recombinantly, synthetically, or by other genetic engineering or chemical methods. In a particular embodiment, the recombinant chimpanzee adenovirus is a chimeric recombinant comprising non-chimpanzee adenoviral polynucleotide sequences. Suitable non-chimpanzee adenoviral sequences can be obtained from human adenoviral strains. For example, the native E4 region can be replaced by hAd5 E4 (Ad5 nt 32816 to nt 35619) or by Ad5E4orf6 (Ad5 nt 33193 to nt 34077) (Ad5 GenBank Accession No: M73260).

Generally speaking, the immunogen (antigenic molecule) delivered by the recombinant adenoviral vector of the invention comprises a polypeptide, protein, or enzyme product which is encoded by a transgene in combination with a nucleotide sequence which provides the necessary regulatory sequences to direct transcription and/or translation of the encoded product in a host cell. The composition of the transgene depends upon the intended use of the vector. For example, if the immunogenic composition is being designed to elicit an antibody response or a cell-mediated immune response in a mammalian host which is specific for an infectious agent, then it is appropriate to utilize a nucleic acid sequence encoding at least one immunogenic product that is predicted to confer pathogen-specific immunity to the recipient. Alternatively, if the composition is being prepared for use as a cancer vaccine, a suitable transgene may comprise an immunogenic portion of a self-antigen, such as a TAA, which has been selected with the goal of eliciting a protective immune response of sufficient potency to

#### ITR0048PV

5

10

15

20

25

30

35

both break host tolerance to a particular TAA and to elicit a long-lived (e.g., memory) response that will be sufficient to prevent the initiation of cancer or to prevent tumor progression. Accordingly, suitable immunogenic gene products may be obtained from a wide variety of pathogenic agents (such as, but not limited to viruses, parasites, bacteria and fungi) that infect mammalian hosts, or from a cancer or tumor cell. Although, the invention is illustrated herein with a particular set of test immunogens it is to be understood that the invention is not limited to the use of the antigens exemplified herein. More specifically, the invention contemplates the use of both heterologous and self-antigens as immunogens, including but not limited to TAAs.

In one embodiment, the invention provides an immunogenic composition (e.g., a vaccine) for inducing an immune response against antigens (i.e., immunogens) expressed by an infectious agent. For example, it is desirable to elicit an immune response against a virus infecting humans and/or non-human animal species. Examples of virus families against which a prophylactic and/or therapeutic immune response would be desirable include the *Picornaviridae* family which includes six different genera such as Aphtovirus, Cardiovirus, Enterovirus, Hepatovirus, Parechovirus, Rhinovirus. Examples of Picornavirus against which an immuneresponse would be desirable are: Foot-and-mouth disease viruses, Encephalomyocarditis viruses, Polioviruses, Coxackieviruses, Human hepatitis A virus, Human parechoviruses, Rhinoviruses. *Caliciviridae* family includes different genera associated with epidemic gastroenteritis in humans caused by the Norwalk group of viruses and other syndromes in animals like the hemorrhagic disease in rabbits associated with rabbit hemorrhagic disease virus or respiratory disease in cats caused by feline calicivirus.

Another family of viruses, against which it may be desirable to elicit an immune response is the *Astroviridae* which comprises viruses isolated from humans as well as many different animal species. Human astroviruses are associated with gastroenteritis and young children diarrhea. Alternatively, it may be desirable to confer mammalian hosts with immunity to members of the *Togaviridae* family of viruses which comprises two genera: alphavirus and rubivirus. Alphaviruses are associated with human and veterinary diseases such as arthritis (i.e. Chikungunya virus, Sindbis virus) or encephalitis (i.e. Eastern Equine Encephalitis Virus, Western Equine Encephalitis Virus).

Rubella virus provides an alternative viral target against which is the only member of the Rubivirus genus is responsible for outbreaks of a mild exanthematic disease associated with fever and lymphoadenopathy. Rubella virus infection is also associated with fetus abnormalities when acquired by mother during in early pregnancy. *Flaviviridae* is an other virus family consisting of three genera: the flaviviruses, the pestiviruses and the hepaciviruses that includes important human as well as animal pathogens. Many of the flavivirus genus members

10

15

20

25

30

35

are arthropod-borne human pathogens causing a variety of diseases including fever, encephalitis and hemorrhagic fevers. Dengue Fever Viruses, Yellow Fever Virus, Japanese Encephalitis Virus, Wst Nile Fever Virus, Tick-borne Encephalitis Virus are pathogens of major global concern or of regional (endemic) concern. Pestivirus genus includes animal pathogens of major economic importance such as Bovine Viral Diarrhea Virus, Classical Swine Fever Virus, Border Disease Virus. Hepatitis C Virus is the only member of the Hepacivirus genus responsible for acute and chronic hepatitis. HCV proteins expressed by a recombinant adenovirus can elicit a protective as well as therapeutic immune response limiting the consequences of a viral infection affecting 170 million people worldwide.

Alternatively, antigens derived from members of the *Coronaviridae* family can be expressed by recombinant adenovirus vectors in order to obtain protection against infection. Protection against the severe acute respiratory syndrome coronavirus (SARS-Co Virus) can be obtained by immunizing with one or more chimpanzee adenovirus choosen from the group including ChAd3, 4, 5,6, 7,9,10,11,16,17,19, 20 expressing one or more SARS-CoV protein including without limitations nucleocapsid (N) protein, polymerase (P) protein, membrane (M) glycoprotein, spike (S) glycoprotein, small envelope (E) protein or any other polypeptide expressed by the virus. *Rhabdoviridae* family members including rabies virus can be target of recombinant vaccine expressing viral proteins.

Other possible targets include the Filoviridae family comprising Ebola-like viruses and Marburg-like viruses genera, that is responsible of outbreaks of severe hemorrhagic fever; the Paramyxoviridae family comprising some of the most prevalent virus known in humans like measles, respiratory syncytial, parainfluenza viruses and viruses of veterinary interest like Newcastle disease and rinderpest viruses; the Orthomyxoviridae family including Influenza A,B,C viruses; Bunyaviridae family mainly transmitted by arthropod to vertebrate hosts comprising important human pathogens like Rift valley fever, Sin Nombre, Hantaan, Puumala viruses; Arenaviridae family comprising Lymphocytic choriomeningitis, Lassa fever, Argentine Hemorragic fever, bolivian Hemorragic fever viruses; Bornaviridae family comprising viruses causing central nervous system diseases mainly in horses and sheep; Reoviridae family including rotaviruses, the most important cause of severe diarrheal illness in infants and young children worldwide, orbiviruses that can affect both humans and other mammals (bluetongue, epizootic hemorrhagic disease viruses); Retroviridae family, a large group of viruses comprising important human pathogens like human immunodeficiency virus 1 and 2 (HIV-1 and HIV-2) and human t-cell leukemia virus type 1 and 2 (HTLV 1 and 2) as well as non-human lentivirus such as Maedi/Visna viruses affecting sheep and goats, Equine infectious anemia virus affecting horses, bovine immunodeficiency virus affecting cattle, feline immunodeficiency virus affecting

20

25

30

cats; Polyomaviridae family groups small DNA oncogenic viruses, prototype viruses are polyoma and SV40 infecting mouse and rhesus monkey respectively, (BK and JC viruses closely related to SV40 were isolated from human patients); *Papillomaviridae* family consists of a group of DNA viruses infecting higher vertebrates including humans generating warts and condylomas.

- Papilloma viral infection is associated with the development of cancer in both humans and animals. Human papilloma viruses are associated with cervical cancer, vaginal cancer and skin cancer. The herpesviridae famils includes subfamilies in which are classified a number of important pathogens for humans and other mammals. Suitable sources of antigens can be but are not limited to herpes simplex viruses 1 and 2, varicella-zoster virus, Epstein-Barr virus,
- Cytomegalovirus, human herpesviruses 6A,6B and 7, Kaposi's sarcoma-associated herpesvirus. Further suitable source of antigens are members of the Poxviridae family like Monkeypox virus, Molluscum contagiusum virus, smallpox virus; Hepatitis B virus, the prototype member of the hepadnaviridae family as well as other virus causing acute and/or chronic hepatitis like hepatitis delta virus, hepatitis E virus.

  The adenoviral vectors of the second of

The adenoviral vectors of the present invention are also suitable for the preparation of immunogenic compositions designed to stimulate an immune response in humans or animals against protein expressed by non-viral pathogens including bacteria, fungi, parasites pathogens For example, the vectors disclosed herein can be used to prepare vaccines against, but not limited to: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Vibrio cholerae, Clostridium tetani, Neisseria meningitis, Corynebacterium diphteriae, Mycobacteria tuberculosis and leprae, Listeria monocytogenes, and Legionella pneumofila. Examples of fungi and mammalian parasites for which it may be desirable to prepare prophylactic or therapeutic vaccines include: Candida albicans, Aspergillus fumigatus, Histoplasma capsulatum, Plasmodium malariae, Leishmania major, Trypanosome cruzi and brucei, Schistosoma haematobium, mansoni and japonicum; Entamoeba histolytica, and numerous species of Filaria known to be responsible for human filariasis.

Cancer typically involves the deregulation of genes that encode polypeptides which contribute to maintaining cell cycle or controlling cell proliferation (e.g., growth factors, oncogenes, receptors and tumor suppressors). The products of many of the genes implicated in cancer are expressed on the surface of a wide variety of tumor cells. A variety of tumor antigens that may be recognized by T and B lymphocytes have been identified in human and animal cancer. The vast majority of human tumor-associated antigens (TAAs) that are suitable for use in an anticancer vaccine trial are described as "self-antigens" due to the fact that in addition to being expressed on tumor cells they also are expressed on normal tissue and/or during fetal

10

15

20

25

30

35

development. Immunotolerance of the target population to TAAs may explain why many cancer vaccines have proven to be ineffective.

Tumor antigens can be produced by oncogenic mutants of normal cellular genes altered proto-oncogenes or tumor suppressor genes such as Ras, p53 or Bcr-Abl protein are examples of altered cellular proteins that can stimulate T/B cell response. Tumor antigens can be normal cellular proteins that are overexpresses in tumor cells (tyrosinase, GP100, MART are normally expressed at low levels in melanocytes and overexpressed in melanoma) or aberrantly expressed in tumor cells (MAGE, BAGE, GAGE expressed in melanomas and many carcinomas but normally expressed in the testis and placenta). Tumor antigens can be products of oncogenic viruses: papillomavirus E6 and E7 proteins expressed by cervical carcinomas; EBV EBNA-1 protein produced by EBV+ lymphomas and nasopharyngeal carcinomas; SV40 T antigen in SV40 induced experimental tumors. Oncofetal antigens are expressed to high levels on cancer cells and in normal developing (fetal) tissues but not in adult tissues. Carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) are examples of well characterized oncofetal antigens.

Recent evidence supports the existence of TAAs that are capable of eliciting an immune response, thus making this class of antigens suitable immunogens for vaccine therapy. However, as a class of antigens TAAs are notoriously poor immunogens and T cells that are highly specific for TAAs are either deleted or anergized during T-cell development. Accordingly, there is an expectation that the immune response of a tumor-bearing host to a particular TAA will be extremely weak. Because of the inherent need to break host tolerance to a target TAA experimental clinical vaccine studies are particularly focused on developing immunization strategies that will enhance TAA-specific T-cell responses. Generally, speaking an effective cancer vaccine must both overcome immunotolerance and enhance host's immune response to a level that is preventitive and/or protective. Anti-tumor effects in many experimental vaccine studies have been correlated with T-cell responses to TAAs.

In an alternative embodiment, the invention contemplates an immunogenic composition (e.g., a cancer vaccine) which can be used to induce an immune response against tumor antigens. A suitable composition would contain a recombinant chimpanzee adenovirus comprising nucleic acid sequence encoding a tumor antigen and a physiologically acceptable carrier. In a particular embodiment, the coding sequence element of the cassette may encode a single immunogen, such as an immunogenic peptide sequence derived from a self-antigen, such as a tumor-associated antigen. In some embodiments, the nucleic acid sequence encoding the immunogen (i.e., the transgene) may be codon optimized for expression in a particular mammalian species. In other embodiments, the coding sequence may encode more than one immunogen, such as one or more codon optimized tumor antigens. For example, a cancer

vaccine utilizing the disclosed adenoviral vectors may encode a combination of self-antigens such as: HER2/neu, CEA, Hepcam, PSA, PSMA, Telomerase, gp100, Melan-A/MART-1, Muc-1, NY-ESO-1, Survivin, Stromelysin 3, Tyrosinase, MAGE3, CML68, CML66, OY-TES-1, SSX-2, SART-1, SART-2, SART-3, NY-CO-58, NY-BR-62, hKLP2, VEGF.

5

10

15

Development of an effective cancer vaccine requires the identification of a strategy that will elicit antigen-specific immunity in vaccinated patients and the generation of an immune response that will persist after active immunization has ended. The success of the strategy will depend on whether a measurable immune response directed against a target antigen will correlate with protection against cancer occurrence or relapse. The effector mechanisms of both cell-mediated immunity and humoral immunity have been show to kill tumor cells. However, data from experimental systems suggest that antigen-specific T cells represent the most powerful immunologic mechanism for the elimination of tumor cells. Recognition of tumorspecific antigens (e.g., TAAs) by effector T-cells is predicted to allow the TAA to function as a tumor-rejection antigen. Published studies suggest that stimulation of CD8+ and CD4+ helper Tcell responses are important for achieving optimal tumor clearance ((Greenberg, P. D. (1991) Adv. Immunol. 49: 281-355; Pardoll, D. M. et al. (1998) Curr. Opin. Immunol. 10: 588-94). Clinical response (i.e., efficacy) has been associated with increases in interferon  $\gamma$ -secreting cytotoxic T cells. The advent of assays, such as the ELISPOT assay used herein, to demonstrate the efficacy of the instant vaccine carriers, allows investigators to measure T-cell responses to vaccination regimens and thereby facilitates the development of cancer vaccines.

20

25

Cancer vaccines can be either prophylactic or therapeutic. The general assumption underlying the prophylactic use of cancer vaccines is that TAAs are extremely weak immunogens or functionally nonimmunogenic in tumor-bearing subjects. More specifically, in the field of cancer immunology, vaccines can be used as immunotherapy in patients afflicted with cancer. Accordingly, cancer vaccines can be designed to elicit an immune response that is that is directed against a TAA that is expressed by a pre-existing tumor or malignancy. Thus, in particular embodiments, therapeutic cancer vaccines are intended for use in tumor-bearing patients who have developed resistance to conventional regimens of treatment or who have a high probability of developing a recurrence following conventional treatment.

30

35

The high immunogenicity of adenoviruses, make adenoviral vectors particularly good candidates for use in the context of a vaccine carrier designed to break host tolerance to a self-antigen. The phenomenon of epitope or determinant spreading, which was first described in autoimmune diseases, has been associated with both MHC class I- and MHC class II-restricted responses and correlated to the development of HER-2/neu protein-specific T-cell immunity. Epitope spreading represents the generation of an immune response to a particular portion of an

24

10

15

20

25

30

35

immunogenic protein followed by the natural spread of immunity to other antigenic determinants present on the same protein. For example, Disis *et al.* observed epitope spreading in 84% of patients afflicted with HER-2/neu overexpressing malignancies who were administered vaccines comprising peptides derived from potential T-helper epitopes of the HER-2 protein mixed with granulocyte-macrophage colony stimulating factor (*J. Clin. Oncol.* (2002) 20(11): 2624-2632). Importantly, epitope spreading was correlated with the generation of a HER-2/neu protein domain response and suggests that immunization effectively circumvented immunologic tolerance.

TAAs that are suitable for use in the disclosed adenoviral vectors and methods as a target for a cancer vaccine should possess a number of characteristics. For example, a target TAA must have a favorable expression profile, meaning that it should be preferentially expressed or overexpressed in the tumor or malignant tissue as compared with normal tissue. In addition, because TAAs that play a role in tumorigenesis are more likely to be retained during the different stages of cancer progression, a suitable target TAA should also preserved throughout tumor progression and metastases. Suitable target TAAs should also be expressed homogenously within the tumor. Third, suitable target TAAs must not be subject to absolute immunologic tolerance. More specifically, there should be some evidence that T cells which can both recognize and respond to the TAA of interest have not been entirely deleted from the host's T-cell repertoire (Berinstein, N. L., J. Clin. Oncol. 29(8): 2197 (2002).

Carcinoembryonic antigen (CEA) has many characteristics which make it an attractive TAA for use as a target antigen for an anticancer vaccine. It is a member of the Ig superfamily which is characterized by a favorable expression pattern. It is expressed in more than 50% of all human cancers and has been implicated in the tumorigenesis process, which suggests that its expression may be selected and conserved throughout cancer progression. In addition, it has been established that immunologic tolerance to CEA is not absolute. Published studies establish that human T cells can recognize, become activated to, and lyse cancer cells that express CEA (Berinstein, N. L., J. Clin. Oncol. 29(8): 2197 (2002). For example, the immunization of patients with recombinant vaccinia virus expressing CEA, combined with subsequent peptide-based in vitro stimulations, generated CD8+ MHC-restricted CTLs capable of lysing autologous tumors (Tsang, K. Y. et al. J. Natl. Cancer Inst., (1995) 87:982-990). Alternatively, immunization of colorectal carcinoma patients after surgery with recombinant CEA was reported to induce weak antibody and cellular responses to recombinant CEA (Samanci, A., et al. (1998) Cancer Immunol. Immunother. 47: 131-142.) Further, the administration of anti-CEA anti-idiotypic antibody to patients diagnosed with colorectal cancer generated anti-CEA antibodies and idiotype-specific T-cell proliferation (Foon, L, A. et al.

10

15

20

25

30

35

(1995) J. Clin. Invest..., 96: 334-342). The literature also indicates that tolerance to CEA in cancer patients can be overcome with several different vaccination approaches (i.e., vaccination with recombinant CEA or recombinant orthopox or avipox-CEA viruses, administration of anti-idiotype antibodies, pulsing dendritic cells with CEA agonist epitopes).

CEA is an oncofetal glycoprotein that is expressed in normal fetal colon and to a much lesser extent in normal colonic mucosa. It is also overexpressed in the vast majority of adenocarcinomas, particularly those of the colon, pancreas, breast, lung, rectum and stomach. Many colorectal cancers and some carcinomas produce high levels of CEA that are measurable in sera, which makes it one of the most widely used serological markers of malignancy, especially in patients with colorectal cancer.

A second TAA which provides a suitable immunogen for use in the compositions and methods of the invention is product of the HER2/erb-2 (also called neu) proto-oncogene. Like, CEA, HER2/neu has a favorable expression pattern and is not subject to absolute tolerance. More specifically, low levels of expression of the HER2/neu transcript, and the 185 kD polypeptide product, are detected in normal adult epithelial cells of various tissues, including the skin and breast, and tissues of the gastrointestinal, reproductive, and urinary tracts; higher levels of expression are detected in the corresponding fetal tissues during embryonic development (Press et al., Oncogene 5: 953-962 (1990). Several lines of evidence suggest a link between the amplification of HER-2 and neoplastic transformation in human breast, lung, prostate, ovarian, endometrial and colorectal tumors (Disis and Cheever, Adv. Cancer Research 71: 343-371(1997). Generally speaking, overexpression of HER2/neu correlates with a poor prognosis and a higher relapse rate for cancer patients (Slamon et al., Science 244: 707-712 (1989). Thus, a vaccine specific for the HER-2/neu protein could have wide application and utility in the prevention of disease recurrence in many different human malignancies.

HER2/neu encodes a transmembrane glycoprotein possessing intrinsic tyrosine kinase activity and displaying extensive homology to the epidermal growth factor (EGF) receptor (Akiyama, T et al., (1986) Science 232: 1644-1646). One of the first clinical studies which utilized HER2 as target for cancer immunotherapy employed the HER-2-specific monoclonal antibody Herceptin for the treatment of breast cancer (Goldenberg MM (1999) Clin. Ther. 21: 309-318). This led to subsequent efforts which focused on the use of HER-2 as a target for the T-cell arm of the immune system to elicit effective antitumor responses, including the use of recombinant fusion proteins comprising HER-2 domains to activate autologous antigen presenting cells. Published reports establish that numerous cancer patients afflicted with neuexpressing mammary and ovarian cancers mount immune responses (e.g., produce antigen-specific antibody and T-cells) against the protein product of the HER2/neu oncogene.

10

15

20

25

30

35

Assembly of the recombinant adenoviral sequences, transgene and other vector elements into various intermediate plasmids and shuttle vectors, and the use of the plasmids and vectors to produce a recombinant viral particle are all achieved using conventional techniques as described in standard textbooks that are well known to those of skill in the art (Sambrook *et al*, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY (1989). Such techniques include, but are not limited to conventional cDNA cloning techniques, use of overlapping oligonucleotde sequences derived from the adenoviral genome, homologous recombination, polymerase chain reaction, standard transfection techniques, plaquing of viruses in agar overlay and other related methodologies.

To assist in preparation of polynucleotides in prokaryotic cells, a plasmid version of the adenovirus vector is often prepared (adenovirus pre-plasmid). The adenovirus pre-plasmid contains an adenoviral portion and a plasmid portion. The adenoviral portion is essentially the same as the adenoviral portion contained in the adenoviral vectors of the invention (containing adenoviral sequences with non-functional or deleted E1 and optionally E3 regions) and an immunogen expression cassette, flanked by convenient restriction sites.

The plasmid portion of the adenovirus pre-plasmid often contains an antibiotic resistance marker under transcriptional control of a prokaryotic promoter so that expression of the antibiotic does not occur in eukaryotic cells. Ampicillin resistance genes, neomycin resistance genes and other pharmaceutically acceptable antibiotic resistance markers may be used. To aid in the high level production of the polynucleotide by fermentation in prokaryotic organisms, it is advantageous for the adenovirus pre-plasmid to contain a prokaryotic origin of replication and be of high copy number. A number of commercially available prokaryotic cloning vectors provide these benefits. It is desirable to remove non-essential DNA sequences. It is also desirable that the vectors not be able to replicate in eukaryotic cells. This minimizes the risk of integration of polynucleotide vaccine sequences into the recipients' genome. Tissue-specific promoters or enhancers may be used whenever it is desirable to limit expression of the polynucleotide to a particular tissue type.

Adenovirus pre-plasmids (plasmids comprising the genome of the replication-defective adenovirus with desired deletions and insertions) can be generated by homologous recombination using adenovirus backbones DNA and an appropriate shuttle vector (designed to target-in specific deletions and incorporate desired restriction sites into the resultant plasmid). Shuttle vectors of use in this process can be generated using general methods widely understood and appreciated in the art, e.g., PCR of the adenoviral terminal ends taking into account the desired deletions, and the sequential cloning of the respective segments into an appropriate cloning plasmid. The adenoviral pre-plasmid can then be digested and transfected into the

10

15

20.

25

30

35

complementing cell line via calcium phosphate co-precipitation or other suitable means. Virus replication and amplification then occurs, a phenomenon made evident by notable cytopathic effect. Infected cells and media are then harvested after viral replication is complete (generally, 7-10 days post-transfection).

Generally speaking, following the construction and assembly of the desired adenovirus pre-plasmids, adenovirus pre-plasmids are rescued into virus by transfecting an adenoviral E1-expressing human cell line. Complementation between the packaging cell line and the viral genes of the vector permits the adenovirus-transgene sequences in the vector to be replicated and packaged into virion capsids, resulting in the production of recombinant adenoviruses. The resulting viruses may be isolated and purified by any of a variety of methods known to those of skill in the art for use in the methods of the invention.

It will be readily apparent to those of skill in the art that when one or more selected deletions of chimpanzee adenoviral genes are introduced into a viral vector, the function of the deleted gene product can be supplied during the production process by sequences present in the production cell line. Thus, the function of the manipulated genes can be provided by a permanently transformed cell line that is characterized by some or all of the adenoviral functions which are required for packaging but which are not functional in the vector (e.g., any of E1A, E1B, E2A, E2B E4). Alternatively, the requisite adenoviral functions can be provided to a suitable packaging cell line by infecting or transiently transfecting a suitable cell with a construct comprising the requisite gene to provide the function.

Accordingly, the present invention also provides a method of producing chimpanzee adenoviral vectors in E1-expressing human cell lines. More specifically, the disclosed vectors can be propagated in an E1 complementing cell lines, including the known cell lines 293 and PER.C6<sup>TM</sup>. Both these cell lines express the adenoviral E1 gene product. PER.C6<sup>TM</sup> is described in WO 97/00326, published January 3, 1997, which is hereby incorporated by reference. It is a primary human retinoblast cell line transduced with an E1 gene segment that complements the production of replication deficient first generation adenoviruses, but is designed to prevent generation of replication competent adenovirus by homologous recombination. 293 cells are described in Graham *et al* (1977) *J. Gen. Virol* 36:59-72, which is also hereby incorporated by reference. One of skill in the art will recognize the term "first generation adenovirus" refers to a replication deficient adenovirus which has either a nonfunctional or deleted E1 region, and optionally a non-functional or deleted E3 region.

Batches of replication-defective adenoviral vectors that are intended for use as a vaccine composition in a clinical trial should be proven to be free of RCA (Fallaux, F.J. et al (1998) Humm Gene Therapy, 9:1909-1917). In practice, this is a labor intensive process which

10

15

20

25

30

35

requires establishing and utilizing an expensive screening program. One of skill in the art will acknowledge that a high frequency of RCA generation not only results in a high failure rate for the batches produced, but also severely limits scale-up efforts. Elimination of sequence homology between the nucleotide sequence of the vector and the adenoviral sequences present in the genome of the helper production/packaging cell line should eliminate the possibility of producing batches of vector that are contaminated with RCAs produced by homologous recombination.

Typically, recombinant replication-defective adenoviral vectors are propagated in cell lines that provide E1 gene products *in trans*. Supplementation of the essential E1 gene products *in* trans is very effective when the vectors are from the same or a very similar serotype. For example, it is well-known that E1-deleted (i.e. ΔΕ1) group C serotype (Ad2 and Ad5) vectors, can be propagated in 293 or PER.C6 cells which contain and express the Ad5 E1 region. However, it has been observed that Ad5 E1 sequences present in the 293 and PER.C6 production cells may not always fully complement the replication of non-group C serotypes. Accordingly, E1-deleted serotypes outside of subgroup C, for example those from subgroups A, B, D, E, and F may replicate with a lower efficiency respect to the corresponding wt virus or may not replicate at all in 293 or PER.C6 cells. This may be due to the inability of the Ad5 (group C) E1B 55K gene product to establish a functional interaction with the E4 orf6 gene product of the non-group C serotypes.

The decrease in replication efficiency in cells expressing Ad5 E1 is variable considering vectors of different subgroups. While  $\Delta$ E1 vectors deriving from subgroup D and E adenovirus can be rescued and propagated in 293 and Per.C6<sup>TM</sup> cells with variable efficiency, the propagation  $\Delta$ E1 vectors of subgroup B is completely impaired (Vogels R, et. al. (2003) Aug. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol.; 77 (15):8263-71).

Although the interaction between Ad5 E1b 55k and vector-expressing E4 orf6 protein is conserved within members of the same subgroup, it may be not sufficiently stable when E4 orf6 protein of a non-C serotype is expressed. This inefficient or unstable formation of E1B-55K/E4-orf6 complex lead to an absent of reduced propagation of the ΔE1 vector. Accordingly, it has been empirically determined that in order to successfully and efficiently rescue recombinant adenovirus of groupB serotypes, a cell line expressing the E1 region of the serotype of interest may need to be generated. In cells expressing Ad5E1 like 293 or Per.C6<sup>TM</sup>, the expression can be limited to E1b 55K protein. Alternatively, a suitable Ad5E1-expressing cell lines could be modified to express the entire Ad5 E4 region (or E4 orf6 only) in addition to

10

15

20

25

30

35

Ad5E1. The generation of cell lines expressing both Ad5 E1 and orf6 are useful in complementing alternative adenovirus serotypes; see, e.g., Abrahamsen et al., 1997 J. Virol. 8946-8951. The incorporation of E4 (orf6) into Ad5 complementing cell lines, is known, as is the generation of serotype-specific cell lines providing a serotype-specific E1 gene product(s) in trans. Alternatively, the efficiency of non-group C vector propagation may be improved by modification of the viral backbone by substituting the native E4 region with Ad5 orf6. Similar results can be achieved by substituting the only the native orf6 with orf6 deriving from Ad5 or other subgroup C viruses (Ad1, Ad2, Ad6).U.S. Patent No. 5,849,561 discloses complementation of an E1-deleted non-group C adenovirus vector in an Ad5-E1 complementing cell line which also expresses portions of the Ad5-E4 gene.

U.S. Patent No. 6,127,175, issued to Vigne, et al., discloses a stably transfected mammalian cell line which expresses a portion of the E4 region of adenovirus, preferably orf6/orf6/7. Such a cell line is useful for complementation of recombinant Ad genomes deficient in the E4 region.

Compositions, including vaccine compositions, comprising the disclosed adenoviral vectors are an important aspect of the present invention. These compositions can be administered to mammalian hosts, preferably human hosts, in either a prophylactic or therapeutic setting. Potential hosts/vaccinees include but are not limited to primates and especially humans and non-human primates, and include any non-human mammal of commercial or domestic veterinary importance. Compositions comprising recombinant chimpanzee adenoviral vectors may be administered alone or in combination with other viral- or non-viral-based DNA/protein vaccines. They also may be administered as part of a broader treatment regimen.

In a particular embodiment of the invention, the disclosed vectors may be used in an immunization protocol designed to break host tolerance to a self-antigen or a tumor-associated antigen. The identification of a number of TAA has enabled the development of active vaccination approaches for the therapy of cancer. Both cell surface antigens and intracellular antigens that are processed and presented provide useful targets. Generally speaking, the disclosed method of breaking host tolerance to a self-antigen comprises: (a) stimulating an antigen-specific response to a self-antigen by administering a first vaccine composition comprising a first ChAd vector or a plasmid vector carrying a nucleotide sequence encoding the self-antigen against which an antigen-specific immune response is desired, and (b) sustaining and expanding the immune response of (a) by administering a second vaccine composition comprising a recombinant ChAd vector of a different serotype containing at least a functional deletion of its genomic E1 gene, and in the site of the E1 gene, a sequence comprising a promoter capable of directing the expression of DNA encoding the same self-antigen delivered in the

10

15

20

25

30

35

priming step, whereby the host mounts an immune response which has the effect of breaking tolerance to the self-antigen.

Accordingly, a skilled artisan can utilize this disclosure to design several different immunization protocols that may be suitable for use to break host tolerance. For example, it may be possible to utilize a protocol in which the first, or priming immunization comprises plasmid DNA which encodes a particular self-antigen, such as a TAA, and any subsequent immunizations comprise a ChAd vector. Plasmid DNA sequences comprising nucleotide sequences that encode self-antigens, may be delivered intramuscularly, with or without electrostimulation, in one or more injections. For example, an immunization protocol based on multiple (e.g., 3 or 4 or 5) intramuscular injections of plasmid DNA encoding a TAA via electroporation followed by one or more intramuscular injections of a ChAd vector comprising a transgene encoding the same TAA is encompassed by the general method disclosed and claimed herein.

Alternatively, a suitable protocol to break tolerance could involve one or more priming immunizations with a ChAd or hAd vector comprising a transgene encoding a self antigen, followed by one or more boosting immunizations with either the same, or a different ChAd vector that is know to be non cross-reactive with the vector used for the priming immunization(s). For example, an immunization protocol using ChAd3 for priming and ChAd6 for boosting, or ChAd3 for priming followed by ChAd6 and ChAd9 for boosting could be used to break host tolerance. In particular embodiments, the invention contemplates the use of selfantigens comprising at least one tumor associated antigen selected from the group consisting of: HER2/neu, CEA, EpCAM, PSA, PSMA, Telomerase, gp100, Melan-A/MART-1, Muc-1, NY-ESO-1, Survivin, Stromelysin 3, Tyrosinase, MAGE3, CML68, CML66, OY-TES-1, SSX-2, SART-1, SART-2, SART-3, NY-CO-58, NY-BR-62, hKLP2, VEGF. In a particular embodiment, the invention provides a method for inducing an immune response (e.g., humoral or cell-mediated) to a tumor-associated antigen which is specific for a selected malignancy by delivering a recombinant chimpanzee adenovirus encoding the TAA to a mammal afflicted with cancer. In a preferred embodiment of this aspect of the invention the elicited immune response constitutes an immune response characterized by the production of antigen-specific CD4+ and CD8+ T cells.

The immunogenic compositions of the invention can be administered to mammalian hosts, preferably human hosts, in either a prophylactic or therapeutic setting. Potential hosts/vaccinees include but are not limited to primates and especially humans and non-human primates, and include any non-human mammal of commercial or domestic veterinary importance. Compositions comprising recombinant chimpanzee adenoviral vectors may be

10

15

20

25

30

35

administered alone or in combination with other viral- or non-viral-based DNA/protein vaccines. They also may be administered as part of a broader treatment regimen. Suitable compositions, for use in the methods of the invention may comprise the recombinant viral vectors of the invention in combination with physiologically acceptable components, such as buffer, normal saline or phosphate buffered saline, sucrose, other salts and polysorbate. It does not cause tissue irritation upon intramuscular injection. It is preferably frozen until use. Optionally, a vaccine composition of the invention may be formulated to contain other components, such as but not limited to, an adjuvant, a stabilizer, a pH adjusting agent, or a preservative. Such components are well known to those of skill in the art.

It is envisioned that the recombinant chimpanzee adenoviruses of the invention will be administered to human or veterinary hosts in an "effective amount," that is an amount of recombinant virus which is effective in a chosen route of administration to transduce host cells and provide sufficient levels of expression of the transgene to invoke an immune response which confers a therapeutic benefit or protective immunity to the recipient/vaccine.

The amount of viral particles in the vaccine composition to be introduced into a vaccine recipient will depend on the strength of the transcriptional and translational promoters used and on the immunogenicity of the expressed gene product. In general, an immunologically or prophylactically effective dose of  $1\times10^7$  to  $1\times10^{12}$  particles (i.e.,  $1\times10^7$ ,  $2\times10^7$ ,  $3\times10^7$ ,  $5\times10^7$ ,  $1\times10^8$ ,  $2\times10^8$ ,  $3\times10^8$ ,  $5\times10^8$  or  $1\times10^9$ ,  $2\times10^9$ ,  $3\times10^9$ ,  $5\times10^9$ ) and preferably about  $1\times10^{10}$  to  $1\times10^{11}$  particles is administered directly into muscle tissue. Subcutaneous injection, intradermal introduction, impression through the skin, and other modes of administration such as intraperitoneal, intravenous, or inhalation delivery are also contemplated.

The recombinant chimpanzee adenoviral vectors of the present invention may be administered alone, as part of a mixed modality prime/boost vaccination regimen or in a vaccination regimen based on combination of multiple injections of different vector serotypes. Typically, a priming dose(s) comprising at least one immunogen is administered to a mammalian host in need of an effective immune response to a particular pathogen or self-antigen. This dose effectively primes the immune response so that, upon subsequent identification of the antigen(s), the host is capable of immediately mounting an enhanced or boosted immune response to the immunogen. A mixed modality vaccination scheme which utilized alternative formulations for the priming and boosting can result in an enhanced immune response. Prime-boost administrations typically involve priming the subject (by viral vector, plasmid, protein, etc.) at least one time, allowing a predetermined length of time to pass, and then boosting (by viral vector, plasmid, protein, etc.). Multiple immunizations, typically 1-4, are usually employed, although more may be used. The length of time between priming and boost

10

15

20

25

30

35

may typically vary from about four months to a year, albeit other time frames may be used as one of ordinary skill in the art will appreciate. Multiple injection of each vector can be administered within approximately a 2 weeks time frame, before neutralizing immunity becomes evident.

In some embodiments of this invention, a vaccine is given more than one administration of adenovirus vaccine vector, and it may be given in a regiment accompanied by the administration of a plasmid vaccine. Suitable plasmid vaccines for use in combination with the vectors disclosed herein comprise a plasmid encoding at least one immunogen against which a primed or boosted immune response is desired, in combination with a heterologous promoter, which is capable of directing expression of the nucleic acid sequences encoding the immunogen(s), operably linked to the immunogen coding sequence, and a transcription terminator sequence.

For example, a dosing regimen which utilizes multiple injection of different serotypes of recombinant replication-defective chimpanzee adenoviral vectors can be used. Alternatively, an individual may be given a first dose (i.e., a priming dose) of a plasmid vaccine, and a second dose (i.e., a boosting dose) which comprises a replication-defective recombinant chimpanzee adenoviral vector which comprises a coding sequence for the same immunogen that was delivered in the plasmid vaccine. Alternatively, the individual may be given a first dose of a human adenovirus vaccine vector encoding at least one immunogen, followed by a second dose comprising a replication-defective recombinant chimpanzee adenoviral vector disclosed herein, which comprises a coding sequence for the same immunogen that was delivered in the priming dose. In a second alternative embodiment a vaccine composition comprising a vector of the invention may be administered first, followed by the administration of a plasmid vaccine. In any of these embodiments, an individual may be given multiple doses of the same immunogen in either viral vector or plasmid form. There may be a predetermined minimum amount of time separating the administrations.

In addition to a single protein or antigen of interest being delivered by the recombinant, replication-defective chimpanzee adenovirus vectors of the present invention, two or more proteins or antigens can be delivered either via separate vehicles or delivered via the same vehicle. Multiple genes/functional equivalents may be ligated into a proper shuttle plasmid for generation of a adenovirus pre-plasmid comprising multiple open reading frames. Open reading frames for the multiple genes/functional equivalents can be operatively linked to distinct promoters and transcription termination sequences.

As shown herein, suitable immunization regimens can employ different adenoviral serotypes. One example of such a protocol would be a priming dose(s) comprising a recombinant adenoviral vector of a first serotype, for example a ChAd3 or ChAd6 followed by a

boosting dose comprising a recombinant chimpanzee adenoviral vector of a second serotype. In an alternative embodiment, the priming dose can comprise a mixture of separate adenoviral vehicles each comprising a gene encoding for a different protein/antigen. In such a case, the boosting dose would also comprise a mixture of vectors each comprising a gene encoding a separate protein/antigen, provided that the boosting dose(s) administers recombinant viral vectors comprising genetic material encoding for the same or similar set of antigens that were delivered in the priming dose(s). These multiple gene/vector administration modalities can further be combined. It is further within the scope of the present invention to embark on combined modality regimes which include multiple but distinct components from a specific antigen.

10

5

Use of recombinant vectors derived from chimpanzee adenoviruses that are not neutralized by preexisting immunity directed against the viral elements of human vector offers an alternative to the use of human Ad vectors as vaccine carriers. Because adenoviruses are highly immunogenicity, adenoviral vectors are particularly good candidates for use in the context of a vaccine carrier designed to break host tolerance to a self-antigen. Furthermore, the ability to propagate the chimp viruses in human cells, particularly in the Per.C6<sup>TMTM</sup> cell line, with an efficiency comparable to human viruses, offers considerable advantages both from a regulatory point of view and for the large scale production of therapeutics or vaccines. Accordingly, the instant invention provides a collection of chimpanzee adenoviral sequences, vectors and plasmids that allow the preparation of recombinant virus which may be used, alone or in combination, as a vaccine carrier for genetic vaccination.

20

15

All publications mentioned herein are incorporated by reference for the purpose of describing and disclosing methodologies and materials that might be used in connection with the present invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

25

Having described preferred embodiments of the invention with reference to the accompanying drawings, it is to be understood that the invention is not limited to those precise embodiments, and that various changes and modifications may be effected therein by one skilled in the art without departing from the scope or spirit of the invention as defined in the appended claims.

30

The following examples illustrate, but do not limit the invention.

10

15

20

25

30

# EXAMPLE 1 ISOLATION, CLONING, SEQUENCING AND CHARACTERIZATION OF ChAds

#### **Chimpanzee Adenovirus Isolation**

Stool specimens were collected in viral transport medium (VTM; Microtest M4-R Multi-Microbe Transport Medium, Remel Inc.) then frozen or frozen directly at -70°C at NIRC (New Iberia Research Center 4401 W. Admiral Doyle Drive New Iberia, LA 70560). The specimens were kept frozen at < -70°C until they were processed for inoculation into cell cultures. At that time, the specimens were thawed and then vortexed in excess of chilled viral transport medium. After the specimens had dissociated into suspensions, they were centrifuged for 10 min at 1500-1800 rpm. The supernatants were filtered through 0.8 and 0.2 µm syringe filters in series and then the filtered material was inoculated into cell cultures (200-250 µL into shell vials and 250-300 µL into tube cultures). Each processed specimen was inoculated into tube cultures and shell vial cultures seeded with 293 cells or A549 cells.

Control (positive and negative) cultures were prepared each time a set of samples was inoculated. Once all of the shell vials in a set-up had been inoculated, they were centrifuged at room temperature for  $60 \pm 10$  min at 2000 rpm (900 x g). The vials were removed from the centrifuge immediately after the rotor stopped spinning to prevent heat damage in the cultures. After centrifugation, the inocula were aspirated from the shell vials, using a fresh sterile pasteur pipet in each vial to prevent cross-contamination. The cultures were washed three times using 1.0-mL fresh culture medium for each wash. Fresh medium (1.0 mL) was pipetted into each vial after the third wash and the shell vials were placed in an incubator at 35-37°C for three to four days (approx. 96 hr).

At the end of the culture period, the supernatants were aspirated from the cultures and the cell layer in each vial was washed twice with Immunofluorescence Assay (IFA) Buffer using approximately 1.0 mL buffer with each wash. The cells were fixed by adding 1.0 mL refrigerated acetone to each vial (10 min at 2-8°C. Acetone-cleaned slides were labeled with the specimen identification number(s) associated with the shell vial coverslips. The shell vial coverslips were processed for fluorescence labeling of Adenovirus-infected cells using a primary mouse anti-adenovirus antibody [MAB8052, Chemicon]. The slides are evaluated with the aid of a fluorescence microscope. Each preparation was scanned using the 10X objective noting the extent of immunofluorescence coverage across the well (1+ to 4+). The presence or absence of specific immunofluorescence was confirmed using the 40X objective. Tube cultures were inoculated in the same sequence as described for the shell vials (e.g., negative control first, followed by clinical specimens and positive controls). The inocula were allowed to adsorb for

60-120 min at 36-38°C. After the adsorption period, the specimens/controls were aspirated from the tubes and replaced by fresh culture medium.

Three to four days post-inoculation, and once a week thereafter, the media was aspirated from the culture tubes and replaced with 1.5 mL fresh media. Culture tubes were visually monitored for CPE at least every other day for at least 21 days after inoculation. Cultures inoculated with chimp specimens were compared against the controls and rated by observing the CPE extent. Cultures showing no CPE were passed to fresh tube cultures after 14 days; culture tubes that were negative for CPE after 21 days were considered negative. Culture tubes with 3-4+ CPE were vortexed for 10 seconds. The cells were scraped from the wall of the tube using a sterile 1.0 mL serological pipet and suspended in the culture supernatant. After labeling a 5 mL snap cap tube with the specimen identification number and date and stored at -70°C. 500 µL of the cell suspension was transferred from the culture tube into the snap cap tube and stored for up to one day at 2-8°C until it was processed using an indirect immunofluorescent antibody technique to detect adenovirus (equivalent to procedure for staining shell vials).

15

20

25

30

10

5

#### **Chimpanzee Adenovirus Amplification**

Wild type chimp adenoviruses CV32, CV33, CV23 and CV68 purchased from the ATCC (ATCC Accession Numbers: CV32, VR-592; CV-33, VR-593;) or from Esoterix Inc. Austin, Texas and original isolates were propagated as follows by using the human E1-expressing cell line PER.C6<sup>TM</sup> or 293. Briefly, cells were cultivated in Dulbecco's Modified Eagles Medium (DMEM; GibcoBRL, Life Technologies) supplemented with 10% Fetal Bovine Serum (FBS GibcoBRL, Life Technologies), 1% Penicillin-Streptomycin, 2mM Glutamine and 10mM MgCl<sub>2</sub> (Per.C6<sup>TM</sup>). Adenovirus infection was carried out in DMEM supplemented with 5% Horse Serum (GibcoBRL, Life Technologies). Infected cells and medium were collected when 100% of the cells exhibited virus-induced cytopathic effect (CPE) and lysed by three cycles of freezing and thawing.

All wild type chimp adenoviral (CV) stocks were cloned by infecting 293 cells seeded in 96-well plates, after the first passage of amplification. The virus cloning was performed by limiting dilution of the cell lysate obtained at the first passage of the virus amplification. 5 isolated clones were picked up and serially propagated. After 3-4 serial passaging of amplification, a large-scale preparation of adenovirus was performed on cells planted on 5 two-layer cell-factories (NUNC) (200 millions of cells/cell factory). Purified viral particles were obtained from cell lysate by two ultra-centrifugation steps on cesium chloride density gradients.

#### **Sequencing of Viral Genomic DNA**

Genomic DNA was isolated from 3 X 10<sup>12</sup> pp of purified virus preparation by digestion with Proteinase K (0.5 mg/ml) in 1% SDS-TEN (2 hrs at 55°C). After a Phenol-Chloroform extraction and Ethanol precipitation, the genomic DNA was resuspended in water and submitted for genomic sequencing.

For full length Ad genome sequencing, the purified viral DNA was nebulized to produce randomly sheared fragments. The DNA fragments were blunt-ended with the klenow fragment of E.coli DNA polymerase and polynucleotide kinase. The blunt end fragment were run on a low melting point agarose gel to purify the fragments in the size range of 1-3 kb and cloned into the Smal site of pUC19 vector to create a shotgun library. The ligations were used to transform competent XL1-Blue MRF'. Positive colonies were identified by white/blue screening on LB agar containing X-gal and IPTG. Three to four 96-well block of plasmid DNA were isolated from the library and sequenced with pUC forward and reverse primers. All sequencing reads were screened for quality and vector sequence using the Phred-Phrap software package. The reads that passed the screening were assembled into contigs. Primers were designed to directly sequence the adenoviral DNA for closing the gaps and determine the DNA sequence of both ends.

Complete viral genome sequencing was obtained for selected viruses including ChAd3 (SEQ ID NO: 1), ChAd6 (SEQ ID NO: 2) and CV32 (SEQ ID NO:3), CV33 (SEQ ID NO: 4), and CV23 (SEQ ID NO:5). Table 1 provides data summarizing the percentage of identity between the nucleotide sequences of ChAd3, ChAd6, Pan5 (CV23), Pan6 (CV32), Pan7 (CV33), C1 and C68 adenoviral genomes. Alignments were calculated using the ALIGN program as part of the FASTA package version 2 (William R. Penson, University of Virginia; Myers & Miller, CABIOS 1989, 4:11-17).

25

5

10

Table 1. Percentage of Nucleotide Sequence Identity Between Chimpanzee Adenovirus Genomes

	ChAd3	ChAd6	Pan5	Pan6	Pan7	C1	C68
ChAd3	100	68.1	68.5	68.2	68.3	64.2	68.0
ChAd6		100	95.5	94.5	95.5	73.6	91.4
Pan5			100	94.9	96.7	73.9	92.7
Pan6				100	95.1	73.6	91.3
Pan7	·				100	73.8	93.0
C1						100	74.3
C68							100

To characterize the new adenoviral isolates (e.g., ChAd20, ChAd4, ChAd5, ChAd7, ChAd9, ChAd10, ChAd11, ChAd16, ChAd17 and ChAd19) the nucleotide sequence of the hexon and fiber genes were also determined by primer walking. Fiber gene: SEQ ID NOS: 6-15: (SEQ ID NO: 6, ChAd20); SEQ ID NO: 7, ChAd4); SEQ ID NO: 8, ChAd5); SEQ ID NO: 9, ChAd7); SEQ ID NO: 10, ChAd9); SEQ ID NO: 11, ChAd10); SEQ ID NO: 12, ChAd11); SEQ ID NO: 13, ChAd16) SEQ ID NO: 14, ChAd17) and SEQ ID NO: 15, ChAd19). Figures 20A-20D provide a comparison of the amino acid sequences of the fiber proteins of the ChAd isolates disclosed and claimed herein.

The hexon gene sequences are set forth in SEQ ID NOS: 16-25: (SEQ ID NO: 16, ChAd20); SEQ ID NO: 17, ChAd4); SEQ ID NO: 18, ChAd5); SEQ ID NO: 19, ChAd7); SEQ ID NO: 20, ChAd9); SEQ ID NO: 21, ChAd10); SEQ ID NO: 22, ChAd11); SEQ ID NO: 23, ChAd16); SEQ ID NO: 24, ChAd17) and SEQ ID NO: 25, ChAd19). Figures 31A-31M provide a comparison of the amino acid sequences of the hexon proteins of the ChAd isolates disclosed and claimed herein.

#### 20 Chimpanzee Adenovirus Classification

15

25

Classification of the different chimp adenoviral strains follows the already proposed classification of human adenovirus serotypes into 6 subgroups (Horowitz, MS (1990) Adenoviridae and their replication. In Virology B.N. Fields and D.M. Knipe, eds (Raven Press, New York) pp.1679-1740) and it was obtained by amino acid and nucleotide sequence alignment by using Align X program (Informax, Inc).

An initial classification of the new isolates was obtained by looking at the restriction pattern of the viral genome with different restriction endonucleases and by sequence

10

15

20

25

30

analysis of the hypervariable region 7 (HVR7) of the hexon gene. To this end two primers were designed on the highly conserved regions flanking HVR7: TGTCCTACCARCTCTTGCTTGA (SEQ ID NO.45) and GTGGAARGGCACGTAGCG (SEQ ID NO.46). The HVR7 was amplified by PCR using purified viral DNA or crude 293 lysate as template and then sequenced. Based on HVR7 sequence analysis we classified the new isolated viruses into the subgroups (A-F) proposed for human Ad viruses (Horowitz, MS (1990) Adenoviridae and their replication. In Virology B.N. Fields and D.M. Knipe, eds (raven Press, New York) pp.1679-1740).

The phylogenetic tree presented in Figure 35 was obtained by alignment of human and chimp adenovirus hexon amino acid sequences. The results are consistent with the initial classification based on nucleotide sequence alignment limited to hexon HVR7 by using Align X program (Informax, Inc). The tree was deduced from a multiple sequence alignment of fulllength hexon peptide sequences using a PAUPSEARCH (Wisconsin Package Version 10.3, Accelrys Inc.) and visualized and manipulated with TREEVIEW. Bootstrap confidence analysis was performed using the PAUPSEARCH program as implemented in the Wisconsin Package. For each of the alignments the program was run on 1000 replicates using "Heuristic Search" as

search criterion and Maximum Parsimony as the optimality criterion and confidence values reported were taken from a 50% majority-rule consensus.

### **EXAMPLE 2 ChAd SHUTTLE VECTOR AND EXPRESSION VECTOR** CONSTRUCTION AND RESCUE

#### **Vector Construction and Rescue**

Genomic viral DNA was cloned into a standard plasmid vector by homologous recombination with an appropriate shuttle vector containing viral DNA sequences derived from both left and right end of viral genome (Figure 2). As described more fully below, the sequence homology observed between viruses classified in the same serotype subgroup was exploited to develop group-specific shuttle vectors. Genomic viral DNA of Chimp adenovirus classified into subgroup D and E resulted to be sufficiently homologous to allow the construction of a common shuttle vector in order to clone viruses belonging to both subgroups.

#### Construction of a Subgroup D/E Shuttle Vector

The ChAd6 viral genome was fully sequenced (SEQ ID NO: 2) and the information obtained was used to construct a shuttle vector to facilitate cloning by homologous recombination of subgroup D and E chimpanzee adenovirus.

Construction of the ChAd6 shuttle vector, referred to herein as

pARS ChAd6-3 is described in Figure 1. Figure 32 provides a list of the oligonucleotide sequences (SEQ ID NOS: 26-40 and SEQ ID NOS: 45-46) used in the cloning experiments described herein. Briefly, 457 bp deriving from the left end of ChAd6 DNA were amplified by PCR with the oligonucleotides 5'-ATGGAA

- 5 TTCGTTTAAACCATCAATAATATACCTC-3 (SEQ ID NO: 27) and 5'- CGCTGGCACTCAAGAGTGGCCTC-3' (SEQ ID NO: 28) digested with EcoRI and SnaBI and cloned into pNEBAd35-2 cut EcoRI-SnaBI, generating pNEBChAd6-LI. The right ChAd6 ITR (bp 36222 to bp 36648) was amplified by PCR using the oligonucleotides: 5'- ATGAAGCTTGTTTAAACCCAT CATCAATAATATACCT-3'
- (SEQ ID NO: 29) and 5'- ATCTAGACAGCGTCCATAGCTTACCG-3' (SEQ ID NO: 30) digested with restriction enzymes HindIII and XbaI and cloned into pNEBChAd6-LI HindIII-XbaI digested thus generating pNEBChAd6-RLI. Finally, the DNA fragment corresponding to nucleotides 3426-3813 of the ChAd6 genomic DNA sequence was amplified with the olinucleotides:

SnaBI and AscI then ligated with SnaBI-AscI digested pNEBChAd6-RLI thus generating pNEBChAd6-RLIdE1.

To improve the efficiency of recombination and plasmid propagation in DH5a *E.coli* strain, the 1306 bp fragment containing both left and right ITRs of ChAd6 as well as pIX gene fragment was excised by PmeI digestion from pNEBChAd6-RLIdE1 and transferred to a different plasmid vector obtained by PCR amplification with the olinucleotides 5'-GATCTAGTTAGTTTAAACGAATTCGGATCTGC

GACGCG-3' (SEQ ID NO: 33) and 5' TTCGATCATGTTTAAACGAA
ATTAAGAATTCGGATCC-3' (SEQ ID NO: 34) from pMRKAd5SEAP. This final ligation step
generated the ChAd6 shuttle vector pARSChAd6-3.

### Construction of a Subgroup C Shuttle Vector

35

The ChAd3 viral genome was fully sequenced (SEQ ID NO: 1) and the information obtained was used to construct a shuttle vector to facilitate cloning by homologous recombination of subgroup C chimpanzee adenovirus.

Briefly, the shuttle vector used to clone subgroup C chimp adenovirus, referred to herein as pChAd3EGFP was constructed as follows: a ChAd3 DNA fragment (nt 3542-4105) containing pIX coding region was amplified by PCR with the oligonucleotides 5'-

20

25

30

TATTCTGCGATCGCTGAGGTGGGTGAGTGGGCG-3' (SEQ ID NO: 35) and 5'-TAGGCGCCCTTAAACGGCATTTGTGGGAG-3' (SEQ ID NO: 36) digested with SgfI-AscI then cloned into pARSCV32-3 digested with SgfI- AscI, generating pARS-ChAd3D. ChAd3 right end (nt 37320-37441) was amplified by PCR with oligonucleotides 5'-5 CGTCTAGAAGACCCGAGTCTTACCAGT-3' (SEQ ID NO: 37) and 5'-CGGGATCCGTTTAAACCATCATCAATAATATACCTTATT-3' (SEQ ID NO: 38) digested with XbaI and BamHI then ligated to pARS-ChAd3D restricted with XbaI and BamHI, generating pARS-ChAd3RD. ChAd3 viral DNA left end (nt 1-460) was amplified by PCR with oligonucleotides 5'- ATGGAATTCGTTTAAACCATCATCAATAATATACCTT-3' (SEQ ID 10 NO: 39) and 5'- ATGACGCGATCGCTGATATCCTATAATAAAAACGCAGACTTTG-3', (SEQ ID NO: 40) digested with EcoRI and SgfI then cloned pARS-ChAd3RD digested with EcoRI and SgfI, thus generating pARS-ChAd3RLD. The viral DNA cassette was also designed to contain restriction enzyme sites (PmeI) located at the end of both ITR's so that digestion will release viral DNA from plasmid DNA.

#### Construction of AE1 Chimp Adenoviral Vectors

Subgroup C: Subgroup C chimp adenovirus vectors were constructed by homologous recombination in *E.coli* strain BJ5183. BJ5183 cells were co-transformed with pChAd3EGFP shuttle vector digested with BstEII and Bst1107I and ChAd3, ChAd11, ChAd19 and ChAd20 purified viral DNA. . Homologous recombination between pIX genes ,right ITR DNA sequences present at the ends of linearized pChAd3EGFP and viral genomic DNA allowed its insertion in the plasmid vector, deleting at the same time the E1 region that was substituted by EGFP expression cassette. Expression cassettes based on human cytomegalovirus (HCMV) promoter and bovine growth hormone polyadenylation signal (Bgh polyA) were constructed to express secreted alkaline phosphatase (SEAP), EGFP, HIV gag, HCV NS region (as described in fig.3 for ChAd6 shuttle vectors) as well as tumor-associated antigens like CEA and HER2/neu from human and Rhesus monkey origin.

Subgroups D and E: In order to construct ΔE1 vectors based on subgroup D and E chimp adenovirus, the shuttle vector pARS ChAd6-3 was digested with AscI and cotransformed into *E.coli* strain BJ5183 with CV32, CV33, CV68, ChAd4, ChAd5, ChAd6, ChAd7, ChAd9, ChAd10 and ChAd16 purified viral DNA. Homologous recombination between DNA sequences from pIX genes and right ITR present at the ends of linearized pARS ChAd6-3 and viral genomic DNA allowed its insertion in the plasmid vector, deleting at the same time the E1 region (figures 2 and 4).

10

15

20

25

30

35

Expression cassettes based on human cytomegalovirus (HCMV) promoter and bovine growth hormone poly-adenylation signal (Bgh polyA) were constructed to express secreted alkaline phosphatase (SEAP), EGFP, HIV gag , HCV NS genes (Figure 3) as well as tumor-associated antigens like CEA and HER2/neu of human and Rhesus monkey origin. All the expression cassette were inserted into the single SnaBI site of pARS ChAd6-3 vector to be transferred by homologous recombination into the  $\Delta E1$  adenovirus pre-plasmids as described in figure 4.

#### Rescue and amplification of $\Delta E1$ Vectors

5X10<sup>6</sup> PER.C6<sup>TM</sup> cells planted on 6cm cell culture dishes were transfected with 10 micrograms of cloned viral vector released from plasmid sequences by endonuclease digestion. DNA transfection was performed using Lipofectamine (Invitrogen). Transfected cells and culture medium were collected 5-10 days post-transfection and lysed by freeze-thaw. Rescued vectors were then amplified by serial passaging on 293 or PER.C6<sup>TM</sup> cells. A large-scale amplification was performed by infecting cells planted on 5-10 cell-factories (NUNC, Inc.) on a total of 1-2x10<sup>9</sup> cells. A purified vector preparation was obtained on cesium chloride gradient by two ultra-centrifuge runs, dialyzed against PBS containing 10% glycerol and stored at -70°C in aliquots.

#### **EXAMPLE 3 NEUTRALIZATION STUDIES**

Neutralization assays were carried out in order to evaluate the prevalence in human sera of neutralizing antibodies against the chimpanzee adenoviruses disclosed herein. The assay evaluated the effects of serum preincubation on the ability of chimp adenoviruses carrying the gene for secreted alkaline phosphatase (SEAP) to transduce human 293 cells. The neutralization titer is defined as the dilution of serum giving a 50% reduction of the SEAP activity observed in the positive control with the virus alone.

From  $2x10^6$  to  $1.5x10^7$  physical particles of CV33-SEAP, CV32-SEAP and ChAd3-SEAP vector were diluted in 100  $\mu$ l of complete medium and added to an equal volume of human or chimp serum diluted in complete medium. Each serum samples was tested at various dilutions (five 4-fold increments starting from 1/18 dilution through 1:4608). Samples were pre-incubated for one hour at 37°C and then added to 293 cells seeded into 96-well plates  $(3x10^4 \text{ cells/well})$ . The inoculum was removed after one hour of incubation, the cells were re-fed with fresh medium and, 24 hours later, 50  $\mu$ l of medium was removed and the SEAP activity was measured by a chemiluminescent assay. The neutralization titer is defined as the dilution of serum giving a 50% reduction of the SEAP activity observed in the positive control with the virus alone. A panel of 100 human sera was tested for ChAd neutralization activity. In parallel the same panel was tested on Ad5 SEAP vector.

10

15

## Table 2. Prevalence of neutralizing antibodies against chimpanzee adenovirus

		v	irus	
titer	hAd5	CV32	CV33	ChAd3
< 200	77%	96%	100%	92%
> 200	33%	4%	0%	8%

The result provided in Table 2 indicates that a very low prevalence in human sera of neutralizing antibodies directed against vector derived from chimpanzee adenoviruses. Only four sera showed a titer over the threshold of 200 on CV32 vector while 8 showed a titer over 200 on ChAd3 SEAP vector. On the contrary, the panel of chimp sera examined showed a very high prevalence of anti-Chimp Ad immunity. These findings confirm that as expected, vectors based on chimp Ads have a very little chance to be neutralized in humans. Therefore they represents an ideal solution to the problem of the pre-existing anti-human Ad immunity that limits the administration of viral vectors based on common human Ad serotypes such as Ad5.

#### **MURINE IMMUNIZATION STUDIES**

#### METHODS AND MATERIALS

### 20 Immunization Protocols and Splenocyte /PBMC Preparation

Immunizations: Mice were immunized with the selected adenoviruses diluted in 0.1 ml of buffer. Each vector dose was divided in two aliquot of 50  $\mu$ l and injected in both quadriceps of mice.

Splenocyte Preparation: Mice were sacrificed 3 weeks post-injection and their spleens excised and transferred in 10 ml of R10 (10% FCS, 55mM 2-mercaptoethanol, 1M HEPES buffer, 2mM L-glutamine, 1X penicillin-streptomicine solution in RPMI medium 1640). Spleens were minced through a steel screen and, after the screen was washed with 2 ml of R10, splenocytes were transferred in a 50 ml Falcon tube and centrifuged at 1200 rpm, 10 min, room temperature (rt). Supernatant was removed and 3 ml of ACK lysis buffer (Gibco BRL Formulation#79-0422DG) were added. Cells were incubated 5 min, rt. 45 ml of 1X PBS were

10

15

20

25

30

added and tubes were centrifuged as above. After washing with 30 ml of R10, cells were resuspended in 5 ml of R10, filtered through a 70 m Nylon cell strainer (Falcon 2350).  $10\mu l$  of cells were diluted with 990  $\mu l$  Turk's solution (Merck 040417345) and counted. Cells were finally diluted to  $10^7$  cells/ml in R10.

Peripheral blood mononuclear cell (PBMC) preparation: Mice blood samples (150 ul) were transferred to 2ml eppendorf tubes with 50ul PBS/2% EDTA. 1 ml ACK buffer was added to each tube. Gently mixed and incubated at RT for 5 min. Samples were centrifuged at 1500rpm in microcentrifuge for 5 min. Supernatant was discharged white cell pellets deriving from the same immunized cohorts were combined. ACK buffer incubation was repeated then pellets of PBMC were resuspended in 1 ml of R10 medium.

#### IFN-γ ELISPOT Assay

Millipore MAIP 45 plates were coated with 100 µl/well of purified rat anti-mouse IFN- $\gamma$  monoclonal antibody (Pharmingen, cat. 551216) diluted at 2.5  $\mu$ g/ml in PBS and incubated over-night (o/n) at 4°C. Plates were washed 2X with sterile PBS and un-specific binding sites were blocked by incubation for 2hrs in the CO2 incubator with 200 µl/well of R10. In the immunization experiments with Ad vectors expressing HIV gag, a 9-mer peptide (AMQMLKETI, a CD8 HIV gag epitope mapped in Balb/C mice) (SEQ ID NO: 47) was diluted to 2 µg/ml in R10 and added to the wells in the amount of 50 µl/well. In immunization experiments conducted with HCV-NS expressing vectors, a pool of peptides covering NS3 helicase domain as well a 9-mer peptide representing a mapped CD8 epitope comprised in helicase domain were used. Immunization experiments with ChAds expressing human CEA antigen were evaluated by pools of overlapping 15-mer peptides covering the entire amino acid sequence. As controls DMSO and Concanavalin A were used. Cells were added to each well at the amount of  $5X10^5$  and  $2.5X10^5$ . After an o/n incubation in the  $CO_2$  incubator, plates were washed with 0.05% Tween 20/PBS and 50  $\mu$ l/ well of biotinylated rat anti-mouse IFN- $\gamma$ monoclonal antibody (PharMingen cat. 554410) diluted 1/250 in assay buffer (5%FBS, 0.005% Tween20, PBS) were added. Plates were incubated o/n at 4°C and washed as above. Streptavidin-alkaline phosphatase conjugate (BD554065) was diluted 1 /2500 in assay buffer and added in the amount of 50  $\mu$ l/well for 2 hrs rt. After washing, plates were developed adding 50

(E

10

15

20

25

30

35

μl/well of BCIP/NBT1-step solution (Pierce 34042). Reaction was stopped by washing wells with deionized water. Spots were automatically counted by an ELISPOT reader.

### Murine IFN-γ Intracellular Staining (ICS)

Splenocytes were diluted at 2X10<sup>6</sup> cells in 1 ml of R10 and stimulated with the same antigens described above at the concentration of 2 μg/ml. As controls, DMSO and Staphylococcal Enterotoxin B (SEB) were used. After an overnight incubation in the CO<sub>2</sub> incubator, cells were washed with FACS buffer (1% FCS, 0.01% NaN3, PBS) and purified antimouse CD16/CD32 Fc block (clone 2.4G2, Pharmingen cat. 553142) was diluted 1/25, added in the amount of 100 μl/sample and incubated for 15min at 4°C. Cells were washed in FACS buffer and APC conjugated anti-mouse CD3e (clone 145-2C11, Pharmingen #553066), PE conjugated anti-mouse CD4 (clone L3T4, BD Pharmingen cat. 553142) and PerCP conjugated anti-mouse CD8a (clone 53-6.7, Pharmingen cat. 553036) diluted 1:50 in FACS buffer were added in the amount of 100 μl/sample. Cells were incubated 30 min rt, washed, fixed and permeabilized (Becton Dickinson, FACS Perm 2) and incubated with FITC conjugated anti-mouse IFN-γ Pharmingen cat.554411) diluted 1:50 in PermWash (100 ul/sample) for 30 min at RT. After washing cells were resuspended in 500 ul 1% formaldehyde/PBS and intracellular cytokine staining (ICS) analyzed on a FACS-Calibur flow cytometer, using CellQuest software (Becton Dickinson).

## EXAMPLE 4 ChAd VECTORS ELICIT STRONG CMI RESPONSES IN MICE

The ability of the ChAd vectors disclosed herein to elicit a cell-mediated immune response (CMI) was evaluated in mice using vectors expressing an HIV gag transgene. Briefly, groups of 5 Balb/C mice were injected with ten-fold increasing doses of the different vectors starting from 10<sup>5</sup> up to 10<sup>10</sup> vp/mouse.

The strength of the immune response was determined three weeks after the injection by quantifying gag-specific CD8+ T cells in the splenocytes. The number of IFN-γ secreting CD8+ T cells was determined by ELISPOT assay or by IFN-γ intracellular staining and FACS analysis after stimulation *in vitro* with a peptide reproducing a gag CD8+ T cell epitope mapped in Balb/C mice.

The results obtained from the 5 immunized animals, reported in Table 3, are expressed as spot forming cells per 10<sup>6</sup> splenocytes. Shown are the number of spot forming cells per million splenocytes following incubation with 9-mer CD8+ gag epitope or with gag peptide pool. The gag peptide pool consisted of 20-aa peptide overlapping by 10aa encompassing the entire gag sequence. Positive values are reported in bold.

5

The data provided in Table 3 indicate that the administration of the ChAd vectors disclosed and claimed herein elicts a strong cell mediated immune response which is comparable to the response elicited by hAd5. By looking at the lowest vector dose resulting in a positive immunization result (immunization breakpoint), we ranked the potency of the different vectors being subgroup C ChAd3gag the most potent with a breakpoint at 10<sup>6</sup> pp vector dose. Ranking by immunization break-points is shown in Figure 33.

Gag-specific T cell response in BalbC mice immunized with chimpanzee Ad Table 3.

		tors.										
Vaccination	10 mock	)^5 vp	1 moct	0^6 vp	1	0^7 vp	10	0^8 vp	1 10	)^9 vp	10	^10 vp
	1 3	пед	1	944	mock 1	Gag 1298	mock	Gag 1258	mock NT	Gag NT	moci	Gag
ChAd3DEtgag	1	neg neg	1 1	1039 659	1:	1958 1923		1962 1931	NT	NT	NT NT	NT NT
	1	neg neg	1 1	1620 1529	1	1388	1	1389	NT NT	NT NT	TN TN	NT NT
	107			1323	5	1442	1.4	1438	NT	NT	NT	NT
CVCCDE	TN	NT NT	;	neg	2	475 433	1 !	2910	NT	NT	NT	NT
CV33DE1gag	NT NT	NT NT	1:	neg	1	243		401 634	NT	NT NT	TN TN	NT NT
ļ	NT	NT	<u> </u>	nag		505 583	2 2	3457 1684	NT NT	NT	NT	NT
	NT	NT	3	nog						NT	NT	NT
CV68DE1gag	NT NT	NT NT	1	neg	1	340 512	0	332 538	0	406 256	2 3	635 1172
	NT	NT	7	neg neg	0	458 148	3	944 519	2	462	2	505
	NT	NT		neg		1418	<u> </u>	243	Lő	488 240	2	1184 789
	NT NT	NT NT	1	neg	7	369	1 1	609	NT	NT	INT	117
ChAd9DE1gag	NT	NT	] ;	neg neg	1 :	508 299	1 16	739	NT	NT	NT	NT NT
	NT NT	NT NT	0.5	neg	2	507	8	291 926	NT NT	NT NT	NT NT	NT NT
				neg	<del></del>	38	40	1034	NT	NT	NT	NT
Oh to de Direction	TN TN	NT NT	1	neg	1	83 42.5	1	822.5	NT	NT	NT	NT
ChAd10DE1gag	TN	NT NT		neg	1	48	!	1033 1339,5	NT NT	NT NT.	NT NT	NT NT
	NT	NT	<u> Li</u>	neg neg		51 486,5	1 1	1132 521.5	NT	NT	NT	NT
	NT	NT	) 1	neg					NT	NT	<u>I NT</u>	NT
ChAd8DE1gag	NT NT	NT	] i	neg	1 10	34 4	1	721 560	NT NT	NT NT	NT NT	NT NT
Curacheigag	NT	NT NT	1	neg neg	1	24	1	624	NT	NT	NT	NT
	NT	NT		neg	1	225 276	3	3002 1738	NT	NT	NT	NT
* (			,					1750	NT	NT	NT	NT
	1	neg neg	;	neg	0	573	NT	NT	NT	NT	NT	NT
ChAd11DE1gag	0	пед		neg	0	919 1438	TN TN	NT NT	NT	NT	NT	NT
	2 1	пед	0	neg	0	0	NT	NT.	NT NT	NT NT	NT NT	NT NT
		neg	<u> </u>	neg	0	456	NT	NT	NT	NT	NT	NT
	0	neg	0	пер	0	1	NT	*				
ChAd20DE1gag	2	пед	0	neg	0	408	NT	NT NT	NT NT	NT NT	NT NT	NT
	1	nėg nėg	0	neg	0 D	414 2	NT NT	NT	NT	NT	NT	NT NT
	0	neg	0	neg	1	311	NT	TN TN	NT NT	NT NT	NT NT	NT NT
* ** * ** *****************************	NT	NT	1	neg	1							
Charron	NT	NT	3	neg	i	род Оот	1	1044 606	NT NT	NT NT	NT	NT
ChAd7DE1gag	NT NT	NT NT	1	neg	8	под	1	407	NT	NT	NT NT	NT NT
	NT_	NT	1	neg neg	1	neg neg	2	567	NT	NT	NT	NT
						neg		1877	NT	NT	NT	NT
	NT NT	NT NT	NT NT	NT	1	neg	0	83	0	291	0	194
CV32DE1gag	NT	NT	NT	NT NT	3 0	neg	0	382	0	805	2	380
	NT	NT	NT	NT	1	дел дел	1 5	97 96	0	138 1162	1	501
	NT	NT I	NT	NT	2	neg	1	328	NT	NT	0	1115 596
	NT	ΤN	1	neg	Ö	tied T						
ChAd4DE1gag	NT TN	TN TN	0	neg	0	neg neg	0	0 159	NT	NT	NT NT	NT NT
	NT	NT	1	neg neg	0	neg neg	0	234	NT NT	NT	NT	NT
	NT	NT I		пед	0	neg	1	0	NT NT	NT NT	NT NT	NT NT
	NT NT	NT	D	neg	0	neg	0	243	NT	NT	.,	NT
ChAdt6DE1gag	NT	NT NT	0	пер	0 2	пед пед	1	296	NT	NT	NT NT	NT
	NT NT	NT NT	0	neg	0	nog	į	68 433	NT NT	NT NT	NT NT	NT NT
						nog	<u> </u>	28	NT_	NT	NT	NT

10

15

20

25

#### EXAMPLE 5 ChAd3 AND CV33 GAG VECTORS ELICIT A CMI RESPONSE CHARACTERIZED BY GAG-SPECIFIC CD8+ T CELLS

In order to characterize the CMI response elicited in response to the ChAd vectors comprising HIV gag transgene, splenocytes pooled from cohorts of five mice immunized with different doses of vector were analyzed by intracellular IFN- $\gamma$  staining. The data shown in table 3 and table 4 were collected in separate experiments.

Splenocytes were diluted at 2X10<sup>6</sup> cells in 1 ml of R10 and stimulated with the same antigens described above at the concentration of 2 μg/ml. As controls, DMSO and SEB (Staphylococcal Enterotoxin B) were used. After an o/n incubation in the CO<sub>2</sub> incubator, cells were washed with FACS buffer (1% FCS, 0.01% NaN3, PBS) and purified anti-mouse CD16/CD32 Fc block (clone 2.4G2, Pharmingen cat. 553142) was diluted 1/25, added in the amount of 100 μl/sample and incubated for 15min at 4<sup>0</sup>C. Cells were washed in FACS buffer and APC conjugated anti-mouse CD3e (clone 145-2C11, Pharmingen #553066), PE conjugated anti-mouse CD4 (clone L3T4, BD Pharmingen cat. 553142) and PerCP conjugated anti-mouse CD8a (clone 53-6.7, Pharmingen cat. 553036) diluted 1:50 in FACS buffer were added in the amount of 100 μl/sample. Cells were incubated 30 min rt, washed, fixed and permeabilized (Becton Dickinson, FACS Perm 2) and incubated with FITC conjugated anti-mouse IFN- γ Pharmingen cat.554411) diluted 1:50 in PermWash (100 ul/sample) for 30 min at RT. After washing cells were resuspended in 500 ul 1% formaldehyde/PBS and analyzed on a FACS-Calibur flow cytometer, using CellQuest software (Becton Dickinson).

Table 4 provides data summarizing the percentage of gag-specific CD3+T cells that were either gag-specific CD8+ or CD4+ T cells. Positive results are reported in bold. The data provided herein indicate that the cellular profile of the immune response elicited by ChAd vectors derived from viruses classified into different serotype subgroups (i.e., subgroups C, D and E) are similar and all of the gag-specific responses characterized predominantly by CD8+ T cells. In addition, it is noted that at high vector doses a gag-specific CD4+ response becomes evident in all immunization experiments. The ICS assay confirmed that ChAd3 vector can stimulate anti-gag CD8+ response at 10<sup>6</sup> vector dose.

Table 4. Characterization of gag-specific T cells in mice immunized with Chimp adenovirus vectors of different subgroups.

vaccine		10	5	10	) <sup>6</sup>	10	07	1	08	10	) <sup>9</sup>
VICONIC		DMSO	gag	DMSO	gag	DMSO	gag	DMSO	gag	DMSO	gag
ChAd3DE1gag	%CD8,CD3,	NT	NT	0.01%	4.65%	0.01%	17.15%	0.04%	24.71%	NT	NT
On Adobe I gag	%CD4*CD3*	NT	NT	0.00%	0.07%	0.03%	0.08%	0.04%	0.28%	NT	NT
CV33DE1gag	%CD8*CD3*	NT	NT	0.02%	0.01%	0.01%	0.83%	0.03%	8.69%	NT	NT
CVSSDETGAS	%CD4*CD3*	NT	NT	0.00%	0.00%	0.00%	0.04%	0.01%	0.10%	NT	NT
ChAd9DE1gag	%CD8*CD3*	NT	NT	0.02%	0.01%	0.01%	0.68%	NT	NT	0.04%	4.73%
CIIAUSDETgag	%CD4*CD3*	NT	NT	0.00%	0.00%	0.00%	0.00%	NT	NT	0.00%	0.01%
ChAd10DE1gag	%CD8*CD3*	NT	NT	0.02%	0.01%	0.01%	0.57%	· NT	NT	0.02%	5.04%
CHAGIODEIgag	%CD4*CD3*	NT	NT	0.00%	0.00%	0.00%	0.00%	NT	NT	0.00%	0.01%
Ch Aden Et ann	%CD8*CD3*	NT	NT	0.00%	0.01%	0.00%	0.59%	0.01%	14.28%	NT	NT
ChAd6DE1gag	%CD4*CD3*	NT	NT	0.00%	0.00%	0.00%	0.05%	0.01%	0.12%	NT	NT
ChAd7DE1gag	%CD8*CD3*	NT	NT	0.01%	0.02%	0.01%	0.00%	0.02%	5.00%	NT	NT
CHAGIDEIGAG	%CD4*CD3*	NT	NT	0.00%	0.01%	0.00%	0.00%	0.01%	0.21%	NT	NT

#### EXAMPE 6 Chad VECTORS ELICIT HCV NS-SPECIFIC T CELL RESPONSE

The potency of CV32-NSmut and CV33-NSmut vectors was evaluated in C57/Black6 mice relative to the potency of MRKAd6NSmut. The animals were injected with 10-fold increasing doses of vector starting from 10<sup>7</sup> up to 10<sup>9</sup> vp/mouse. CMI was analyzed 3 weeks after a single injection by IFN-γ ELISPOT and IFN-γ intracellular staining by stimulating T cells with a 9-mer peptide reproducing a CD8+ T cell epitope mapped in the helicase domain of NS3 protein. The data provided in Table 5 summarize the number of spot-forming cells per million splenocytes following incubation in absence (mock) or in presence of NS3 9-mer peptide.

The data indicate that both CV32 and CV33 vectors expressing HCV-NS stimulate strong T cell responses. Based on the observation that the first positive result for the CV32 vector was obtained by injecting 10<sup>9</sup> vp/dose, the immunization potency of CV32DE1E3 NSmut vector appears to be approximately 100-fold lower than human subgroup C Ad6DE1E3 NSmut vector. The parallel experiment with MRKAd6NSmut indicated that a dose of 10<sup>7</sup> vp/animal was sufficient to stimulate cell mediated immunity. Therefore, these results confirm the lower immunization potency of CV32-derived vectors relative to human subgroup C vectors

20

15

5

20

(such as hAd5 and hAd6) that was also observed in the experiment with gag expressing vectors (see Table 3).

Table 5. HCV NS-specific T cell response in mice immunized with MRKAd6 NSmut, CV32NSmut or CV33NSmut

Vaccination	10^	7 vp	10^8	3 VD	10^9	9 vp	1001	0 vp
	Mock	NS3	mock	NS3	mock	NS3		
	1	345	1 1	449	NT		mock	NS3
	1	248	1 1	1590		NT	NT	NT
MRKAd6NSmut	1	1	1	549	NT	NT	NT	NT
	1	262	'	343	NT	NT	NT	NT
	·	202	1		NT	NT	NT	NT
			<u></u>		NT	NT_	NT	NT
		1	1	195	2	338	NT	NT
CV33NSmut		2	1	409	1	1136	NT	NT
Ovosivolitut	]	1	1	396	1	497	NT	NT
	7	2	2	172	1	344	NT	NT
	1	237			1 1	163	NT	
								NT -
	neg	neg	1	181	1	118		
	neg	neg	1	71	' -i		1	176
CV32NSmut	neg	neg	1	56	•	239	1	238
	neg	neg	1	459	,	862	1	555
	neg	neg	•		1	219	1	545
	, <u>g</u>	neg		195		123	1	578

# EXAMPLE 7 ANTI -Ad5 PRE-EXISTING IMMUNITY DOES NOT ABROGATE ANTI-GAG CMI ELICITED BY ChAd3gag

To evaluate the impact on ChAd3 immunization of the pre-existing immunity against the high seroprevalent Ad5, 4 cohorts of 5 BalbC mice were pre-immunized with two injection of 10<sup>10</sup> vp of Ad5 wt in the quadriceps at week 0 and 2. As control, 2 cohorts of 5 mice were injected at the same time points with buffer only. Cohorts of Ad5 pre-immunized mice were then immunized with 10<sup>6</sup> and 10<sup>7</sup> vp/mouse of either Ad5gag or ChAd3gag vectors. Cohorts of control (naïve) mice were immunized with 106 vp/mouse of Ad5gag or ChAd3gag vectors.

Anti-Ad5 and ChAd3 neutralizing immunity was evaluated at week 4 by the neutralization assay described above using Ad5 and ChAd3 SEAP vectors. Anti-gag immunity was evaluated by ELISPOT analysis on purified splenocytes stimulated with gag 9-mer peptide containing a gag epitope mapped in BalbC mice. The results reported in figure 36 demonstrated that Anti-Ad5 immunity does not abrogate anti-gag CMI elicited by ChAd3gag while, as expected, anti-Ad5 immunity completely block Ad5gag immunization.

10

15

20

25

30

# EXAMPLE 8 ChAd3hCEA IMMUNIZATION ELICITS A STRONG CEA-SPECIFIC IMMUNE RESPONSE IN TRANSGENIC MICE EXPRESSING HUMAN CEA

The ability of the ChAd vectors disclosed and claimed herein to elicit an immune response against a self-antigen therefore breaking the tolerance was also evaluated in transgenic mice expressing human CEA (Clarke, P et al. Cancer Res. (1998) 58(7):1469-77.)

Cohorts of 8 mice were injected in the quadriceps with 10^10 vp of ChAd3hCEA or Ad5hCEA as already described. The immune response against CEA was followed weekly up to day 75 on PBMC stimulated with a pool of 15-mer peptides encompassing human CEA aminoacid sequence from aa 497 to the end (aa 703). Anti-CEA immunity was evaluated by ICS determining CD4-CD8+ T cells secreting interferon-γ in response to CEA peptide pool incubation.

The results reported in figure 37 demonstrate that ChAd3hCEA vector immunization stimulate a more sustained CD8+ T cell response against human CEA than Ad5 expressing the same transgene.

#### PRIMATE IMMUNIZATION STUDIES

#### METHODS AND MATERIALS

#### **Immunization Protocol**

The ability of the ChAd vectors disclosed and claimed herein to elicit CMI in Rhesus macaques (referred to herein as monkeys) was also evaluated. The macaques were anesthetized (ketamine/xylazine) and the vaccines were delivered i.m. in 0.5-mL aliquots into both deltoid muscles using tuberculin syringes (Becton-Dickinson). In all cases the macaques were between 3-10 kg in weight, and the total dose of each vaccine was administered in 1 mL of buffer.

Sera and peripheral blood mononuclear cells (PBMC) were prepared from blood samples collected at several time points during the immunization regimen. All animal care and treatment were in accordance with standards approved by the Institutional Animal Care and Use Committee according to the principles set forth in the *Guide for Care and Use of Laboratory Animals*, Institute of Laboratory Animal Resources, National Research Council.

#### **ELISPOT Assay**

5

10

15

20

25

30

35

The IFN-γ ELISPOT assays for rhesus macaques were conducted following a previously described protocol (Allen *et al.*, 2001 *J. Virol.* 75(2):738-749), with some modifications. For gag-specific stimulation, a peptide pool was prepared from 20-aa peptides that encompass the entire HIV-1 gag sequence with 10-aa overlaps (Synpep Corp., Dublin, CA). For HCV NS-specific stimulation 6 peptide pools were prepared from 15-aa peptides that encompass the entire HCV-NS sequence from NS3 to NS5b with 10-aa overlaps.

HER2/neu and CEA-specific stimulations were performed with 15-aa peptides that encompass the entire protein sequence with 10-aa overlaps.

To each well, 50 μL of 2-4 x 10<sup>5</sup> peripheral blood mononuclear cells (PBMCs) were added; the cells were counted using Beckman Coulter Z2 particle analyzer with a lower size cut-off set at 80 fL. Either 50 μL of media or the gag peptide pool at 8 μg/mL concentration per peptide was added to the PBMC. The samples were incubated at 37°C, 5% CO<sub>2</sub> for 20-24 hrs. Spots were developed accordingly and the plates were processed using custom-built imager and automatic counting subroutine based on the ImagePro platform (Silver Spring, MD); the counts were normalized to 10<sup>6</sup> cell input.

#### **Intracellular Cytokine Staining (ICS)**

To 1 ml of 2 x 10<sup>6</sup> PBMC/mL in complete RPMI media (in 17x100mm round bottom polypropylene tubes (Sarstedt, Newton, NC)), anti-hCD28 (clone L293, Becton-Dickinson) and anti-hCD49d (clone L25, Becton-Dickinson) monoclonal antibodies were added to a final concentration of 1 µg/mL. For gag-specific stimulation, 10 µL of the peptide pool (at 0.4 mg/mL per peptide) were added. Similar conditions were used for HCV NS-specific stimulation. The tubes were incubated at 37 °C for 1 hr., after which 20 µL of 5 mg/mL of brefeldin A (Sigma) were added. The cells were incubated for 16 hr at 37 °C, 5% CO<sub>2</sub>, 90% humidity. 4 mL cold PBS/2%FBS were added to each tube and the cells were pelleted for 10 min at 1200 rpm. The cells were re-suspended in PBS/2%FBS and stained (30 min, 4 °C) for surface markers using several fluorescent-tagged mAbs: 20 µL per tube anti-hCD3-APC, clone FN-18 (Biosource); 20 µL anti-hCD8-PerCP, clone SK1 (Becton Dickinson, Franklin Lakes, NJ); and 20 µL anti-hCD4-PE, clone SK3 (Becton Dickinson). Sample handling from this stage was conducted in the dark. The cells were washed and incubated in 750 µL 1xFACS Perm buffer (Becton Dickinson) for 10 min at room temperature. The cells were pelleted and resuspended in PBS/2%FBS and 0.1 µg of FITC-anti-hIFN-y, clone MD-1 (Biosource) was added. After 30 min incubation, the cells were washed and re-suspended in PBS. Samples were analyzed using all four color channels of the Becton Dickinson FACSCalibur instrument. To

10

15

20

analyze the data, the low side- and forward-scatter lymphocyte population was initially gated; a common fluorescence cut-off for cytokine-positive events was used for both CD4<sup>+</sup> and CD8<sup>+</sup> populations, and for both mock and gag-peptide reaction tubes of a sample.

## EXAMPLE 9 A HOMOLOGOUS PRIME-BOOST REGIMEN USING ChAd ΔΕ1-gag VECTORS ELICITS GAG-SPECIFIC T CELLS IN MONKEYS

Cohorts of 3 animals were given intramuscular injection at week 0 and week 4 of either of the following constructs: 10^10 vp of CV-32ΔE1-gag; or 10^10 vp CV33ΔE1-gag; or 10^10 vp and 10^8 vp MRKAd5ΔE1gag. PBMCs collected at regular 4-wks intervals were analyzed in an ELISPOT assay. The results provided in Table 6, which indicate the number of spot-forming cells per million PBMC following incubation in absence (mock) or presence of Gag peptide pool establish that both CV32ΔE1-gag and CV-33ΔE1gag are able to induce significant levels of gag-specific T cells in non-human primates. It is interesting to note that after a single dose (wk 4), the CV32ΔE1-gag responses were comparable to MRKAd5 ΔE1-gag 10^8 vp dose and lower than that of MRKAd5-gag 10^10 vp/dose. CV33ΔE1-gag 10^10 vp/dose induces a response comparable to that of MRKAd5-gag 10^10 vp/dose. This result was confirmed at week 8 after the second dose.

Table 6. Gag-specific T cell response in monkeys immunized with MRKAd5 ΔE1-gag, CV32ΔE1-gag, CV33ΔE1-gag.

Vaccination	vector	Monk #	Pre-	bleed	T:	=4	T:	=8
T=0	dose		Mock	Gag	Mock	Gag	Mock	Gag
		01C023	. 1	0	14	353	3	278
CV32∆E1gag	10^10 vp	01C029	1	3	13	605	3	419
<u> </u>	<u> </u>	01C032	1	0	5	274	1	179
		01C033	0	0	9	1545	1	659
CV33∆E1gag	10^10 vp	01C036	4	5	4	1540	13	881
	11	01D303	0	3	19	949	10	628
		01D267	0	0	4	473	0	341
MRKAd5gag	10^8 vp	01D279	1	4	44	831	6	336
	1 1	01D284	4	· 5_	4	264	5	129
1		99C218	0	3	5	2500	0	1580
MRKAd5gag	10^10 vp	99C227	6	1	4	529	5	365
	11	99D185	ND	ND	0	425	0	310

# EXAMPLE 10 Chad VECTORS ELICIT A HCV NS-SPECIFIC T-CELL RESPONSE IN A HETEROLOGOUS PRIME-BOOST REGIMEN

In a separate experiment, groups of two and three monkeys were given immunization at week 0, 4 of MRK Ad6NSoptmut vector at 10^8 or 10^10 vp per animal. The animals were boosted with the same virus at the same dose at week 24 and then boosted again at week 104 with CV33-NSmut at 10^10 vp per animal. The results are presented in Tables 7 and 8 which summarize the number of spot-forming cells per million PBMC following incubation in absence (mock) or presence of HCV NS peptide pool.

10

5

T cell immunity, as assessed by IFN-γ ELISPOT, showed a peak response at week 4 after the first dose in the animals injected with 10^10 vp (Table 8) and at week 8 (post-dose 2) in the animals injected at 10^8 (Table 7). The response was not boosted by the injection at week 24 ("homologous boost"), while a strong boost effect was observed after the injection with CV33-NSmut ("heterologous boost").

15

Table 7. HCV NS-specific T cell response in monkeys immunized with MRK Ad6NSoptmut at 10^8 vp/animal and boosted with CV33-NSmut.

Vaccine				MRKAde	Soptmut 10^8	d vp			r			
time point	Tz	4		T=8		ous boost 24		ogous boost	1	CV33-NSm ogous boost 104	1	logous boost
monkey	95116	1387	95116	1387	95116	138T	95116	138T	95116			:108
poolF	44	112	77	124	115	176	105			1387	95116	138T
poolG	20	2110	86	1975	201	1105	94	55	120	150	188	2228
pooiH	12	18	54	22	169	221	N .	884	120	192	96	4590
pooii	14	53	62	47	163	189	28	9	81	33	447	543
poolL,	33	88	58	44	353		96	18	80	67	71	515
poo!M	184	75	168	138	204	608	235	33	110	131	224	308
DMSO	14	3	44				67	44	55	46	2028	1570
	·	Y	<del></del>	′	104	79	33	6	57	40	33	es es

20

Table 8. HCV NS-specific T cell response in monkeys immunized MRK Ad6NSoptmut at and 10^10 vp/animal and boosted with CV33-NSmut.

Vaccine	L				MRK	Ad6NSo	ptmut 10^1	0 vn		<del></del>	<u> </u>							
time point	<u> </u>	ming i T=4	dose	post-p	riming II T=8		pre-homo		boost	post-hom	ologous T=28	boost		rologou		mut 10^1	erologo	ıs boost
poolF	98D209 3110	106Q 263	113Q 404	98D209	106Q 300	1130	98D209	105Q			106Q	113Q		T=104 106Q	113Q	98D209	T≃108 106Q	113Q
poolG poolH	2115 373	642 72	1008	1070	316	723 2205	678 685	61 71	583 701	321 251	123 178	1438 1758	204 166	192 106	326 625	1581	1525	1714
pooll	103	37	19 347	358 80	43 36	43 531	424 237	24 39	42 169	51 12	23 35	18 485	92	45	55	1118 413	524 58	4238 211
pooiL pooiM	149 _314	22 428	10 19	93 153	36 243	29 20	279 333	46	48	11	49	51	66 89	79 109	376 73	459 199	85 76	2738 431
DMSO	0	1	3	18	16	5	128	81 8	38 9	38 8	134	11	20	81 51	9	228 18	1440	227

The efficiency of heterologous boost with chimp Ad vectors was evaluated in a second experiment. Cohorts of three monkeys were immunized at week 0 and week 4 with MRKAd5gag (10^10 vp/animal), MRKAd6NSmut (10^10 vp/animal) or with the combination of both vectors (10^10 vp/animal each vector) then boosted with the same immunogen at week 24 (homologous boost). Homologous boost was performed with the same immunogens; heterologous boost was performed with CV33gag, CV32 NSmut or with the two vectors in combination. The results provided in Table 9 summarize the number of spot-forming cells per million PBMC following incubation in absence (mock) or presence of HCV NS peptide pool.

The same cohorts were boosted again at week 51 with CV33gag (10^10 vp/animal), CV32NSmut (10^10 vp/animal) and with the combination of the two vectors (10^10 vp/animal) each vector). The results provided in Table 9 further indicate that the homologous boost was not efficient since the responses are below the peak observed at week 4 after the injection of the first dose of vaccine. A strong boosting effect was measured by IFN-γ ELISPOT at week 54 after immunization with heterologous chimp vectors.

25

20

5

10

10

15

Table 9. Immunization with Chimp Ad vectors efficiently boost Gag and HCV NS-specific T cell response in monkeys immunized with MRK Ad5gag or MRK Ad6NSoptmut at 10^10 vp/animal.

Vaccine_						MRK	Ad5gag								CV3	3gag		
time point	post	dose 1	(T=4)	post	-dose 2 (	T=8)	pre-hor	nol. boo:	st (T=24)	post-hor	nol. boo:	st (T=28)	pre-hete	erol. boos	t (T=51)	post-het	erol. boo	st (T=54)
animal ID	00D105	00D076	000299	00D105	00D076	00D299	00D105	00D076	00D299	000105	00D076	00D299	00D105	00D076	00D299	00D105	00D076	00D299
poolF	18	35	60	16	29	14	37	76	40	37	8	14	37	27	44	43	44	70
poolG \	16	23	49	4	28	31	54	95	106	81	2	46	36	27	37	84	108	109
poolH	45	51 .	57	18	31	42	55	88	55	47	11	32	69	36	60	85	58	120
pooll	21	21	48	4	26	11	19	54	26	38	6	6	22	11	32	33	26	24
poolL	15	21	58	9	31	20	71	183	128	106	6	27	61	21	65	28	45	44
poolM_	39	24	49	26	14	49	38	93_	39	59	6	19	62	23	38	27	19	14
Gag	1764	2208	2762	574	1906	1959	391	935	702	2123 ·	336	736	485	833	1384	4003	4333	3863
DMSO	9	13	37	7	14	13	16	76	33	26	3	11	28	19	39	23	16	53

Vaccine					MRK	Ad5gag +	MRKAdi	SNSmut						CV	33gag +	CV32NS	mut	
time point	post-	dose 1 (	T=4)	post	dose 2	(T=8)	pre-hon	nol. boos	t (T=24)	post-hon	iol. boos	t (T=28)	pre-hete	rol. boos	t (T=51)	post-het	erol. boo	st (T=54)
animal ID	880C00	00D099	00D240	00D088	00D099	00D240	00D088	00D099	00D240	00D088	000099	00D240	000088	00D099	00D240	880CO	00D099	00D240
poolF	438	118	105	720	116	154	206	108	242	408	99	219	778	135	56	1701	1121	424
poolG	21	784	1483	44	362	940	19	234	548	47	781	844	78	363	265	228	3180	2770
poolH	24	53	8	46	27	19	13	66	93	49	41	87	115	50	28	97	291	104
pooll	83	28	9	90	24	8	16	40	68	33	16	42	56	19	8	165	145	22
poolL	13	14	13	16	17	9	28	101	140	39	27	78	59	28	15	137	815	463
poolM	39	31	6	101	27	16	21	73	107	44	26	78	114	28	10	219	109	21
Gag	2138	1044	1063	2260	505	819	454	241	456	1100	368	716	1542	237	161	4460	2908	1764
DMSO	5	6	3	8	5	1	10	18	43	9	13	28	14	18	12	9	21	6

Vaccine						MRKAd	6 NSmu	1							CV32	NSmut		
time point	post	dose 1 (	T=4)	post	dose 2	(T=8)	pre-ho	nol boos	st (T=24)	post-hor	nol. boos	st (T=28)	pre-hete	ral. boos	t (T=51)	post-het	erol, boo	st (T=54)
animal ID	00D065	00D116	00D159	00D065	00D11	6 00D159	00D065	00D116	00D159	00D065	000116	00D159	00D065	000116	00D159	00D065	00D116	00D159
poolF	139	44	82	92	121	63	62	116	54	44	42	23	57	85	53	313	385	261
poolG	154	253	119	77	156	108	93	165	126	104	59	39	44	198	48	196	764	559
poolH	1284	41	211	768	35	124	394	84	77	24	817	48	624	31	116	3758	90	925
pooli	302	22	1174	221	16	1069	134	31	561	18	133	478	84	16	362	485	51	2951
poolL.	28	16	48	35	32	21	141	113	78	19	48	17	46	33	46	379	339	541
рооІМ	1329	1007	36	579	392	30	314	293	43	558	398	22	159	369	33	1278	1750	16
Gag	15	9	7	13	5	2	36	33	36_	9	23	14	16	8	10	37	9	26
DMSO	16	4	5	9	6	4	23	17	8	1	9	3	23	8	6	26	9	10

# EXAMPLE 11 VACCINATION WITH A ChAd VECTOR COMPRISING A TAA BREAKS TOLERANCE AND ELICITS A TAA-SPECIFIC T CELL RESPONSE IN MONKEYS

Experiments designed to determine whether chimpanzee adenoviral vectors are sufficiently immunogenic to break the tolerance to a self-antigen and to document the utility of chimpanzee vectors for boosting an immune response primed with a human adenoviral vector were performed in cohorts of four monkeys. Animals were immunized with three injection at

5

10

week 0, 2 and 4 of Ad5DE1 RhCEA (10<sup>11</sup> vp), comprising the tumor associated antigen CEA, followed by vaccination at week 16, 18 and 20 with CV33DE1 RhCEA (10<sup>11</sup> vp). T cell response was measured by IFNγ ELISPOT with rhesus CEA peptides.

The results reported in figure 34, which provide the number of spot-forming cells per million PBMC following incubation in absence (DMSO) or in presence of rhesus CEA C and D peptides pools, establish that an immunization protocol based on vaccination with two different Ad serotypes leads to a sustained T cell response against CEA in non-human primates.

While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

#### **CLAIMS**

What is claimed is:

- 5 1. An isolated chimpanzee nucleic acid sequence selected from the group consisting of:
  - a) SEQ ID NO:1
  - b) SEQ ID NO: 2; and
  - c) a nucleic acid sequence complementary to the sequence of (a) or (b).
- 2. An isolated recombinant chimpanzee serotype comprising any combination of hexon and fiber nucleic acid sequences selected from the groups of:
  - a) hexon sequences SEQ ID NOS: 16-25; and
  - b) fiber sequences SEQ ID NOS: 6-15.,
- 3. A replication defective chimpanzee adenoviral (ChAd) vector comprising the nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:2 and a transgene which encodes at least one immunogen operatively linked to regulatory sequences which direct expression of said transgene in mammalian cells, wherein said vector lacks the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2 which comprises at least one gene selected from the group consisting of adenoviral E1, E2, E3, and E4.
  - 4. A replication defective ChAd vector which comprises a deletion/disruption in the E1 nucleotide sequence in the region from bp 460 to bp 3542 of SEQ ID NO: 1 or from bp 457 to bp 3425 of SEQ ID NO:2.
  - 5. The ChAd vector according to claim 4, wherein the vector comprises a transgene selected from the group consisting of: HIV, HBV, HCV, HPV, HSV1, HSV2, SARS CoV, *Plasmodium malariae*, Ebola virus, West Nile virus, Dengue virus, Influenza A, Influenza B, and *Mycobacterium tubercolosis*.
  - 6. The ChAd vector according to claim 4, wherein the vector comprises a deletion/disruption in the E1 nucleotide sequence in the region from bp 460 to bp 3542 of SEQ ID NO: 1 or from bp 457 to bp 3425 of SEQ ID NO:2 and further wherein the vector comprises a transgene encoding at least one tumor associated antigen (TAA).

35

25

5

10

15

- 7. The ChAd vector according to claim 6 wherein the at least one TAA is selected from the group consisting of: HER2 NEU, CEA, EPCAM, PSA, PSMA, TELOMERASE, GP100, MELAN-A/MART-1, MUC-1, NY-ESO-1, SURVIVIN, STROMELYSIN 3, TYROSINASE, MAGE3, CML68, CML66, OY-TES-1, SSX-2, SART-1, SART-2, SART-3, NY-CO-58, NY-BR-62, HKLP2, 5T4 and VEGFR2.
- 8. A host cell comprising a nucleic acid molecule according to claim 1 or claim 2, wherein said host cell expresses one or more adenoviral regions selected from the group consisting of E1a, E1b, E2a, E2b, E4 orfs 1, 2, 3, 4, 5, 6, 6/7, pIX, IVa2, regions L1, L2, L3, L4, L5.
- 9. A method of producing a replication-defective chimpanzee adenoviral vector comprising introducing an adenoviral vector according to Claims 3 into an adenoviral E-1 expressing human cell, and harvesting the resulting adenoviruses.
- 10. The method according to Claim 9, wherein the human cell is a 293 cell or a PER.C6 $^{\text{TM}}$  cell.
- 11. A vaccine composition comprising a replication-defective ChAd vector according to any20 one of Claims 3-7.
  - 12. An adenoviral E1-expressing human cell comprising the nucleotide sequence set forth in SEQ ID NO:1.
- 25 13. An adenoviral E1-expressing human cell comprising the nucleotide sequence set forth in SEQ ID NO: 2.
- 14. A method of boosting an antigen-specific immune response in a mammal comprising administering to said mammal a sufficient amount of a recombinant ChAd vector comprising a chimpanzee adenovirus genome containing at least a functional deletion of its E1 gene, a nucleotide sequence encoding a target antigen and a promoter sequence capable of directing expression of the nucleotide sequence encoding the target antigen, wherein administration of said chAd vector elicits a boosted response.

- 15. The method of claim 14, wherein the ChAd vector comprises a complete deletion of its E1 genes and further wherein the vector optionally comprises a deletion of its E3 genes.
- 16. The method of claim 14, wherein the boosted immune response is specific for an antigen derived from an infectious agent selected from the group consisting of: HIV, HBV, HCV, HPV, HSV1, HSV2, SARS CoV, *Plasmodium malariae*, Ebola virus, West Nile virus, Dengue virus, Influenza A, Influenza B, and *Mycobacterium tubercolosis*.
- 17. The method of claim 14, wherein the immune response is a boosted immune response that is specific for a TAA.
  - 18. The method of claim 17, wherein the boosted immune response comprises the production of antigen-specific CD8+ T cells.
- 15 19. The method of claim 14, wherein the boosted immune response comprises the production of antigen-specific CD8+ T cells.
- 20. A method of eliciting an immune response in a naïve mammal comprising administering to said mammal a sufficient amount of a ChAd vector which comprises a chimpanzee adenovirus genome containing at least a functional deletion of its E1 gene, a nucleotide encoding a target antigen and a promoter sequence capable of directing expression of the nucleotide sequence encoding the target antigen, wherein administration of the ChAd vector elicits a primary immune response.
- 21. The method of claim 20, wherein the primary immune response is specific for an antigen derived from an infectious agent such as, but not limited to HIV, HCV, HPV, HSV1, HSV2, SARS CoV, *Plasmodium malariae*, Ebola virus, West Nile virus, Dengue virus, Influenza A, Influenza B, *Mycobacterium tubercolosis*.
- The method of claim 14, wherein the immune response is a primary immune response that is specific for a TAA against which the mammal is tolerant.

- 23. A method of claim according to any one of claims 14 to 22, wherein the recombinant adenovirus comprises a nucleotide sequence encoding a hexon peptide selected from the group consisting of: SEQ ID NOS: 14-21.
- 5 24. A method of claim according to any one of claims 14 to 22,, wherein the recombinant adenovirus comprises a nucleotide sequence encoding a fiber protein sequence selected from the group consisting of: SEQ ID NOS: 6-15.
- 25. A method of inducing an immune response against an antigen derived from an infectious agent selected from the group consisting of: HIV, HCV, HPV, HSV1, HSV2, SARS, Plasmodium maleriae, Ebola virus, West Nile virus, Dengue virus, Influenza A, Influenza B, and Mycobacterium tubercolosis comprising: (a) priming a host to respond to a infectious agent-antigen by administering a first vaccine composition comprising a nucleotide sequence encoding a infectious agent-antigen against which an antigen-specific immune response is desired; and (b) boosting the immune response of step (a) by administering a second vaccine composition comprising a recombinant ChAd vector containing at least a functional deletion of its E1 gene, and in the site of the E1 gene deletion, a sequence comprising a promoter capable of directing expression of DNA encoding the same infectious agent-antigen delivered in the priming step.
- wherein administration of the boosting composition elicits an immune response which has the effect of conferring protective immunity.
  - 26. The method according to claim 25, wherein the first vaccine composition comprises plasmid DNA which is administered intramuscularly in combination with electrical stimulation.
  - 27. The method of claim 25, wherein the second vaccine composition comprises a ChAd vector comprising DNA encoding an antigen derived from an infectious agent selected from the group consisting of: HIV, HCV, HPV, HSV1, HSV2, SARS, Malaria, Ebola virus, West Nile virus, Dengue virus, Influenza A, Influenza B, and *Mycobacterium tubercolosis*.
  - 28. The method of Claim 27, wherein the immune response comprises the production of antigen-specific CD8+ T cells.

- 29. The method of claim 27, wherein the ChAd vector is selected from the group consisting of: ChAd3, ChAd6, ChAd20, ChAd4, ChAd5, ChAd7, ChAd9, ChAd10, ChAd11, ChAd 16, ChAd17, and ChAd19.
- 5 30. The method of claim 25, wherein the ChAd vector comprises a nucelotide sequence encoding a hexon peptide selected from the group consisting of: SEQ ID NO: 16-25.
  - 31. The method of claim 25, wherein the ChAd vector comprises a nucelotide sequence encoding a fiber peptide selected from the group consisting of: SEQ ID NOS: 6-15.
  - 32. The method of claim 25, wherein the first and second vaccine compositions are both ChAd vectors characterized by different serotypes.
- 33. A method of breaking host tolerance to a self-antigen comprising: (a) priming a host to respond to a self-antigen by administering a first vaccine composition comprising a nucleotide sequence encoding a self-antigen against which an antigen-specific immune response is desired, thereby eliciting a primed response; and (b) boosting the primed immune response of step (a) by administering a second vaccine composition comprising a recombinant ChAd vector containing at least a functional deletion of its E1 gene, and in the site of the E1 gene deletion, a sequence comprising a promoter capable of directing expression of DNA encoding the same self-antigen delivered in the priming step, wherein administration of the boosting composition elicits an immune response which has the effect of breaking host tolerance to the self-antigen.
- 34. The method according to claim 33, wherein the first vaccine composition comprises
   plasmid DNA which is administered intramuscularly in combination with electrical stimulation.
  - 35. The method of claim 33, wherein the second vaccine composition comprises a ChAd vector comprising DNA encoding a self antigen selected from the group consisting of: HER2 NEU, CEA, HEPCAM, PSA, PSMA, TELOMERASE, GP100, MELAN-A/MART-1, MUC-1, NY-ESO-1, SURVIVIN, STROMELYSIN 3, TYROSINASE, MAGE3, CML68, CML66, OY-TES-1, SSX-2, SART-1, SART-2, SART-3, NY-CO-58, NY-BR-62, HKLP2, 5T4 and VEGFR2.
- 36. The method of Claim 35, wherein the immune response comprises the production of antigen-specific CD8+ T cells.

- 37. The method of claim 35, wherein the ChAd vector is selected from the group consisting of: ChAd3, ChAd6, ChAd20, ChAd4, ChAd5, ChAd7, ChAd9, ChAd10, ChAd11, ChAd16, ChAd17, and ChAd19.
- 38. The method of claim 35, wherein the ChAd vector comprises a nucleotide sequence encoding a hexon peptide selected from the group consisting of: SEQ ID NO: 16-25.
- 39. The method of claim 35, wherein the ChAd vector comprises a nucleotide sequence encoding a fiber peptide selected from the group consisting of: SEQ ID NOS: 6-15.
  - 40. The method of claim 35, wherein the first and second vaccine compositions are both ChAd vectors characterized by different serotypes.
  - 41. The method of claim 35, wherein the host is a tumor-bearing mammal who has developed resistance to cancer chemotherapy.

20

15

5

25

30

5

10

15

20

#### ABSTRACT OF THE DISCLOSURE

The present invention provides recombinant replication-defective adenoviral vectors derived from chimpanzee adenoviruses and methods for generating recombinant adenoviruses in human E1-expressing cell lines. The invention also provides compositions and methods suitable for use for the delivery and expression of transgenes encoding immunogens against which a boosted immune response is desired. The invention further provides methods of generating clinical grade vector stocks suitable for use in humans. In a particular embodiment the invention contemplates the use of vectors comprising transgenes which encode tumor associated antigens in vaccines and pharmaceutical compositions for the prevention and treatment of cancer.




Fig. 1





Fig. 2



NS3-NS5B

Bgh polyA




Fig. 3




Fig. 4

SEQ ID NO:1

# 5/153

	1 CATCATCAAT AATATACCTT ATTTTGGATT GAAGCCAATA TGATAATGAG ATGGGCGGCG
6	1 CGAGGCGGGG CGCGGGGCGG GAGGCGGGTT TGGGGGGGGGG
12	
18	
24	
30:	
361	
421	
481	
541	
601	
661	
721	
781	
841	•
901	CCTGAGACTA TGCCCCAGCT GCTACCTGAG GTGATCGATC TCACCTGTAA TGAGTCTGGT
961	TTTCCACCCA GCGAGGATGA GGACGAAGAG GGTGAGCAGT TTGTGTTAGA TTCTGTGGAA
1021	CAACCCGGGC GAGGATGCAG GTCTTGTCAA TATCACCGGA AAAACACAGG AGACTCCCAG
1081	ATTATGTGTT CTCTGTGTTA TATGAAGATG ACCTGTATGT TTATTTACAG TAAGTTTATC
1141	ATCGGTGGGC AGGTGGCTA TAGTGTGGGT GGTGGTCTTT GGGGGGTTTT TTAATATATG
1201	TCAGGGGTTA TGCTGAAGAC TTTTTTATTG TGATTTTTAA AGGTCCAGTG TCTGAGCCCG
1261	AGCAAGAACC TGAACCGGAG, CCTGAGCCTT CTCGCCCCAG GAGAAAGCCT GTAATCTTAA
1321	CTAGACCCAG CGCACCGGTA GCGAGAGGCC TCAGCAGCGC GGAGACCACC GACTCCGGTG
1381	CTTCCTCATC ACCCCCGGAG ATTCACCCCC TGGTGCCCCT ATGTCCCGTT AAGCCCGTTG
1441	CCGTGAGAGT CAGTGGGCGG CGGTCTGCTG TGGAGTGCAT TGAGGACTTG CTTTTTGATT
1501	CACAGGAACC TTTGGACTTG AGCTTGAAAC GCCCCAGGCA TTAAACCTGG TCACCTGGAC
1561	TGAATGAGTT GACGCCTATG TTTGCTTTTG AATGACTTAA TGTGTATAGA TAATAAAGAG
1621	TGAGATAATG TTTTAATTGC ATGGTGTGTT TAACTTGGGC GGAGTCTGCT GGGTATATAA
1681	GCTTCCCTGG GCTAAACTTG GTTACACTTG ACCTCATGGA GGCCTGGGAG TGTTTGGAGA

SEQ ID NO:1

6/153

174	1 ACTTTGCCGG AGTTCGTGCC TTGCTGGACG AGAGCTCTAA CAATACCTCT TGGTGGTGGA
180	1 GGTATTTGTG GGGCTCTCCC CAGGGCAAGT TAGTTTGTAG AATCAAGGAG GATTACAAGT
186	1 GGGAATTTGA AGAGCTTTTG AAATCCTGTG GTGAGCTATT GGATTCTTTG AATCTAGGCC
192	1 ACCAGGCTCT CTTCCAGGAG AAGGTCATCA GGACTTTGGA TTTTTCCACA CCGGGGCGCA
198	1 TTGCAGCCGC GGTTGCTTTT CTAGCTTTTT TGAAGGATAG ATGGAGCGAA GAGACCCACT
204	1 TGAGTTCGGG CTACGTCCTG GATTTTCTGG CCATGCAACT GTGGAGAGCA TGGATCAGAC
210	1 ACAAGAACAG GCTGCAACTG TTGTCTTCCG TCCGCCCGTT GCTGATTCCG GCGGAGGAGC
2161	AACAGGCCGG GTCAGAGGAC CGGGCCCGTC GGGATCCGGA GGAGAGGGCA CCGAGGCCGG
2221	L GCGAGAGGAG CGCGCTGAAC CTGGGAACCG GGCTGAGCGG CCATCCACAT CGGGAGTGAA
2281	L TGTCGGGCAG GTGGTGGATC TTTTTCCAGA ACTGCGGCGG ATTTTGACTA TTAGGGAGGA
2341	TGGGCAATTT GTTAAGGGTC TTAAGAGGGA GAGGGGGGCT TCTGAGCATA ACGAGGAGGC
2401	CAGTAATTTA GCTTTTAGCT TGATGACCAG ACACCGTCCA GAGTGCATCA CTTTTCAGCA
2461	GATTAAGGAC AATTGTGCCA ATGAGTTGGA TCTGTTGGGT CAGAAGTATA GCATAGAGCA
2521	GCTGACCACT TACTGGCTGC AGCCGGGTGA TGATCTGGAG GAAGCTATTA GGGTGTATGC
2581	TAAGGTGGCC CTGCGGCCCG ATTGCAAGTA CAAGCTCAAG GGGCTGGTGA ATATCAGGAA
2641	TTGTTGCTAC ATTTCTGGCA ACGGGGCGGA GGTGGAGATA GAGACCGAAG ACAGGGTGGC
2701	TTTCAGATGC AGCATGATGA ATATGTGGCC GGGGGTGCTG GGCATGGACG GGGTGGTGAT
2761	TATGAATGTG AGGTTCACGG GGCCCAACTT TAACGGCACG GTGTTTTTGG GGAACACCAA
2821	CCTGGTCCTG CACGGGGTGA GCTTCTATGG GTTTAACAAC ACCTGTGTGG AGGCCTGGAC
2881	CGATGTGAAG GTCCGCGGTT GCGCCTTTTA TGGATGTTGG AAGGCCATAG TGAGCCGCCC
2941	TAAGAGCAGG AGTTCCATTA AGAAATGCTT GTTTGAGAGG TGCACCTTGG GGATCCTGGC
3001	CGAGGGCAAC TGCAGGGTGC GCCACAATGT GGCCTCCGAG TGCGGTTGCT TCATGCTAGT
3061	CAAGAGCGTG GCGGTAATCA AGCATAATAT GGTGTGCGGC AACAGCGAGG ACAAGGCCTC
3121	ACAGATGCTG ACCTGCACGG ATGGCAACTG CCACTTGCTG AAGACCATCC ATGTAACCAG
3181	CCACAGCCGG AAGGCCTGGC CCGTGTTCGA GCACAACTTG CTGACCCGCT GCTCCTTGCA
3241	TCTGGGCAAC AGGCGGGGG TGTTCCTGCC CTATCAATGC AACTTTAGTC ACACCAAGAT
3301	CTTGCTAGAG CCCGAGAGCA TGTCCAAGGT GAACTTGAAC GGGGTGTTTG ACATGACCAT
3361	GAAGATCTGG AAGGTGCTGA GGTACGACGA GACCAGGTCC CGGTGCAGAC CCTGCGAGTG
3421	CGGGGGCAAG CATATGAGGA ACCAGCCCGT GATGCTGGAT GTGACCGAGG AGCTGAGGAC

3481	AGACCACTTG GTTCTGGCCT GCACCAGGGC CGAGTTTGGT TCTAGCGATG AAGACACAGA
3541	TTGAGGTGGG TGAGTGGGCG TGGCCTGGGG TGGTCATGAA AATATATAAG TTGGGGGTCT
3601	TAGGGTCTCT TTATTTGTGT TGCAGAGACC GCCGGAGCCA TGAGCGGGAG CAGCAGCAGC
3661	AGCAGTAGCA GCAGCGCCTT GGATGGCAGC ATCGTGAGCC CTTATTTGAC GACGCGGATG
3721	CCCCACTGGG CCGGGGTGCG TCAGAATGTG ATGGGCTCCA GCATCGACGG CCGACCCGTC
3781	CTGCCCGCAA ATTCCGCCAC GCTGACCTAT GCGACCGTCG CGGGGACGCC GTTGGACGCC
3841	ACCGCCGCCG CCGCCGCCAC CGCAGCCGCC TCGGCCGTGC GCAGCCTGGC CACGGACTTT
3901	GCATTCCTGG GACCACTGGC GACAGGGGCT ACTTCTCGGG CCGCTGCTGC CGCCGTTCGC
3961	GATGACAAGC TGACCGCCCT GCTGGCGCAG TTGGATGCGC TTACTCGGGA ACTGGGTGAC
4021	CTTTCTCAGC AGGTCATGGC CCTGCGCCAG CAGGTCTCCT CCCTGCAAGC TGGCGGGAAT
	GCTTCTCCCA CAAATGCCGT TTAAGATAAA TAAAACCAGA CTCTGTTTGG ATTAAAGAAA
	AGTAGCAAGT GCATTGCTCT CTTTATTTCA TAATTTTCCG CGCGCGATAG GCCCTAGACC
	AGCGTTCTCG GTCGTTGAGG GTGCGGTGTA TCTTCTCCAG GACGTGGTAG AGGTGGCTCT
	GGACGTTGAG ATACATGGGC ATGAGCCCGT CCCGGGGGTG GAGGTAGCAC CACTGCAGAG
	CTTCATGCTC CGGGGTGGTG TTGTAGATGA TCCAGTCGTA GCAGGAGCGC TGGGCATGGT
	GCCTAAAAAT GTCCTTCAGC AGCAGGCCGA TGGCCAGGGG GAGGCCCTTG GTGTAAGTGT
	TTACAAAACG GTTAAGTTGG GAAGGGTGCA TTCGGGGAGA GATGATGTGC ATCTTGGACT
	GTATTTTTAG ATTGGCGATG TTTCCGCCCA GATCCCTTCT GGGATTCATG TTGTGCAGGA
	CCACCAGTAC AGTGTATCCG GTGCACTTGG GGAATTTGTC ATGCAGCTTA GAGGGAAAAG
	CGTGGAAGAA CTTGGAGACG CCCTTGTGGC CTCCCAGATT TTCCATGCAT TCGTCCATGA
	GATGGCAAT GGGCCCGCGG GAGGCAGCTT GGGCAAAGAT ATTTCTGGGG TCGCTGACGT
4741 C	GTAGTTGTG TTCCAGGGTG AGGTCGTCAT AGGCCATTTT TACAAAGCGC GGGCGGAGGG
	GCCCGACTG GGGGATGATG GTCCCCTCTG GCCCTGGGGC GTAGTTGCCC TCGCAGATCT
	CATTTCCCA GGCCTTAATC TCGGAGGGGG GAATCATATC CACCTGCGGG GCGATGAAGA
4921 A	AACGGTTTC CGGAGCCGGG GAGATTAACT GGGATGAGAG CAGGTTTCTA AGCAGCTGTG
4981 A	TTTTCCACA ACCGGTGGGC CCATAAATAA CACCTATAAC CGGTTGCAGC TGGTAGTTTA
5041 GZ	AGAGCTGCA GCTGCCGTCG TCCCGGAGGA GGGGGGCCAC CTCGTTGAGC ATGTCCCTGA
	GCGCATGTT CTCCCCGACC AGATCCGCCA GAAGGCGCTC GCCGCCCAGG GACAGCAGCT
	TTGCAAGGA AGCAAAGTTT TTCAGCGGCT TGAGGCCGTC CGCCGTGGGC ATGTTTTTCA

5221	GGGTCTGGC	T CAGCAGCTC	C AGGCGGTCC	C AGAGCTCGG	r gacgtgctct	ACGGCATCTC
5281	. TATCCAGCA	T ATCTCCTCG	T TTCGCGGGT	T GGGGCGACT	r TCGCTGTAGG	GCACCAAGCG
5341	. GTGGTCGTC	C AGCGGGGCC	A AAGTCATGT	C CTTCCATGG	G CGCAGGGTCC	TCGTCAGGGT
5401	GGTCTGGGT	C ACGGTGAAG	G GGTGCGCTC	C GGGCTGAGC	G CTTGCCAAGG	TGCGCTTGAG
5461	GCTGGTTCT	G CTGGTGCTG	A AGCGCTGCC	G GTCTTCGCC	TGCGCGTCGG	CCAGGTAGCA
5521	TTTGACCAT	G GTGTCATAG	r ccagccct	CGCGGCGTGT	CCCTTGGCGC	GCAGCTTGCC
5581	CTTGGAGGT	G GCGCCGCAC	G AGGGGCAGA(	G CAGGCTCTTC	G AGCGCGTAGA	GCTTGGGGGC
5641	GAGGAAGAC	C GATTCGGGG	G AGTAGGCGTC	CGCGCCGCAG	ACCCCGCACA	CGGTCTCGCA
5701	CTCCACCAG	CAGGTGAGC	r cggggcgcgc	: CGGGTCAAAA	ACCAGGTTTC	CCCCATGCTT
5761	TTTGATGCG'	TTCTTACCT	GGGTCTCCAT	GAGGTGGTGT	CCCCGCTCGG	TGACGAAGAG
5821	GCTGTCCGT	G TCTCCGTAG	CCGACTTGAG	GGGTCTTTTC	TCCAGGGGGG	TCCCTCGGTC
5881	TTCCTCGTAG	G AGGAACTCGG	ACCACTCTGA	GACGAAGGCC	CGCGTCCAGG	CCAGGACGAA
5941	GGAGGCTATO	TGGGAGGGGT	AGCGGTCGTT	GTCCACTAGG	GGGTCCACCT	TCTCCAAGGT
6001	GTGAAGACAC	: ATGTCGCCTT	CCTCGGCGTC	CAGGAAGGTG	ATTGGCTTGT	AGGTGTAGGC
6061	CACGTGACCG	GGGGTTCCTG	ACGGGGGGGT	ATAAAAGGGG	GTGGGGGCGC	GCTCGTCGTC
6121	ACTCTCTTCC	GCATCGCTGT	CTGCGAGGGC	CAGCTGCTGG	GGTGAGTATT	CCCTCTCGAA
6181	GGCGGGCATG	ACCTCCGCGC	TGAGGTTGTC	AGTTTCCAAA	AACGAGGAGG	ATTTGATGTT
6241	CACCTGTCCC	GAGGTGATAC	CTTTGAGGGT	ACCCGCGTCC	ATCTGGTCAG	AAAACACGAT
6301	CTTTTTATTG	TCCAGCTTGG	TGGCGAACGA	CCCGTAGAGG	GCGTTGGAGA	GCAGCTTGGC
6361	GATGGAGCGC	AGGGTCTGGT	TCTTGTCCCT	GTCGGCGCGC	TCCTTGGCCG	CGATGTTGAG
6421	CTGCACGTAC	TCGCGCGCGA	CGCAGCGCCA	CTCGGGGAAG	ACGGTGGTGC	GCTCGTCGGG
6481	CACCAGGCGC	ACGCGCCAGC	CGCGGTTGTG	CAGGGTGACC	AGGTCCACGC	TGGTGGCGAC
6541	CTCGCCGCGC	AGGCGCTCGT	TGGTCCAGCA	GAGACGGCCG	CCCTTGCGCG	AGCAGAAGGG
6601	GGGCAGGGGG	TCGAGCTGGG	TCTCGTCCGG	GGGGTCCGCG	TCCACGGTGA	AAACCCCGGG
6661	GCGCAGGCGC	GCGTCGAAGT	AGTCTATCTT	GCAACCTTGC	ATGTCCAGCG (	CCTGCTGCCA
6721	GTCGCGGGCG	GCGAGCGCGC	GCTCGTAGGG	GTTGAGCGGC	GGGCCCCAGG (	CATGGGGTG
6781	GGTGAGTGCG	GAGGCGTACA	TGCCGCAGAT	GTCATAGACG	TAGAGGGGCT (	CCGCAGGAC
6841	CCCGATGTAG	GTGGGGTAGC	AGCGGCCGCC	GCGGATGCTG	GCGCGCACGT A	\GTCATACAG
6901	CTCGTGCGAG	GGGGCGAGGA	GGTCGGGGCC	CAGGTTGGTG	CGGGCGGGGC G	CTCCGCGCG

69	61 GAAGACGATC TGCCTGAAGA TGGCATGCGA GTTGGAAGAG ATGGTGGGGC GCTGGAAGAC
702	
708	
714	
720	
726	
732	
738	
744	
750.	1 CGAGAAGTCG GTGCGCTTCT TGGAGCGGGG GTTGGGCAGA GCGAAGGTGA CATCGTTGAA
756:	GAGGATTTTG CCCGCGCGG GCATGAAGTT GCGGGTGATG CGGAAGGGCC CCGGCACTTC  AGAGCCGTTG TTCATGAGGT GGGGGTGATG
7623	TOTAL TIGATGACCT GGGCGGCGAG CACGATCTCG TCGAAGCCGT TGATGTTGTG
7681	TAGAGITCCA GGAAGCGGGG CCGGCCCTTT ACGGTGGGCA GCTTCTTTAG
7741	TOTAL GIGAGETECT CGGGCGAGGC GAGGCCGTGC TCGGCCAGGG CCCAGTCCGC
	CCAGAGGTCG CGGGCCAGGA GGGTCTGCAG
7801	TOTOLOGIC AAGGICCIGA ACTGGCGGCC CACGGCCATT TTTTCGGGGG TGATGCAGTA
7861	GENERAL GENERA
7921	AGGCGCTCGT CGCCCCCGAA TTTCATGACC AGCATGAAGG GCACGAGCTG
7981	TOTAL GEOCCEATICE AAGTGTAGGT CTCTACATCG TAGGTGACAA AGAGGCGCTC
8041	TOGGGAGGAG CTGGATCTCC CGCCACCAGT TGGAGGAGTG
8101	GCTGTTGATG TGGTGGAAGT AGAAGTCCCG TCGCCGGGCC GAACACTCGT GCTGGCTTTT
8161	GTAAAAGCGA GCGCAGTACT GGCAGCGCTG CACGGGCTGT ACCTCCTGCA CGAGATGCAC
8221	CTTTCGCCCG CGCACGAGGA AGCCGAGGGG AAATCTGAGC CCCCCGCCTG GCTCGCGGCA
8281	TGGCTGGTGC TCTTCTACTT TGGATGCGTG TCCGTCTCCG TCTGGCTCCT CGAGGGGTGT
8341	TACGGTGGAG CGGACCACCA CGCCGCGCGA GCCGCAGGTC CAGATATCGG CGCGCGGCGG
8401	TCGGAGTTTG ATGACGACAT CGCGCAGCTG GGAGCTGTCC ATGGTCTGGA GCTCCCGCGG
8461	CGGCGGCAGG TCAGCCGGGA GTTCTTGCAG GTTCACCTCG CAGAGTCGGG CCAGGGCGCG
8521	GGGCAGGTCT AGGTGGTACC TGATCTCTAG GGGCGTGTTG GTGGCGGCGT CGATGGCTTG
8581	CAGGAGCCCG CATCCCCGGG GGGCGACGAC GGTGCCCCGC GGGGTGGTGG TGGTGGTGGT
8641	GGTGGTGGTG GTGGCGGTGC AGCTCAGAAG CGGTGCCGCG GGCGGGCCCC CGGAGGTAGG
	GGCGGGCCCC CGGAGGTAGG

870	1 GGGGGCTC	CG GTCCCGCCG	G CAGGGGCG	GC AGCGGCACG	T CGGCGTGGAG	CGCGGGCAGG
876					A CGCGGCGGTT	
882	1 ATCTGGCG	CC TCTGCGTGA	A GACGACGGG	C CCGGTGAGC	T TGAACCTGAA	AGAGAGTTCG
888	1 ACAGAATC	AA TCTCGGTGT	C ATTGACCGC	G GCCTGGCGC	A GGATCTCCTG	CACGTCTCCC
894:	1 GAGTTGTC1	TT GGTAGGCGA	T CTCGGCCAT	G AACTGCTCG	A TCTCTTCCTC	CTGGAGGTCT
9001	L CCGCGTCCG	G CGCGTTCCA	C GGTGGCCGC	C AGGTCGTTG	G AGATGCGCCC	CATGAGCTGC
9061	GAGAAGGCG	T TGAGTCCGC	C CTCGTTCCA	G ACTCGGCTG	r agaccacgcc	CCCCTGGTCA
9121	. TCGCGGGCG	C GCATGACCA	CTGCGCGAG	G TTGAGCTCC	A CGTGCCGCGC	GAAGACGGCG
9181	TAGTTGCGC	A GACGCTGGA	A GAGGTAGTT	G AGGGTGGTG	G CGGTGTGCTC	GGCCACGAAG
9241	AAGTTCATG	A CCCAGCGGCG	G CAACGTGGA	r TCGTTGATG	CCCCCAAGGC	CTCCAGCCGT
9301	TCCATGGCC	T CGTAGAAGTC	CACGGCGAA	G TTGAAAAACT	GGGAGTTGCG	CGCCGACACG
9361	GTCAACTCC	T CCTCCAGAAG	ACGGATGAG	TCGGCGACGG	TGTCGCGCAC	CTCGCGCTCG
9421	AAGGCTATG	G GGATCTCTTC	CTCCGCTAGC	ATCACCACCT	CCTCCTCTTC	CTCCTCTTCT
9481	GGCACTTCC	A TGATGGCTTC	CTCCTCTTCC	GGGGGGGGG	GCGGCGGCGG	TGGGGGAGGG
9541	GGCGCTCTG	C GCCGGCGGCG	GCGCACCGG	AGGCGGTCCA	CGAAGCGCGC	GATCATCTCC
9601	CCGCGGCGG	GGCGCATGGT	CTCGGTGACG	GCGCGGCCGT	TCTCCCGGGG	GCGCAGTTGG
9661	AAGACGCCGC	CGGACATCTG	GTGCTGGGGC	GGGTGGCCGT	GAGGCAGCGA	AACGGCGCTG
9721	ACGATGCATC	TCAACAATTG	CTGCGTAGGT	ACGCCGCCGA	GGGACCTGAG	GGAGTCCATA
9781	TCCACCGGAT	CCGAAAACCT	TTCGAGGAAG	GCGTCTAACC	AGTCGCAGTC	GCAAGGTAGG
9841	CTGAGCACCG	TGGCGGGCGG	CGGGGGGTGG	GGGGAGTGTC	TGGCGGAGGT (	GCTGCTGATG
9901	ATGTAATTGA	AGTAGGCGGA	CTTGACACGG	CGGATGGTCG	ACAGGAGCAC (	CATGTCCTTG
9961					AGGCTTCGTT (	
10021	CGCAGGTCCT	TGTAGTAGTC	TTGCATGAGC	CTTTCCACCG	GCACCTCTTC 1	CCTTCCTCT
10081					GCGCCCCCT G	
10141	CGCGTGACCC	CGAACCCCCT	GAGCGGTTGG	AGCAGGGCCA	GGTCGGCGAC G	ACGCGCTCG
10201	GCCAGGATGG	CCTGCTGCAC	CTGCGTGAGG	GTGGTTTGGA	AGTCATCCAA G	TCCACGAAG
10261					CCATGACGGA C	
10321					GCGAGTAGGC G	
10381	AAGACGTAGT	CGTTGCAAGT (	CCGCACCAGG	TACTGGTAGC	CCACCAGGAA G	TGCGGCGGC

SEQ ID NO:1 11/153

						•
10441	. GGCTGGCGG	T AGAGGGGCC	A GCGCAGGGT	G GCGGGGGCT	C CGGGGGCCA	GTCTTCCAGC
10501	. ATGAGGCGG	T GGTAGGCGT	A GATGTACCI	G GACATCCAG	G TGATACCCG	C GGCGGTGGTG
10561	. GAGGCGCGC	G GGAAGTCGC	G CACCCGGTT	C CAGATGTTG	C GCAGGGGCAG	AAAGTGCTCC
10621	ATGGTAGGC	G TGCTCTGTC	C AGTCAGACG	C GCGCAGTCG	T TGATACTCTA	GACCAGGGAA
10681	AACGAAAGC	C GGTCAGCGG	G CACTCTTCC	G TGGTCTGGT	G AATAGATCGO	AAGGGTATCA
10741	TGGCGGAGG	G CCTCGGTTC	G AGCCCCGGG	T CCGGGCCGG.	A CGGTCCGCCA	TGATCCACGC
10801	GGTTACCGC	C CGCGTGTCG	A ACCCAGGTG	T GCGACGTCA	G ACAACGGTGG	AGTGTTCCTT
10861	TTGGCGTTT	TCTGGCCGG	G CGCCGGCGT	C GCGTAAGAG	A CTAAGCCGCG	AAAGCGAAAG
10921	CAGTAAGTG	G CTCGCTCCC	GTAGCCGGA	G GGATCCTTG	C TAAGGGTTGC	GTTGCGGCGA
10981	ACCCCGGTTC	GAATCCCGT	A CTCGGGCCG	G CCGGACCCG	C GGCTAAGGTG	TTGGATTGGC
11041	CTCCCCCTCG	TATAAAGACO	CCGCTTGCG	G ATTGACTCC	GACACGGGGA	CGAGCCCCTT
11101	TTATTTTTGC	TTTCCCCAGA	TGCATCCGG	r GCTGCGGCAC	ATGCGCCCC	CGCCCCAGCA
11161	GCAGCAACAA	CACCAGCAAG	AGCGGCAGC	A ACAGCAGCGG	GAGTCATGCA	GGGCCCCCTC
11221					GTGTCTGGCG	
11281	CGGCGGGGGG	CCGGCTGACG	ACCCCGAGGA	ccccccccc	GCAGGGCCA	GACACTACCT
11341	GGACCTGGAG	GAGGGCGAGG	GCCTGGCGCG	GCTGGGGGCG	CCGTCTCCCG	AGCGCCACCC
11401					CCTCGGCAGA	
11461	GGACCGCGCG	GGCGAGGAGC	CCGAGGAGAT	' GCGGGACAGG	AGGTTCAGCG	CAGGGCGGGA
11521					GAGGACTTTG	
11581					GCCGACCTGG	
11641					TTCAACAACC	
11701					CTGTGGGACT	
11761					CTGTTCCTGA	
11821					ATCACCGAGC	
11881					GTGCAGGAGC	
11941					AGCCTGGGCA	
12001					GAGGTGAAGA	
12061					GACCTGGGCG	
12121	•				GAGCTGAGCG	

1218	1 GATGCACAGC CTGCAGCGGG CGCTGGCGGG CGCCGGCAGC GGCGACAGGG AGGCGGAGTC
1224	
1230	
1236	
1242	
1248	
1254	
1260	·
12661	
12721	
12781	
12841	
12901	
12961	
13021	AAGAACCTGC GGGGGTGTG GGGCGTGAAG GCGCCCACCG GCGACCGGGC GACGGTGTCC
13081	AGCCTGCTGA CGCCCAACTC GCGCCTGCTG CTGCTGCTGA TCGCGCCGTT CACGGACAGC
13141	GGCAGCGTGT CCCGGGACAC CTACCTGGGG CACCTGCTGA CCCTGTACCG CGAGGCCATC
13201	GGGCAGGCGC AGGTGGACGA GCACACCTTC CAGGAGATCA CCAGCGTGAG CCGCGCGCTG
13261	GGGCAGGAGG ACACGAGCAG CCTGGAGGCG ACTCTGAACT ACCTGCTGAC CAACCGGCGG
13321	CAGAAGATTC CCTCGCTGCA CAGCCTGACC TCCGAGGAGG AGCGCATCTT GCGCTACGTG
13381	CAGCAGAGCG TGAGCCTGAA CCTGATGCGC GACGGGGTGA CGCCCAGCGT GGCGCTGGAC
13441	
13501	ATGACCGCGC GCAACATGGA ACCGGGCATG TACGCCGCGC ACCGGCCTTA CATCAACCGC
13561	CTGATGGACT ACCTGCATCG CGCGGGGGC GTGAACCCCG AGTACTTTAC CAACGCCATC
13621	CTGAACCCGC ACTGGCTCCC GCCGCCCGGG TTCTACAGCG GGGGCTTCGA GGTCCCGGAG GCCAACGATG GCTTCCTGTG CCACGAGATG GARGAGATG GARGAGATG
13681	GCCAACGATG GCTTCCTGTG GGACGACATG GACGACAGCG TGTTCTCCCC GCGGCCGCAG
13741	GCGCTGGCGG AAGCGTCCCT GCTGCGTCCC AAGAAGGAGG AGGAGGAGGC GAGTCGCCGC
13801	CGCGGCAGCA GCGCGCGCGC TTCTCTGTCC GAGCTGGGGG CGGCAGCCGC CGCGCGCCCC
	GGGTCCCTGG GCGGCAGCCC CTTTCCGAGC CTGGTGGGGT CTCTGCACAG CGAGCGCACC
	ACCCGCCCTC GGCTGCTGGG CGAGGACGAG TACCTGAATA ACTCCCTGCT GCAGCCGGTG

13/153 SEQ ID NO:1 13921 CGGGAGAAA ACCTGCCCC CGCCTTCCCC AACAACGGGA TAGAGAGCCT GGTGGACAAG 13981 ATGAGCAGAT GGAAGACCTA TGCGCAGGAG CACAGGGACG CGCCCGCGCT CCGGCCGCCC 14041 ACGCGGCGCC AGCGCCACGA CCGGCAGCGG GGGCTGGTGT GGGATGACGA GGACTCCGCG 14101 GACGATAGCA GCGTGCTGGA CCTGGGAGGG AGCGGCAACC CGTTCGCGCA CCTGCGCCCC 14161 CGCCTGGGGA GGATGTTTTA AAAAAAAAA AAGCAAGAAG CATGATGCAA AATTAAATAA 14221 AACTCACCAA GGCCATGGCG ACCGAGCGTT GGTTTCTTGT GTTCCCTTCA GTATGCGGCG 14281 CGCGGCGATG TACCAGGAGG GACCTCCTCC CTCTTACGAG AGCGTGGTGG GCGCGGCGGC 14341 GGCGGCGCC TCTTCTCCCT TTGCGTCGCA GCTGCTGGAG CCGCCGTACG TGCCTCCGCG 14401 CTACCTGCGG CCTACGGGGG GGAGAAACAG CATCCGTTAC TCGGAGCTGG CGCCCCTGTT 14461 CGACACCACC CGGGTGTACC TGGTGGACAA CAAGTCGGCG GACGTGGCCT CCCTGAACTA 14521 CCAGAACGAC CACAGCAATT TTTTGACCAC GGTCATCCAG AACAATGACT ACAGCCCGAG 14581 CGAGGCCAGC ACCCAGACCA TCAATCTGGA TGACCGGTCG CACTGGGGCG GCGACCTGAA 14641 AACCATCCTG CACACCAACA TGCCCAACGT GAACGAGTTC ATGTTCACCA ATAAGTTCAA 14701 GGCGCGGGTG ATGGTGTCGC GCTCGCACAC CAAGGAAGAC CGGGTGGAGC TGAAGTACGA 14761 GTGGGTGGAG TTCGAGCTGC CAGAGGGCAA CTACTCCGAG ACCATGACCA TTGACCTGAT 14821 GAACAACGCG ATCGTGGAGC ACTATCTGAA AGTGGGCAGG CAAAACGGGG TCCTGGAGAG 14881 CGACATCGGG GTCAAGTTCG ACACCAGGAA CTTCCGCCTG GGGCTGGACC CCGTGACCGG 14941 GCTGGTTATG CCCGGGGTGT ACACCAACGA GGCCTTCCAT CCCGACATCA TCCTGCTGCC 15001 CGGCTGCGGG GTGGACTTCA CTTACAGCCG CCTGAGCAAC CTCCTGGGCA TCCGCAAGCG 15061 GCAGCCCTTC CAGGAGGGCT TCAGGATCAC CTACGAGGAC CTGGAGGGGG GCAACATCCC 15121 CGCGCTCCTC GATGTGGAGG CCTACCAGGA TAGCTTGAAG GAAAATGAGG CGGGACAGGA 15181 GGATACCACC CCCGCCGCCT CCGCCGCCGC CGAGCAGGGC GAGGATGCTG CTGACACCGC 15241 GGCCGCGGAC GGGCCAGAGG CCGACCCCGC TATGGTGGTG GAGGCTCCCG AGCAGGAGGA 15301 GGATATGAAT GACAGTGCGG TGCGCGGAGA CACCTTCGTC ACCCGGGGGG AGGAAAAGCA 15361 AGCGGAGGCC GAGGCCGCGG CCGAGGAAAA GCAACTGGCG GCAGCAGCGG CGGCGGCGGC 15421 GTTGGCCGCG GCGGAGGCTG AGTCTGAGGG GACCAAGCCC GCCAAGGAGC CCGTGATTAA

Fig. 5I

15481 GCCCCTGACC GAAGATAGCA AGAAGCGCAG TTACAACCTG CTCAAGGACA GCACCAACAC

15541 CGCGTACCGC AGCTGGTACC TGGCCTACAA CTACGGCGAC CCGTCGACGG GGGTGCGCTC

15601 CTGGACCCTG CTGTGCACGC CGGACGTGAC CTGCGGCTCG GAGCAGGTGT ACTGGTCGCT

156	61 GCCCGACATG ATGCAAGACC CCGTGACCTT CCGCTCCACG CGGCAG	
1572		
	GOLGGIGGE GCCGAGCTGC TGCCCGTGCA CTCCAAGAGC TTCTAC	
1578	TOTOGRA CICATOCGCC AGTTCACCTC TCTGACCCAC GTGTTC	
1584	CIGGEGEGE CGCCCGCCC CACCATCACC ACCGTC	AGTG AAAACGTTCC
1590	01 TGCTCTCACA GATCACGGGA CGCTACCGCT GCGCAACAGC ATCGGA	GGAG TCCAGCGAGT
1596		
1602		
1608		
1614		
1620		
1626		
1632		
16381		
16441		
16501		
16561		
16621		
16681	ACCGGCACGC GCGTGCCCGT GCGCTTCCGC CCCCCGCGGA CTTGAGA	
16741	THE STATE OF THE S	
16801	AGAGATGUTC CAGGTCGTCG CGCCGGA	
	. COMMONAGO ANGAGCAGGA TTCGAAGCCC CGCAAGATAA AGCGGGT	
16861	TOOMTOCCOA TOGGGAGGTG GAGTTCCTGC GCGCCACG	
16921	COCCTCCTGC GCCCCGTAAAG CGCGTCCTGC GCCCCGGC	
16981	TTCACGCCCG GCGAGCGCTC CACCCGGACT TTCAAGCGCG TCTATGAC	GA GGTGTACGGC
17041	GACGAAGACC TGCTGGAGCA GGCCAACGAG CGCTTCGGAG AGTTTGCT	TA CGGGAAGCGT
17101		
17161		
17221		
17281		
17341	GACATCAGGG TCCGTCCCAT CAAGCAGGTG GCGCCGGGCC TCGGCGTGC	
	The substitution of the su	A GACCGTGGAC

i	SEQ ID 1	NO:1	-	L5/15	3		
	17401	GTGGTCATC	C CCACCGGCA	A CTCCCCCGC	C GCCACCACC	A CTACCGCTGC	CTCCACGGAC
	17461				C GCAGCCGCC		
	17521				G CCGGCGATGT		
	17581				G CTCCTGCCC		
	17641				r acctaccgcc		
	17701				C ACCACCCGCC		
	17761				A GTGGCGCGCG		
	17821				TAAAAGCCTG		
	17881				CCGGGATACC		
	17941				GGAGGCAGCC		
	18001				GTGCTGCCCC		
	18061				TCCGTGGCCT		
	18121				АААААААА	•	
	18181				TTTGTAGAAT		
	18241				TCCTGGGACA		
	18301				GCTCTCTGTG		
	18361				CCTGGAACAG		
	18421				AGAAGGTGGT		
	18481				CCGTGCAGAA		
	18541				CGGCGCTGGA		
	18601				AAGAGACCAC		
	18661				AAGGTCTGCC		
	18721				CCCCCGCCAC		
					AGCCGGGCCC		
	400						acc receding

F	i	g		5K
		$\boldsymbol{\Xi}$	•	

18841 CCTCCGCCGG TCCTCTGCGC CGCGCGCCCA GCGGCCCCCG CGGGGGGGTC GCGAGGCACG

18901 GCAACTGGCA GAGCACGCTG AACAGCATCG TGGGTCTGGG GGTGCGGTCC GTGAAGCGCC

18961 GCCGATGCTA CTGAATAGCT TAGCTAACGT GTTGTATGTG TGTATGCGCC CTATGTCGCC

19021 GCCAGAGGAG CTGCTGAGTC GCCGCCGTTC GCGCGCCCAC CACCACCGCC ACTCCGCCCC

19081 TCAAGATGGC GACCCCATCG ATGATGCCGC AGTGGTCGTA CATGCACATC TCGGGCCAGG

1914	1 ACGCCTCG	GA GTACCTGAG	C CCCGGGCTG	G TGCAGTTCG	C CCGCGCCACC	GAGAGCTACT
1920	1 TCAGCCTG	AG TAACAAGTT	T AGGAACCCC	A CGGTGGCGC	C CACGCACGAT	GTGACCACCG
1926	1 ACCGGTCTC	CA GCGCCTGAC	G CTGCGGTTC	A TTCCCGTGG	A CCGCGAGGAC	ACCGCGTACT
1932	1 CGTACAAGO	GCGGTTCAC	C CTGGCCGTG	G GCGACAACC	G CGTGCTGGAC	ATGGCCTCCA
1938	1 CCTACTTTG	A CATCCGCGG	G GTGCTGGAC	C GGGGTCCCA	TTTCAAGCCC	TACTCTGGCA
1944	1 CCGCCTACA	A CTCCCTGGC	CCCAAGGGC	G CTCCCAACT	CTGCGAGTGG	GAGCAAGAGG
1950	1 AAACTCAGG	C AGTTGAAGA	A GCAGCAGAA	G AGGAAGAAGA	A AGATGCTGAC	GGTCAAGCTG
1956	1 AGGAAGAGC	A AGCAGCTACO	AAAAAGACTO	CATGTATATGO	TCAGGCTCCC	CTTTCTGGCG
1962:	1 ААААААТТА	G TAAAGATGG1	CTGCAAATA	GAACGGACGC	TACAGCTACA	GAACAAAAAC
19681	l CTATTTATG	C AGACCCTACA	TTCCAGCCC	AACCCCAAA	CGGGGAGTCC	CAGTGGAATG
19741	L AGGCAGATG	C TACAGTCGCC	GGCGGTAGAC	G TGCTAAAGAA	ATCTACTCCC	ATGAAACCAT
19801	GCTATGGTT	C CTATGCAAGA	CCCACAAATG	CTAATGGAGG	TCAGGGTGTA	CTAACGGCAA
19861	ATGCCCAGG	G ACAGCTAGAA	TCTCAGGTTG	AAATGCAATT	CTTTTCAACT	TCTGAAAACG
19921		A GGCTAACAAC				
19981	TGGAGACCC	C GGATACGCAC	CTTTCTTACA	AGCCCGCAAA	AAGCGATGAC	AATTCAAAAA
20041	TCATGCTGG	G TCAGCAGTCC	ATGCCCAACA	GACCTAATTA	CATCGGCTTC	AGAGACAACT
20101	TTATCGGCCT	CATGTATTAC	AATAGCACTG	GCAACATGGG	AGTGCTTGCA	GGTCAGGCCT
20161	CTCAGTTGAZ	TGCAGTGGTG	GACTTGCAAG	ACAGAAACAC	AGAACTGTCC	TACCAGCTCT
20221	TGCTTGATTC	CATGGGTGAC	AGAACCAGAT	ACTTTTCCAT	GTGGAATCAG	GCAGTGGACA
20281	GTTATGACCC	AGATGTTAGA	ATTATTGAAA	ATCATGGAAC	TGAAGACGAG	CTCCCCAACT
20341		TCTGGGTGGC				
20401	ATGGCAATAA	CGGGGGCCAG	GTGACTTGGA	CAAAAGATGA	AACTTTTGCA	GATCGCAATG
20461	AAATAGGGGT					
20521		CTCCAACGTG				
20581		CTCTGACAAC				
20641		GGACTGCTAC				
20701		CTTCAACCAC				
20761		CTACGTGCCC				
20821		CCTGCCGGGC				

SEQ ID N	I:O	1	7/153	3		
20881	TGGTCCTCC	A GAGCTCTCTG	GGTAACGATC	: TCAGGGTGGA	CGGGGCCAGC	ATCAAGTTCG
20941	AGAGCATCT	CCTCTACGCC	ACCTTCTTCC	: CCATGGCCCA	CAACACGGCC	TCCACGCTCG
21001	AGGCCATGCT	CAGGAACGAC	ACCAACGACC	AGTCCTTCAA	TGACTACCTT	TCCGCCGCCA
21061	ACATGCTCTA	CCCCATACCC	GCCAACGCCA	CCAACGTCCC	CATCTCCATC	CCCTCGCGCA
21121	ACTGGGCGGC	: CTTCCGCGGC	TGGGCCTTCA	CCCGCCTCAA	GACCAAGGAG	ACCCCCTCCC
21181	TGGGCTCGGG	ATTCGACCCC	TACTACACCT	ACTCGGGCTC	TATTCCCTAC	CTGGACGGCA
21241	CCTTCTACCT	' CAACCACACT	TTCAAGAAGG	TCTCGGTCAC	CTTCGACTCC	TCGGTCAGCT
21301	GGCCGGGCAA	CGACCGTCTG	CTCACCCCCA	ACGAGTTCGA	GATCAAGCGC	TCGGTCGACG
21361	GGGAAGGCTA	CAACGTGGCC	CAGTGCAACA	TGACCAAGGA	CTGGTTCCTG	GTCCAGATGC
21421	TGGCCAACTA	CAACATCGGC	TACCAGGGCT	TCTACATCCC	AGAGAGCTAC	AAGGACAGGA
21481	TGTACTCCTT	CTTCAGGAAC	TTCCAGCCCA	TGAGCCGGCA	GGTGGTGGAC	CAGACCAAGT
21541	ACAAGGACTA	CCAGGAGGTG	GGCATCATCC	ACCAGCACAA	CAACTCGGGC	TTCGTGGGCT
21601	ACCTCGCCCC	CACCATGCGC	GAGGGACAGG	CCTACCCCGC	CAACTTCCCC	TACCCGCTCA
21661	TAGGCAAGAC	CGCGGTCGAC	AGCATCACCC	AGAAAAAGTT	CCTCTGCGAC	CGCACCCTCT
21721	GGCGCATCCC	CTTCTCCAGC	AACTTCATGT	CCATGGGTGC	GCTCTCGGAC	CTGGGCCAGA
21781	ACTTGCTCTA	CGCCAACTCC	GCCCACGCCC	TCGACATGAC	CTTCGAGGTC	GACCCCATGG
21841	ACGAGCCCAC	CCTTCTCTAT	GTTCTGTTCG	AAGTCTTTGA	CGTGGTCCGG	GTCCACCAGC
21901	CGCACCGCGG	CGTCATCGAG	ACCGTGTACC	TGCGTACGCC	CTTCTCGGCC	GGCAACGCCA
21961	CCACCTAAAG	AAGCAAGCCG	CAGTCATCGC	CGCCTGCATG	CCGTCGGGTT	CCACCGAGCA
22021	AGAGCTCAGG	GCCATCGTCA	GAGACCTGGG	ATGCGGGCCC	TATTTTTGG	GCACCTTCGA
22081	CAAGCGCTTC	CCTGGCTTTG	TCTCCCCACA	CAAGCTGGCC	TGCGCCATCG	TCAACACGGC
22141	CGGCCGCGAG	ACCGGGGGCG	TGCACTGGCT	GGCCTTTGCC	TGGAACCCGC	GCTCCAAAAC
22201	ATGCTTCCTC	TTTGACCCCT	TCGGCTTTTC	GGACCAGCGG	CTCAAGCAAA	TCTACGAGTT
22261	CGAGTACGAG	GGCTTGCTGC	GTCGCAGCGC	CATCGCCTCC	TCGCCCGACC	GCTGCGTCAC
22321	CCTCGAAAAG	TCCACCCAGA	CCGTGCAGGG	GCCCGACTCG	GCCGCCTGCG	GTCTCTTCTG
22381	CTGCATGTTT	CTGCACGCCT	TTGTGCACTG	GCCTCAGAGT	CCCATGGACC	GCAACCCCAC
22441	CATGAACTTG	CTGACGGGGG	TGCCCAACTC	CATGCTCCAA	AGCCCCCAGG	TCGAGCCCAC
22501	CCTGCGCCGC	AACCAGGAGC	AGCTCTACAG	CTTCCTGGAG	CGCCACTCGC	CCTACTTCCG
22561	CCGCCACAGC	GCACAGATCA	GGAGGGCCAC	CTCCTTCTGC	CACTTGCAAG	AGATGCAAGA

Fig. 5M

2262	1 2000					
2262				T CAATAAATG		
2268	1 AAGCTCTCT	TG GGGTATTCA	T TTCCCACCA	.C CACCACCCG	CGTTGTCGCC	ATCTGGCTCT
2274	1 ATTTAGAAA	T CGAAAGGGT	T CTGCCGGGA	G TCGCCGTGC	CCACGGGCAG	GGACACGTTG
2280	1 CGATACTGG	T AGCGGGTGC	C CCACTTGAA	C TCGGGCACCA	CCAGGCGAGG	CAGCTCGGGG
2286	1 AAGTTTTCG	C TCCACAGGC	T GCGGGTCAG	C ACCAGCGCGT	TCATCAGGTC	GGGCGCCGAG
2292	1 ATCTTGAAG	T CGCAGTTGG	G GCCGCCGCC	C TGCGCGCGCG	AGTTGCGGTA	CACCGGGTTG
2298	1 CAGCACTGG	A ACACCAACA	G CGCCGGGTG	C TTCACGCTGG	CCAGCACGCT	GCGGTCGGAG
2304	1 ATCAGCTCG	G CGTCCAGGT	C CTCCGCGTT	G CTCAGCGCGA	ACGGGGTCAT	CTTGGGCACT
2310	TGCCGCCCC.	A GGAAGGGCG	C GTGCCCGG	r ttcgagttgc	AGTCGCAGCG	CAGCGGGATC
23161	AGCAGGTGC	C CGTGCCCGG	A CTCGGCGTT	G GGGTACAGCG	CGCGCATGAA	GGCCTGCATC
23221	TGGCGGAAG	G CCATCTGGGC	C CTTGGCGCC	C TCCGAGAAGA	ACATGCCGCA	GGACTTGCCC
23281	GAGAACTGG	r ttgcggggc	A GCTGGCGTC	G TGCAGGCAGC	AGCGCGCGTC	GGTGTTGGCG
23341	. ATCTGCACC	A CGTTGCGCCC	CCACCGGTT	C TTCACGATCT	TGGCCTTGGA	CGATTGCTCC
23401	TTCAGCGCGC	C GCTGCCCGTT	CTCGCTGGT	ACATCCATCT	CGATCACATG	TTCCTTGTTC
23461	ACCATGCTGC	TGCCGTGCAG	ACACTTCAGO	TCGCCCTCCG	TCTCGGTGCA	GCGGTGCTGC
23521	CACAGCGCGC	AGCCCGTGGG	CTCGAAAGAC	TTGTAGGTCA	CCTCCGCGAA	GGACTGCAGG
23581	TACCCCTGCA	AAAAGCGGCC	CATCATGGTC	ACGAAGGTCT	TGTTGCTGCT	GAAGGTCAGC
23641	TGCAGCCCGC	GGTGCTCCTC	GTTCAGCCAG	GTCTTGCACA	CGGCCGCCAG	CGCCTCCACC
23701	TGGTCGGGCA	GCATCTTGAA	GTTCACCTTC	AGCTCATTCT	CCACGTGGTA	CTTGTCCATC
23761	AGCGTGCGCG	CCGCCTCCAT	GCCCTTCTCC	CAGGCCGACA	CCAGCGGCAG	GCTCACGGGG
23821	TTCTTCACCA	TCACCGTGGC	CGCCGCCTCC	GCCGCGCTTT	CGCTTTCCGC	CCCGCTGTTC
23881	TCTTCCTCTT	CCTCCTCTTC	CTCGCCGCCG	CCCACTCGCA	GCCCCCGCAC	CACGGGGTCG
23941	TCTTCCTGCA	GGCGCTGCAC	CTTGCGCTTG	CCGTTGCGCC	CCTGCTTGAT	GCGCACGGGC
24001	GGGTTGCTGA	AGCCCACCAT	CACCAGCGCG	GCCTCTTCTT	GCTCGTCCTC	GCTGTCCAGA
24061				CTCAGTACCG		
24121	CTGGGGGCGT	TCGCCAGCTC	CGCGGCTGCG	GCCGCTGCCG	AGGTCGAAGG (	CCGAGGGCTG
24181				CCGTCCTCGT		
24241				GGCGGCGGAG		
24301				CGGCGGGCCG		

24361	GTGGTTTCGC	GCTGGTCCTC	TTCCCGACTG	GCCATCTCCC	ACTGCTCCTT	CTCCTATAGG
24421	CAGAAAGAGA	TCATGGAGTC	TCTCATGCGA	GTCGAGAAGG	AGGAGGACAG	CCTAACCGCC
24481	CCCTCTGAGC	CCTCCACCAC	CGCCGCCACC	ACCGCCAATG	CCGCCGCGGA	CGACGCGCCC
24541	ACCGAGACCA	CCGCCAGTAC	CACCCTCCCC	AGCGACGCAC	CCCCGCTCGA	GAATGAAGTG
24601	CTGATCGAGC	AGGACCCGGG	TTTTGTGAGC	GGAGAGGAGG	ATGAGGTGGA	TGAGAAGGAG
24661	AAGGAGGAGG	TCGCCGCCTC	AGTGCCAAAA	GAGGATAAAA	AGCAAGACCA	GGACGACGCA
24721	GATAAGGATG	AGACAGCAGT	CGGGCGGGG	AACGGAAGCC	ATGATGCTGA	TGACGGCTAC
24781	CTAGACGTGG	GAGACGACGT	GCTGCTTAAG	CACCTGCACC	GCCAGTGCGT	CATCGTCTGC
24841	GACGCGCTGC	AGGAGCGCTG	CGAAGTGCCC	CTGGACGTGG	CGGAGGTCAG	CCGCGCCTAC
24901	GAGCGGCACC	TCTTCGCGCC	GCACGTGCCC	CCCAAGCGCC	GGGAGAACGG	CACCTGCGAG
24961	CCCAACCCGC	GTCTCAACTT	CTACCCGGTC	TTCGCGGTAC	CCGAGGTGCT	GGCCACCTAC
25021	CACATCTTCT	TCCAAAACTG	CAAGATCCCC	CTCTCCTGCC	GCGCTAACCG	CACCCGCGCC
25081	GACAAAACCC	TGACCCTGCG	GCAGGGCGCC	CACATACCTG	ATATTGCCTC	TCTGGAGGAA
25141	GTGCCCAAGA	TCTTCGAGGG	TCTCGGTCGC	GACGAGAAAC	GGGCGGCGAA	CGCTCTGCAC
25201	GGAGACAGCG	AAAACGAGAG	TCACTCGGGG	GTGCTGGTGG	AGCTCGAGGG	CGACAACGCG
25261	CGCCTGGCCG	TACTCAAGCG	CAGCATAGAG	GTCACCCACT	TTGCCTACCC	GGCGCTCAAC
25321	CTGCCCCCCA	AGGTCATGAG	TGTGGTCATG	GGCGAGCTCA	TCATGCGCCG	CGCTCAGCCC
25381	CTGGCCGCGG	ATGCAAACTT	GCAAGAGTCC	TCCGAGGAAG	GCCTGCCCGC	GGTCAGCGAC
25441	GAGCAGCTAG	CGCGCTGGCT	GGAGACCCGC	GACCCCGCGC	AGCTGGAGGA	GCGGCGCAAG
25501	CTCATGATGG	CCGCGGTGCT	GGTCACCGTG	GAGCTCGAGT	GTCTGCAGCG	CTTCTTCGCG
25561	GACCCCGAGA	TGCAGCGCAA	GCTCGAGGAG	ACCCTGCACT	ACACCTTCCG	CCAGGGCTAC
25621	GTGCGCCAGG	CCTGCAAGAT	CTCCAACGTG	GAGCTCTGCA	ACCTGGTCTC	CTACCTGGGC
25681	ATCCTGCACG	AGAACCGCCT	CGGGCAGAAC	GTCCTGCACT	CCACCCTCAA	AGGGGAGGCG
25741	CGCCGCGACT	ACATCCGCGA	CTGCGCCTAC	CTCTTCCTCT	GCTACACCTG	GCAGACGGCC
25801	ATGGGGGTCT	GGCAGCAGTG	CCTGGAGGAG	CGCAACCTCA	AGGAGCTGGA	AAAGCTACTC
25861	AAGCGCACCC	TCAGGGACCT	CTGGACGGGC	TTCAACGAGC	GCTCGGTGGC	CGCCGCGCTG
25921	GCGGACATCA	TCTTCCCCGA	GCGCCTGCTC	AAGACCCTGC	AGCAGGGCCT	GCCCGACTTC
25981	ACCAGCCAGA	GCATGCTGCA	GAACTTTAGG	ACTTTCATCC	TGGAGCGCTC	GGGCATCCTG
26041	CCTGCCACTT	GCTGCGCGCT	GCCCAGCGAC	TTCGTGCCCA	TCAAGTACAG	GGAGTGCCCG

SE	Q ID NC	): <b>1</b>	2	0/153	3		
	26101	CCGCCGCTCT	GGGGCCACTG	CTACCTCTTC	CAGCTGGCCA	ACTACCTCGC	CTACCACTCG
	26161	GACCTCATGG	AAGACGTGAG	CGGCGAGGGC	CTGCTCGAGT	GCCACTGCCG	CTGCAACCTC
	26221	TGCACGCCCC	ACCGCTCTCT	AGTCTGCAAC	CCGCAGCTGC	TCAGCGAGAG	TCAGATTATC
	26281	GGTACCTTCG	AGCTGCAGGG	TCCCTCGCCT	GACGAGAAGT	CCGCGGCTCC	GGGGCTGAAA
	26341	CTCACTCCGG	GGCTGTGGAC	TTCCGCCTAC	CTACGCAAAT	TTGTACCTGA	GGACTACCAC
	26401	GCCCACGAGA	TCAGGTTCTA	CGAAGACCAA	TCCCGCCCGC	CCAAGGCGGA	GCTCACCGCC
	26461	TGCGTCATCA	CCCAGGGGCA	CATCCTGGGC	CAATTGCAAG	CCATCAACAA	AGCCCGCCGA
	26521	GAGTTCTTGC	TGAAAAAGGG	TCGGGGGGTG	TACCTGGACC	CCCAGTCCGG	CGAGGAGCTA
	26581	AACCCGCTAC	CCCCGCCGCC	GCCCCAGCAG	CGGGACCTTG	CTTCCCAGGA	TGGCACCCAG
	26641	AAAGAAGCAG	CAGCCGCCGC	CGCCGCAGCC	ATACATGCTT	CTGGAGGAAG	AGGAGGAGGA
	26701	CTGGGACAGT	CAGGCAGAGG	AGGTTTCGGA	CGAGGAGCAG	GAGGAGATGA	TGGAAGACTG
	26761	GGAGGAGGAC	AGCAGCCTAG	ACGAGGAAGC	TTCAGAGGCC	GAAGAGGTGG	CAGACGCAAC
	26821	ACCATCACCC	TCGGTCGCAG	CCCCCTCGCC	GGGCCCCTG	AAATCCTCCG	AACCCAGCAC
	26881	CAGCGCTATA	ACCTCCGCTC	CTCCGGCGCC	GGCGCCACCC	GCCCGCAGAC	CCAACCGTAG
	26941	ATGGGACACC	ACAGGAACCG	GGGTCGGTAA	GTCCAAGTGC	CCGCCGCCGC	CACCGCAGCA
	27001	GCAGCAGCAG	CGCCAGGGCT	ACCGCTCGTG	GCGCGGGCAC	AAGAACGCCA	TAGTCGCCTG
	27061	CTTGCAAGAC	TGCGGGGGCA	ACATCTCTTT	CGCCCGGCGC	TTCCTGCTAT	TCCACCACGG
	27121	GGTCGCCTTT	CCCCGCAATG	TCCTGCATTA	CTACCGTCAT	CTCTACAGCC	CCTACTGCAG
	27181	CGGCGACCCA	GAGGCGGCAG	CGGCAGCCAC	AGCGGCGACC	ACCACCTAGG	AAGATATCCT
	27241	CCGCGGGCAA	GACAGCGGCA	GCAGCGGCCA	GGAGACCCGC	GGCAGCAGCG	GCGGGAGCGG
	27301	TGGGCGCACT	GCGCCTCTCG	CCCAACGAAC	CCCTCTCGAC	CCGGGAGCTC	AGACACAGGA
	27361	TCTTCCCCAC	TTTGTATGCC	ATCTTCCAAC	AGAGCAGAGG	CCAGGAGCAG	GAGCTGAAAA
	27421	TAAAAAACAG	ATCTCTGCGC	TCCCTCACCC	GCAGCTGTCT	GTATCACAAA	AGCGAAGATC
	27481	AGCTTCGGCG	CACGCTGGAG	GACGCGGAGG	CACTCTTCAG	CAAATACTGC	GCGCTCACTC
	27541	TTAAAGACTA	GCTCCGCGCC	CTTCTCGAAT	TTAGGCGGGA	GAAAACTACG	TCATCGCCGG
	27601	CCGCCGCCCA	GCCCGCCCAG	CCGAGATGAG	CAAAGAGATT	CCCACGCCAT	ACATGTGGAG
	27661	CTACCAGCCG	CAGATGGGAC	TCGCGGCGGG	AGCGGCCCAG	GACTACTCCA	CCCGCATGAA
	27721	CTACATGAGC	GCGGGACCCC	ACATGATCTC	ACAGGTCAAC	GGGATCCGCG	CCCAGCGAAA
	27781	CCAAATACTG	CTGGAACAGG	CGGCCATCAC	CGCCACGCCC	CGCCATAATC	TCAACCCCCG

2784	1 AAATTGGC	CC GCCGCCCT	CG TGTACCAC	GA AACCCCCTC	C GCCACCACCG	TACTACTTCC
2790				AC TAACTCAGG		
2796	1 TCGTCACG	GG GCGCGGCC	GC TCCGACCA	.GG TATAAGACA	CTGATGATCA	GAGGCCGAGG
2802	1 TATCCAGC	rc aacgacga	GT CGGTGAGC	TC TTCGCTCGGT	CTCCGTCCGG	ACGGAACTTT
2808	1 CCAGCTCG	CC GGATCCGG	CC GCTCTTCG	TT CACGCCCCGC	CAGGCGTACC	TGACTCTGCA
2814:	1 GACCTCGT	CC TCGGAGCCC	CC GCTCCGGA	GG CATCGGAACC	CTCCAGTTCG	TGGAGGAGTT
28203	l CGTGCCCTC	CG GTCTACTTC	CA ACCCCTTC	TC GGGACCTCCC	GGACGCTACC	CCGACCAGTT
28261	L CATTCCGAA	C TTTGACGCG	G TGAAGGAC	TC GGCGGACGGC	TACGACTGAA	TGTCAGGTGC
28321	CGAGGCAGA	G CAGCTTCGC	C TGAGACAC	CT CGAGCACTGC	CGCCGCCACA	AGTGCTTCGC
28381	CCGCGGTTC	C GGTGAGTTC	T GCTACTTT	CA GCTACCCGAG	GAGCATACCG	AGGGGCCGGC
28441	GCACGGCGT	C CGCCTGACC	A CCCAGGGC	SA GGTTACCTGT	TCCCTCATCC	GGGAGTTCAC
28501	CCTCCGTCC	C CTGCTAGTG	G AGCGGGAGC	G GGGTCCCTGT	GTCCTAACTA	TCGCCTGCAA
28561	CTGCCCTAA	C CCTGGATTA	C ATCAAGATO	T TTGCTGTCAT	CTCTGTGCTG	AGTTTAATAA
28621	ACGCTGAGA:	T CAGAATCTA	C TGGGGCTCC	T GTCGCCATCC	TGTGAACGCC	ACCGTCTTCA
28681	CCCACCCCG	A CCAGGCCCAC	G GCGAACCTC	A CCTGCGGTCT	GCATCGGAGG	GCCAAGAAGT -
28741	ACCTCACCTC	GTACTTCAA(	GGCACCCC	T TTGTGGTTTA	CAACAGCTTC (	BACGGGGACG
28801	GAGTCTCCCT	r gaaagaccac	G CTCTCCGGT	C TCAGCTACTC	CATCCACAAG A	/ACACCACCC
28861	TCCAACTCTT	CCCTCCCTAC	CTGCCGGGA	A CCTACGAGTG	CGTCACCGGC (	GCTGCACCC
28921	ACCTCACCCG	CCTGATCGTA	AACCAGAGC	r ttccgggaac	AGATAACTCC (	TCTTCCCCA
28981	GAACAGGAGG	TGAGCTCAGG	AAACTCCCC	G GGGACCAGGG	CGGAGACGTA C	CTTCGACCC
29041	TTGTGGGGTT	' AGGATTTTTT	ATTACCGGG	TGCTGGCTCT	TTTAATCAAA G	CTTCCTTGA
29101	GATTTGTTCT	TTCCTTCTAC	GTGTATGAAC	CACCTCAGCCT	ССААТААСТС Т	ACCCTTTCT
29161	TCGGAATCAG	GTGACTTCTC	TGAAATCGGG	CTTGGTGTGC	IGCTTACTCT G	TTGATTTTT
29221				AGGCTCGCCG (		
29281				CGCCACCCAA (		
29341				CCTGCAGCGC (		
29401				AGCCCGAGGG 1		
29461				GCATCGACTA C		
29521	TTGCGGTCTA	TAGTGTGTTT	ACGCCCGGAG	ACCCCTCTAA C	TACTCTGTC AC	CGTCTTCC

SEQ ID NO:1	22/153
	——/ <del>—</del> ——

2958	1 AGGGCGGA	CA GTCTAAGA	ТА ТТСААТТА	CA CTTTCCCT	TT TTATGAGTTA	TGCGATGCGG
2964	1 TCATGTAC	AT GTCAAAAC	AG TACAACCT	GT GGCCTCCC	TC TCCCCAGGCG	TGTGTGGAAA
2970	1 ATACTGGG	TC TTACTGCT	GT ATGGCTTT	GG CAATCACT	AC GCTCGCTCTA	ATCTGCACGG
2976					GA TGAAAAGAAA	
2982					CA CCTCCCTACT	
2988					G TGCCAGTGGG	
2994:					G AAAAATTTGT	
30001					A GAGCCATCTG	
30061					T ACTATTACGG	
30121					C TGCATGTAGT	
30181					A CCACCACTAC	
30241					A TGATTAGCAC	
30301					T CAGAAACCAC	
30361					G ACCTGGAGAA	
30421					C CCGTTGCCCT	
30481					G AATACCCTCC	
30541					PACCTGATGCT	
30601					TCTGCTGCCT	
30661					CCTTCCCCTA	
30721					CGCTTTACTA	
30781					AGCTGTGGCA (	
30841					TGGCTCAGGT A	
30901					CAAGTACCAA T	
30961					ACTCTATGTA (	
31021					AGTTCGCCAG (	
31081					CACCATCACC A	
31141					GGCCAGCTCA T	
31201					CCACCGCCCA G	
31261					CAACATCACC C	
					_	

Fig. 5R

S	EQ ID N	O:1	2	3/153	3		
	31321	TTCAAATGGG	G ACTTACAAGO	CCCACTCCAA	AACCAGTGGA	TGCGGCCGAG	GTCTCCGCCC
	31381	TCGTCAATGA	CTGGGCGGG	CTGGGAATGT	' GGTGGTTCGC	CATAGGCATG	ATGGCGCTCT
	31441	GCCTGCTTCT	GCTCTGGCTC	ATCTGCTGCC	TCCACCGCAG	GCGAGCCAGA	CCCCCATCT
	31501	ATAGACCCAT	CATTGTCCTG	AACCCCGATA	ATGATGGGAT	CCATAGATTG	GATGGCCTGA
	31561	AAAACCTACT	TTTTTCTTT	ACAGTATGAT	AAATTGAGAC	ATGCCTCGCA	TTTTCTTGTA
	31621	CATGTTCCTT	CTCCCACCTT	TTCTGGGGTG	TTCTACGCTG	GCCGCTGTGT	CTCACCTGGA
	31681	GGTAGACTGC	CTCTCACCCT	TCACTGTCTA	CCTGCTTTAC	GGATTGGTCA	CCCTCACTCT
	31741	CATCTGCAGC	CTAATCACAG	TAATCATCGC	CTTCATCCAG	TGCATTGATT	ACATCTGTGT
	31801	GCGCCTCGCA	TACTTCAGAC	ACCACCCGCA	GTACCGAGAC	AGGAACATTG	CCCAACTTCT
	31861	AAGACTGCTC	TAATCATGCA	TAAGACTGTG	ATCTGCCTTC	TGATCCTCTG	CATCCTGCCC
	31921	ACCCTCACCT	CCTGCCAGTA	CACCACAAAA	TCTCCGCGCA	AAAGACATGC	CTCCTGCCGC
	31981	TTCACCCAAC	TGTGGAATAT	ACCCAAATGC	TACAACGAAA	AGAGCGAGCT	CTCCGAAGCT
	32041	TGGCTGTATG	GGGTCATCTG	TGTCTTAGTT	TTCTGCAGCA	CTGTCTTTGC	CCTCATGATC
	32101	TACCCCTACT	TTGATTTGGG	ATGGAACGCG	ATCGATGCCA	TGAATTACCC	CACCTTTCCC
	32161	GCACCCGAGA	TAATTCCACT	GCGACAAGTT	GTACCCGTTG	TCGTTAATCA	ACGCCCCCA
	32221	TCCCCTACGC	CCACTGAAAT	CAGCTACTTT	AACCTAACAG	GCGGAGATGA	CTGACGCCCT
	32281	AGATCTAGAA	ATGGACGGCA	TCAGTACCGA	GCAGCGTCTC	CTAGAGAGGC	GCAGGCAGGC
	32341	GGCTGAGCAA	GAGCGCCTCA	ATCAGGAGCT	CCGAGATCTC	GTTAACCTGC	ACCAGTGCAA
	32401	AAGAGGCATC	TTTTGTCTGG	TAAAGCAGGC	CAAAGTCACC	TACGAGAAGA	CCGGCAACAG
	32461	CCACCGCCTC	AGTTACAAAT	TGCCCACCCA	GCGCCAGAAG	CTGGTGCTCA	TGGTGGGTGA
	32521	GAATCCCATC	ACCGTCACCC	AGCACTCGGT	AGAGACCGAG	GGGTGTCTGC	ACTCTCCCTG
	32581	TCGGGGTCCA	GAAGACCTCT	GCACCCTGGT	AAAGACCCTG	TGCGGTCTCA	GAGATTTAGT
	32641	CCCCTTTAAC	TAATCAAACA	CTGGAATCAA	TAAAAAGAAT	CACTTACTTA	AAATCAGACA
	32701	GCAGGTCTCT	GTCCAGTTTA	TTCAGCAGCA	CCTCCTTCCC	CTCCTCCCAA	CTCTGGTACT
	32761	CCAAACGCCT	TCTGGCGGCA	AACTTCCTCC	ACACCCTGAA	GGGAATGTCA	GATTCTTGCT
	32821	CCTGTCCCTC	CGCACCCACT	ATCTTCATGT	TGTTGCAGAT	GAAGCGCACC	AAAACGTCTG
	32881	ACGAGAGCTT	CAACCCCGTG	TACCCCTATG	ACACGGAAAG	CGGCCCTCCC	TCCGTCCCTT
	32941	TCCTCACCCC	TCCCTTCGTG	TCTCCCGATG	GATTCCAAGA	AAGCCCCCCC	GGGGTCCTGT

33001 CTCTGAACCT GGCCGAGCCC CTGGTCACTT CCCACGGCAT GCTCGCCCTG AAAATGGGAA

### SEQ ID NO:1 24/153

3306	1 GTGGCCTC	TC CCTGGACGA	C GCTGGCAAC	C TCACCTCTC	A AGATATCACO	CACCGCTAGCC
3312	1 CTCCCCTC	AA AAAAACCAA	G ACCAACCTC	A GCCTAGAAA	C CTCATCCCC	CTAACTGTAA
3318					T GGCAGTGGCC	
3324:					C AAAACTCACO	
33301					A AACATCGGCC	
33361					C AATTAATGTA	
33421		•			A TGGAAAACTG	
33481	TTGGGGGTC	C ACTAAGAGT!	GTAGACAGC	r tgcacacac	r cactgtagtt	ACCGGAAATG
33541	GACTAACTG	T AGATAACAAT	GCCCTCCAA	A CTAGAGTTA	C GGGCGCCCTA	GGTTATGACA
33601	CATCAGGAA	A TCTACAATTO	AGAGCTGCA	GAGGTATGC	G AATTGATGCA	AATGGCCAAC
33661	TTATCCTTA	A TGTGGCATAC	CCATTTGAT	G CTCAGAACA	A TCTCAGCCTT	AGACTTGGTC
33721	AGGGACCCC	г стататааас	ACAGACCACA	ACCTGGATT	GAATTGCAAC	AGAGGTCTAA
33781	CCACAACTA	C CACCAACAAC	ACAAAAAA	TTGAGACTA	AATTAGCTCA	GGCTTAGACT
33841	ATGACACCA	A TGGTGCTGTC	ATTATTAAAC	TTGGCACTGG	TCTAAGCTTC	GACAACACAG
33901	GCGCCCTAAC	TGTGGGAAAC	ACTGGTGATG	ATAAACTGAC	TCTGTGGACG	ACCCCAGACC
33961	CATCTCCAA	A TTGCAGAATT	CACTCAGACA	AAGACTGCAA	GTTTACTCTA	GTCCTAACTA
34021	AGTGTGGAAG	CCAAATCCTG	GCCTCTGTCG	CCGCCCTAGC	GGTATCAGGA	AATCTGGCTT
34081	CGATAACAGG	CACCGTTGCC	AGCGTTACCA	TCTTTCTCAG	ATTTGATCAG	AATGGAGTGC
34141	TTATGGAAAA	CTCCTCGCTA	GACAGGCAGT	ACTGGAACTT	CAGAAATGGC	AACTCAACTA
34201	ACGCTGCCCC	CTACACCAAT	GCAGTTGGGT	TCATGCCAAA	CCTCGCAGCA	TACCCCAAAA
34261					TTACTTGAAT	
34321					TGAATCCAGT	
					AAGTGGGCAA	
					TGAACAATAA	
34501	ACTGATGTTC	ATTTCTGATT	CTTATTTTAT	TATTTTCAAA	CACAACAAAA	TCATTCAAGT
34561					GACCCAGTAG	
34621	CATTCTAGCT	TATAGATCAG	ACAGTGATAA	TTAACCACCA	CCACCACCAT	ACCTTTTGAT
34681	TCAGGAAATC	ATGATCATCA	CAGGATCCTA	GTCTTCAGGC	CGCCCCCTCC (	CTCCCAAGAC
34741	ACAGAATACA	CAGTCCTCTC	CCCCGACTG	GCTTTAAATA	ACACCATCTG (	GTTGGTCACA

3	4801	GACATGTTC	T TAGGGGTTA	T ATTCCACAC	G GTCTCCTGC	C GCGCCAGGCG	CTCGTCGGTG
3	4861	ATGTTGATA	A ACTCTCCCG	G CAGCTCGCT	C AAGTTCACG	r cgctgtccag	CGGCTGAACC
3	4921	TCCGGCTGA	C GCGATAACT	G TGCGACCGG	C TGCTGGACA	A ACGGAGGCCG	CGCCTACAAG
3	4981	GGGGTAGAG	T CATAATCCT	C GGTCAGGAT	A GGGCGGTGA	r gcagcagcag	CGAGCGAAAC
3	5041	ATCTGCTGC	C GCCGCCGCT	C CGTCCGGCA	G GAAAACAAC	A AGCCGGTGGT	CTCCTCCGCG
3	5101	ATAATCCGC.	A CCGCCCGCA	G CATCAGCTT	C CTCGTTCTCC	GCGCGCAGCA	CCTCACCCTG
3!	5161	ATCTCGCTC.	A AGTCGGCGC	A GTAGGTACA	G CACAGCACCA	CGATGTTATT	CATGATCCCA
35	5221	CAGTGCAGG	G CGCTGTATC	C AAAGCTCAT	G CCGGGAACCA	CCGCCCCAC	GTGGCCATCG
35	5281	TACCACAAG	C GCACGTAAA:	r taagtgtcg	CCCCTCATGA	ACGTGCTGGA	CACAAACATT
35	341	ACTTCCTTG	G GCATGTTGT	ATTCACCACO	TCCCGGTACC	AGATAAACCT	CTGGTTAAAC
35	401	AGGGCACCT	r ccaccacca:	CCTGAACCA	GAGGCCAGAA	CCTGCCCACC	GGCTATGCAC
35	461	TGCAGGGAA	C CCGGGTTGG	A ACAATGACAA	TGCAGACTCC	AAGGCTCGTA	ACCGTGGATC
35	521	ATCCGGCTGC	C TGAAGGCATC	GATGTTGGCA	CAACACAGAC	ACACGTGCAT	GCACTTTCTC
35	581	ATGATTAGC	A GCTCTTCCCT	CGTCAGGATC	ATATCCCAAG	GAATAACCCA	TTCTTGAATC
35	641	AACGTAAAAC	CCACACAGCA	GGGAAGGCCT	CGCACATAAC	TCACGTTGTG	CATGGTCAGC
35	701	GTGTTGCATT	CTGGAAACAG	CGGATGATCC	TCCAGTATCG	AGGCGCGGGT	CTCCTTCTCA
35	761	CAGGGAGGTA	AAGGGTCCCT	GCTGTACGGA	CTGCGCCGGG	ACGACCGAGA	TCGTGTTGAG
35	821	CGTAGTGTCA	TGGAAAAGGG	AACGCCGGAC	GTGGTCATAC	TTCTTGAAGC	AGAACCAGGT
35	881	TCGCGCGTGG	CAGGCCTCCT	TGCGTCTGCG	GTCTCGCCGT	CTAGCTCGCT	CCGTGTGATA
35	941	GTTGTAGTAC	AGCCACTCCC	GCAGAGCGTC	GAGGCGCACC	CTGGCTTCCG	GATCTATGTA
360	001	GACTCCGTCT	TGCACCGCGG	CCCTGATAAT	ATCCACCACC	GTAGAATAAG	CAACACCCAG
360	061	CCAAGCAATA	CACTCGCTCT	GCGAGCGGCA	GACAGGAGGA	GCGGGCAGAG	ATGGGAGAAC
361	l21	CATGATAAAA	AACTTTTTTT	AAAGAATATT	TTCCAATTCT	TCGAAAGTAA	GATCTATCAA
361	181	GTGGCAGCGC	TCCCCTCCAC	TGGCGCGGTC	AAACTCTACG	GCCAAAGCAC	AGACAACGGC
362	41	ATTTCTAAGA	TGTTCCTTAA	TGGCGTCCAA	AAGACACACC	GCTCTCAAGT	TGCAGTAAAC
363	01	TATGAATGAA	AACCCATCCG	GCTGATTTTC	CAATATAGAC	GCGCCGGCGG	CGTCCACCAA
363	61	ACCCAGATAA	TTTTCTTCTC	TCCAGCGGTT	TAGAATCTGT	CTAAGCAAAT	СССТТАТАТС
364	21	AAGTCCGGCC	ATGCCAAAAA	TCTGCTCAAG	AGCGCCCTCC	ACCTTCATGA	CCAAGCAGCG
364	81	CATCATGATT	GCAAAAATTC	AGGTTCTTCA	GAGACCTGTA	TAAGATTCAA	AATGGGAACA

### SEQ ID NO:1 26/153

36541	ТТААСАААА	TTCCTCTGTC	GCGCAGATCC	CTTCGCAGGG	CAAGCTGAAC	ATAATCAGAC
36601	AGGTCTGAAC	GGACCAGTGA	GGCCAAATCC	CCACCAGGAA	CCAGATCCAG	AGACCCTATA
36661	CTGATTATGA	CGCGCATACT	CGGGGCTATG	CTGACCAGCG	TAGCGCCGAT	GTAGGCGTGC
36721	TGCATGGGCG	GCGAGATAAA	ATGCAAAGTG	CTGGTTAAAA	AATCAGGCAA	AGCCTCGCGC
36781	AAAAAAGCTA	ACACATCATA	ATCATGCTCA	TGCAGGTAGT	TGCAGGTAAG	CTCAGGAACC
36841	AAAACGGAAT	AACACACGAT	TTTCCTCTCA	AACATGACTT	CGCGGATACT	GCGTAAAACA
36901	AAAATTATAA	ATAAAAAATT	AATTAACTTA	AACATTGGAA	GCCTGTCTCA	CAACAGGAAA
36961	AACCACTTTA	ATCAACATAA	GACGGGCCAC	GGGCATGCCG	GCATAGCCGT	AAAAAAATTG
37021	GTCCCCGTGA	TTAACAAGTA	CCACAGACAG	CTCCCCGGTC	ATGTCGGGGG	TCATCATGTG
37081	AGACTCTGTA	TACACGTCTG	GATTGTGAAC	ATCAGACAAA	CAAAGAAATC	GAGCCACGTA
37141	GCCCGGAGGT	ATAATCACCC	GCAGGCGGAG	GTACAGCAAA	ACGACCCCCA	TAGGAGGAAT
37201	CACAAAATTA	GTAGGAGAAA	AAAATACATA	AACACCAGAA	AAACCCTGTT	GCTGAGGCAA
37261	AATAGCGCCC	TCCCGATCCA	AAACAACATA	AAGCGCTTCC	ACAGGAGCAG	ССАТААСААА
37321	GACCCGAGTC	TTACCAGTAA	AAGAAAAAAG	ATCTCTCAAC	GCAGCACCAG	CACCAACACT
37381	TCGCAGTGTA	AAAGGCCAAG	TGCCGAGAGA	GTATATATAG	GAATAAAAAG	TGACGTAAAC
37441	GGGCAAAGTC	CAAAAAACGC	CCAGAAAAAC	CGCACGCGAA	CCTACGCCCC	GAAACGAAAG
37501	CCAAAAAACA	CTAGACACTC	CCTTCCGGCG	TCAACTTCCG	CTTTCCCACG	CTACGTCACT
37561	TGCCCCAGTC	АААСАААСТА	CATATCCCGA	ACTTCCAAGT	CGCCACGCCC	AAAACACCGC
37621	CTACACCTCC	CCGCCCGCCG	GCCCGCCCCC	AAACCCGCCT	CCCGCCCCGC	GCCCCGCCTC
37681	GCGCCGCCCA	TCTCATTATC	ATATTGGCTT	CAATCCAAAA	TAAGGTATAT	TATTGATGAT
37741	G					

	1 CATCATCAAT AATATACCTC AAACTTTTGG TGCGCGTTAA TATGCAAATG AGCCGTTTGA
6	1 ATTTGGGGAT GCGGGGCGCT GATTGGCTGC GGGAGCGGCG ACCGTTAGGG GCGGGGCGGG
12	1 TGACGTTTTG ATGACGTGTT TGTGAGGCGG AGCCGGTTTG CAAGTTCTCG TGGGAAAAGT
18:	1 GACGTCAAAC GAGGTGTGGT TTGAACACGG AAATACTCAA TTTTCCCGCG CTCTCTGACA
24:	1 GGAAATGAGG TGTTTCTGGG CGGATGCAAG TGAAAACGGG CCATTTTCGC GCGAAAACTG
302	AATGAGGAAG TGAAAATCTG AGTAATTTCG CGTTTATGGC AGGGAGGAGT ATTTGCCGAG
361	L GGCCGAGTAG ACTTTGACCG ATTACGTGGG GGTTTCGATT ACCGTATTTT TCACCTAAAT
421	TTCCGCGTAC GGTGTCAAAG TCCGGTGTTT TTACGTAGGC GTCAGCTGAT CGCCAGGGTA
481	TTTAAACCTG CGCTCTCTAG TCAAGAGGCC ACTCTTGAGT GCCAGCGAGT AGAGTTTTCT
541	CCTCCGCGCC GCGAGTCAGA TCTACACTTT GAAAGATGAG GCACCTGAGA GACCTGCCCG
601	GTAATGTTTT CCTGGCTACT GGGAACGAGA TTCTGGAACT GGTGGTGGAC GCCATGATGG
661	GTGACGACCC TCCTGAGCCC CCTACCCCAT TTGAGGCGCC TTCGCTGTAC GATTTGTATG
721	ATCTGGAGGT GGATGTGCCC GAGAACGACC CCAACGAGGA GGCGGTGAAT GATTTGTTTA
781	GCGATGCCGC GCTGCTGGCC GCCGAGCAGG CTAATACGGA CTCTGGCTCA GACAGCGATT
841	CCTCTCTCCA TACCCCGAGA CCCGGCAGAG GTGAGAAAA GATCCCCGAG CTTAAAGGGG
901	AAGAGCTCGA CCTGCGCTGC TATGAGGAAT GCTTGCCTCC GAGCGATGAT GAGGAGGACG
961	AGGAGCGAT TCGAGCTGCA GCGAGCGAGG GAGTGAAAGC TGCGGGCGAG AGCTTTAGCC
1021	TGGACTGTCC TACTCTGCCC GGACACGGCT GTAAGTCTTG TGAATTTCAT CGCATGAATA
1081	CTGGAGATAA GAATGTGATG TGTGCCCTGT GCTATATGAG AGCTTACAAC CATTGTGTTT
1141	ACAGTAAGTG TGATTAACTT TAGCTGGGAA GGCAGAGGGT GACTGGGTGC TGACTGGTTT
1201	ATTTATGTAT ATGTTTTTA TGTGTAGGTC CCGTCTCTGA CGTAGATGAG ACCCCCACTT
1261	CAGAGTGCAT TTCATCACCC CCAGAAATTG GCGAGGAACC GCCCGAAGAT ATTATTCATA
1321	GACCAGTTGC AGTGAGAGTC ACCGGGCGGA GAGCAGCTGT GGAGAGTTTG GATGACTTGC
1381	TACAGGGTGG GGATGAACCT TTGGACTTGT GTACCCGGAA ACGCCCCAGG CACTAAGTGC
1441	CACACATGTG TGTTTACTTA AGGTGATGTC AGTATTTATA GGGTGTGGAG TGCAATAAAA
1501	TCCGTGTTGA CTTTAAGTGT GTGGTTTATG ACTCAGGGGT GGGGACTGTG GGTATATAAG
1561	CAGGTGCAGA CCTGTGTGGT CAGTTCAGAG CAGGACTCAT GGAGATCTGG ACGGTCTTGG
1621	AAGACTTTCA CCAGACTAGA CAGCTGCTAG AGAACTCATC GGAGGAAGTC TCTTACCTGT
1681	GGAGATTTTG CTTCGGTGGG GCTCTAGCTA AGCTAGTCTA TAGGGCCAAA CAGGATTATA

1741	AGGATCAAT	T TGAGGATAT	T TTGAGAGAG	T GTCCTAGT	TTTTGACTCT	CTCAACTTGG
1801					T TGACTTTTCT	
1861					A CAAATGGAGT	
1921					C TTTGTGGAGA	
1981					A GCCGGTAGAC	
2041					A GCAGCCGCAG	
2101					C GAGAGCCGGT	
2161					G CTGCGCCGGG	
2221					G CATGAGGAGA	
2281					A GAATCGGTGT	
2341					r gagaaatatt	
2401				÷.	GTAGCCATCA	
2461					AAACTGATTA	
2521					AGTACCCAGG	
2581			•		GGCATGGAGG	
2641					GTCTTTATGG	
2701					ATGTGCATCG	
2761					ATGGGGGTCG	1
2821					TGCCACCTGG	
2881					ACGGGCTGCT	
2941					GCCTCGGATG .	
3001					GCCACCGTGC .	
3061					ATGACCCGCT	
					AACATGCAAT	
					GGGGTGTTTG A	
					AGGTGCCGGG (	
					GTGACGGAGG A	
					TCCAGCGGGG A	
					GATGGGCAGA A	

3481	. TCTGTGTTT	T TCTGCGCAG	C AGCATGAGC	G GAAGCGCCT	C CTTTGAGGG	GGGGTATTCA
3541	GCCCTTATC	T GACGGGGCG	T CTCCCCTCC	T GGGCGGGAG	T GCGTCAGAA1	GTGATGGGAT
3601	CCACGGTGG	A CGGCCGGCC	C GTGCAGCCC	G CGAACTCTT	C AACCCTGACC	TACGCGACCC
3661	TGAGCTCCT	C GTCCGTGGA	C GCAGCTGCC	G CCGCAGCTG	C TGCTTCCGCC	GCCAGCGCCG
3721	TGCGCGGAA	T GGCCTTGGG	C GCCGGCTAC	T ACAGCTCTC	r ggtggccaac	TCGAGTTCCA
3781	CCAATAATC	C CGCCAGCCT	G AACGAGGAG	A AGCTGCTGC	r GCTGATGGCC	CAGCTCGAGG
3841	CCCTGACCC.	A GCGCCTGGG	C GAGCTGACC	C AGCAGGTGG	TCAGCTGCAG	GCGGAGACGC
3901	GGGCCGCGG	r TGCCACGGT	G AAAACCAAA	Г ААААААТСА	ч тсаатааата	AACGGAGACG
3961	GTTGTTGAT	r ttaacacag	A GTCTTGATC	r ttatttgatt	TTTCGCGCGC	GGTAGGCCCT
4021	GGACCACCG	G TCTCGATCA	T TGAGCACCC	GTGGATTTT	TCCAGGACCC	GGTAGAGGTG
4081	GGCTTGGAT	F TTGAGGTAC	A TGGGCATGAG	G CCCGTCCCGG	GGGTGGAGGT	AGCTCCATTG
4141	CAGGGCCTCC	TGCTCGGGGG	G TGGTGTTGT	AATCACCCAG	TCATAGCAGG	GGCGCAGGGC
4201	GTGGTGCTGC	CACGATGTCCT	TGAGGAGGAG	ACTGATGGCC	ACGGGCAGCC	CCTTGGTGTA
4261	GGTGTTGAC	AACCTGTTGA	GCTGGGAGGG	ATGCATGCGG	GGGGAGATGA	GATGCATCTT
4321	GGCCTGGATC	TTGAGATTGG	CGATGTTCCC	GCCCAGATCC	CGCCGGGGGT	TCATGTTGTG
4381	CAGGACCACC	AGCACGGTGT	ATCCGGTGCA	CTTGGGGAAT	TTGTCATGCA	ACTTGGAAGG
4441	GAAGGCGTGA	AAGAATTTGG	AGACGCCCTT	GTGACCGCCC	AGGTTTTCCA	TGCACTCATC
4501	CATGATGATG	GCGATGGGCC	CGTGGGCGGC	GGCCTGGGCA	AAGACGTTTC	GGGGGTCGGA
4561	CACATCGTAG	TTGTGGTCCT	GGGTGAGCTC	GTCATAGGCC	ATTTTAATGA	ATTTGGGGCG
4621	GAGAGTGCCC	GACTGGGGGA	CGAAGGTGCC	CTCGATCCCG	GGGGCGTAGT	TCCCCTCGCA
4681	GATCTGCATC	TCCCAGGCCT	TGAGCTCGGA	GGGGGGGATC	ATGTCCACCT	GCGGGGCGAT
4741	GAAAAAAACG	GTTTCCGGGG	CGGGGGAGAT	GAGCTGGGCC	GAAAGCAGGT	TCCGGAGCAG
4801	CTGGGACTTG	CCGCAGCCGG	TGGGACCGTA	GATGACCCCG	ATGACCGGCT	GCAGGTGGTA
4861					GCCACCTCGT	
4921					CGCTCGCCCC	
					CCGTCGGCCA	
					TCGGTGATGT (	
					GACTGCGGGA (	
					AGGGTCGCAG (	

5221	AGCGTGGTCT	CCGTCACGGT	GAAGGGGTGC	GCGCCGGGCT	GGGCGCTTGC	GAGGGTGCGC
5281	TTCAGGCTCA	TCCGGCTGGT	CGAGAACCGC	TCCCGGTCGG	CGCCCTGCGC	GTCGGCCAGG
5341	TAGCAATTGA	GCATGAGTTC	GTAGTTGAGC	GCCTCGGCCG	CGTGGCCCTT	GGCGCGGAGC
5401	TTACCTTTGG	AAGTGTGTCC	GCAGACGGGA	CAGAGGAGGG	ACTTGAGGGC	GTAGAGCTTG
5461	GGGGCGAGGA	AGACGGACTC	GGGGGCGTAG	GCGTCCGCGC	CGCAGCTGGC	GCAGACGGTC
5521	TCGCACTCCA	CGAGCCAGGT	GAGGTCGGGG	CGGTCGGGGT	CAAAAACGAG	GTTTCCTCCG
5581	TGCTTTTTGA	TGCGTTTCTT	ACCTCTGGTC	TCCATGAGCT	CGTGTCCCCG	CTGGGTGACA
5641	AAGAGGCTGT	CCGTGTCCCC	GTAGACCGAC	TTTATGGGCC	GGTCCTCGAG	CGGGGTGCCG
5701	CGGTCCTCGT	CGTAGAGGAA	CCCCGCCCAC	TCCGAGACGA	AGGCCCGGGT	CCAGGCCAGC
5761	ACGAAGGAGG	CCACGTĢGGA	GGGGTAGCGG	TCGTTGTCCA	CCAGCGGGTC	CACCTTCTCC
5821	AGGGTATGCA	AGCACATGTC	CCCCTCGTCC	ACATCCAGGA	AGGTGATTGG	CTTGTAAGTG
5881	TAGGCCACGT	GACCGGGGGT	CCCGGCCGGG	GGGGTATAAA	AGGGGGCGGG	CCCCTCCTCG
5941	TCCTCACTGT	CTTCCGGATC	GCTGTCCAGG	AGCGCCAGCT	GTTGGGGTAG	GTATTCCCTC
6001	TCGAAGGCGG	GCATGACCTC	GGCACTCAGG	TTGTCAGTTT	CTAGAAACGA	GGAGGATTTG
6061	ATATTGACGG	TGCCGTTGGA	GACGCCTTTC	ATGAGCCCCT	CGTCCATCTG	GTCAGAAAAG
6121	ACGATCTTTT	TGTTGTCGAG	CTTGGTGGCG	AAGGAGCCGT	AGAGGGCGTT	GGAGAGGAGC
6181	TTGGCGATGG	AGCGCATGGT	CTGGTTCTTT	TCCTTGTCGG	CGCGCTCCTT	GGCGGCGATG
6241	TTGAGCTGCA	CGTACTCGCG	CGCCACGCAC	TTCCATTCGG	GGAAGACGGT	GGTGAGCTCG
6301	TCGGGCACGA	TTCTGACCCG	CCAGCCGCGG	TTGTGCAGGG	TGATGAGGTC	CACGCTGGTG
6361	GCCACCTCGC	CGCGCAGGGG	CTCGTTGGTC	CAGCAGAGGC	GCCCGCCCTT	GCGCGAGCAG
6421	AAGGGGGCA	GCGGGTCCAG	CATGAGCTCG	TCTGGGGGGT	CGGCGTCCAC	GGTGAAGATG
6481	CCGGGCAGGA	GCTCGGGGTC	GAAGTAGCTG	ATGGAAGTGG	CCAGATCGTC	CAGGGAAGCT
6541	TGCCAGTCGC	GCACGGCCAG	CGCGCGCTCG	TAGGGGCTGA	GGGGCGTGCC	CCAGGGCATG
6601	GGGTGCGTGA	GCGCGGAGGC	GTACATGCCG	CAGATGTCGT	AGACGTAGAG	GGGCTCCTCG
6661	AGGATGCCGA	TGTAGGTGGG	GTAGCAGCGC	CCCCCGCGGA	TGCTGGCGCG	CACGTAGTCG
6721	TACAGCTCGT	GCGAGGGCGC	GAGGAGCCCC	GTGCCGAGAT	TGGAGCGCTG	CGGCTTTTCG
6781	GCGCGGTAGA	CGATCTGGCG	GAAGATGGCG	TGGGAGTTGG	AGGAGATGGT	GGGCCTCTGG
6841	AAGATGTTGA	AGTGGGCGTG	GGGCAGGCCG .	ACCGAGTCCC	TGATGAAGTG	GGCGTAGGAG
6901	TCCTGCAGCT	TGGCGACGAG	CTCGGCGGTG .	ACGAGGACGT	CCAGGGCGCA	GTAGTCGAGG

6961	GTCTCTTG	GA TGATGTCAT	A CTTGAGCTG	G CCCTTCTGC	T TCCACAGCTC	GCGGTTGAGA
7021	AGGAACTCT	T CGCGGTCCT	T CCAGTACTC	T TCGAGGGG	A ACCCGTCCTG	ATCGGCACGG
7081	TAAGAGCCC	A CCATGTAGA	A CTGGTTGAC	G GCCTTGTAG	G CGCAGCAGCC	CTTCTCCACG
7141	GGGAGGGCG	T AAGCTTGCG	C GGCCTTGCG	C AGGGAGGTG	T GGGTGAGGGC	GAAGGTGTCG
7201	CGCACCATG	A CCTTGAGGA	A CTGGTGCTT	G AAGTCGAGG	r CGTCGCAGCC	GCCCTGCTCC
7261					G GCAAAGCGAA	
7321					G TGATGCGGAA	
7381					A TCTCGTCGAA	i.
7441					CCTTGACGTG	
7501					CGTGCTGTTC	
7561					GATCCACGGC	,
7621					CCATTTTTC	
7681					'TGAGCTGGAG	
7741					TGACCAGCAT	
7801					CATCGTAGGT	
7861					TCTCCTGCCA	
7921					GCGCCGAGCA	
7981					GATGCACGTG	
8041					GGAGCGCTGG	
8101					CTGCCTCGAT	
8161					GGACGGGTCG	
8221					GCTGCGGAGT	
8281					GGGCGCGCGG (	
8341					CGGCTTGCAG	
8401					CTGGTTCCAT (	
8461					GGGGCCCGGA (	
8521					CTGCGCCCGG A	
8581					CCTCTGGGTG A	
					AATCTCGGTA 1	

SEQ ID NO:2 32/153

8701	CGGCCTGCCG	G CAGGATCTCT	TGCACGTCGC	CCGAGTTGTC	CTGGTAGGCG	ATCTCGGTCA
8761	TGAACTGCTC	GATCTCCTCC	TCCTGAAGGT	CTCCGCGGCC	GGCGCGCTCG	ACGGTGGCCG
8821	CGAGGTCGTT	GGAGATGCGG	CCCATGAGCT	GCGAGAAGGC	GTTCATGCCG	GCCTCGTTCC
8881	AGACGCGGCT	GTAGACCACG	GCTCCGTCGG	GGTCGCGCGC	GCGCATGACC	ACCTGGGCGA
8941	GGTTGAGCTC	GACGTGGCGC	GTGAAGACCG	CGTAGTTGCA	GAGGCGCTGG	TAGAGGTAGT
9001	TGAGCGTGGT	GGCGATGTGC	TCGGTGACGA	AGAAGTACAT	GATCCAGCGG	CGGAGCGGCA
9061	TCTCGCTGAC	GTCGCCCAGG	GCTTCCAAGC	GCTCCATGGC	CTCGTAGAAG	TCCACGGCGA
9121	AGTTGAAAAA	CTGGGAGTTG	CGCGCCGAGA	CGGTCAACTC	CTCCTCCAGA	AGACGGATGA
9181	GCTCGCCGAT	GGTGGCGCGC	ACCTCGCGCT	CGAAGGCCCC	GGGGGGCTCC	TCTTCTTCCA
9241	TCTCCTCCTC	CTCTTCCTCC	TCCACTAACA	TCTCTTCTAC	TTCCTCCTCA	GGAGGCGGTG
9301.	GCGGGGGAGG	GGCCCTGCGT	CGCCGGCGGC	GCACGGGCAG	ACGGTCGATG	AAGCGCTCGA
9361	TGGTCTCCCC	GCGCCGGCGA	CGCATGGTCT	CGGTGACGGC	GCGCCCGTCC	TCGCGGGGCC
9421	GCAGCGTGAA	GACGCCGCCG	CGCATCTCCA	GGTGGCCGCC	GGGGGGGTCT	CCGTTGGGCA
9481	GGGAGAGGC	GCTGACGATG	CATCTTATCA	ATTGGCCCGT	AGGGACTCCG	CGCAAGGACC
9541	TGAGCGTCTC	GAGATCCACG	GGATCCGAAA	ACCGCTGAAC	GAAGGCTTCG	AGCCAGTCGC
9601	AGTCGCAAGG	TAGGCTGAGC	CCGGTTTCTT	CGGGTATTTG	GTCGGGAGGC	GGGCGGCGA
9661	TGCTGCTGGT	GATGAAGTTG	AAGTAGGCGG	TCCTGAGACG	GCGGATGGTG	GCGAGGAGCA
9721	CCAGGTCCTT	GGGCCCGGCT	TGCTGGATGC	GCAGACGGTC	GGCCATGCCC	CAGGCGTGGT
9781	CCTGACACCT	GGCGAGGTCC	TTGTAGTAGT	CCTGCATGAG	CCGCTCCACG	GGCACCTCCT
9841	CCTCGCCCGC	GCGGCCGTGC	ATGCGCGTGA	GCCCGAACCC	GCGCTGCGGC	TGGACGAGCG
9901	CCAGGTCGGC	GACGACGCGC	TCGGCGAGGA	TGGCCTGCTG	GATCTGGGTG	AGGGTGGTCT
9961	GGAAGTCGTC	GAAGTCGACG	AAGCGGTGGT	AGGCTCCGGT	GTTGATGGTG	TATGAGCAGT
10021	TGGCCATGAC	GGACCAGTTG	ACGGTCTGGT	GGCCGGGGCG	CACGAGCTCG	TGGTACTTGA
10081	GGCGCGAGTA	GGCGCGCGTG	TCGAAGATGT	AGTCGTTGCA	GGTGCGCACG	AGGTACTGGT
10141	ATCCGACGAG	GAAGTGCGGC	GGCGGCTGGC	GGTAGAGCGG	CCATCGCTCG	GTGGCGGGG
10201	CGCCGGGCGC	GAGGTCCTCG	AGCATGAGGC	GGTGGTAGCC	GTAGATGTAC	CTGGACATCC
10261	AGGTGATGCC	GGCGGCGGTG	GTGGAGGCGC	GCGGGAACTC	GCGGACGCGG	TTCCAGATGT
10321	TGCGCAGCGG	CAGGAAGTAG	TTCATGGTGG	CCGCGGTCTG	GCCCGTGAGG	CGCGCGCAGT
10381	CGTGGATGCT	CTATACGGGC	AAAAACGAAA	GCGGTCAGCG	GCTCGACTCC	GTGGCCTGGA

1044	l GGCTAAGCG	A ACGGGTTGG	G CTGCGCGTG	T ACCCCGGTT	C GAATCTCGA	A TCAGGCTGGA
1050	l GCCGCAGCT	A ACGTGGTAC	T GGCACTCCC	G TCTCGACCC	A AGCCTGCAC	AAACCTCCAG
10563	L GATACGGAG	G CGGGTCGTI	T TGCAACTTI	T TGAGGCCGG	A AATGAAACTA	GTAAGCGÇGA
10623	AAAGCGGCC	G ACCGCGATG	G CTCGCTGCC	G TAGTCTGGA	G AAGAATCGCC	AGGGTTGCGT
10681					C TAACGAGGGC	
10741					T ACGGAGCGAG	
10801					A GATGCGCCC	
10861					C CCCGCCCCAG	
10921				4	G ACAGACTTCT	
10981					G GGCGTCGTCG	
11041					A CGTGCCCAAG	
11101	,				GGCCCGGTTC	
11161					GGACGAGGAT	
11221					CGCGGCCAAC	
11281					ATCCTTCAAC	
11341					GCACCTGTGG	
11401					GCAGCTGTTC	
11461					GAATATCACC	
11521					CGTGGTGCAG	
11581					GCTGAGTCTG	
11641						
11701					CAAGGAGGTG	
11761					CGACGATCTG	
11821					GCGCGAGCTG	
11881					GACCGAGGGG	
11941					GGCCTTGGAA	
					GGGCGAGTAC	
12001					CCGCCGCCTC (	
12061					TCCTCGGACG A	
12121	GGCCATGCAA	CGCATCATGG	CGCTGACGAC	CCGCAATCCC	GAAGCCTTTA (	SACAGCAGCC

34/153 SEQ ID NO:2 12181 TCAGGCCAAC CGGCTCTCGG CCATCCTGGA GGCCGTGGTG CCCTCGCGCT CGAACCCCAC 12241 GCACGAGAAG GTGCTGGCCA TCGTGAACGC GCTGGTGGAG AACAAGGCCA TCCGCGGCGA 12301 CGAGGCCGGG CTGGTGTACA ACGCGCTGCT GGAGCGCGTG GCCCGCTACA ACAGCACCAA 12361 CGTGCAGACG AACCTGGACC GCATGGTGAC CGACGTGCGC GAGGCGGTGT CGCAGCGCGA 12421 GCGGTTCCAC CGCGAGTCGA ACCTGGGCTC CATGGTGGCG CTGAACGCCT TCCTGAGCAC 12481 GCAGCCCGCC AACGTGCCCC GGGGCCAGGA GGACTACACC AACTTCATCA GCGCGCTGCG 12541 GCTGATGGTG GCCGAGGTGC CCCAGAGCGA GGTGTACCAG TCGGGGCCGG ACTACTTCTT 12601 CCAGACCAGT CGCCAGGGCT TGCAGACCGT GAACCTGAGC CAGGCTTTCA AGAACTTGCA 12661 GGGACTGTGG GGCGTGCAGG CCCCGGTCGG GGACCGCGCG ACGGTGTCGA GCCTGCTGAC 12721 GCCGAACTCG CGCCTGCTGC TGCTGCTGGT GGCGCCCTTC ACGGACAGCG GCAGCGTGAG 12781 CCGCGACTCG TACCTGGGCT ACCTGCTTAA CCTGTACCGC GAGGCCATCG GGCAGGCGCA 12841 CGTGGACGAG CAGACCTACC AGGAGATCAC CCACGTGAGC CGCGCGCTGG GCCAGGAGGA 12901 CCCGGGCAAC CTGGAGGCCA CCCTGAACTT CCTGCTGACC AACCGGTCGC AGAAGATCCC 12961 GCCCCAGTAC GCGCTGAGCA CCGAGGAGGA GCGCATCCTG CGCTACGTGC AGCAGAGCGT 13021 GGGGCTGTTC CTGATGCAGG AGGGGGCCAC GCCCAGCGCC GCGCTCGACA TGACCGCGCG 13081 CAACATGGAG CCCAGCATGT ACGCCCGCAA CCGCCCGTTC ATCAATAAGC TGATGGACTA 13141 CTTGCATCGG GCGGCCGCCA TGAACTCGGA CTACTTTACC AACGCCATCT TGAACCCGCA 13201 CTGGCTCCCG CCGCCCGGGT TCTACACGGG CGAGTATGAC ATGCCCGACC CCAACGACGG 13261 GTTCCTGTGG GATGACGTGG ACAGCAGCGT GTTCTCGCCG CGCCCCGCCA CCACCGTGTG 13321 GAAGAAAGAG GGCGGGGACC GGCGGCCGTC CTCGGCGCTG TCCGGTCGCG CGGGTGCTGC 13381 CGCGGCGGTG CCCGAGGCCG CCAGCCCCTT CCCGAGCCTG CCCTTTTCGC TGAACAGCGT GCGCAGCAGC GAGCTGGGAC GGCTGACGCG GCCGCGCCTG CTGGGCGAGG AGGAGTACCT 13441 13501 GAACGACTCC TTGTTGAGGC CCGAGCGCGA GAAGAACTTC CCCAATAACG GGATAGAGAG 13561 CCTGGTGGAC AAGATGAGCC GCTGGAAGAC GTACGCGCAC GAGCACAGGG ACGAGCCGCG 13621 AGCTAGCAGC AGCACCGGCG CCCGTAGACG CCAGCGGCAC GACAGGCAGC GGGGACTGGT GTGGGACGAT GAGGATTCCG CCGACGACAG CAGCGTGTTG GACTTGGGTG GGAGTGGTGG 13681 13741 TGGTAACCCG TTCGCTCACC TGCGCCCCCG TATCGGGCGC CTGATGTAAG AATCTGAAAA

Fig. 6H

13801 AATAAAAAC GGTACTCACC AAGGCCATGG CGACCAGCGT GCGTTCTTCT CTGTTGTTTG

13861 TAGTAGTATG ATGAGGCGCG TGTACCCGGA GGGTCCTCCT CCCTCGTACG AGAGCGTGAT

SEQ ID 1	0:2 35/153	
13921	GCAGCAGGCG GTGGCGGCGG CGATGCAGCC CCCGCTGGAG GCGCCTTACG TG	CCCCCGCG
13981	GTACCTGGCG CCTACGGAGG GGCGGAACAG CATTCGTTAC TCGGAGCTGG CA	
14041	CGATACCACC CGGTTGTACC TGGTGGACAA CAAGTCGGCG GACATCGCCT CG	
14101	CCAGAACGAC CACAGCAACT TCCTGACCAC CGTGGTGCAG AACAACGATT TC	
14161	GGAGGCCAGC ACCCAGACCA TCAACTTTGA CGAGCGCTCG CGGTGGGGCG GC	
14221	AACCATCATG CACACCAACA TGCCCAACGT GAACGAGTTC ATGTACAGCA AC	
14281	GGCGCGGTC ATGGTCTCGC GCAAGACCCC CAACGGGGTC GCGGTAGGGG AT	
14341	TGGTAGTCAG GACGAGCTGA CCTACGAGTG GGTGGAGTTT GAGCTGCCCG AG	
14401	CTCGGTGACC ATGACCATCG ATCTGATGAA CAACGCCATC ATCGACAATT AC	TTGGCGGT
14461	GGGACGGCAG AACGGGGTGC TGGAGAGCGA CATCGGCGTG AAGTTCGACA CG	CGCAACTT
14521	CCGGCTGGGC TGGGACCCCG TGACCGAGCT GGTGATGCCG GGCGTGTACA CCA	AACGAGGC
14581	CTTCCACCCC GACATCGTCC TGCTGCCCGG CTGCGGCGTG GACTTCACCG AGA	AGCCGCCT
14641	CAGCAACCTG CTGGGCATCC GCAAGCGGCA GCCCTTCCAG GAGGGCTTCC AGA	ATCCTGTA
14701	CGAGGACCTG GAGGGGGGCA ACATCCCCGC GCTCTTGGAT GTCGAAGCCT ATC	GAAGAAAG
14761	TAAGGAAAAA GCAGAGGCTG AGGCAACTGC AGCCGTGGCT ACTGCCGCTG TCA	ACCGATGC
14821	AGATGCAGCT ACTACCAGGG GCGATACATT CGCCACTGTG GCTGAAGAAG CAG	GCCGCCGT
14881	AGCGGCGACC GATGATAGTG AAAGTAAGAT AGTCATCAAG CCGGTGGAGA AGC	GACAGCAA
14941	GAACAGGAGC TACAACGTTC TATCGGATGG AAAGAACACC GCCTACCGCA GCT	TGGTACCT
15001	GGCCTACAAC TACGGCGACC CCGAGAAGGG CGTGCGCTCC TGGACGCTGC TCA	ACCACCTC
15061	GGACGTCACC TGCGGCGTGG AGCAAGTCTA CTGGTCGCTG CCCGACATGA TGC	CAAGACCC
15121	GGTCACCTTC CGCTCCACGC GTCAAGTTAG CAACTACCCG GTGGTGGGCG CCG	FAGCTCCT
15181	GCCCGTCTAC TCCAAGAGCT TCTTCAACGA GCAGGCCGTC TACTCGCAGC AGC	TGCGCGC
15241	CTTCACCTCG CTCACGCACG TCTTCAACCG CTTCCCCGAG AACCAGATCC TCG	TCCGCCC
15301	GCCCGCGCC ACCATTACCA CCGTCAGTGA AAACGTTCCT GCTCTCACAG ATC	ACGGGAC
15361	CCTGCCGCTG CGCAGCAGTA TCCGGGGAGT CCAGCGCGTG ACCGTCACTG ACG	CCAGACG
15421	CCGCACCTGC CCCTACGTCT ACAAGGCCCT GGGCGTAGTC GCGCCGCGC TCC	TCTCGAG
15481	CCGCACCTTC TAAAAAATGT CCATTCTCAT CTCGCCCAGT AATAACACCG GTT	GGGGCCT
15541	GCGCGCGCCC AGCAAGATGT ACGGAGGCGC TCGCCAACGC TCCACGCAAC ACCC	CCGTGCG
15601	CGTGCGCGGG CACTTCCGCG CTCCCTGGGG CGCCCTCAAG GGCCGCGTGC GCTC	CGCGCAC

 $SEQ ID NO:2 \qquad \qquad 36/153$ 

15661	CACCGTCGAC	GACGTGATCG	G ACCAGGTGGT	GGCCGACGCG	GCAACTACA	CGCCCGCCGC
15721	CGCGCCCGTC	TCCACCGTGG	ACGCCGTCAT	CGACAGCGTG	GTGGCCGACG	CGCGCCGGTA
15781	CGCCCGCGCC	AAGAGCCGGC	GGCGGCGCAT	cecceecee	CACCGGAGCA	CCCCCGCCAT
15841	GCGCGCGGCG	G CGAGCCTTGC	: TGCGCAGGGC	CAGGCGCACG	GGACGCAGGG	CCATGCTCAG
15901	GGCGGCCAGA	CGCGCGGCCT	CTGGCAGCAG	CAGCGCCGGC	AGGACCCGCA	GACGCGCGGC
15961	CACGGCGGCG	GCGGCGGCCA	TCGCCAGCAT	GTCCCGCCCG	CGGCGCGGCA	ACGTGTACTG
16021	GGTGCGCGAC	GCCGCCACCG	GTGTGCGCGT	GCCCGTGCGC	ACCCGCCCC	CTCGCACTTG
16081	AAGATGCTGA	CTTCGCGATG	TTGATGTGTC	CCAGCGGCGA	GGAGGATGTC	CAAGCGCAAA
16141	TTCAAGGAAG	AGATGCTCCA	GGTCATCGCG	CCTGAGATCT	ACGGCCCCGC	GGCGGCGGTG
16201	AAGGAGGAAA	GAAAGCCCCG	CAAACTGAAG	CGGGTCAAAA	AGGACAAAAA	GGAGGAGGAA
16261	GATGTGGACG	GACTGGTGGA	GTTTGTGCGC	GAGTTCGCCC	CCCGGCGGCG	CGTGCAGTGG
16321	CGCGGGCGGA	AAGTGAAACC	GGTGCTGCGA	CCCGGCACCA	CCGTGGTCTT	CACGCCCGGC
16381	GAGCGTTCCG	GCTCCGCCTC	CAAGCGCTCC	TACGACGAGG	TGTACGGGGA	CGAGGACATC
16441	CTCGAGCAGG	CGGCCGAGCG	TCTGGGCGAG	TTTGCTTACG	GCAAGCGCAG	CCGCCCCGCG
16501	CCCTTGAAAG	AGGAGGCGGT	GTCCATCCCG	CTGGACCACG	GCAACCCCAC	GCCGAGTCTG
16561	AAGCCGGTGA	CCCTGCAGCA	GGTGCTGCCG	AGCGCGGCGC	cececceeeè	CTTCAAGCGC
16621	GAGGGCGGCG	AGGATCTGTA	CCCGACCATG	CAGCTGATGG	TGCCCAAGCG	CCAGAAGCTG
16681	GAGGACGTGC	TGGAGCACAT	GAAGGTGGAC	CCCGAGGTGC	AGCCCGAGGT	CAAGGTGCGG
16741	CCCATCAAGC	AGGTGGCCCC	GGGCCTGGGC	GTGCAGACCG	TGGACATCAA	GATCCCCACG
16801	GAGCCCATGG	AAACGCAGAC	CGAGCCCGTG	AAGCCCAGCA	CCAGCACCAT	GGAGGTGCAG
16861	ACGGATCCCT	GGATGCCGGC	GCCGGCTTCC	ACCACCACCA	CTCGCCGAAG	ACGCAAGTAC
16921	GGCGCGGCCA	GCCTGCTGAT	GCCCAACTAC	GCGCTGCATC	CTTCCATCAT	CCCCACGCCG
16981	GGCTACCGCG	GCACGCGCTT	CTACCGCGGC	TACAGCAGCC	GCCGCAAGAC	CACCACCCGC
17041	CGCCGCCGTC	GTCGCACCCG	CCGÇAGCAGC	ACCGCGACTT	CCGCCGCCTT	GGTGCGGAGA
17101	GTGTACCGCA	GCGGGCGCGA	GCCTCTGACC	CTGCCGCGCG	CGCGCTACCA	CCCGAGCATC
17161	GCCATTTAAC	TCTGCCGTCG	CCTCCTACTT	GCAGATATGG	CCCTCACATG	CCGCCTCCGC
17221	GTCCCCATTA	CGGGCTACCG	AGGAAGAAAG	CCGCGCCGTA	GAAGGCTGAC	GGGGAACGGG
17281	CTGCGTCGCC	ATCACCACCG	GCGGCGGCGC	GCCATCAGCA	AGCGGTTGGG	GGGAGGCTTC
17341	CTGCCCGCGC	TGATCCCCAT	CATCGCCGCG	GCGATCGGGG	CGATCCCCGG	CATAGCTTCC

1740	1 GTGGCGGT	GC AGGCCTCT	CA GCGCCAC1	rga gacacagci	TT GGAAAATTTG	ТААТААААА
1746					T GGAAGACATC	
1752	1 CCCTGGCA	CC GCGACACG	GC ACGCGGCC	GT TTATGGGC	AC CTGGAGCGAC	ATCGGCAACA
1758	1 GCCAACTG	AA CGGGGGCG	CC TTCAATTG	GA GCAGTCTCT	G GAGCGGGCTT	AAGAATTTCG
1764					G CAGCACAGGG	
1770					T CGATGGCCTG	
1776	L TCAACGGG	GT GGTGGACC	rg gccaacca	GG CCGTGCAGA	A ACAGATCAAC	AGCCGCCTGG
17823	ACGCGGTC	CC GCCCGCGG	G TCCGTGGA	GA TGCCCCAGG	T GGAGGAGGAG	CTGCCTCCCC
17881	. TGGACAAGO	CG CGGCGACAZ	G CGACCGCG	TC CCGATGCAG	A GGAGACGCTG	CTGACGCACA
17941	CGGACGAG	CC GCCCCGTA	C GAGGAGGC	GG TGAAACTGG	G TCTGCCCACC	ACGCGGCCCG
18001	TGGCGCCTC	T GGCCACCGG	G GTGCTGAA	AC CCAGCAGCA	G CAGCCAGCCC	GCGACCCTGG
18061	ACTTGCCTC	C GCCTGCTTC	C CGCCCCTCC	CA CAGTGGCTA	A GCCCCTGCCG	CCGGTGGCCG
18121	TCGCGTCGC	G CGCCCCCG	A GGCCGCCC	CC AGGCGAACTO	G GCAGAGCACT	CTGAACAGCA
. 18181	TCGTGGGTC	T GGGAGTGCA	G AGTGTGAAG	C GCCGCCGCTC	G CTATTAAAAG	ACACTGTAGC
18241	GCTTAACTT	G CTTGTCTGT	G TGTATATGT	A TGTCCGCCG	CCAGAAGGAA	GAGGCGCGTC
18301	GCCGAGTTG	C AAGATGGCC	A CCCCATCGA	T GCTGCCCAG	TGGGCGTACA	TGCACATCGC
18361	CGGACAGGA	C GCTTCGGAG	r acctgagtc	C GGGTCTGGTG	CAGTTCGCCC	GCGCCACAGA
18421	CACCTACTT	C AGTCTGGGG	A ACAAGTTTA	G GAACCCCACG	GTGGCGCCCA (	CGCACGATGT
18481	GACCACCGA	CGCAGCCAGC	GGCTGACGC	T GCGCTTCGTG	CCCGTGGACC (	ECGAGGACAA
18541	CACCTACTCO	TACAAAGTGC	GCTACACGC	r GGCCGTGGGC	GACAACCGCG '	GCTGGACAT
18601	GGCCAGCACC	TACTTTGACA	TCCGCGGCG	r GCTGGATCGG	GGCCCCAGCT 1	CAAACCCTA
18661	CTCCGGCACC	GCCTACAACA	GCCTGGCTC	CAAGGGAGCG	CCCAACACCT C	ACAGTGGAT
18721	AACCAAAGAC	AATGGAACTG	ATAAGACATA	A CAGTTTTGGA	AATGCTCCAG T	'CAGAGGATT
18781	GGACATTACA	GAAGAGGGTC	TCCAAATAGG	ACCCGATGAG	TCAGGGGGTG A	AAGCAAGAA
18841	AATTTTTGCA	GACAAAACCT	ATCAGCCTGA	ACCTCAGCTT	GGAGATGAGG A	ATGGCATGA
18901	TACTATTGGA	GCTGAAGACA	AGTATGGAGG	CAGAGCGCTT	AAACCTGCCA C	CAACATGAA
18961	ACCCTGCTAT	GGGTCTTTCG	CCAAGCCAAC	TAATGCTAAG	GGAGGTCAGG C	TAAAAGCAG
19021	AACCAAGGAC	GATGGCACTA	CTGAGCCTGA	TATTGACATG	GCCTTCTTTG A	CGATCGCAG
19081	TCAGCAAGCT	AGTTTCAGTC	CAGAACTTGT	TTTGTATACT	GAGAATGTCG A	rctggacac

SEQ ID N	O:2	3	8/153	3		
19141	CCCGGATACC	CACATTATTT	ACAAACCTGG	CACTGATGAA	ACAAGTTCTT	CTTTCAACTT
19201	GGGTCAGCAG	TCCATGCCCA	ACAGACCCAA	CTACATCGGC	TTCAGAGACA	ACTTTATCGG
19261	TCTCATGTAC	TACAACAGTA	CTGGCAATAT	GGGTGTACTA	GCTGGACAGG	CCTCCCAGCT
19321	GAATGCTGTG	GTGGACTTGC	AGGACAGAAA	CACTGAACTG	TCCTACCAGC	TCTTGCTTGA
19381	CTCTCTGGGT	GACAGAACCA	GGTATTTCAG	TATGTGGAAC	CAGGCGGTGG	ACAGCTACGA
19441	CCCCGATGTG	CGCATTATTG	AAAATCACGG	TGTGGAGGAT	GAACTACCCA	ACTATTGCTT
19501	CCCTTTGAAT	GGTGTGGGCT	TTACAGATAC	ATTCCAGGGA	ATTAAGGTTA	AAACTACCAA
19561	TAACGGAACA	GCAAATGCTA	CAGAGTGGGA	ATCTGATACC	TCTGTCAATA	ATGCTAATGA
19621	GATTGCCAAG	GGCAATCCTT	TCGCCATGGA	GATCAACATC	CAGGCCAACC	TGTGGCGGAA
19681	CTTCCTCTAC	GCGAACGTGG	CGCTGTACCT	GCCCGACTCC	TACAAGTACA	CGCCGGCCAA
19741	CATCACGCTG	CCCGCCAACA	CCAACACCTA	CGATTACATG	AACGGCCGCG	TGGTAGCGCC
19801	CTCGCTGGTG	GACGCCTACA	TCAACATCGG	GGCGCGCTGG	TCGCTGGACC	CCATGGACAA
19861	CGTCAACCCC	TTCAACCACC	ACCGCAACGC	GGGCCTGCGC	TACCGCTCCA	TGCTCCTGGG
19921	CAACGGGCGC	TACGTGCCCT	TCCACATCCA	GGTGCCCCAA	AAGTTTTTCG	CCATCAAGAG
19981	CCTCCTGCTC	CTGCCCGGGT	CCTACACCTA	CGAGTGGAAC	TTCCGCAAGG	ACGTCAACAT
20041	GATCCTGCAG	AGCTCCCTCG	GCAACGACCT	GCGCACGGAC	GGGGCCTCCA	TCGCCTTCAC
20101	CAGCATCAAC	CTCTACGCCA	CCTTCTTCCC	CATGGCGCAC	AACACCGCCT	CCACGCTCGA
20161	GGCCATGCTG	CGCAACGACA	CCAACGACCA	GTCCTTCAAC	GACTACCTCT	CGGCGGCCAA
20221	CATGCTCTAC	CCCATCCCGG	CCAACGCCAC	CAACGTGCCC	ATCTCCATCC	CCTCGCGCAA
20281	CTGGGCCGCC	TTCCGCGGCT	GGTCCTTCAC	GCGCCTCAAG	ACCCGCGAGA	CGCCCTCGCT
20341	CGGCTCCGGG	TTCGACCCCT	ACTTCGTCTA	CTCGGGCTCC	ATCCCCTACC	TCGACGGCAC
20401	CTTCTACCTC	AACCACACCT	TCAAGAAGGT	CTCCATCACC	TTCGACTCCT	CCGTCAGCTG
20461	GCCCGGCAAC	GACCGCCTCC	TGACGCCCAA	CGAGTTCGAA	ATCAAGCGCA	CCGTCGACGG
20521	AGAGGGGTAC	AACGTGGCCC	AGTGCAACAT	GACCAAGGAC	TGGTTCCTGG	TTCAGATGCT
20581	GGCCCACTAC	AACATCGGCT	ACCAGGGCTT	CTACGTGCCC	GAGGGCTACA	AGGACCGCAT
20641	GTACTCCTTC	TTCCGCAACT	TCCAGCCCAT	GAGCCGCCAG	GTCGTGGACG	AGGTCAACTA
20701	CAAGGACTAC	CAGGCCGTCA	CCCTGGCCTA	CCAGCACAAC	AACTCGGGCT	TCGTCGGCTA
20761	CCTCGCGCCC	ACCATGCGCC	AGGGACAGCC	CTACCCCGCC	AACTACCCCT	ACCCGCTCAT
20821	CGGCAAGAGC	GCCGTCGCCA	GCGTCACCCA	GAAAAAGTTC	CTCTGCGACC	GGGTCATGTG

Fig. 6L

20881	GCGCATCCCC	TTCTCCAGCA	ACTTCATGTC	CATGGGCGCG	CTCACCGACC	TCGGCCAGAA
20941	CATGCTCTAC	GCCAACTCCG	CCCACGCGCT	AGACATGAAT	TTCGAAGTCG	ACCCCATGGA
21001	TGAGTCCACC	CTTCTCTATG	TTGTCTTCGA	AGTCTTCGAC	GTCGTCCGAG	TGCACCAGCC
21061	CCACCGCGGC	GTCATCGAGG	CCGTCTACCT	GCGCACGCCC	TTCTCGGCCG	GTAACGCCAC
21121	CACCTAAGCC	CCGCTCTTGC	TTCTTGCAAG	ATGACGGCCT	GTGCGGGCTC	CGGCGAGCAG
21181	GAGCTCAGGG	CCATCCTCCG	CGACCTGGGC	TGCGGGCCCT	GCTTCCTGGG	CACCTTCGAC
21241	AAGCGCTTCC	CGGGATTCAT	GGCCCCGCAC	AAGCTGGCCT	GCGCCATCGT	CAACACGGCC
21301	GGCCGCGAGA	CCGGGGGCGA	GCACTGGCTG	GCCTTCGCCT	GGAACCCGCG	CTCCCACACC
21361	TGCTACCTCT	TCGACCCCTT	CGGGTTCTCG	AACGAGCGCC	TCAAGCAGAT	CTACCAGTTC
21421	GAGTACGAGG	GCCTGCTGCG	CCGCAGCGCC	CTGGCCACCG	AGGACCGCTG	CGTCACCCTG
21481	GAAAAGTCCA	CCCAGACCGT	GCAGGGTCCG	CGCTCGGCCG	CCTGCGGGCT	CTTCTGCTGC
21541	ATGTTCCTGC	ACGCCTTCGT	GCACTGGCCC	GACCGCCCCA	TGGACAAGAA	CCCCACCATG
21601	AACTTGCTGA	CGGGGGTGCC	CAACGGCATG	CTCCAGTCGC	CCCAGGTGGA	ACCCACCCTG
21661	CGCCGCAACC	AGGAAGCGCT	CTACCGCTTC	CTCAACGCCC	ACTCCGCCTA	CTTTCGCTCC
21721	CACCGCGCGC	GCATCGAGAA	GGCCACCGCC	TTCGACCGCA	TGAATCAAGA	CATGTAAACC
21781	GTGTGTGTAT	GTGAATGCTT	TATTCATAAT	AAACAGCACA	TGTTTATGCC	ACCTTCTCTG
21841	AGGCTCTGAC	TTTATTTAGA	AATCGAAGGG	GTTCTGCCGG	CTCTCGGCAT	GCCCCGCGGG
21901	CAGGGATACG	TTGCGGAACT	GGTACTTGGG	CAGCCACTTG	AACTCGGGGA	TCAGCAGCTT
21961	GGGCACGGGG	AGGTCGGGGA	ACGAGTCGCT	CCACAGCTTG	CGCGTGAGTT	GCAGGGCGCC
22021	CAGCAGGTCG	GGCGCGGAGA	TCTTGAAATC	GCAGTTGGGA	CCCGCGTTCT	GCGCGCGAGA
22081	GTTGCGGTAC	ACGGGGTTGC	AGCACTGGAA	CACCATCAGG	GCCGGGTGCT	TCACGCTCGC
22141	CAGCACCGTC	GCGTCGGTGA	TGCCCTCCAC	GTCCAGATCC	TCGGCGTTGG	CCATCCCGAA
22201	GGGGGTCATC	TTGCAGGTCT	GCCGCCCCAT	GCTGGGCACG	CAGCCGGGCT	TGTGGTTGCA
22261	ATCGCAGTGC	AGGGGGATCA	GCATCATCTG	GGCCTGCTCG	GAGCTCATGC	CCGGGTACAT
22321	GGCCTTCATG	AAAGCCTCCA	GCTGGCGGAA	GGCCTGCTGC	GCCTTGCCGC	CCTCGGTGAA
22381	GAAGACCCCG	CAGGACTTGC	TAGAGAACTG	GTTGGTGGCG	CAGCCCGCGT	CGTGCACGCA
22441	GCAGCGCGCG	TCGTTGTTGG	CCAGCTGCAC	CACGCTGCGC	CCCCAGCGGT	TCTGGGTGAT
22501	CTTGGCCCGG	TCGGGGTTCT	CCTTCAGCGC	GCGCTGTCCG	TTCTCGCTCG	CCACATCCAT
22561	CTCGATCGTG	TGCTCCTTCT	GGATCATCAC	GGTCCCGTGC	AGGCACCGCA	GCTTGCTCTC

Fig. 6M

		4	0 /1 = 1			
SEQ ID N	O:2	4	0/153	3		
22621	GGCCTCGGTG	CACCCGTGCA	GCCACAGCGC	GCAGCCGGTG	CTCTCCCAGT	TCTTGTGGGC
22681	GATCTGGGAG	TGCGAGTGCA	CGAAGCCCTG	CAGGAAGCGG	CCCATCATCG	CGGTCAGGGT
22741	CTTGTTGCTG	GTGAAGGTCA	GCGGGATGCC	GCGGTGCTCC	TCGTTCACAT	ACAGGTGGCA
22801	GATGCGGCGG	TACACCTCGC	CCTGCTCGGG	CATCAGCTGG	AAGGCGGACT	TCAGGTCGCT
22861	CTCCACGCGG	TACCGGTCCA	TCAGCAGCGT	CATGACTTCC	ATGCCCTTCT	CCCAGGCCGA
22921	AACGATCGGC	AGGCTCAGGG	GGTTCTTCAC	CGTTGTCATC	TTAGTCGCCG	CCGCCGAGGT
22981	CAGGGGGTCG	TTCTCGTCCA	GGGTCTCAAA	CACTCGCTTG	CCGTCCTTCT	CGATGATGCG
23041	CACGGGGGGG	AAGCTGAAGC	CCACGGCCGC	CAGCTCCTCC	TCGGCCTGCC	TTTCGTCCTC
23101	GCTGTCCTGG	CTGATGTCTT	GCAAAGGCAC	ATGCTTGGTC	TTGCGGGGTT	TCTTTTTGGG
23161	CGGCAGAGGC	GGCGGCGGAG	ACGTGCTGGG	CGAGCGCGAG	TTCTCGCTCA	CCACGACTAT
23221	TTCTTCTTCT	TGGCCGTCGT	CCGAGACCAC	GCGGCGGTAG	GCATGCCTCT	TCTGGGGCAG
23281	AGGCGGAGGC	GACGGGCTCT	CGCGGTTCGG	CGGGCGGCTG	GCAGAGCCCC	TTCCGCGTTC
23341	GGGGGTGCGC	TCCTGGCGGC	GCTGCTCTGA	CTGACTTCCT	CCGCGGCCGG	CCATTGTGTT
23401	CTCCTAGGGA	GCAACAACAA	GCATGGAGAC	TCAGCCATCG	TCGCCAACAT	CGCCATCTGC
23461	ccccccccc	GACGAGAACC	AGCAGAATGA	AAGCTTAACC	GCCCGCCGC	CCAGCCCCAC
23521	CTCCGACGCC	GCGGCCCCAG	ACATGCAAGA	GATGGAGGAA	TCCATCGAGA	TTGACCTGGG
23581	CTACGTGACG	CCCGCGGAGC	ACGAGGAGGA	GCTGGCAGCG	CGCTTTTCAG	CCCCGGAAGA
23641	GAACCACCAA	GAGCAGCCAG	AGCAGGAAGC	AGAGAGCGAG	CAGAACCAGG	CTGGGCTCGA
23701	GCATGGCGAC	TACCTGAGCG	GGGCAGAGGA	CGTGCTCATC	AAGCATCTGA	CCCGCCAATG
23761	CATCATCGTC	AAGGACGCGC	TGCTCGACCG	CGCCGAGGTG	CCCCTCAGCG	TGGCGGAGCT
23821	CAGCCGCGCC	TACGAGCGCA	ACCTCTTCTC	GCCGCGCGTG	CCCCCCAAGC	GCCAGCCCAA
23881	CGGCACCTGC	GAGCCCAACC	CGCGCCTCAA	CTTCTACCCG	GTCTTCGCGG	TGCCCGAGGC
23941	CCTGGCCACC	TACCACCTCT	TTTTCAAGAA	CCAAAGGATC	CCCGTCTCCT	GCCGCGCCAA
24001	CCGCACCCGC	GCCGACGCCC	TGCTCAACCT	GGGCCCCGGC	GCCCGCCTAC	CTGATATCAC
24061	CTCCTTGGAA	GAGGTTCCCA	AGATCTTCGA	GGGTCTGGGC	AGCGACGAGA	CTCGGGCCGC
24121	GAACGCTCTG	CAAGGAAGCG	GAGAGGAACA	TGAGCACCAC	AGCGCCCTGG	TGGAGTTGGA
24181	AGGCGACAAC	GCGCGCCTGG	CGGTGCTCAA	GCGCACGGTC	GAGCTGACCC	ACTTCGCCTA

Fig. 6N

24241 CCCGGCGCTC AACCTGCCCC CCAAGGTCAT GAGCGCCGTC ATGGACCAGG TGCTCATCAA

24301 GCGCGCCTCG CCCATTGAGG ACATGCAGGA CCCCGAGAGC TCGGACGAGG GCAAGCCCGT

SEQ ID	TO:2 41/153
2436	GGTCAGCGAC GAGCAGCTGG CGCGCTGGCT GGGAGCGAGT AGCACCCCCC AGAGCCTGGA
2442	AGAGCGGCGC AAGCTCATGA TGGCCGTGGT CCTGGTGACC GTGGAGCTGG AGTGTCTGCG
2448	CCGCTTCTTC GCCGACGCAG AGACCCTGCG CAAGGTCGAG GAGAACCTGC ACTACCTCTT
2454:	CAGGCACGGG TTCGTGCGCC AGGCCTGCAA GATCTCCAAC GTGGAGCTGA CCAACCTGGT
24603	CTCCTACATG GGCATCCTGC ACGAGAACCG CCTGGGGCAG AACGTGCTGC ACACCACCCT
24661	GCGCGGGGAG GCCCGCCGC ACTACATCCG CGACTGCGTC TACCTGTACC TCTGCCACAC
- 24721	
24781	
24841	
24901	
24961	CTCCGGGATC CTGCCCGCCA CCTGCTCCGC GCTGCCCTCG GACTTCGTGC CGCTGACCTT
25021	CCGCGAGTGC CCCCCGCCGC TCTGGAGCCA CTGCTACTTG CTGCGCCTGG CCAACTACCT
25081	GGCCTACCAC TCGGACGTGA TCGAGGACGT CAGCGGCGAG GGTCTGCTGG AGTGCCACTG
25141	CCGCTGCAAC CTCTGCACGC CGCACCGCTC CCTGGCCTGC AACCCCCAGC TGCTGAGCGA
25201	GACCCAGATC ATCGGCACCT TCGAGTTGCA AGGCCCCGGC GAGGAGGGCA AGGGGGGTCT
25261	GAAACTCACC CCGGGGCTGT GGACCTCGGC CTACTTGCGC AAGTTCGTGC CCGAGGACTA
25321	CCATCCCTTC GAGATCAGGT TCTACGAGGA CCAATCCCAG CCGCCCAAGG CCGAGCTGTC
25381	GGCCTGCGTC ATCACCCAGG GGGCCATCCT GGCCCAATTG CAAGCCATCC AGAAATCCCG
25441	CCAAGAATTT CTGCTGAAAA AGGGCCACGG GGTCTACTTG GACCCCCAGA CCGGAGAGGA
25501	GCTCAACCCC AGCTTCCCCC AGGATGCCCC GAGGAAGCAG CAAGAAGCTG AAAGTGGAGC
25561	TGCCGCCGCC GGAGGATTTG GAGGAAGACT GGGAGAGCAG TCAGGCAGAG GAGGAGATGG
25621	AAGACTGGGA CAGCACTCAG GCAGAGGAGG ACAGCCTGCA AGACAGTCTG GAGGAGGAAG
25681	ACGAGGTGGA GGAGGAGG GCAGAGGAAG AAGCAGCCGC CGCCAGACCG TCGTCCTCGG
25741	CGGAGAAAGC AAGCAGCACG GATACCATCT CCGCTCCGGG TCGGGGTCGC GGCGGCCGGG
25801	CCCACAGTAG GTGGGACGAG ACCGGGCGCT TCCCGAACCC CACCACCAG ACCGGTAAGA
25861	AGGAGCGGCA GGGATACAAG TCCTGGCGGG GGCACAAAAA CGCCATCGTC TCCTGCTTGC
25921	AAGCCTGCGG GGGCAACATC TCCTTCACCC GGCGCTACCT GCTCTTCCAC CGCGGGGTGA
25981	ACTTCCCCCG CAACATCTTG CATTACTACC GTCACCTCCA CAGCCCCTAC TACTGTTTCC
26041	AGAAGAGGC AGAAACCCAG CAGCAGCAGA AAACCAGCGA CAGCGGCAGC AGCTAGAAAA

42/153 SEQ ID NO:2 26101 TCCACAGCGG CAGGTGGACT GAGGATCGCG GCGAACGAGC CGGCGCAGAC CCGGGAGCTG 26161 AGGAACCGGA TCTTTCCCAC CCTCTATGCC ATCTTCCAGC AGAGTCGGGG GCAGGAGCAG 26221 GAACTGAAAG TCAAGAACCG TTCTCTGCGC TCGCTCACCC GCAGTTGTCT GTATCACAAG 26281 AGCGAAGACC AACTTCAGCG CACTCTCGAG GACGCCGAGG CTCTCTTCAA CAAGTACTGC 26341 GCGCTCACTC TTAAAGAGTA GCCCGCGCCC GCCCACACAC GGAAAAAGGC GGGAATTACG 26401 TCACCACCTG CGCCCTTCGC CCGACCATCA TCATGAGCAA AGAGATTCCC ACGCCTTACA 26461 TGTGGAGCTA CCAGCCCCAG ATGGGTCTGG CCGCCGGCGC CGCCCAGGAC TACTCCACCC 26521 GCATGAACTG GCTCAGTGCC GGGCCCGCGA TGATCTCACG GGTGAATGAC ATCCGCGCCC 26581 ATCGAAACCA GATACTCCTA GAACAGTCAG CGATCACCGC CACGCCCCGC CATCACCTTA 26641 ATCCGCGTAA TTGGCCCGCC GCCCTGGTGT ACCAGGAAAT TCCCCAGCCC ACGACCGTAC 26701 TACTTCCGCG AGACGCCCAG GCCGAAGTCC AGCTGACTAA CTCAGGTGTC CAGCTGGCCG 26761 GCGGCGCCGC CCTGTGTCGT CACCGCCCCG CTCAGGGTAT AAAGCGGCTG GTGATCCGAG GCAGAGGCAC ACAGCTCAAC GACGAGGTGG TGAGCTCTTC GCTGGGTCTG CGACCTGACG 26821 26881 GAGTCTTCCA ACTCGCCGGA TCGGGGAGAT CTTCCTTCAC GCCTCGTCAG GCCGTCCTGA 26941 CTTTGGAGAG TTCGTCCTCG CAGCCCCGCT CGGGCGGCAT CGGCACTCTC CAGTTCGTGG 27001 AGGAGTTCAC TCCCTCGGTC TACTTCAACC CCTTCTCCGG CTCCCCCGGC CACTACCCGG ACGAGTTCAT CCCGAACTTC GACGCCATCA GCGAGTCGGT GGACGGCTAC GATTGAATGT 27061 27121 CCCATGGTGG CGCAGCTGAC CTAGCTCGGC TTCGACACCT GGACCACTGC CGCCGCTTCC 27181 GCTGCTTCGC TCGGGATCTC GCCGAGTTTG CCTACTTTGA GCTGCCCGAG GAGCACCCTC 27241 AGGGCCCGGC CCACGGAGTG CGGATCATCA TCGAAGGGGG CCTCGACTCC CACCTGCTTC 27301 GGATCTTCAG CCAGCGACCG ATCCTGGTCG AGCGCGAGCA AGGACAGACC CGTCTGACCC TGTACTGCAT CTGCAACCAC CCCGGCCTGC ATGAAAGTCT TTGTTGTCTG CTGTGTACTG 27361 27421 AGTATAATAA AAGCTGAGAT CAGCGACTAC TCCGGACTCG ATTGTGGTGT TCCTGCTATC 27481 AACCGGTCCC TGTTCTTCAC CGGGAACGAG ACCGAGCTCC AGCTCCAGTG TAAGCCCCAC 27541 AAGAAGTACC TCACCTGGCT GTTCCAGGGC TCTCCGATCG CCGTTGTCAA CCACTGCGAC 27601 AACGACGGAG TCCTGCTGAG CGGCCCTGCC AACCTTACTT TTTCCACCCG CAGAAGCAAG 27661 CTCCAGCTCT TCCAACCCTT CCTCCCCGGG ACCTATCAGT GCGTCTCGGG ACCCTGCCAT 27721 CACACCTTCC ACCTGATCCC GAATACCACA GCGCCGCTCC CCGCTACTAA CAACCAAACT

Fig. 6P

27781 ACCCACCAAC GCCACCGTCG CGACCTTTCC TCTGAATCTA ATACTACCAC CCACACCGGA

	_					
2784						
2790						
2796	- 1001011CG1 AC					
2802	1 TGAGCTGCGG TG	TGCTGGTG	GCGGTGTTG	C TTTCGATTC	T GGGACTGGGC	GGCGCGGCTG
2808:	L TAGTGAAGGA GG	AGAAGGCC	GATCCCTGC	T TGCATTTCA	A TCCCGACAAA	TGCCAGCTGA
2814:	GTTTTCAGCC CG	ATGGCAAT	CGGTGCACG	G TGCTGATCA	A GTGCGGATGG	GAATGTGAGA
28201	ACGTGAGAAT CG	AGTACAAT	AACAAGACT	C GGAACAATA	C TCTCGCGTCC	GTGTGGCAAC
28261	CCGGGGACCC CG	AGTGGTAC	ACCGTCTCT	G TCCCCGGTG	C TGACGGCTCC	CCGCGCACCG
28321	TGAATAATAC TT	<b>PCATTTTT</b>	GCGCACATG	F GCGACACGG	T CATGTGGATG	AGCAAGCAGT
28381						
28441	GCACGGCGCT AAT	CACCGCT	ATCGTGTGC	TGAGCATTC	A CATGCTCATC	GCTATTCGCC
28501	CCAGAAATAA TGC	CGAAAAA	GAGAAACAGO	CATAACACG	TTTTTCACAC	ACCTTTTTCA
28561	GACCATGGCC TCT	GTTACTG	CCCTAATTA1	TTTTTTGGG	CTCGTGGGCA	CTAGCAGCAC
28621	TTTTCAGCAT ATA					
28681	ATCACACCAG AAA	GTTTCAT (	GTACTGGTA	TGATAAAAA	AACACGCCAG	TCACACTCTG
28741	CAAGGGTCAT CAA					
28801	TATTACACTA CTT					
28861	CATAAAACAG GAC					
28921	TACAAAACCC ACAA					
28981	CAAAACAACA ACTA					
29041	AACTACACAC ACAC					
29101	GCAAAAGGGG GATA					
29161	TATTGTTGCT GTAG					
	CTGCTACAGA AAGC					
29281	ATTTTTTAGA ACCA					
29341	TTGTGAATCA GTGA					
29401	GCCACCCTCA GGTA					
29461	ATTATGCAAT TTTC					
29521	TGGCACTGAT CTGAT					

29581	TGGACAAAA	C ACTGAAGAA	A TGATTTTTT	A CAAAGTGGA	A GTGGTTGATC	CCACTACTCC
29641	ACCCACCAC	C ACAACTACT	C ACACCACACA	A CACAGAACA	ACCACAGCAG	AGGAGGCAGC
29701	AAAGTTAGC	C TTGCAGGTC	C AAGACAGTTO	: ATTTGTTGGC	ATTACCCCTA	CACCTGATCA
29761	GCGGTGTCC	G GGGCTGCTAC	G TCAGCGGCAT	TGTCGGTGTC	CTTTCGGGAT	TAGCAGTCAT
29821	AATCATCTG	C ATGTTCATT	TTGCTTGCTC	CTATAGAAGG	CTTTACCGAC	AAAAATCAGA
29881	CCCACTGCTC	AACCTCTATO	TTTAATTTT	TCCAGAGCCA	TGAAGGCAGT	TAGCACTCTA
29941	GTTTTTTGTT	CTTTGATTGG	G CATTGTTTT	AGTGCTGGGT	TTTTGAAAAA	TCTTACCATT
30001	TATGAAGGTO	S AGAATGCCAC	TCTAGTGGGC	ATCAGTGGTC	AAAATGTCAG	CTGGCTAAAA
30061	TACCATCTAC	ATGGGTGGAA	AGACATTTGC	GATTGGAATG	TCACTGTGTA	TACATGTAAT
30121	GGAGTTAACC	CTCACCATTAC	TAATGCCACC	CAAGATCAGA	ATGGTAGGTT	TAAGGGTCAG
30181	AGTTTCACTA	GAAATAATGG	GTATGAATCC	CATAACATGT	TTATCTATGA	CGTCACTGTC
30241	ATCAGAAATG	AGACCGCCAC	CACCACACAG	ATGCCCACTA	CACACAGTTC	TACCACTACT
30301	ACCAAGCAAA	CCACACAGAC	AACCACTTTT	TATACATCAA	CTCAGCATAT	GACCACCACT
30361	ACAGCAGCAA	AGCCAAGTAG	CGCAGCGCCT	CAGCCACAGG	CTTTGGCTTT	GAAAGCTGCA
30421	CAACCTAGTA	CAACTACTAA	GACCAATGAG	CAGACTACTG	ATTTTTTGTC	CACTGTCGAG
30481	AGCCACACCA	CAGCTACCTC	CAGTGCCTTC	TCTAGCACCG	CCAATCTCTC	CTCGCTTTCC
30541	TCTACACCAA	TCAGTCCCGC	TACTACTCCT	AGCCCCGCTC	CTCTTCCCAC	TCCCCTGAAG
30601	CAAACAGACG	GCGGCATGCA	ATGGCAGATC	ACCCTGCTCA	TTGTGATCGG	GTTGGTCATC
30661	CTGGCCGTGT	TGCTCTACTA	CATCTTCTGC	CGCCGCATTC	CCAACGCGCA	CCGCAAGCCG
30721	GTCTACAAGC	CCATCGTTGT	CGGGCAGCCG	GAGCCGCTTC	AGGTGGAAGG	GGGTCTAAGG
30781	AATCTTCTCT	TCTCTTTTAC	AGTATGGTGA	TTGAACTATG	ATTCCTAGAC	AATTCTTGAT
30841	CACTATTCTT	ATCTGCCTCC	TCCAAGTCTG	TGCCACCCTC	GCTCTGGTGG	CCAACGCCAG
30901	TCCAGACTGT	ATTGGGCCCT	TCGCCTCCTA	CGTGCTCTTT	GCCTTCATCA	CCTGCATCTG
30961	CTGTTGTAGC	ATAGTCTGCC	TGCTTATCAC	CTTCTTCCAG	TTCATTGACT	GGATCTTTGT
31021	GCGCATCGCC	TACCTGCGCC	ACCACCCCCA	GTACCGCGAC	CAGCGAGTGG	CGCGACTGCT
31081	CAGGCTCCTC	TGATAAGCAT	GCGGGCTCTG	CTACTTCTCG	CGCTTCTGCT	GTTAGTGCTC
31141	CCCCGTCCCG	TCGACCCCCG	GTCCCCGAG	GAGGTCCGCA	AATGCAAATT	CCAAGAACCC
31201	TGGAAATTCC	TCAAATGCTA	CCGCCAAAAA	TCAGACATGC	ATCCCAGCTG	GATCATGATC
31261	ATTGGGATCG	TGAACATTCT	GGCCTGCACC	СТСАТСТССТ	TTGTGATTTA	CCCCTGCTTT

31321	GACTTTGGTT	GGAACTCGCC	AGAGGCACTC	TATCTCCCGC	CTGAGCCTGA	CACACCACCA
31381	CAGCAGCAAC	CTCAGGCACA	CGCACTACCA	CCACCACAGC	CTAGGCCACA	ATACATGCCC
31441	ATATTAGACT	ATGAGGCCGA	GCCACAGCGA	CCCATGCTCC	CCGCTATTAG	TTACTTCAAT
31501	CTAACCGGCG	GAGATGACTG	ACCCACTGGC	CAACAACAAC	GTCAACGACC	TTCTCCTGGA
31561	CATGGACGGC	CGCGCCTCGG	AGCAGCGACT	CGCCCAACTC	CGCATCCGCC	AGCAGCAGGA
31621	GAGAGCCGTC	AAGGAGCTGC	AGGATGCGGT	GGCCATCCAC	CAGTGCAAGA	AAGGCATCTT
31681	CTGCCTGGTG	AAGCAGGCCA	AGATCTCCTA	CGAGGTCACC	CAGACCGACC	ATCGCCTCTC
31741	CTACGAGCTC	CTGCAGCAGC	GCCAGAAGTT	CACCTGCCTG	GTCGGAGTCA	ACCCCATCGT
31801	CATCACCCAG	CAGTCGGGCG	ATACCAAGGG	GTGCATCCAC	TGCTCCTGCG	ACTCCCCGA
31861	GTGCGTTCAC	ACCATGATCA	AGACCCTCTG	CGGCCTCCGC	GACCTCCTCC	CCATGAACTA
31921	ATCACCCCT	TATCCAGTGA	AATAAAGATC	ATATTGATGA	TGATTTAAAT	ААААААТАА
31981	TCATTTGATT	TGAAATAAAG	ATACAATCAT	ATTGATGATT	TGAGTTTAAC	AAAAATAAAG
32041	AATCACTTAC	TTGAAATCTG	ATACCAGGTC	TCTGTCCATG	TTTTCTGCCA	ACACCACCTC
32101	ACTCCCCTCT	TCCCAGCTCT	GGTACTGCAG	GCCCCGGCGG	GCTGCAAACT	TCCTCCACAC
32161	GCTGAAGGGG	ATGTCAAATT	CCTCCTGTCC	CTCAATCTTC	ATTTTCTCTT	CTATCAGATG
32221	TCCAAAAAGC	GCGCGCGGGT	GGATGATGAC	TTCGACCCCG	TGTACCCCTA	CGATGCAGAC
32281	AACGCACCGA	CTGTGCCCTT	CATCAACCCT	CCCTTCGTCT	CTTCAGATGG	ATTCCAAGAA
32341	AAGCCCCTGG	GGGTGTTGTC	CCTGCGACTG	GCCGATCCCG	TCACCACCAA	GAACGGGGCT
32401	GTCACCCTCA	AGCTGGGGGA	GGGGGTGGAC	CTCGACGACT	CGGGAAAACT	CATCTCCAAA
32461	AATGCCACCA	AGGCCACTGC	CCCTCTCAGT	ATTTCCAACA	ACACCATTTC	CCTTAACATG
32521	GATACCCCTC	TTTACAACAA	CAATGGAAAG	CTAGGTATGA	AGGTAACCGC	ACCATTAAAG
32581	ATATTAGACA	CAGATCTACT	AAAAACACTT	GTTGTTGCTT	ATGGGCAGGG	ATTAGGAACA
32641	AACACCAATG	GTGCTCTTGT	TGCCCAACTA	GCATACCCAC	TTGTTTTTAA	TACCGCTAGC
32701	AAAATTGCCC	TTAATTTAGG	CAATGGACCA	TTAAAAGTGG	ATGCAAATAG	ACTGAACATT
32761	AATTGCAAAA	GAGGTATCTA	TGTCACTACC	ACAAAAGATG	CACTGGAGAT	TAATATCAGT
32821	TGGGCAAATG	CTATGACATT	TATAGGAAAT	GCCATTGGTG	TCAATATTGA	САСАААААА
32881	GGCCTACAGT	TCGGCACTTC	AAGCACTGAA	ACAGATGTTA	AAAATGCTTT	TCCACTCCAA
32941	GTAAAACTTG	GAGCTGGTCT	TACATTTGAC	AGCACAGGTG	CCATTGTTGC	TTGGAACAAA
33001	GAAGATGACA	AACTTACACT	GTGGACCACA	GCCGATCCAT	CTCCAAACTG	TCACATATAT

33061	TCTGCAAAGG	ATGCTAAGCT	TACACTCTGC	TTGACAAAGT	GTGGTAGTCA	GATACTGGGC
33121	ACTGTTTCTC	TCATAGCTGT	TGATACTGGT	AGCTTAAATC	CAATAACAGG	AAAAGTAACC
33181	ACTGCTCTTG	TTTCACTTAA	ATTCGATGCC	AATGGAGTTT	TGCAAGCCAG	TTCAACACTA
33241	GATAAAGAAT	ATTGGAATTT	CAGAAAAGGA	GATGTGACAC	CTGCTGACCC	CTACACTAAT
33301	GCTATAGGCT	TTATGCCCAA	CCTTAATGCA	TACCCAAAAA	ACACAAACGC	AGCTGCAAAA
33361	AGTCACATTG	TTGGAAAAGT	ATACCTACAT	GGGGATGAAA	GCAAGCCACT	AGACTTGATA
33421	ATTACATTTA	ATGAAACCAG	TGATGAATCC	TGTACTTATT	GCATTAACTT	TCAGTGGCAG
33481	TGGGGAACTG	ACCAATATAA	AGATGAAACA	CTTGCAGTCA	GTTCATTCAC	CTTCTCATAC
33541	ATTGCTAAAG	AATAACATCC	ACCCTGCATG	CCAACCCATT	TCCCTCTATC	TATACATGGA
33601	AAACTCTGAA	GCAGAAAAAA	TAAAGTTCAA	GTGTTTTATT	GATTCAACAG	TTTTTACAGA
33661	ATTCGAGTAG	TTATTTTCCC	TCCACCCTCC	CAACTCATGG	AATACACCAT	CCTCTCCCCA
33721	CGCACAGCCT	TAAACATCTG	AATGCCATTG	GTAATGGACA	TGGTTTTGGC	CTCCACATTC
33781	CACACAGTTT	CAGAGCGAGC	CAGTCTCGGG	TCGGTCAGGG	AGATGAAACC	CTCCGGGCAC
33841	TCCTGCATCT	GCACCTCACA	GTTCAACAGC	TGAGGGCTGT	CCTCGGTGGT	CGGGATCACA
33901	GTTATCTGGA	AGAAGAGCGA	TGAGAGTCAT	AATCCGCGAA	CGGGATCGGG	CGGTTGTGGC
33961	GCATCAGGCC	CCGCAGCAGT	CGCTGTCTGC	GCCGCTCCGT	CAAGCTGCTG	CTCAAGGGGT
34021	CCGGGTCCAG	GGACTCCCCG	CGCATGATGC	CGATGGCCCT	GAGCATCAGT	CGCCTGGTGC
34081	GGCGGGCGCA	GCAGCGGATG	CGGATCTCAC	TCAGGTCGGA	ACAGTACGTG	CAGCACAGCA
34141	CTACCAAGTT	GTTCAACAGT	CCATAGTTCA	ACGTGCTCCA	GCCAAAACTC	ATCTGTGGAA
34201	CTATGCTGCC	CACATGTCCA	TCGTACCAGA	TCCTGATGTA	AATCAGGTGG	CGCCCCCTCC
34261	AGAACACACT	GCCCATGTAC	ATGATCTCCT	TGGGCATGTG	CAGGTTCACC	ACCTCCCGGT
34321	ACCACATCAC	CCGCTGGTTG	AACATGCAGC	CCCGGATGAT	CCTGCGGAAC	CACAGGGCCA
34381	GCACCGCCCC	GCCCGCCATG	CAGCGCAGGG	ACCCCGGGTC	CTGGCAATGG	CAGTGGATGA
34441	TCCACCGCTC	GTACCCGTGG	ATCATCTGGG	AGCTGAACAA	GTCTATGTTG	GCACAGCACA
34501	GGCACACGCT	CATGCATCTC	TTCAGCACTC	TCAGCTCCTC	GGGGGTCAAA	ACCATATCCC
34561	AGGGTACGGG	GAACTCTTGC	AGGACAGCGA	ACCCCGCAGA	ACAGGGCAAA	CCTCGCACAG
34621	AACTTACATT	GTGCATGGAC	AGGGTATCGC	AATCAGGCAG	CACCGGGTGA	TCCTCCACCA
34681	GGGAAGCGCG	GGTCTCGATT	TCCTCACAGC	GTGGTAAGGG	GGCCGGTCGA	TACGGGTGAT
34741	GGCGGGACGC	GGCTGATCGT	GTTCGCGATC	GTGTCATGAT	GCAGTTGCTT	TCGGACATTT

34801	TCGTACTTGC	TATAGCAGAA	CCTGGTCCGG	GCGCTGCACA	CCGATCGCCG	GCGGCGGTCT
34861	CGGCGCTTGG	AACGCTCCGT	GTTGAAATTG	TAAAACAGCC	ACTCTCTCAG	ACCGTGCAGC
34921	AGATCTAGGG	CCTCAGGAGT	GATGAAGATC	CCATCATGCC	TGATGGCTCT	GATCACATCG
34981	ACCACCGTGG	AATGGGCCAG	ACCCAGCCAG	ATGATGCAAT	TTTGTTGGGT	TTCGGTGACG
35041	GCGGGGGAGG	GAAGAACAGG	AAGAACCATG	ATTAACTTTA	ATCCAAACGG	TCTCGGAGCA
35101	CTTCAAAATG	AAGGTCGCGG	AGATGGCACC	TCTCGCCCCC	GCTGTGTTGG	TGGAAAATAA
35161	CAGCCAGGTC	AAAGGTGATA	CGGTTCTCGA	GATGTTCCAC	GGTGGCTTCC	AGCAAAGCCT
35221	CCACGCGCAC	ATCCAGAAAC	AAGACAATAG	CGAAAGCGGG	AGGGTTCTCT	AATTCCTCAA
35281	TCATCATGTT	ACACTCCTGC	ACCATCCCCA	GATAATTTTC	ATTTTTCCAG	CCTTGAATGA
35341	TTCGAACTAG	TTCCTGAGGT	AAATCCAAGC	CAGCCATGAT	AAAGAGCTCG	CGCAGAGCGC
35401	CCTCCACCGG	CATTCTTAAG	CACACCCTCA	TAATTCCAAG	ATATTCTGCT	CCTGGTTCAC
35461	CTGCAGCAGA	TTGACAAGCG	GAATATCAAA	CTCTCTGCCG	CGATCCCTAA	GCTCCTCCCT
35521	CAGCAATAAC	TGTAAGTACT	CTCTCATATC	CTCTCCGAAA	TTTTTAGCCA	TAGGACCGCC
35581	AGGAATAAGA	TTAGGGCAAG	CCACAGTACA	GATAAACCGA	AGTCCTCCCC	AGTGAGCATT
35641	GCCAAATGCA	AGACTGCTAT	AAGCATGCTG	GCTAGACCCG	GTGATATCTT	CCAGATAATT
35701	GGACAGAAAA	TCGCCCAGGC	AATTTTTAAG	AAAATCAACA	AAAGAAAAAT	CCTCCAGGTG
35761	CACGTTTAGA	GCCTCGGGAA	CAACGATGGA	GTAAATGCAA	GCGGTGCGTT	CCAGCATGGT
35821	TAGTTAGCTG	ATCTGTAGAA	ААААСААААА	TGAACATTAA	ACCATGCTAG	CCTGGCGAAC
35881	AGGTGGGTAA	ATCGTTCTTT	CCAGCACCAG	GCAGGCCACG	GGGTCTCCGG	CGCGACCCTC
35941	GTAAAAATTG	TCGCTATGAT	TGAAAACCAT	CACAGAGAGA	CGTTCCCGGT	GGCCGGCGTG
36001	AATGATTCGA	CAAGACGAAT	ACACCCCCGG	AACATTGGCG	TCCGCGAGTG	AAAAAAAGCG
36061	CCCGAGGAAG	CAATAAGGCA	CTACAATGCT	CAGTCTCAAG	TCCAGCAAAG	CGATGCCATG
36121	CGGATGAAGC	ACAAAATTCT	CAGGTGCGTA	CAAAATGTAA	TTACTCCCCT	CCTGCACAGG
36181	CAGCAAAGCC	CCCGATCCCT	CCAGGTACAC	ATACAAAGCC	TCAGCGTCCA	TAGCTTACCG
36241	AGCAGCAGCG	GCACACAACA	GGCGCAAAAG	TCAGAGAAAG	GCTGAGAGCT	CTAACCTGTC
36301	CACCCGCTCT	CTGCTCAATA	TATAGCCCAG	ATCTACACTG	ACGTAAAGGC	CAAAGTCTAA
36361	AAATACCCGC	CAAATAATCA	CACACGCCCA	GCACACGCCC	AGAAACCGGT	GACACACTCA
36421	GAAAAATACG	CGCACTTCCT	CAAACGCCCA	AACTGCCGTC	ATTTCCGGGT	TCCCACGCTA
36481	CGTCATCAAA	ATTCAACTTT	CAAATTCCGT	CGACCGTTAA	AAACGTCACC	CGCCCGCCC

### ITR0048PV

SEQ ID NO:2

48/153

36541 CTAACGGTCG CCGCTCCCGC AGCCAATCAG CGCCCCGCAT CCCCAAATTC AAACGGCTCA

36601 TTTGCATATT AACGCGCACC AAAAGTTTGA GGTATATTAT TGATGATG

JO 101	•					
	SEQ ID NO:3	4	9/15	3		
:	1 CATCATCAAT				ጥልጥርር አል አጥር	AGCTGTTTGA
6:	l ATTTGGGGAG	GGAGGAAGGT	GATTGGCTG	GGGAGCGGCG	ACCGTTAGGG	GCGGGGCGGG
12:	L TGACGTTTTC	ATGACGTGGC	TATGAGGCG	AGCCGGTTTG	CAAGTTCTCG	TCCCAAAACT
TA.	L GACGTCAAAC	: GAGGTGTGG1	' TTGAACACGO	B AAATACTCAA	TTTTCCCCCC	CTCTCTCACA
241	L GGAAATGAGG	F TGTTTCTGGG	CGGATGCAAC	TGAAAACGGG	CCATTTTCCC	CCCAAAACTC
30.	L AATGAGGAAG	GAAAATCTG	AGTAATTTCC	CGTTTATGGC	AGGGAGGAGT	ATTTCCCGAC
36.	L GGCCGAGTAG	ACTTTGACCG	ATTACGTGGG	GGTTTCGATT	ACCGTATTTT	ጥሮልሮሮሞልልልሞ
42.	L TTCCGCGTAC	GGTGTCAAAG	TCCGGTGTTT	TTACGTAGGC	GTCAGCTGAT	CCCCACCCTA
48]	L TTTAAACCTG	CGCTCTCTAG	TCAAGAGGCC	ACTCTTGAGT	GCCAGCGAGT	<b>አር</b> ልርጥጥጥጥርጥ
541	LCCTCCGCGCC	GCGAGTCAGA	TCTACACTTI	GAAAGATGAG	GCACCTGAGA	CACCTCCCCC
603	L GTAATGTTT	CCTGGCTACT	GGGAACGAGA	TTCTGGAATT	GGTGGTGGAC	GCCATGATGG
201	GTGACGACCC	TCCAGAGCCC	CCTACCCCAT	TTGAGGCGCC	TTCGCTGTAC	GATTTGTATG
721	. ATCTGGAGGT	GGATGTGCCC	GAGAGCGACC	CTAACGAGGA	GGCGGTGAAT	GATTTGTTTA
781	. GCGATGCCGC	GCTGCTGGCT	GCCGAGCAGG	CTAATACGGA	CTCTGGCTCA	GACAGCGATT
041	. CCTCTCTCCA	TACCCCGAGA	CCCGGCAGAG	GTGAGAAAA	GATCCCCGAG	CTTAAAGGGG
961	AAGAGCICGA	. CCTGCGCTGC	TATGAGGAAT	GCTTGCCTCC	GAGCGATGAT	GAGGAGGACG
1021	TAUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU	TCGAGCTGCG	GTGAACCAGG	GAGTGAAAAC	TGCGGGCGAG	AGCTTTAGCC
1021	CTCCACATAA	CAATCTCTGCCC	GGACACGGCT	GTAAGTCTTG	TGAATTTCAT	CGCATGAATA
1141	ACAGTAAGTAA	TCATTA ACTOR	TGTGCCCTGT	GCTATATGAG GGCAGAGGGT	AGCTTACAAC	CATTGTGTTT
1201	ТОЛИТОЛО В ТОТОЛО В ТОТОЛО В ТОТОЛО В	TOWITHWCII.	TAGTTGGGAA	CCCGTCTCTG	GACTGGGTGC	TGACTGGTTT
1261	TCAGAGTGCA	ጥጥጥሮልጥሮልሮሮ	WIGIGINGGI	GGCGAGGAAC	ACGTAGATGA	GACCCCCACT
1321	AGACCAGTTG	CAGTGAGAGT	CACCEGGGGG	AGAGCAGCTG	TOCA CA CERT	TATTATTCAT
1381	CTACAGGGTG	GGGATGAACC	TTTCCACTTC	TGTACCCGGA	1GGAGAGTTT	GGATGACTTG
1441	CCACACATGT	GTGTTTACTT	AAGGTGATGT	CAGTATTTAT	ACCCTCTCTCCA	GUACTAAGTG
1501	ATCCGTGTTG	ACTTTAAGTG	CGTGTTTTAT	GACTCAGGGG	TCCCCACTCT	CCCTATAAA
1561	GCAGGTGCAG	ACCTGTGTGG	TCAGTTCAGA	GCAGGACTCA	TECACATOTE	CACTCTCTTC
1621	GAAGACTTTC	ACCAGACTAG	ACAGTTGCTA	GAGAACTCAT	CGCAGGGAGT	CTCTTACCTC
TOST	TGGAGATTCT	GCTTCGGTGG	GCCTCTAGCT	AAGCTAGTCT	ATAGGGCCAA	ACAGGATTAT
1741	AAGGAACAAT	TTGAGGATAT	TTTGAGAGAG	TGTCCTGGTA	<b>ጥጥጥጥGACTC</b>	ጥርጥሮል ልርጥጥር
T80T	GGCCATCAGT	CTCACTTTAA	CCAGAGTATT	CTGAGAGCCC	ጥጥርልሮጥጥጥጥር	ጥልሮሞሮሮሞሮሮሮ
TRPT	AGAACTACCG	CCGCGGTAGC	CTTTTTTGCC	TTTATTCTTG	ACABATGGAG	ጥሮልልፎልልልሮሮ
1921	CATTTCAGCA	GGGATTACCG	TCTGGACTGC	TTAGCAGTAG	CTTTCTCCAC	AACATCCACC
1981	TGCCAGCGCC	TGAATGCAAT	CTCCGGCTAC	TTGCCAGTAC	AGCCGGTAGA	CACCCTCACC
204T	ATCCTGAGTC	TCCAGTCACC	CCAGGAACAC	CAACGCCGCC	AGCAGCCGCA	GCAGGAGGAG
STOT	CAGCAAGAGG	AGGACCGAGA	AGAGAACCCG	AGAGCCCGCTC	TECACCCTCC	CCTCCCCAC
7101	GAGGAGGAGT	AGCTGACTTG	TTTCCCGAGC	TGCGCCGGGT	GCTGACTAGG	TCTTCCAGTG
2221	CMCMCA CMCM	GGGGATTAAG	CGGGAGAGGC	ATGAGGAGAC	TAGCCACAGA	ACTGAACTGA
2201	ACCCCAMACA	GATGAGCCGC	AGGCGCCCAG	AATCGGTGTG	GTGGCATGAG	GTGCAGTCGC
2341	CTTCCTTCCA	TGAGGTCTCG	GTGATGCATG	AGAAATATTC	CCTAGAACAA	GTCAAGACTT
2461	TCAACCCACA	GCCCGAGGAT.	GATTGGGAGG	TAGCCATCAG	GAATTATGCC	AAGCTGGCTC
2521	TTTCACCGAA	TEGEGGCCCAC	CECCACAECA	AACTGATTAA	TATCAGAAAT	TCCTGCTACA
2581	GTATGATGAA	TATGTACCCG	GCCCTCCTCC	GTACCCAGGA GCATGGAGGG	GAGGGTGGCC	TTCAGATGTT
2641	GGTTCAGGGG	TGATGGGTAT	AATCCCCTCC	TCTTTATGGC	AGTCACCTTT	ATGAACACGA
2701	ACGGATGCTC	CTTCTTTGGC	TALGGGGIGG	TGTGCATCGA	CAACACCAAG	CTGACAGTGC
2761	TGAGGGGATG	CAGCTTTTCA	GCCDDCTGCD	TGGGGGTCGT	CCCCACAACC	AGTGTTTCAG
2821	TGTCAGTGAA	GAAATGCCTG	TTCGAGAGGT	GCCACCTGGG	CCTCATCACC	CACCCCCAAGG
2881	CCAAAGTCAA	ACACTGCGCC	TCTACCGAGA	CGGGCTGCTT	TCTCCTCATC	AACCCCAAG
2941	CCCAAGTCAA	GCATAACATG	ATCTGTGGGG	CCTCGGATGA	GCGCGGCTAC	CACATCCTCA
200T	CCTGCGCCGG	TGGGAACAGC	CATATGCTGG	CCACCGTGCA	<b>TGTGGCCTTCG</b>	CACCCCCCCA
2007	AGACATGGCC	CGAGTTCGAG	CACAACGTCA	TGACCCGCTG	CAATGTGCAC	CTCCCCTCCC
2121	GCCGAGGCAT	GTTCATGCCC	TACCAGTGCA	ACATGCAATT	ТСТСААССТС	CTCCTCCACC
2101	CCGATGCCAT	GTCCAGAGTG	AGCCTGACGG	CCCTCTTTGA	САТСААТСТС	CACCTCTCCA
3247	MANITCIGAG	ATATGATGAA	TCCAAGACCA	GCTGCCGGGC	СТСССААТСС	CCACCCAACC
J J U I	WCGCCWGGCT.	TCAGCCCGTG	TGTGTGGAGG	TGACGGAGGA	CCTGCGACCC	CATCATTTCC
330T	IGITGTCCTG	CAACGGGACG	GAGTTCGGCT	CCAGCGGGGA	AGAAጥርጥርልር	ጥልሮልሮጥሮልሮጥ
3421	WG I G I I I I G G G	GCIGGGTGTG	AGCCTGCATG	AGGGGCAGAA	ፐርልርጥል ል ል ልጥ	<u> </u>
2407	CIGICICITG	CAGCAGCATG .	AGCGGAAGCG	CCTCCTTTGA (	CCCACCCCTA	ጥጥሮ አርሮሮሮጥጥ
JJ41 .	WICIGACCCC	CCCLCLCCCCC .	TCCTGGGGGG	CACTCTCTCA (	ር እ አጥር ጥጥ አጥር	CNIATICCACCC
TOOL	+GGACGGCCG	GCCCGTGCAG	CCCGCGAACT	CTTCAACCCT	GACCTACGCG	ACCCTGAGCT

SEQ ID NO: 3 50/153

366	1 CCTCGTCCG	T GGACGCAGC'	F GCCGCCGCA	G CTGCTGCTT	CGCCGCCAG	CGCGTGCGCG
3 / 2	T GWWIGGCCC	T GGGCGCCCGG	J TACTACAGC	${f T}$ - ${f C}{f T}{f C}{f T}{f C}{f C$	<sup>ጊ</sup> ሮልአሮሞሮሮአር፣	B ####################################
3/0	T ATCCCGCCA	G CCTGAACGA	<b>GAGAAGCTG</b>	ር ጥርርጥርርጥርልሳ	P GGCCCACCMC	CACCCCCCCCC
204	T CCCAGCGCC	T GGGCGAGCT(	G ACCCAGCAG	G TGGCTCAGC1	P GCAGGCGGAG	ACCCCCCCCCC
390	T CGGTTGCCA	C GGTGAAAAC(	: AAATAAAA	<b>ል ጥርልልጥሮልልጥ</b> ፣	\	CACCCCCCCCC
396	1 GATTTTAAC	A CAGAGTCTT	3 AAጥርጥጥጥΔጥ	$\Gamma$ $\Gamma$ CATTCATT	, www.www.cech	GCCCTGGACC
402	1 ACCGGTCTC	G ATCATTGAGG	ACCCCCTCC	T TGATITIO	CGCGCGGTAG	GCCCTGGACC AGGTGGGCTT
408	1 GGATGTTGA	G GTACATGGG	NTCACCCCC	R CCCCCCCCC	GACCCGGTAG	G AGGTGGGCTT CATTGCAGGG
414	1 CCTCCTCCT	C CCCCAMCCM(	THE CHARLES	r ccceeeeer	GAGGTAGCTC	CATTGCAGGG
420	1 GCTGCACGA	T CTCCTTCACA	3 TIGIAAATCA	A CCCAGTCATA	L GCAGGGGCGC	AGGGCGTGGT
426	TCACCAACCA	T GICCIIGAGO	AGGAGACTGA	A TGGCCACGG	CAGCCCCTTG	GTGTAGGTGT
432	1 CCARCRECA	T GITGAGCTGG	GAGGGATGC	A TGCGGGGGGA	GATGAGATGC	ATCTTGGCCT
430	1 CCACCACCA	G ATTGGCGATG	TTCCCGCCC	A GATCCCGCCG	GGGGTTCATC	TTGTGCAGGA
430.	1 CCACCAGCA	GGTGTATCCG	GTGCACTTG	G GGAATTTGTC	ATGCAACTTG	GAAGGGAAGG
444.	L CGIGAAAGA	A TTTTGGAGACC	CCCTTGTGAC	CGCCCAGGTT	TTCC7TCC7C	mcamccamoa
400.	r reareacea.	r GGGCCCGTGG	GCGGCGGCCT	r GGGCAAAGAC	GTTTCCCCCC	TO CO TO
450.	r CGTAGTTGT	# GTCCTGGGTC	AGCTCGTCAT	l AGGCCATTT	` <u>እ</u> ልጥር እለጥጥጥር	CCCCCCTTCCC
402.	1 TGCCCGACT	∍ GGGGACGAAG	GTGCCCTCGZ	A TCCCGGGGGGC	CTACTTCCCC	macay ay mam
400.	L GCATCTCCC	4 GGCCTTGAGC	TCGGAGGGG	GGATCATGTC	CACCTCCCCC	CCCAMCAAAA
4/4	L AMACGGTTTC	CGGGGCGGGG	GAGATGAGCI	' GGGCCGAAAG	CACCTTCCC	ACCACCMCCC
400	L ACTIGCCGCA	ACCGGTGGGG	CCGTAGATGA	L CCCCGATGAC	CCCCTCCACC	mccma cmmoa
4861	L GGGAGAGACA	GCTGCCGTCC	TCGCGGAGGA	CGGGGGGCCAC	CTCCTTCATC	ATCTCGCGCA
4921	LCATGCATGTT	CTCGCGCACG	AGTTCCGCCA	GGAGGCGCTC	CICGLICALC	ATCTCGCGCA
4981	CTTGCAGCGA	GGCGAAGTTT	TTCAGCGGCT	TGAGTCCGTC	CCCCAMCC	GAGAGGAGCT
5041	GGGTCTGTTG	CAAGAGTTCC	AGACCCTCCC	AGAGCTCGGT	GGCCATGGGC	ATTTTTGGAGA
5101	GATCCAGCAG	ACCTCCTCCT	TTCCCCCCCTT	GGGGCGACTG	GATGTGCTCT	AGGGCATCTC
5161	ATGGGCGTCC	, ycccyccccy	CCCTCCCGGGTT	CTTCCAGGGC	CGGGAGTAGG	GCACCAGGCG
5221	GGTCTCCGTC	ACCCTCA ACC	CCCCCCCCC	CTTCCAGGGC	CGCAGGGTCC	GCGTCAGCGT
5281	CCTCATCCCC	CTCCTCCACA	3.0000macca	GGGCTGGGCG	CTTGCGAGGG	TGCGCTTCAG
5341	$\Delta TTCACCATC$	CIGGICGAGA	ACCGCTCCCG	GTCGGCGCCC	TGCGCGTCGG	CCAGGTAGCA
5401		MOTOGRAGI	TGAGCGCCTC	GGCCGCGTGG	CCCTTGGCGC	GGAGCTTACC
5/61	CACCAAAGIC	TGTCCGCAGA	CGGGACAGAG	GAGGGACTTG	AGGGCGTAGA	GCTTGGGGGC
5501	CMCCAAGACG	GACTCGGGGG	CGTAGGCGTC	CGCGCCGCAG	CTGGCGCAGA	CGGTCTCGCA
7277	CICCACGAGC	CAGGTGAGGT	CGGGGGCGGTT	CCCCTCAAAA	$\lambda C C \lambda C C D D D D C$	amaaamaamm
2207	TITIGHTGCGT	TTCTTACCTC	TGGTCTCCAT	GACCTCCTCT	CCCCCCCCCCCCC	MORORARO
2047	GCTGTCCGTG	TCCCCGTAGA	CCGACTTTAT	GGGCCGGTCC	TOCACOCCO	maaaaaaaa
3/01	CICGICGIAG	AGGAACCCCCG	CCCACTCCGA	GACGAAGGCC	CCCCTCCACC	CCACCACCAA
2,07	GGAGGCCACG	TGGGAGGGGT	AGCGGTCGTT	GTCCACCAGC.	CCCTCCACCT	TOTO A COOM
3021	ATGUAAGUAU	ATGTCCCCCT	CGTCCACATC	CAGGAAGGTG	$\Delta TTCCCTTCT$	7 7 CMCM2 CCC
2001	CACGIGACCG	GGGGTCCCGG	CCGGGGGGGT	ATAAAACCCC	CCCCCCCCCC	CCMCCMCCMC
2347	ACTUILLE	GGATCGCTGT	CCAGGAGCGC	CACCTCTTCC	CCTACCTATO	CCCMCMCCAAA
OOOT	GGCGGGCW.	ACCTCGGCAC	TCAGGTTGTC	<b>Δርጥጥጥሮጥ৯ሮ</b> ል	77CC7CC7CC	7 MMMC 7 M 7 MM
COOT	GHCGGTGCCG	TTGGAGACGC	CTTTCATGAG	<u> </u>	ልጥጥጥርርጥርእር	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
0121	CTTTTTGTIG	TUGAGUTTGG	TGGCGAAGGA	CCCCTACACC	CCCTTCCAACA	CONCOMMOGG
OTOT	GATGGAGCGC	ATGGTCTGGT	TCTTTTCCTT	GTCGGCGCGC	TOTOTOTOTO	CCAMOMMOAG
024T	CIGCACGTAC	TUGUGUGUCA	CGCACTTCCA	ጥጥሮርርርርር አክር	NCCCMCCMC2	COMCOMOCO
0202	CWCGWIICIG	ACCUGULACE	CGCGGTTCTC	C $A$ $C$ $C$ $C$ $C$ $C$ $C$ $C$ $A$ $C$ $C$ $A$ $C$ $C$ $C$ $A$ $A$ $C$ $A$	A CCMCCA CCC	MOOMOOOO
6361	CTCGCCGCGC	AGGGGCTCGT	TGGTCCAGCA	GAGGCGCCCG	CCCMMCCCCC	1GG1GGCCAC
6421	GGGCAGCGGG	TCCAGCATGA	GCTCGTCGGG	GGGGTCGGCG	TOO COORD	AGCAGAAGGG
6481	CAGGAGCTCG	GGGTCGAAGT	AGCTGATGCA	GGTGCCCAGA	TCCACGGTGA	AGATGCCGGG
6541	GTCGCGCACG	GCCAGCGCGC	CCTCCTACCA	GCTGAGGGGC	TTGTCCAGCG	CCGCTTGCCA
6601	CGTGAGCGCG	GAGGCGTACA	TCCCCCACAM	GCTGAGGGGC	GTGCCCCAGG	GCATGGGGTG
6661	GCCGATGTAG	CTCCCCTACA	ACCCCCCAGAT	GTCGTAGACG	TAGAGGGGCT	CCTCGAGGAC
6721	СТССТСССАС	GCCCCCACCA	COCCCCCCCC	GCGGATGCTG	GCGCGCACGT	AGTCGTACAG
6781	CTACACCAMO	TOCOCOCO A CO	GCCCCGTGCC	GAGGTTGGAG	CGTTGCGGCT	TTTCGGCGCG
0,07	GIAGACGAIC	ADARADOJOUL	TGGCGTGGGA	GTTCCACCAC	AMCCMCCCCC	MMMAA A AA M
0047	GTIGWWGIGG	GCGTGGGCA	GGCCGACCGA	ርጥርርርጥሮልጥሮ	AACTCCCCCC	7 CO2 OMOOMO
0 > 0 1	CAGCTIGGCG	ACGAGCTCGG	CGGTGACGAG	GACCTCCACC	CCCCACMACM	
0901	TIGGATGATG	TCATACTTGA	GCTGGCCCTT	CTCCTTCCAC	ACCTCCCCCT	מי בטטע ביי בטעע ביי
, 024	CICILGCGG	TUCTTUCAGT	ACTCTTCGAG	GGGGAACCCC	ጥርርጥር እጥርርር	Caccanaaca
100T	GCCCACCATG	TAGAACTGGT	TGACGGCCTT	GTACCCCCAC	<b>で</b> ね ごべてででかがてか	CCACCCCAC
,	GGCGTWWGCT	TGCGCGCCT	TUCCACCE	CCTCTCCCTC	3 <i>00000</i> 03300	MOMOROS
/ Z U I	CATGACCTTG	AGGAACTGGT	GCTTGAAGTC	GAGGTCGTCG	CAGCCGCCCT	GCTCCCAGAG
					•	

SEQ ID NO: 3 51/153

726	1 TTGGAAGTC	C GTGCGCTTC	TGTAGGCGG	GTTAGGCAA	GCGAAAGTAZ	CATCGTTGAA
132	T GAGGATCTT	3 CCCGCGCGCGG	GCATGAAGT1	C GCGAGTGATO	CGGAAAGGCT	CCCCCACCTC
/38	T GGCCCGGTTC	F TTGATGACC	r GGGCGGCGAG	GACGATCTCC	TCCAACCCCT	$m_{C}$ $\Delta m_{C}$ $m_{C}$ $m_{C}$
744	1 CCCGACGATO	TAGAGTTCC	CGAATCGCGC	GCGGCCCTTG	ACGTGGGGGG	GCTTCTTGAG
750	1 CTCGTCGTAC	GTGAGCTCG	CGGGGTCGCT	GAGCCCGTGC	TCCTCCACCC	CCCAGTCGGC
756	1 GACGTGGGG	TTGGCGCTG	GGAAGGAAGT	CCAGAGATCC	' ACCCCCACCC	G CCCAGTCGGC G CGGTCTGCAA
762	1 GCGGTCCCG	TACTGACGG	ACTGTTGGC	CACCCCAM	TURBUCCAGGG	G CGGTCTGCAA G TGACGCAGTA
768	1 GAAGGTGCGC	GGGTCGCCG	CCCANCGGTC	CACGGCCAII	TILICGGGGG	GGTCGTGGGC
774	1 GAGCTCGACG	AGCGGCGGG	CCCCCCACAC	. CONCILONGO	. IGGAGGGGGA	GGACGAGCTG
780	1 CTTGCCGAAG	GACCCCATCC	* ACCTCTACTACCT	TITCATGACC	AGCATGAAGG	GGACGAGCTG AGAGCCTTTC
786	1 GGTGCGAGGZ	TGCGAGCCGZ	TCCCCAACAA	CTCCACATCG	TAGGTGAGGA	AGAGCCTTTC TGGAGGAATG
792	1 ССТСТТСАТО	TCATCCAACG	, ycyyymcccc	L CIGGATCICC	TGCCACCAGT	TGGAGGAATG CCTTGTGTTT
798	1 ATACAAGCGT	, , , , , , , , , , , , , , , , , , , ,	CCCAACCCCC	ACGGCGCGCC	GAGCACTCGT	GCTTGTGTTT
804	1 CTGCGTTCCT	· TTCCCCACCA	A MUMACA CINCO	CACGGGATGC	ACGTGCTGCA	CGAGCTGTAC
810	CTCTACTACC	1100C0AGGA	ATTICAGIGG	GCAGTGGAGC	GCTGGCGGCT	GCATCTCGTG
816	CAGCCCCCCCC	CCCACCCAA	CGGCGTGGCC	ATCGTCTGCC	TCGATGGTGG	TCATGCTGAC
822	L GECCCCCGCGC	CCCCACCACC	TCCAGACCTC	GGCTCGGACG	GGTCGGAGAG	CGAGGACGAG
222	L CCCCCCCCCCC	CCGGAGCTGT	CCAGGGTCCT	GAGACGCTGC	GGAGTCAGGT	CAGTGGGCAG
93/1		CGGTTGACTT	GCAGGAGCTT	TTCCAGGGCG	CGCGGGAGGT	CCAGATGGTA
0343	CTTGATCTCC	ACGGCGCCGT	TGGTGGCTAC	GTCCACGGCT	TGCAGGGTGC	CGTGCCCCTG
0403	GGGCGCCACC	ACCGTGCCC	GTTTCTTCTT	GGGCGCTGCT	TCCATGTCGG	TCAGAAGCGG
0401	CGGCGAGGAC	GCGCGCCGGG	CGGCAGGGGC	GGCTCGGGGC	CCGGAGGCAG	GGGCGGCAGG
8521	GGCACGTCGG	CGCCGCGCGC	GGGCAGGTTC	TGGTACTGCG	CCCGGAGAAG	ACTGGCGTGA
8581	GCGACGACGC	GACGGTTGAC	GTCCTGGATC	TGACGCCTCT	GGGTGAAGGC	CACGGGACCC
8641	L GTGAGTTTGA	ACCTGAAAGA	GAGTTCGACA	GAATCAATCT	СССТАТССТТ	GACGGCGGCC
8701	. TGCCGCAGGA	TCTCTTGCAC	GTCGCCCGAG	TTGTCCTGGT	AGGCGATCTC	CCTCATCAAC
8/67	. TGCTCGATCT	CCTCCTCCTG	AAGGTCTCCG	CGGCCGGCGC	GCTCGACGGT	GCCCCCCACC
8871	. TCGTTGGAGA	TGCGGCCCAT	GAGCTGCGAG	AAGGCGTTCA	<b>ጥፍሮሮርርርርር</b>	CTTCCACACC
8887	. CGGCTGTAGA	CCACGGCTCC	GTCGGGGTCG	CGCGCGCGCA	TGACCACCTG	CCCCACCTTC
8941	. AGCTCGACGT	GGCGCGTGAA	GACCGCGTAG	TTGCAGAGGC	GCTGGTAGAG	CTACTTCACC
9001	. GTGGTGGCGA	TGTGCTCGGT	GACGAAGAAG	TACATGATCC	AGCGGCGGAG	CCCCATCTCC
3091	CTGACGTCGC	CCAGGGCTTC	CAAGCGTTCC	ATGGCCTCGT	AGAAGTCCAC	ርርርርል አርጥጥር
3171	AAAAACTGGG	AGTTGCGCGC	CGAGACGGTC	AACTCCTCCT	CCAGAAGACG	CATCACCTCC
ATRI	GCGATGGTGG	CGCGCACCTC	GCGCTCGAAG	GCCCCGGGGG	<b>CCTCCTCTTC</b>	CATCTCCTCC
9241	TCTTCCTCCT	CCACTAACAT	CTCTTCTACT	TCCTCCTCAG	GAGGCGGTCC	CCCCCCACCC
9301	GCCCTGCGTC	GCCGGCGGCG	CACGGGCAGA	CGGTCGATGA	AGCGCTCGAT	CCTCTCCCCC
9361	CGCCGGCGAC	GCATGGTCTC	GGTGACGGCG	CGCCCGTCCT	CCCCCCCCCC	CACCAMCAAC
9421	ACGCCGCCGC	GCATCTCCAG	GTGGCCGCCG	GGGGGGTCTC	CGCGGGGGCCG	CAGCAIGAAG
9481	CTGACGATGC	ATCTTATCAA	TTGACCCGTA	GGGACTCCCC	CGIIGGGCAG	CACCOCOCOCO
9541	AGATCCACGG	GATCCGAAAA	CCCCTGAACG	A A C C C TTC C A	CCCACGCCCT	GAGCGTCTCG
9601	AGGCTGAGCC	CGGTTTCTTG	ጥጥርጥጥርርርርጥ	AMMINICONCOC	CACCCCCCCCC	GTCGCAAGGT
9661	TGGTGATGAA	GTTGAAGTAG	CCCCTCCTCA	CACCCCCCAM	GAGGCGGCGG	GCGATGCTGC
9721	CCTTGGGCCC	GCCTTCCTCC	AUCCCCACAC	COMOGOGOAT	GGTGGCGAGG	AGCACCAGGT
9781	ACCTGGCGAG	CTCCTTCTAC	TACTCCTCCTC	GGTCGGCCAT	GCCCCAGGCG	TGGTCCTGAC
9841	CCCCCCCCCC	GTCCTTGTAG	CTCACCCCCA	AGGGGGGGG	CACGGGCACC	TCCTCCTCGC
9901	CCGCGCGGCC	GLGCALGCGC	ACCAMCCCCGA	ACCUGUCGUTG	CGGCTGGACG	AGCGCCAGGT
9961	CGGCGACGAC	GCGCICGGIG	MCCMX CCCMC	GCTGGATCTG	GGTGAGGGTG	GTCTGGAAGT
10021	CGTCGAAGTC	COMMON COCOMO	TGGTAGGCTC	CGGTGTTGAT	GGTGTAGGAG	CAGTTGGCCA
10021	TGACGGACCA	COMOMOGRA	TGGTGGCCGG	GTCGCACGAG	CTCGTGGTAC	TTGAGGCGCG
10001	AGTAGGCGCG	CGTGTCGAAG	ATGTAGTCGT	TGCAGGCGCG	CACGAGGTAC	TGGTATCCGA
0201	CGAGGAAGTG	CGGCGGCGGC	TGGCGGTAGA	GCGGCCATCG	CTCGGTGGCG	GGGGCGCCGG
0201	GCGCGAGGTC	CTCGAGCATG	AGGCGGTGGT	AGCCGTAGAT	GTACCTGGAC	ATCCAGGTGA
10201	TGCCGGCGGC	GGTGGTGGAG	GCGCGCGGGA	ACTCGCGGAC	GCGGTTCCAG	ATGTTGCGCA
.U3ZI	GCGGCAGGAA	GTAGTTCATG	GTGGCCGCGG	TCTGGCCCGT	GAGGCGCGCG	CACTCCTCCA
.0301	TGCTCTAGAC	ATACGGGCAA	AAACGAAAGC	GGTCAGCGGC	ጥሮርልሮጥሮርርጥ	CCCCTCCACC
.0441	CTAAGCGAAC	GGGTTGGGCT	GCGCGTGTAC	CCCGGTTCGA	<b>Δ</b> ጥሮጥሮር	A C C C TT C C A C C
TOCO	CGCAGCTAAC	GTGGTACTGG	CACTCCCGTC	TCGACCCAAG	CCTCCTAACC	እ እ እ <b>ሮሮ</b> ምሮሮ እ ሮ
7000	GATACGGAGG	CGGGTCGTTT	TTTGGCCTTG	GTCGCTGGTC	<b>ልጥሮልልልልልልሮጥ</b>	ACMA ACCCCC
0021	GAAAGCGGCC	GCCCGCGATG	GCTCGCTGCC	GTAGTCTCGA	CAAACAATCC	CCXCCCmmca
COOT	GTTGCGGTGT	GCCCCGGTTC	GAGCCTCAGC	GCTCGGCGCC	CCCCCCATTC	CCCCCCMAAC
0/41	GIGGGCGIGG	CTGCCCCGTC	GTTTCCAAGA	CCCCTTAGCC	ACCCCACTTC	TOCACIONACO
0801	GAGCGAGCCC	CTCTTTTTTT	TTCTTGTGTT	TTTGCCAGAT	GCATCCCGTA	CACCCCCACA
					COCO1M	ADMODUDOLL

10001		~~~~~~~~~	~~~~~~~	ma googa oos	~~~~~~	~~~~~~~
					GCAGCAACAG	
					CGCCGTGAGC	
					GCGGCTGGGG	
					CGAGGCCTAC	
					GATGCGCGCC	
					GGTGCTGAGG	
					GCACGTGGTC	
					CTTCCAAAAA	
					GGGCCTGATG	
11401	ACCTGCTGGA	GGCCATCGTG	CAGAACCCCA	CGAGCAAGCC	GCTGACGGCG	CAGCTGTTTC
					GGCGCTGCTG	
11521	AGCCCGAGGG	CCGCTGGCTC	CTGGACCTGG	TGAACATTTT	GCAGAGCATC	GTGGTGCAGG
11581	AGCGCGGGCT	GCCGCTGTCC	GAGAAGCTGG	CGGCCATCAA	CTTCTCGGTG	CTGAGTCTGG
11641	GCAAGTACTA	CGCTAGGAAG	ATCTACAAGA	CCCCGTACGT	GCCCATAGAC	AAGGAGGTGA
11701	AGATCGACGG	GTTTTACATG	CGCATGACCC	TGAAAGTGCT	GACCCTGAGC	GACGATCTGG
11761	GGGTGTACCG	CAACGACAGG	ATGCACCGCG	CGGTGAGCGC	CAGCCGCCGG	CGCGAGCTGA
11821	GCGACCAGGA	GCTGATGCAC	AGCCTGCAGC	GGGCCCTGAC	CGGGGCCGGG	ACCGAGGGGG
11881	AGAGCTACTT	TGACATGGGC	GCGGACCTGC	GCTGGCAGCC	CAGCCGCCGG	GCCTTGGAAG
11941	CTGCCGGCGG	TTCCCCCTAC	GTGGAGGAGG	TGGACGATGA	GGAGGAGGAG	GGCGAGTACC
12001	TGGAAGACTG	ATGGCGCGAC	CGTATTTTTG	CTAGATGCAG	CAACAGCCAC	CGCCGCCGCC
					TCCGGCATTA	
12121	CGATTGGACC	CAGGCCATGC	AACGCATCAT	GGCGCTGACG	ACCCGCAATC	CCGAAGCCTT
					GAGGCCGTGG	
					GCGCTGGTGG	
					CTGGAGCGCG	
					ACCGACGTGC	
					TCCATGGTGG	
					GAGGACTACA	
					GAGGTGTACC	
					GTGAACCTGA	
					GGGGACCGCG	
					GTGGCGCCCT	
					AACCTGTACC	
					ACCCACGTGA	
					TTCCTGCTGA	
					GAGCGCATCC	
					ACGCCCAGCG	
					ACCGCCCGT	
					GACTACTTTA	
					GGCGAGTACG	
					GTGTTCTCGC	
					CCGTCCTCGG	
					CCCTTCCCGA	
					ACGCGACCGC	
					CGCGAGAAGA	
					AAGACGTACG	
					CGCCAGCGGC	
					AGCAGCGTGT	
					ATCGGGCGCC	
					GACCAGCGTG	
					GGTCCTCCTC	
					CCGCTGGAGG	
					ATTCGTTACT	
					AAGTCGGCAG	
					GTGGTGCAGA	
					GAGCGCTCGC	
					AACGAGTTCA	
					AACGGGGTGG	
					TTTGAGCTGC	
14401	${\tt CTTCTCGGTG}$	ACCATGACCA	TCGATCTGAT	GAACAACGCC	ATCATCGACA	ACTACTTGGC

SEQ ID NO: 3 53/153

14461 GGTGGGCGG CAGAACGGGG TGCTGGAGAG CGACATCGGC GTGAAGTTCG ACAC 14521 CTTCCGGCTG GGCTGGGACC CCGTGACCGA GCTGGTGATG CCGGGCGTGT ACAC 14581 GGCCTTCCAC CCCGACATCG TCCTGCTGC CGGCTGCGGC GTGGACTTCA CCGA	CCAACGA
14581 GGCCTTCCAC CCCGACATCG TCCTCCTCCC CCCGTGATG CCGGGCGTGT ACAC	CCAACGA
14821 GCGGGCGAT AATTTGCTA GCGCTGCGGC AGCGCCGAG GCGGCTGAAA CCGA	CGAGGT
14881 GATAGTCATC CAGCCGGTGG AGAAGGACAG CAGGCGACG GCGGCTGAAA CCGA	AAGTAA
15001 GGGCGTGCGC TCCTGGACGC TGCTCACCAC CTCGGACGTC ACCTGCGCG TGCACACAC CTCGGACGTC ACCTGCGCGC TGCACACACACACACACACACACACACACACACACACACA	CGAGAA
15181 CGAGCAGGCC GTCTACTCGC AGNAGCTGCC CGCCTTCACC TCGCTCACGC ACGT	CTTCAA
15301 AAAACGTTCC TGCTCTCACA CATTGCCCC CCGCCGCGCC CACCATTACC ACCG	TCAGTG
15301 AAAACGTTCC TGCTCTCACA GATCACGGGA CCCGCCGCCC CACCATTACC ACCG	GGGGAG
15721 TCGACAGCGT GGTGGCCGAC GCGCGCGCGT CTCCACCGTG GACGC 15781 TCGCCCGCCG GCACCGGAC ACCCCGCAC CAAGAGCCGG CGCC	GCCCC A
16021 TGCCCGTGCG CACCCGCCCC CCTCGCACTT GAAGATGCTG ACTTCGCGAT GTTGA	ALCACA ALCACA
16801 GCCCAGCACC AGCACCATGG AGGTGCAGAC GGATCCCTGG ATGCCAGCAC CAGCT 16861 CAGCACTCGC CGAAGACGCA ACTACGCAGCAC GGATCCCTGG ATGCCAGCAC CAGCT	GTGAA
16861 CAGCACTCGC CGAAGACGCA ACGTGCAGAC GGATCCCTGG ATGCCAGCAC CAGCT	TCCAC
17041 CCGCGACTTC CGCCTTGGTG CGGAGAGTGT ATCGCAGCGG CCGCAGCCT CTGACC CGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGC	CCTGC
17101 CGCGCGCGCG CTACCACCG AGCATCGCCA TTTAACTACC GCCTCCTACT TGCAG	ATATG
17461 TTTTAGATGG AAGACATCAA TTTTTCGTCC CTGCCCCC GACACGCCAC GCGCCC	Coror
17521 ATGGGCACCT GGAGCGACAT CGGCAACGC CAACTGAACG GGGGCGCCTT CAATTG	GACC
17641 TGGAACAGCA GCACAGGCA GGCGCTGAGGG TCCACGCTCA AAACCTATGG CAACAA	CCXC
17761 GTGCAGAAAC AGATCAACAG CCGCCTGGAC GCGGTCCGC CCGCGGGGTC CGTGGAC 17821 CCCCAGGTGG AGGAGGACT CCCTGGAC GAGTCACCGC CCGCGGGGTC CGTGGA	Came
17881 GACGCGGAGG AGACGCTGCT GACGCACAGC GCGACAAGCG ACCGCG 17941 AAACTGGGCC TGCCCACCAC GCGCGCGGGGGGGGGGG	COM
18001 AGCAGCAGCC AGCCCGCGAC CCTGGACTTG CCTCCGCCTC GCCCCTCCAC AGTGGC	ACCC
AGTGGC GCCCTCCAC AGTGGC	T'AAG

SEQ ID NO: 3 54/153

1806	1 00000000000	CGGTGGCCGT	COCCECCO			
1812	1 CACACCACTC	,	COCOTCOCO	GCCCCCCGAG	GCCGCCCCCA	GGCGAACTGG
1919	T TATABAGCACIC	TGAACAGCAT	CGTGGGTCTG	GGAGTGCAGA	GTGTGAAGCG	CCGCCGCTGC
1924	L LYLINAWAGE	CACTGTAGCG	CTTAACTTGC	TTGTCTGTGT	' GTATATGTAT	GTCCGCCGAC
1930	T TOCOCOA CTO	AGTGTGAAGA	GGCGCGTCGC	CGAGTTGCAA	GATGGCCACC	CCATCGATGC
1030.	COCOCCAGIO	GGCGTACATG	CACATCGCCG	GACAGGACGC	TTCGGAGTAC	CTGAGTCCGG
10/0	L GICTGGTGCA	GTTCGCCCGC	GCCACAGACA	CCTACTTCAG	TCTGGGGAAC	AAGTTTAGGA
1044	L ACCCCACGG1	GGCGCCCACG	CACAATGTGA	CCACCGACCG	CAGCCAGCGG	CTGACGGTGC
1048.	L GCTTCGTGCC	CGTGGACCGC	GAGGACAACA	CCTACTCGTA	CAAAGTGCGC	TACACGCTGG
1854.	L CCGTGGGCGA	CAACCGCGTG	CTGGACATGG	CCAGCACCTA	CTTTGACATC	CGCGGCGTGC
18607	L TGGACCGGGG	CCCTAGCTTC	AAACCCTACT	CTGGCACCGC	CTACAACAGC	CTAGCTCCCA
1800	LAGGGAGCTCC	CAATTCCAGC	CAGTGGGAGC	AAGCAAAAAC	AGGCAATGGG	GGAACTATGG
18721	AAACACACAC	ATATGGTGTG	GCCCCAATGG	GCGGAGAGAA	ТАТТАСАААА	GATGGTCTTC
18781	LAAATTGGAAC	TGACGTTACA	GCGAATCAGA	ATAAACCAAT	TTATGCCGAC	AAAACATTTC
18841	LAACCAGAACC	GCAAGTAGGA	GAAGAAAATT	GGCAAGAAAC	TGAAAACTTT	TATGGCGGTA
18901	L GAGCTCTTAA	AAAAGACACA	AACATGAAAC	CTTGCTATGG	CTCCTATGCT	AGACCCACCA
18961	. ATGAAAAAGG	AGGTCAAGCT	AAACTTAAAG	TTGGAGATGA	TGGAGTTCCA	ACCAAAGAAT
19021	. TCGACATAGA	CCTGGCTTTC	TTTGATACTC	CCGGTGGCAC	CGTGAACGGT	CAAGACGAGT
19081	. ATAAAGCAGA	CATTGTCATG	TATACCGAAA	ACACGTATTT	GGAAACTCCA	GACACGCATG
19141	. TGGTATACAA	ACCAGGCAAG	GATGATGCAA	GTTCTGAAAT	TAACCTGGTT	CAGCAGTCTA
19201	. TGCCCAACAG	ACCCAACTAC	ATTGGGTTCA	GGGACAACTT	TATCGGTCTT	ATGTACTACA
19261	. ACAGCACTGG	CAATATGGGT	GTGCTTGCTG	GTCAGGCCTC	CCAGCTGAAT	GCTGTGGTTG
19321	. ATTTGCAAGA	CAGAAACACC	GAGCTGTCCT	ACCAGCTCTT	GCTTGACTCT	TTGGGTGACA
19381	GAACCCGGTA	TTTCAGTATG	TGGAACCAGG	CGGTGGACAG	TTATGACCCC	GATGTGCGCA
19441	TCATCGAAAA	CCATGGTGTG	GAGGATGAAT	TGCCAAACTA	TTGCTTCCCC	TTCCACCCT
19501	CTGGCACTAA	CGCCGCATAC	CAAGGTGTGA	AAGTAAAAGA	TCCTCAACAT	CCTCATCTTC
19561	AGAGTGAATG	GGAAAATGAC	GATACTGTTG	CACCTCGAAA	ጥሮልልጥጥልጥርጥ	A A A C C TA A C A
19621	TTTTCGCCAT	GGAGATTAAT	CTCCAGGCTA	ACCTGTGGAG	ልልርጥጥጥርርጥር	TACTCCAACC
19681	TGGCCCTGTA	CCTGCCCGAC	TCCTACAAGT	ACACGCCGAC	CAACCTCACC	CTCCCCACCA
19741	ACACCAACAC	CTACGATTAC	ATGAATGGCA	CACTCACACC	TCCCTCCCTC	CIGCCGACCA
19801	ACCTCAACAT	CGGGGCGCGC	TECTTCCCTCC	ACCCCATCCA	CAACCTCAAC	COCEMON ACC
19861	ACCACCGCAA	CGCGGGCCTG	CCCTACCCCT	CCATGGA	CCCCAACCCC	CCCTTCAACC
19921	CCTTCCACAT	CCAGGTGCCC	CAAAACTTTT	TCCATGCTCCT	CACCOMCOMO	CGCTACGTGC
19981	GGTCCTACAC	CTACGAGTGG	AACTTCCCCA	ACCACCATCAA	CAMCAMCOMO	CTCCTGCCCG
20041	TAGGCAACGA	CCTGCGCACG	CACCCCCCCC	CCAMCCCCC	CATGATCCTG	CAGAGCTCCC
20101	CCACCTTCOTT	CCCCATGGCG	CACAACACCCI	CCATCGCCTT	CACCAGCATC	AACCTCTACG
20161	ACACCAACGA	CCAGTCCTTC	AACCACHACACCG	MCMCGCGCG	CGAGGCCATG	CTGCGCAACG
20221	CCCCCAACCC	CACCAACGTG	CCCAMCMCCA	TCTCGGCGGC	CAACATGCTC	TACCCCATCC
20281	CATCCTCCTT	CACGCGCCTG	AACACCCCCC	ACAGGGGGG	CAACTGGGCC	GCCTTCCGCG
20201	CCTACTTCCT	CHCGCGCCTG	MAGACCCGCG	AGACGCCCTC	GCTCGGCTCC	GGGTTCGACC
20341	CCTACTICGI	CTACTCGGGC	ACCUTOCCCT	ACCTAGACGG	CACCTTCTAC	CTCAACCACA
20401	TCCTCAAGAA	GGTCTCCATC	ACCTTCGACT	CCTCCGTCAG	CTGGCCCGGC	AACGACCGCC
20401	CCCACTICCAA	CAACGAGTTC	GAAATCAAGC	GCACCGTCGA	CGGAGAGGGA	TACAACGTGG
20521	CCCAGIGCAA	CATGACCAAG	GACTGGTTCC	TGGTCCAGAT	GCTGGCCCAC	TACAACATCG
20301	ACTITICA COC	CTTCTACGTG	CCCGAGGGCT	ACAAGGACCG	CATGTACTCC	TTCTTCCGCA
20041	MC ACCOMOCO	CATGAGCCGC	CAGGTCGTGG	ACGAGGTCAA	CTACAAGGAC	TACCAGGCCG
20701	CCCTGGC	CTACCAGCAC	AACAACTCGG	GCTTCGTCGG	CTACCTCGCG	CCCACCATGC
20/01	GCCAGGGCCA	GCCCTACCCC	GCCAACTACC	CCTACCCGCT	CATCGGCAAG	AGCGCCGTCG
20821	CCAGCGTCAC	CCAGAAAAAG	TTCCTCTGCG	ACCGGGTCAT	GTGGCGCATC	CCCTTCTCCA
2088T	GCAACTTCAT	GTCCATGGGC	GCGCTCACCG	ACCTCGGCCA	GAACATGCTC	TACGCCAACT
20941	CCGCCCACGC	GCTAGACATG	AATTTCGAAG	TCGACCCCAT	GGATGAGTCC	ACCCTTCTCT
5100T	ATGTTGTCTT	CGAAGTCTTC	GACGTCGTCC	GAGTGCACCA	GCCCCACCGC	GGCGTCATCG
21061	AAGCCGTCTA	CCTGCGCACG	CCCTTCTCGG	CCGGCAACGC	CACCACCTAA	CCCCCTCTTC
<b>21121</b>	CTTCTTGCAA	GATGACGGCG	GGCTCCGGCG	AGCAGGAGCT	CAGGGCCATC	CTCCGCGACC
STIRT	TGGGCTGCGG	GCCCTGCTTC	CTGGGCACCT	TCGACAAGCG	CTTCCCTGGA	ጥጥሮልጥሮፎሮሮሮ
21241	CGCACAAGCT	GGCCTGCGCC	ATCGTGAACA	CGGCCGGCCG	CGAGACCGGG	GGCGAGCACT
7730T	GGCTGGCCTT	CGCCTGGAAC	CCGCGCTCCC	ACACATGCTA	CCTCTTCGAC	CCCTTCCCCT
21361	TCTCGGACGA	GCGCCTCAAG	CAGATCTACC	AGTTCGAGTA	CGAGGGCCTG	CTGCGTCGCA
21421	GCGCCCTGGC	CACCGAGGAC	CGCTGCGTCA	CCCTGGAAAA	GTCCACCCAG	ACCGTGCAGG
7148T	GTCCGCGCTC	GGCCGCCTGC	GGGCTCTTCT	GCTGCATGTT	CCTGCACGCC	ጥጥሮርጥርሮልሮጥ
21541	GGCCCGACCG	CCCCATGGAC	AAGAACCCCA	CCATGAACTT	ACTGACGGGG	GTGCCCAACG
21601	GCATGCTCCA	GTCGCCCCAG	GTGGAACCCA	CCCTGCGCCG	CAACCAGGAA	GCGCTCTACC
				-		

SEQ ID NO: 3 55/153

2160	GCTTCCTC	AA TGCCCACTO	CC GCCTACTT	C GCTCCCACC	G CGCGCGCATI	C GAGAAGGCCA
		M CCGCATGAA	11. L'AAC'AC'A'PC	ም ልክአአአለውው	C Mamamana	~
	A WITCHIMM	IA AACAGCACA	VP CPPPPATCCC	'A CCMmcmcmc	A 000momos	
	DODAMOULA P	36 TIUIGUUG	ic proportion	'C CCCCCCCCC	C 30003m30m	
	- CINCIIOGO	C AGCCACTION	A AUTUCACA	''' '''' '''' '''' '''' ''''''''''''''	~ ~~~~~~~	
	~ COURTER	· CACAGCTTO	AC GCCCTCCACCTT	G CACCCCCCC	C 700700000	~ ~~~~~~~
	~ CIIOMATIC	A CHGIIIGGA	ac: c:c:c:c:c:c::::::::::::::::::::::::	C CCCCCCACA	C TMCCCCTT ~-	
	- OCUCIONE	IL ALLATI AU	3.4 ( ) ( ) 2.6.26.29.19.26.93.	T CINCOMMOO	^ ~~~~~~~~	
	- GCCCTCCMC	G ICCAGATE	ar ceaceannea	ሮ ሮኔሞሮሮሮሮአኒ	~ ^^~~~~~~~~~~	
	- CCCCCCAI	G CIGGGCACG	C. AGCCCGGGGCT	T CTCCMMCCX	7 MOOO3 omoo-	
	- 0111011010	G GCCIGCIC	La Alacini Angeri	(' ('C'C'C'M'A C'AM'	7 <i>777</i> 77777	
	- CIGGCGGWW	G GCCTGCTGC	G CCTTCCCCC	C CTCCCCCCXX	7 770700000	
	- 1101101111CIG	G TIGGICALIA	C: AGCCC3202019	ני נייות ברא מממא ו	7 ~~~~~~~~	
	- CINCILOCAC	C ACCULIGATION	C CCCAGCGGG	TO CONCIONATION TO A TOTAL OF THE PARTY OF T	7 MMAAAAAA	
	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	G CGC11-1.1.1.1-	T	יה מכוכות מכוליויי	7 MAARE	
	- CITTOTALCMC	G GICCEGIGE	A GGCACCACCA	2 CMMCCCCCMC/	' COMmoonaa	
		G CMGCCGGGGG	C ACTIVICATION	T COMPONDO	3 MAMAAAA ~~	
	- 0.2.00000	し みいしみんしししじ	C CCATCATCA	`` (2(2)\$\C\C\C\C\C\C\C\C\C\C\C\C\C\C\C\C\C\C\C	TOOMOOMO	
		a ceerecitie	1'   U.G. 21"1" ("A/ "A/")	ል ሮሽርሮሞሮሮሮሽ	<sup>3</sup> 3000000000	
		し みょしみいしょしょ	A AGGCCACACTU	P CACCMCCCMC	* MAA* AAAA	
	- 011001100011		A 9646 CT TOPIN TO	' '''' ''' ''' '''' '''' '''' ''''' ''''	************************	
2292	1 GTTCTTCAC	C GCCATTGTC	1 TCTTAGTCG(	CCCCCCCCC	GTCAGGGGGT	GGCTCAGGGG
		2 MACACILLIA	0 11040 1006 110 11 110 1	י רייויריריא ווויריא וווירי	• ^^^\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	A
	· OCCCACGGC	- GCCAGCTCC	וי כיכיווינינצנצניניתיתנ	· CCMMMCCMCC	I MACCARONA	
	rocerragge	- AUAIGUTTG	4 TETINGCOCCCCC			
		1 CAUCULUAL.	. 11 11 11 12 11 11 1 1 X	' ('')		
23223	CGAGACCAC	G CGGCGGTAGG	CATCCCTCAC	CHCCCCCA	GGCGGAGGCG	GGCCGTCGTC
		. (3)(3)(3)(-1)(-1)(-1)(-1)(-1)(-1)(-1)(-1)(-1)(-1	* ( 'A(2A(2)') '' '' ''	' MCCCCCCAMMAA		
23341	CTGCTCTGAC	TGACTTCCTC	CGCGGCCCCT	· CAMMOMOMOM	GGGGTGCGCT TCCTAGGGAG	CCTGGCGGCG
23401	. CATGGAGACT	CAGCCATCGT	CCCCAACATC	CCCAMOMOGO	CCCGCCGCCA	CAACAACAAG
23461	GAACCAGCAG	CAGAATGAAA	GCTTA ACCCC	CCCCCCCCCCC	AGCCCCACCT	CCGCCGACGA
23521	GGCCCCAGAC	ATGCAAGAGA	TGGACCAAMC	COUGUUGUU	AGCCCCACCT GACCTGGGCT	CCGACGCCGC
23581	CGCGGAGCAC	GAGGAGGAGC	TGGGGGAAIC	CATCGAGATT	GACCTGGGCT CCGGAAGAGA	ACGTGACGCC
23641	GCAGCCAGAG	CAGGAAGCAG	ACAACCACCA	CTTTTCAGCC	CCGGAAGAGA GGGCACGAGC	ACCACCAAGA
23701	CCTGAGCGGG	GCAGAGGACG	. <u>доддоодоод</u> . тогтолители	GAACCAGGCT	GGCCACGAGC CGCCAATGCA	ATGGCGACTA
23761	GGACGCGCTG	CTCGACCGCG	CCCACCTCAA	CCMCLCCCC	CGCCAATGCA GCGGAGCTCA	TCATCGTCAA
23821	CGAGCGCAAC	CTCTTCTCC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCTCAGCGTG	GCGGAGCTCA CAGCCCAACG	GCCGCGCCTA
23881	GCCCAACCCG	CGCCTCAACT	TOUR COCOCO	CUUCAAGUGU	CCCGAGGCCC	GCACCTGTGA
23941	CCACCTCTTT	TTCAAGAACC	TOTACCCOGT.	CTTCGCGGTG	CCCGAGGCCC	TGGCCACCTA
24001	CGACGCCCTG	CTCAACCTGG	GCCCCCCCC	CGTCTCCTGC	CGCGCCAACC GATATCACCT	GCACCCGCGC
24061	GGTTCCCAAG	ATCTTCGAGG	GTCTCCCCAC	CCGCCTACCT	GATATCACCT CGGGCCGCGA	CCTTGGAAGA
24181	GCGCCTGGCG	GTCCTCAAGC	GCACCCACAG	CCCCTGGTG	GAGTTGGAAG TTCGCCTACC	GCGACAACGC
24241	CCTGCCCCCC	AAGGTCATGA	GCGCCCGTCAT	CCACCCAC	TTCGCCTACC	CGGCGCTCAA
24301	CCTCTCGGAG	GAGGAGATGC	ACCACCCCCA	CACCAGGTG	CTCATCAAGC GAGGGCAAGC	GCGCCTCGCC
24361	CGACGAGCAG	CTGGCGCGCT	GGCTGCGACC	CACTACGGAC	GAGGGCAAGC CCCCAGAGCC	CCGTGGTCAG
24421	GCGCAAGCTC	ATGATGGCCG	TGGTCCTCCT	CACCORDOR	CCCCAGAGCC CTGGAGTGTC	TGGAAGAGCG
24481	CTTTGCCGAC	GCGGAGACCC	TGCCCCAACCT	GACCGTGGAG	CTGGAGTGTC CTGCACTACC	TGCGCCGCTT
24541	CGGGTTCGTG	CGCCAGGCCT	CCAACAACGI	CAAGGAGAAC	CTGCACTACC CTGACCAACC	TCTTCAGGCA
24661	GGAGGCCCGC	CGCGACTACA	TCCGCCTGGG	GCAAAACGTG	TACCTCTGCC	CCCTGCGCGG
24721	GACGGGCATG	GGCGTGTGGC	ACCACTACTCC	CGTCTACCTG	TACCTCTGCC . AACCTGAAAG .	ACACCTGGCA
24781	GCTCCTGCAG	AAGAACCTCA	AGCAGIGCCT	GGAGGAGCAG	AACCTGAAAG .	AGCTCTGCAA
					AACCTGAAAG GACGAGCGTA ACGCTGCGCA	
		011CGUG1	- GCMAGGCCC	CGGCGACGC	CAGCTGCTGA ( GAGGGCAAGG (	GGGTCTGAA

2526	1 20002000	a cccc				
2520	1 ACTUACCUC	G GGGCTGTGG	A CCTCGGCCT	A CTTGCGCAA	G TTCGTGCCC	G AGGACTACCA
2002	T TOCCTION	G AICAGGITT	T ACCARCATO	<b>Δ ΧΨΥΥΥΝΟΝΙ</b>	~ ~~~~~~~~~	
2000	T CIGCGICHI	し みしししみらほぼぼ	G CCATCCTGG	<u> </u>	7 CCC3 MCC3 C3	*********
2544	r MOWNITICIA	J CIGAAAAAG	G GCCACGGGG	ጥ ሮጥልሮጥጥሮሮል	~ ~~~~~~~~~~~	7 72777777
2550.	L CANCCCAG	- IICCCCAG	G ATGCCCCGA	G GAAGCAGCA:	ሊ ሮአአሮሮመሮአአ፣	CMCC2 CCMCC
2330.	T CGCCGCCGG	A GGATTTGGA	G GAAGACTCC	C ACACCACTC:	N CCCXCXCXC	0700707mco
2002.	t thought agging	1 CAGCACTCA	G GCACACCAC	כ אפאפפפיים	* ************************************	
2500.	r wegwagiagi	A GGAGGCAGA	G GAACAAACCA	C CCCCCCCX	3 3000maamaa	
49, <del>4</del> .	L TUGCHUGCW(	5 CACGGATAC	C ATCTCCCCC	~ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	* MAAAAAAAA	
25803	L GTAGGTGGG	CGAGACCGG	G CGCTTCCGA	A CCCCACCAC	7 C2C2CCCC	AGAAGGAGCG
25861	L GCAGGGATAC	AAGTCCTGG	C GGGGGCACA	A AAACCCCAC	CAGACCGGTA	TGCAAGCCTG
25921	CGGGGGCAAC	ATCTCCTTC	A CCCCCCCCCC	ANACGCCATC	GICICCIGCI	TGCAAGCCTG TGAACTTCCC
25981	CCGCAACATO	TTCCATTAC	P ACCCMCACC	CCIGCICITI	CACCGCGGGG	TGAACTTCCC TCCAAGAAGA
26041	GGCAGAAACC	CACCACCAC	T ACCOLCACC.	CCACAGCCCC	: TACTACTGTT	TCCAAGAAGA
26101	CGGCAGGTGG	ACTOR CONTRA	COCCOCCA	GGGCAGCAGC	: AGCTAGAAAA	TCCACAGCAG
26161	CCATCTTTCC	' CACCCMCMAN	GCGGCGAAC(	AGCCGGCGCZ	A GACCCGGGAG	TCCACAGCGG CTGAGGAACC
26221	A DETECTION A	CACCUTCTAT	GCCATCTTC(	AGCAGAGTCC	GGGGCAGGAG	CTGAGGAACC CAGGAACTGA
2022	. PRIGICARGAM	CCGTTCTCTC	GCTCGCTC7	\	*	7707000770
20201	. ACCARCIACE	L GCGCACTCTC	: GAGGACGCCG	: ልርርርጥጥጥጥጥ	ነ ሮአአሮአአሮጠአረ	maaaaaaaa
20247	CICITAAAGA	GTAGCCCGCC	G CCCGCCCAC	CACCCAAAAA	CCCCCCAAmm	ACCMCA CCAC
20401	CIGCOCCLII	CGCCCGACCA	\ TCATCACCAZ	እርእሮአመመው <b>ር</b> ር	* *******	
5040T	CCAGCCCCAG	ATGGGCCTGG	CCGCCGGCGC	' CCCCCACCAC	TACTICO ACCO	CCT TCT TCTC
	CCTCTGTGCC	- ひらひしししにいいか	\ 115-A116-114-Δ14.	י אישה א אישייני	3 MCCCCCCC	
40000	OWINCIFFIN	GAACAGTCAG	: CGATCACCC	' Carerre	Camoacomma	3.550000000
	110000000	GCCCTGGTGT	΄ ΑΓΤ'ΑΓΙΙΔΑΔΤ	' ጥርርርር እርርርር	3 7773 77777 7	
20,01	いっしょうしゅうしょう	GCCGAAGTCC	AGCTCACTA	ביייר א כיכיישכישכי	CACCMCCCCC	~~~~~~
,	CCIGIGICGI	しんしししししししし	i CTCAGGGTAT	' AAACCCCCCTC	CTCTTCCCTTC	00303030
20021	TCAGC 1 CAAC	GALGAGGT	: Transport	CCTCCCTCTC	00200020202	~- ~
20001	かいりょうひしょうな	T CGGGGAGAT	י ביוייויניניטיזימימארי	こここうけんしゅう こうしゅうしゅう	COCOMOCMOS	Ommer
	CO - CC - CG	CAGCCCCCC	CRECEDITION AT	CCCCACMOMO		
~,001	TCCCTCGGIM	INCLICANCE	- CCTTCTCCGG	CTCCCCCCCC	CACMACCOCC	3 CC3 Cmmca -
2,001	CCCGUACTIC	GAUGUCATUA	GCGAGTCGGT	-CCACCCCMAC		~~~~~~
27121	CGCAGCTGAC	CTAGCTCGGC	TTCCACACCT	CCACCACMC	CGCCGCTTCC	CCCATGGTGG
27181	TCGGGATCTC	GCCGAGTTTG	CCTACTTTCA	CCTCCCCCC	GAGCACCCTC	GCTGCTTCGC
27241	CCACGGAGTG	CGGATCATCG	TCCAACCCCC	COMOCACAG	CACCTCCTTC	AGGGCCCAGC
27301	CCAGCGACCG	ATCCTGGTCG	ACCCCCAACA	ACCACACACACA	CACCTGCTTC CTTCTTACTT	GGATCTTCAG
27361	CTGCAACCAC	CCCGGCCTCG	ACCOCCAMON ACCOCCAMON	AGGACAGACC	CTTCTTACTT CTGTGTACTG	TGTACTGCAT
27421	AAGCTGAGAT	CACCCACTAC	WCCCCO CROS	TTGTTGTCTG	CTGTGTACTG	AGTATAATAA
27481	ТСТТСТТСАС	CCCCAACCAC	ACCONCERNO	ATTGTGGTGT	TCCTGCTATC	AACCGGTCCC
27541	TCACCTGGCT	COUGAACGAG	ACCGAGCTCC	AGCTCCAGTG	TAAGCCCCAC	AAGAAGTACC
27601	TCCTCCTCAC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	TCCCCGATCG	CCGTTGTCAA	CCACTGCGAC	AACGACGGAG
27661	TCCIGCIGAG	CGGCCCTGCC	AACCTTACTT	TTTCCACCCG	CAGAAGCAAG	CTCCAGCTCT
2,001	TOCUMOCOTI	CUTUCULITIES	AUTUAUTACT	CCCTCTCTCACA	3 CCCCCCCC	
27721	CCCACCCTCC	GAATACCACA	GCGCCGCTCC	CCGCTACTAA	CAACCAAACT	ACCCACCAAC
-,,	CCCMCCGICG	CGMCCTTTCC	ΤΥ ΤΥ ΑΑΤΥ ΤΙΔ	<b>ልጥአ</b> ሮሮአሮመአሮ	COOMMONA	~~~~~
	0170011100110	TOGGMITIM.	TAUGUTT	CCCACCOOC		
	1120110000	10000111111	(4) "14 "14 "17(2C 94)	$\Lambda CCM \Lambda M \Lambda CCM$	CCCmmccmc	
2,201	1001001010	TIGCIGGILL	AAUAAATKKK	$C \lambda \lambda C \lambda T C \lambda C C$	CM3 CMC3 CC-	~~~~
~ ~ ~ ~ ~	COTOCCOCIO	A-LUCLILICIAN	1")"(4")"(4"(2"(2"\DAC "\P"	CCCCCCCCCC	COMORD COLOR	
	COLLICCTOC	A I G CATTILA	ΑΠΤΙΤΙΔΑΙΙΔΑ	ሽጥሮሮሮሽ <u></u> ሮሮጠር	7 Ammmon on	
	~ - W YOU W JOE JO T	COGMACAAIA	1.711.714.324.324.4	CUMCMCCCAC	~~~~~~~	
	7 0 0 0 0 1 1 0 1 1 0	TOCKMUALISTS	TI ATTATTACAM	これいい カカ へのカム	MX 00= m=	
		CONTRACMINA	1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - Δ1 - Δ	מממתיתיתייייייואיי	MM202020	
	~~~~~~~~~	GIAGGAICIG	ATTECHNAL ALTE	ひになびれつのみつつ	~~~~~~~	<del>* *</del>
		TATAGRACCA	ACACHTTANT	ል ሲጥጥን እ እ ለጥጥ	MAMPRACACA :	
	***************************************	ACTUCAL TA	[ · Δ·[ "[ "[ · Δ ( 2 · Γ · Γ · Γ · Γ · Γ · Γ · Γ · Γ · Γ ·	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	7 2 man	
28801	TACAAAACAA	PATACTGGTA	C4454456116	TACAATAAT Tacaaa	AATCTTACAC ( CATACAGGAC )	L'I'TTTCAAT
			~- ++++ TUCMG	TUCWWWC.I.I.I.	CATACAGGAC I	AAGATAAATA

SEQ ID NO: 3 57/153

2886	1 TTATACTGT	r aaggtagaaa	ATCCTACCAC	CTCCTAGAACT	ACCACCACCA	CCACTACTGC
2892	I AAAGCCCAC	l GTGAAAACTA	CAACTAGGAC	CACCACAACT	¹ <b>እ</b> ሮልፎልልልሮሮል	CCACCACCAC
2898	I AACACTTGC	r gcaactacac	ACACACACAC	: TAAGCTAACC	: ጥጥልሮልሮልሮሮ <b>ል</b>	ርጥልልጥርልጥጥ
2904	I GATCGCCCT	<i>G</i> CTGCAAAAGG	GGGATAACAC	CACCACTTCC	' AATCACCACA	TO CCCO A A DOC
2910	1 CATGATTGG	CATTATTGTTG	CTGTAGTGGT	GTGCATGTTC	ATCATCCCCT	TACCCAMATC
2916	1 GTACTATGC	C TTCTGCTACA	GAAAGCACAG	ACTGAACGAC	' AACCTCGCCAAC	: ACTTACTAAG
2922	1 TGTTGAATT	TAATTTTTTA	GAACCATGAZ	GATCCTACCC		ACTIACTAAG
2928:	1 TACCTCTGC	CTTTGTGAAT	CAGTGGATAG	ACATCTAGGC	, CITITIAGII	TTTCTATCAT
2934:	1 TACACTGAAA	A GGGCCACCCT	CACCTATIC	, wastattwe	AT TACCACTG	GITCTAATTA
2940:	1 TGATCAAACT	GAATTATGCA	ስጥጥጥጥር አ አ ለ ለ ለ ለ ለ ለ ለ ለ ለ ለ ለ ለ ለ ለ ለ ለ ለ	ACCCAAAACC	TGCTATTTTG	GAACTGACAC
2946:	1 TTATCAATGO	AATGGCACTG		AGGCAAAACC	TCAAACTCTA	AAATCTCTAA
2952	L TTATTATTCC	CCTGGACAAA	ALCIGATACT	ACTCAATGTC	ACGAAAGCAT	ATGGTGGCAG
2958	TCCCACTACZ	CCIGGACAAA	ACACTGAAGA	AATGATTTTT	TACAAAGTGG	AAGTGGTTGA
29641	GCCAACAGAZ	A CCACCCACCA	CCACAACTAT	TCATACCACA	CACACAGAAC	AAACACCAGA
29701	TACACCCA	GCAGAGTTGG	CCTTCCAGGT	TCACGGAGAT	TCCTTTGCTG	TCAATACCCC
29761	L THUNCUCUM!	CAGCGGTGTC	CGGGGCCGCT	, AGTCAGCGGC	ATTGTCGGTG	TGCTTTCGGG
2000	ATTAGCAGIC	ATAATCATCT	GCATGTTCAT	TTTTGCTTGC	TGCTATAGAA	GGCTTTACCG
2002	L ACAAAAATCA	GACCCACTGC	TGAACCTCTA	TGTTTAATTT	TTTCCAGAGC	CATGAAGGCA
2000	GITAGUGUTU	TAGTTTTTTG	TTCTTTGATT	' GGCATTGTTT	TTAATAGTAA	AATTACCAGA
20001	GTTAGCTTTA	TTAAACATGT	TAATGTAACT	' GAAGGAGATA	ACATCACACT	AGCAGGTGTA
30001	GAAGGTGCTC	AAAACACCAC	CTGGACAAAA	TACCATCTAG	GATGGAGAGA	TATTTGCACC
20007	. TGGAATGTAA	CTTATTATTG	CATAGGAGTT	AATCTTACCA	<b>ጥጥርጥጥል ል</b> ቦርር	ጥል አሮሮ እ አጥሮም
20T51	. CAGAATGGG1	` TAATTAAAGG	ACAGAGTGTT	AGTGTGACCA	GTGATGGGTA	CTATACCCAC
POTRI	. CATAGTTTA	ACTACAACAT	TACTGTCATA	CCACTGCCTA	CGCCTAGCCC	ACCUACCACU
30241	. ACCACACAGA	CAACCACATA	CAGTACATCA	AATCAGCCTA	CCACCACTAC	ACCACCACAC
20201	. GTTGCCAGCT	CGTCTGGGGT	CCGAGTGGCA	TTTTTGATCT	ጥርርርርርርር	TACCA CTCCC
30301	. ACTGCTAGTA	CCAATGAGCA	GACTACTGAA	TTTTTTCTCCA	CTCTCCACAC	CCACACCACA
30421	GCTACCTCCA	GTGCCTTCTC	TAGCACCGCC	AATCTCTCCT	CCCTTTCCTC	ጥ እር አር ርር አ አመር
30401	AGCCCCGCTA	CTACTCCTAG	CCCCGCTCCT	CTTCCCACTC	CCCTGAAGCA	AACACACCCC
30347	GGCATGCAAT	GGCAGATCAC	CCTGCTCATT	GTGATCGGGT	ጥርርጥር አጥርርጥ	CCCCCCCCCC
2000T	CTCTACTACA	TCTTCTGCCG	CCGCATTCCC	AACGCGCACC	GCAAGCCGGC	CTACAACCCC
2000T	ATCGTTATCG	GGCAGCCGGA	GCCGCTTCAG	GTGGAAGGGG	GTCTA AGGA A	ጥርጥጥርጥርጥጥር
30721	TCTTTTACAG	TATGGTGATT	GAANTATGAT	TCCTAGACAA	TTCTTCATCA	CONTROLOGIA
30781	CTGCCTCCTC	CAAGTCTGTG	CCACCCTCGC	TCTGGTGGCC	AACCCCACTC	CIMITCHAI
30841	TGGGCCCTTC	GCCTCCTACG	TGCTCTTTGC	CTTCCTCACC	TCC NTCTCCT	CAGACTGTAT
30901	AGTCTGCCTG	CTTATCACCT	TCTTCCACTT	CITCGICACC	AMCMMMCMCC	GCTGTAGCAT
30961	CCTGCGCCAC	CACCCCCAGT	ACCGCGACCA	CATIGACIGG	CACCOCCOCCOCCA	GCATCGCCTA
31021	ATAAGCATGC	GGGCTCTGCT	ACTIVITYCECE	CULLCUCCUCC	CAGCTGCTCA	GGCTCCTCTG
31081	GACCCCCGGT	CCCCACTCA	CTCCCCCCAC	CITCIGCIGI	TAGTGCTCCC	CCGTCCCGTC
31141	TGGAAATTCC	TCAAATGCTA	CCCCCAAAA	GAGGITCGCA	AATGCAAATT	CCAAGAACCC
31201	ATTGGGATCG	TGAACATTCT	CCCCCCCAAAAA	TCAGACATGC	ATCCCAGCTG	GATCATGATC
31261	CACTTTCCTT	CCAACTICI	ACACCCCCCCCCC	CTCATCTCCT	TTGTGATTTA	CCCCTGCTTT
31321	CACCATCAAC	GGAACTCGCC	AGAGGCGCTC	TATCTCCCGC	CTGAACCTGA	CACACCACCA
31321	AMAMMACACM	CTCAGGCACA	CGCACTACCA	CCACCACAGC	CTAGGCCACA	ATACATGCCC
31///1	CULTURGACT	ATGAGGCCGA	GCCACAGCGA	CCCATGCTCC	CCGCTATTAG	TTACTTCAAT
31501	CIMMCCGGGG	GAGATGACTG	ACCCACTGGC	CAATAACAAC	GTCAACGACC	TTCTCCTGGA
31561	CATGGACGGC	CGCGCCTCGG	AGCAGCGACT	CGCCCAACTT	CGCATTCGTC	AGCAGCAGGA
31631	GAGAGCCGTC	AAGGAGCTGC	AGGACGGCAT	AGCCATCCAC	CAGTGCAAGA	GAGGCATCTT
TOST	CTGCCTGGTG	AAACAGGCCA	AGATCTCCTA	CGAGGTCACC	CAGACCGACC	Amerecamena
つてのロエ	CTACGAGCTC	CTGCAGCAGC	GCCAGAAGTT	CACCTGCCTG	CTCCCACTCA	ACCCC ATTCCT
21/47	CATCACCCAG	CCAGCAGTCG	GGCGATACCA	AGGGGGTGCAT	CCACTCCTCC	TOCONOROGO
TOOT	CCGACTGCGT	CCACACTCTG	ATCAAGACCC	TCTGCGGCCT	CCCCCACCTC	CTCCCCATCA
TOOT	ACTAATCACC	CCCTTATCCA	GTGAAATAAA	GATCATATTC	አጥሮአጥሮአጥጥጥ	א א א א א א א א א א א
27277	AATAATCATT	TGATTTGAAA	TAAAGATACA	ATCATATTCA	ጥር አጥጥጥር አርጥ	ת ת ת ת ת כת ת חווח
コエンロエ	THANGHATCA	CTTACTTGAA	ATCTGATACC	AGGTCTCTCT	<u> </u>	TOCOUNTORO
22047	ACCICACICC	CCTCTTCCCA	GCTCTGGTAC	TGCAGGCCCC	CCCCCCCTCC	A A A COMMCCOMC
24101	CACACGCTGA	AGGGGATGTC .	AAATTCCTCC	<b>ጥርጥር የተሰ</b> ላል ል	ጥር ተመፈጥ እስተመሰጥ	AMCMMOMAMO
22101	AGATGTCCAA	AAAGCGCGTC	CGGGTGGATG	ATGACTTCGA	<b>CCCCCTCTAC</b>	CCCMACCAMC
22221	CAGACAACGC	ACCGACCGTG	CCCTTCATCA	ACCCCCCCCC	CCTCTCTTTTT	C x maax mmaa
3440I	AAGAGAAGCC	CCTGGGGGTG	TTGTCCCTGC	GACTGGCTGA	CCCCCTCACC	አሮሮክ አሮክ አሮሮ
25247	GGGAAATCAC	CCTCAAGCTG	GGAGAGGGGG	TCCDCCTCCD	CTCCTCCCA	7 2 2 CMC 2 MCM
32401	CCAACACGGC	CACCAAGGCC	GCCGCCCCTC	TCACTATION	TICGICGGGW	AAACTCATCT
				-CUGINITIC	MAACAACACC	ATTTCCCTTA

SEQ ID NO: 3 58/153

32461	1 እ እ እ <u>ር</u> መርርመር	C CCCMmmama				
32521	TARCIGCIG	C CCCTTTCTA	C AACAACAAT	G GAACTTTAA	G CCTCAATGT(	TCCACACCAT
32521	LINGCAGTAT	T TCCCACATIT	P AACACTTTAG	G GCATAAGTC	r tggaaacggt	CTTCAGACTT
22501	CAMATAAGT	T GTTGACTGT	A CAACTAACT	C ATCCTCTTA(	C ATTCAGCTCA	AATAGCATCA
32043	L CAGTAAAAA	C AGACAAAGG	G CTATATATT	A ACTCCAGTG	2 3330303000	COMORCACCOMA
32/03	ATATAAGCC	T AAAAAGAGG	A CTAGTTTTT	G ACGGTAATG	" ጥልጥጥር <b>ር</b> አለር አ	<b>のみかみのかぐぐみ</b> る
22101	AIGGCTTAG	A CTATGGATC	l' TATGATAGT(	3 ΑΤΚΚΑΑΑΑΑΑ	T AACACCCCTTA	ለመመአ <i>ሮሮ</i> አአአአ
32021	. TTGGAGCAG	G ATTAAATTT	P GATGCTAAC	ል ልልሮሮልልጥልሮር	י שכשכאאא משא	CCCAACACCC
32001	- TAAGTTTTG	A CTCCGCTGG	r GCCTTGACAC	G CTGGAAACA	A CACCATCAC	1 77CCm77C7C
22347	. IIIGGACIA	L CCCTGACCCA	A AGCCCTAATT	ቦ ርጥሮልልጥጥልሮ፣	የ ጥጥሮአሮአሮአሮአ	Camacaaaam
22007	. TTACTCTCT	G TCTTACAAA	A TGCGGTAGT(	: AAATACTACC	CACTCTCCCA	CMCCCCCCCC
22001	. TTACTGTAG	3 ATCAGCACTA	AATCCAATTA	ATGACACAG1	' CAAAAGCCCC	$\lambda m \lambda c m m m m c c$
33741	TIAGATITE	A TTCCGATGG	r GTACTCATG	ቦ ሮልልልሮጥሮልጥር	ነ አአጥሮሮሞአሮሮብ	Cammadmoda
22727	ACTITAGGG	A GGGACAGACO	CACTCAAAGTO	TACCCTATAC	<sup>1</sup> ልልልጥርርጥርጥር	CCAMMCAMCC
33241	CAAATATAG	• TGCATATCC	AAAACCCAAA	GTAAAACACC	' ጥልልልልልጥልሮሮ	አመአሮመሮ አሮመሮ
33301	AGGTATATT.	r aactggagaz	ACTACTATGO	: CAATGACACT	ነ ልልሮሮልሞልልሮሞ	TOTAL A TOTAL
22201	CIGATGAAAA	A AGACACAACO	CCAGTTAGCA	CCTACTCTAT	' Cacmmmaca	TICCCA CTICCA
33421	CTGGAGACTA	A TAAGGACAA	AATATTACCT	TTGCTACCA	CTCATTCTCT	TTTTCCTACA
33481	TCGCCCAGGA	ATAATCCCAC	CCAGCAAGCC	· AACCCCTTTTT	CICALICICI	TTGTCTACA
33541	GGAAACTCTC	AAACAGAAAA	ATAAAGTTCA	. ACTCCCCIIII	TOURCOACCT	GTTTTACAGG
33601	ACTCGAGCAG	TTATTTTCC	. TCCVCCCTCC	CACCACAMOC	AATACACCAC	GTTTTACAGG
33661	CGCACAGCCT	TGAACATCTC	ADTCCCATTCC	CMCAMCAIGG	TGCTTTTGGT	CCTCTCCCCC
33721	CACACAGTTT	CAGAGCGAGC	CACACACACA	TOCOTOR CO	AGATGAAACC	CTCCACGTTC
33781	TCCCGCATCT	CCACCTCACA	CCCCAACACA	TCGGTCAGGG	G AGATGAAACC CCTCGGTGGT	CTCCGGGCAC
33841	GTTATCTCC	ACARCTCACA	GCTCAACAGC	TGAGGATTGT	CCTCGGTGGT	CGGGATCACG
33901	GGTGGTGTCC	CATCACCCCC	GAGCGGCGGT	GGGAATCATA	GTCCGCGAAC	GGGATCGGCC
33961	TCACCCCCTT	CCCCCCCC	CGCAGCAGTC	GCTGCCGCCG	CCGCTCCGTC	AAGCTGCTGC
3/021	CTCTCCTCCTCCC	CGGGTCCAGG	GACTCCCTCA	GCATGATGCC	CACGGCCCTC	AGCATCAGTC
3/1021	A A C A C A C C A C	GCGGGGCGCAG	CAGCGCATGC	GAATCTCGCT	CAGGTCACTG	CAGTACGTGC
2/1/1	MCCCCCC	CACCAGGTTG	TTCAACAGTC	CATAGTTCAA	CACGCTCCAG	CCGAAACTCA
34301	COMOCOMOCA	GATGCTACCC	ACGTGGCCGT	CGTACCAGAT	CCTCAGGTAA	ATCAAGTGGC
3420I	GCTCCCTCCA	GAAGACGCTG	CCCATGTACA	TGATCTCCTT	GGGCATGTGG	CGGTTCACCA
2470T	CCTCCCGGTA	CCACATCACC	CTCTGGTTGA	ACATGCAGCC	CCCCATCATC	CECCCCAAACC
3434I	ACAGGGCCAG	CACCGCCCCG	CCCGCCATGC	AGCGAAGAGA	CCCCCCATCC	CCCCAAMCAC
24207	AATGGAGGAC	CCACCGCTCG	TACCCGTGGA	ጥሮልጥሮጥርርርል	<b>CCTC カカウカカウ</b>	mama mamaaa
つみみみず	CACAGCACAG	GCATATGCTC	ATGCATCTCT	ጥሮልሮሮልሮጥሮሞ	CACCMCCMCC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
24201	CCATATCCCA	GGGCACGGGG	AACTCTTGCA	CCACACCCAA	CCCCCCCACAA	CACCCCA A MC
2#20T	CICGCACATA	ACTTACATTG	IGCATGGACA	CCCTATCCCA	እጥሮ አ <i>ርርር</i> አርር	7 00000000 m
34021	CCICCACCAG	AGAAGUGUGG	GTCTCCCTCT	CCTCACACCC	ጥርርጣን አርርርር	OCCOCCCC M
つきののエ	ACGGGTGATG	GUGGGAUGCG	GCTGATCGTG	ጥጥርጥርርልርርር	ጥሮጥር አጥር አጠረ	CACMMCCMmm
24147	COGACALLIL	CGTACTTGCT	GTAGCAGAAC	CTCCTCCCC	CCCTCCAAAA	COMMODOGG
24007	CAGCAGICIC	GGCGCTTGGA	ACGCTCGGTG	ጥጥል ል ልርጥጥርጥ	7777C7CCC7	CMCMCMCACA
PADOT	CCGIGCMGCA	GATCTAGGGC	CTCAGGAGTG	<b>ልጥሮል አሮልጥሮ</b> ሮ	でながでながべてのか	Camacama
24277	MICACAICGA	CCACCGTGGA	ATGGGCCAGG	CCCACCCACA	TCATCCAAmm	mmcmmcccmm
34701	TCGGIGHCGG	SOURGOOD	AAGAACAGGA	<u>እርአ እ</u> ርሮልጥርአ	ጥጥአአሮመመመጠአ	70007777000
22047	TUTUGGAGCA	CTTCAAAATG	AAGGTCACGG	ACATCCCACC	TOTOCOCCCC	CCMCMCMMAA
33101	TOGWWWYIWW	CAGCCAGGTC	AAAGGTGATA	CCCTTCTCA	CATCHMCCAC	CCMCCCMMCC
22707	AGCAAAGCCT	CCACGCGCAC	ATCAGAAACA	ACACAATACC	CAAACCCCCA	CCCMMCMCmx
35221	ATTCCTCAAC	CATCATGTTA	CACTCCTGCA	CCATCCCCAG	ATAATTTTCA	MMMMMCGA GG
35281	CTTGAATGAT	TCGAACTAGT	TCCTGAGGTA	AATCCAACCC	AGCCATGATA	11111CCAGC
35341	GCAGAGCACC	CTCCACCGGC	ATTCTTAACC	ACA CCCTCAT	AATTCCAAGA	MAMAGCTCGC
35401	CTGGTTCACC	TGCAGCAGAT	TGACAAGCGG	ACACCCICAI	TCTCTGCCGC	TATTCTGCTC
35461	CTCCTCCCTC	AGCAATAACT	GTA A GTA CTC	MATAICAAAA	TCTCCGAAAT	GATCCCTGAG
35521	AGGACCCCCA	GGAATAAGAG	AAGGGCAAGG	TITCATATCG	ATAAACCGAA	TTTTAGCCAT
35581	GTGAGCATTG	ССАААТСТАА	CATTCACATAGC	ACCAMOCHEC	ATAAACCGAA CTAGACCCGG	GTCCCCCCCA
35641	CAGATAACTC	CACAGAAAAm	CCCCMN V CC2	AGCATGCTGG	CTAGACCCGG	TGATATCTTC
35701	TTCCAGGTGC	ACCTOMMAN	COGGIAAGCA	ATTTTTAAGA	AAATCAACAA	AAGAAAAATC
35761	CAGCATGCTGC	ACMUNICOUCA ACMUNICOUCA		AACGATGGAG	TAAGTGCAAG	GGGTGCGTTC
35821	CCTCCCTGGTT	ACCIPCOCIDA	AUCCUMOUS-	AACAAAAAAT	AAAACATTAA	ACCATGCTAG
35881	CCCACCCAAC	CULY A A A MUNC	WICCOMARCS =	CCAGCACCAG	GCAGGCCACG	GGGTCTCCGG
359/11	CCCGACCCTC	A A MC A MMCCC	TUGUTATGAT	TGAAAACCAT	CACAGAGAGA	CGTTCCCGGT
36001	COCCGCCTG	CCCCCCACCA	GAAGAAGCAT	ACACCCCCCG	GAACATTGGA	GTCCGTGAGT
		GGCCGAGGAA	GCAATGAGGC	ACTACAACGC	TCACTCTCAA	GTCCAGCAAA

#### ITR0048PV

SEQ ID NO: 3	59/153

36061	GCGATGCCAT	GCGGATGAAG	CACAAAAmm	mar aa====		ATTACTCCCC
36131	mccmcca ca c	CCCCITTORAG	CACAAAATTT.	TCAGGTGCGT	AAAAAATGTA	ATTACTCCCC
2011	TCC TGCACAG	GCAGCGAAGC	יויניניניניבאַתירירי	<b>かんしょしょしょしょ</b>	0303033300	~~~~
36181	ATAGCTTACC	GAGCGCCACC	ACCACCCCC	03.033.03	CITIZCHARGC	CICMGCGICC
362/1	TCACCITICA A	CARCECOCAGE	AGCAGCGGCA	CACAACAGGC	GCAAGAGTCA	CTCAGCGTCC GAGAAAAGAC
	TOWOCICIAM	CCIGICCGCC	CGCTCTCTCC	ጥሮ እስጥ እጥ አጥ አ	CCCCCCACAMO	M3.03.0===
36301	TAAAGGCCAA	AGTCTAAAAA	TACCCCCCAA	7077002020	CCCCAGAIC	IACACTGACG
36361	AACCCCCCCC	2020ZZZZZZZ	TACCCGCCAA	ATAATCACAC	ACGCCCAGCA	CACGCCCAGA
00001	THICCOGLIGAC	ACACICAGAA	AAATACCCCC	<b>አ ሲ</b> ተመር ርብር ላ ል	ACCCCCCA A A A C	maaaaaa
36421	TCCGGGTTCC	CACGCTACGT	$C \Lambda T C \Lambda \Lambda \Lambda \Lambda C \Lambda$	CC2 CMMmc2.		IGCCGICATT
36481	CATCACCCCC	00000011001	CHICHMAACA	CGACTTTCAA	ATTCCGTCGA	CCGTTAAAAA
00101	CALCACCCGC	CCCGCCCCTA	ACGGTCGCCG	CTCCCCCACC	CAAMOAGGmm	~~~~~
36541	CAAATTCAAA	CACCTCATTT	CCAMAMMAAA	000000000		CCICCICCC
36601	CAAATTCAAA TGATGG		GCATATTAAC	GUGUACCAAA	AGTTTGAGGT	ATATTATTGA
2007	TOUTOR					

SEQ ID No: 4	, .	60/15	3		
1 CATCATCA	AT AATATACC	rc ΔΔΔCσσσσσσσ	TC MCCCCCCC	A TATGCAAAT(	
1621 GAAGACTTT 1681 TGGAGATTC 1741 AAGGATCAA					
1741 AAGGATCAA 1801 GGCCATCAG	T TTGAGGATAT	TOTAL TARGET	AAGCTAGTCT	ATAGGGCCAA	ACAGGATTAT
3361 ATTTGGTGTT	GTCCTGCAAC	CCCGIGIGIG	TGGAGGTGAC (	GGAGGACCTG C	GACCCGATC
3421 GTGAGTAGTG	TTTGGGGGAG	GGGACGGAGT	TCGGCTCCAG (	CGGGGAAGAA T	'CTGACTAGA
3481 GTTTTTCTGT					
		DJDMDIRJUS	GWWGCGCCIG (	JTTTGAGGGA G	GGGTATTCA

SE	EQ ID No: 4	6	1/153	3		
	-				ርሮርምሮ አር አ አጠ	GTGATGGGAT
360:	L CCACGGTGGA	CGGCCGGCCC	GTGCAGCCCG	CGAACTCTTC	AACCCTCACACC	TACGCGACCC
3663	L TGAGCTCCTC	GTCCGTGGAC	GCAGCTGCCG	CCGCAGCTGC	TGCTTCCGCC	GCCAGCGCCG
3723	L TGCGCGGAAT	GGCCCTGGGC	GCCGGCTACT	ACAGCTCTCT	GGTGGCCAAC	TCGACTTCCA
378.	L CCAATAATCC	CGCCAGCCTG	AACGAGGAGA	AGCTGCTGCT	GCTGATGGCC	CACCTCGAGG
3841	L CCCTGACCCA	L GCGCCTGGGC	GAGCTGACCC	AGCAGGTGGC	TCAGCTGCAG	CCCCACACCC
390	L GGGCCGCGGI	' TGCCACGGTG	AAAACCAAAT	AAAAAATGAA	ТСААТАААТА	AACGGAGACG
3961	L GTTGTTGATT	' TTAACACAGA	GTCTTGAATC	TTTATTTGAT	TTTTCGCGCG	CCCTACCCC
402	L TGGACCACCG	GTCTCGATCA	TTGAGCACCC	GGTGGATTTT	TTCCAGGACC	CCCTACACCT
4083	L GGGCTTGGAT	' GTTGAGGTAC	ATGGGCATGA	GCCCGTCCCG	GGGGTGGAGG	ייי <b>אככרייררראייי</b> י
414]	. GCAGGGCCTC	GTGCTCGGGG	GTGGTGTTGT	AAATCACCCA	GTCATAGCAG	GCCCCCACCC
4201	. CGTGGTGCTG	CACGATGTCC	TTGAGGAGGA	GACTGATGGC	CACGGGCAGC	СССФФССФСФ
426]	. AGGTGTTGAC	GAACCTGTTG	AGCTGGGAGG	GATGCATGCG	GGGGGAGATC	ልርልጥርርልጥርጥ
4321	. TGGCCTGGAT	' CTTGAGATTG	GCGATGTTCC	CGCCCAGATC	CCGCCGGGGG	TTCATGTTGT
4381	. GCAGGACCAC	CAGCACGGTG	TATCCGGTGC	ACTTGGGGAA	TTTGTCATGC	AACTTGGAAG
4441	. GGAAGGCGTG	AAAGAATTTG	GAGACGCCCT	TGTGACCGCC	CAGGTTTTCC	ATGCACTCAT
4501	. CCATGATGAT	GGCGATGGGC	CCGTGGGCGG	CGGCCTGGGC	AAAGACGTTT	CGGGGGTCGG
4501	ACACATCGTA	GTTGTGGTCC	TGGGTGAGCT	CGTCATAGGC	CATTTTAATG	AATTTGGGGC
4021	GGAGGGTGCC	CGACTGGGGG	ACGAAGGTGC	CCTCGATCCC	GGGGGCGTAG	TTGCCCTCGC
4001	AGATCTGCAT	CTCCCAGGCC	TTGAGCTCGG	AGGGGGGAT	CATGTCCACC	TGCGGGGCGA
4/41	TGAAAAAAC	GGTTTCCGGG	GCGGGGGAGA	TGAGCTGGGC	CGAAAGCAGG	TTCCGGAGCA
4861	GCTGGGACTT	GCCGCAGCCG	GTGGGGCCGT	AGATGACCCC	GATGACCGGC	TGCAGGTGGT
4921	AGTTGAGGGA	CAMCOMOCOCO	CCGTCCTCGC	GGAGGAGGGG	GGCCACCTCG	TTCATCATCT
4981	CGCGCACATG	CATGITUTUG	A A COMMUNICA	CCGCCAGGAG	GCGCTCGCCC	CCCAGCGAGA
5041	GGAGCTCTTG TGGAGAGGGT	CAGCGAGGCG	AAGTTTTTCA	GCGGCTTGAG	CCCGTCGGCC	ATGGGCATTT
5101	CATCTCGATC	CAGCAGACCO	AGTICCAGAC	GGTCCCAGAG	CTCGGTGATG	TGCTCTAGGG
5161	CAGGCGATGG	GCGTCCAGCG	AGGCCAGGGT	CCCCTCCTTCC	CACCOURGE	AGTAGGGCAC
5221	CAGCGTGGTC	TCCGTCACGG	TCAACCCCTC	CCGGICCIIC	MCCCCCCMMC	GGGTCCGCGT
5281	CTTCAGGCTC	ATCCGGCTGG	TCGAGAACCG	CTCCCCCTCC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CGAGGGTGCG
5341	GTAGCAATTG	AGCATGAGTT	ССТАСТТСАС	CCCCTCCCCC	CCCTCCCCC	TCCCCCCCCAG
5401	CTTACCTTTG	GAAGTGTGTC	CGCAGACGGG	ACAGAGGAGG	GACTTGACCC	TGGCGCGGAG
5461	GGGGGCGAGG	AAGACGGACT	CGGGGGCGTA	GGCGTCCGCG	CCGCAGCTGG	CGCAGACCCT
5521	CTCGCACTCC	ACGAGCCAGG	TGAGGTCGGG	CCGGTTGGGG	TCAAAAACGA	<b>CC</b> かかかしてかして
5581	GTGCTTTTTG	ATGCGTTTCT	TACCTCTGGT	CTCCATGAGC	TCGTGTCCCC	CCTCCCTCAC
564I	AAAGAGGCTG	TCCGTGTCCC	CGTAGACCGA	CTTTATGGGC	CGGTCCTCGA	GCGGGGTGCC
2/07	GCGGTCCTCG	TCGTAGAGGA	ACCCCGCCCA	CTCCGAGACG	AAGGCCCGGG	TCCAGGCCAG
5761	CACGAAGGAG	GCCACGTGGG	AGGGGTAGCG	GTCGTTGTCC	ACCAGCGGGT	CCACCTTCTC
5821	CAGGGTATGC	AAGCACATGT	CCCCCTCGTC	CACATCCAGG	AAGGTGATTG	<b>ርርጥጥርጥ</b> አርጥ
2887	GTAGGCCACG	TGACCGGGGG	TCCCGGCCGG	GGGGGTATAA	AAGGGGGCCCC	CCCCCTCCTC
5941	GTCCTCACTG	TCTTCCGGAT	CGCTGTCCAG	GAGCGCCAGC	${\tt TGTTGGGGTA}$	GGTATTCCCT
POOT	CTCGAAGGCT	GGCATAACCT	CGGCACTCAG	GTTGTCAGTT	TCTAGAAACG	ACCACCATTO
600T	GATATTGACG	GTGCCGTTGG	AGACGCCTTT	CATGAGCCCC	TCGTCCATCT	GGTCAGAAAA
6121	GACGATCTTT	TTGTTGTCGA	GCTTGGTGGC	GAAGGAGCCG	TAGAGGGCGT	TGGAGAGGAG
6241	CTTGGCGATG	AGGERATEG	TCTGGTTCTT	TTCCTTGTCG	GCGCGCTCCT	TGGCGGCGAT
6301	GTTGAGCTGC	ACGTACTCGC	GCGCCACGCA	CTTCCATTCG	GGGAAGACGG	TGGTGAGCTC
6361	GTCGGGCACG	ATTCTGACCC	GCCAGCCGCG	GTTGTGCAGG	GTGATGAGGT	CCACGCTGGT
6421	GGCCACCTCG	ACCCCCCCCC	CCAECACCEC	CCAGCAGAGG	CGCCCGCCCT	TGCGCGAGCA
6481	GAAGGGGGC	AGCGGGGGCC	CCAACMACCM	GTUGGGGGGG	TCGGCGTCCA	CGGTGAAGAT
6541	GCCGGGCAGA TTGCCAGTCG	CCCACCCCCCA	CCCCCCCCCC	GATGCAGGTG	TCCAGATCGT	CCAGCGCCGC
6601	GGGGTGCGTG	ACCCCCCACC	CCTACATCCC	CCACAMOMO	AGGGGCGTGC	CCCAGGGCAT
6661	GAGGACGCCG	ATGTAGGTGG	CGTACAIGCC	CCCCCCCCCC	AMCCMCCCCC	GGGGCTCCTC
6721	GTACAGCTCG	TGCGAGGGCG	CGAGGAGCCC	CCTCCCCCCCCC	WIRCIPECTO	GCACGTAGTC
6781	GGCGCGGTAG	ACGATCTGGC	GGAAGATGCC	GTGCCGAGG	TIGGWGCGLT.	GCGGCTTTTC
6841	GAAGATGTTG	AAGTGGGCGT	GGGGCAGGCC	GACCGAGTIG	CTCATCA A CT	TGGGCCTCTG
6901	GTCCTGCAGC	TTGGCGACGA	GCTCGGCGGT	GACGAGGACG	TCCACCCCCC	ACMACMCCAC
PAPT	GGTCTCTTGG	ATGATGTCGT	ACTTGAGCTG	GCCCTTCTGC	ጥጥርርልርልርርጥ	CCCCCTTCAC
7021	AAGGAACTCT	TCGCGGTCCT	TCCAGTACTC	TTCGAGGGGG	AACCCGTCCT	CATCCCCACC
7081	GTAAGAGCCC	ACCATGTAGA	ACTGGTTGAC	GGCCTTGTAG	GCGCAGCAGC	CCTTCTCCAC

SEQ ID No: 4	6	52/15	3		
7141 GGGGAGGGC	TAAGCTTCT	G CGGCCTTCC	C CACCCAACC	0 maaamar aa	
7201 GCGCACCATO	ACCTTGAGG	A ACTRICTION	T CARGGAGGT	G TGGGTGAGG	GCGAAGGTGTC
7261 CCAGAGCTGG	AAGTCCGTG	C CCTTCTTCT	A CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	G TOGTOGCAGO	CGCCCTGCTC
7321 GTTGAAGAG	ATCTTGCCC	G CCCCCCCC	T CAACUUGGGTT	G GGCAAAGCGA	A AAGTAACATC
7381 CACCTCGGCC	CGGTTGTTG	A TGACCTCCC	C CCCCACCAC	A GTGATGCGG	A AAGGCTGGGG
7441 GTTGTGCCCC	ACGATGTAG	A CTTCCACCA	TOCCOCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	ATCTCGTCG	A AGCCGTTGAT
7501 CTTGAGCTCC	TCGTAGGTG	A GCTCCCCCC	CECCOMON CO	G CCCTTAACG	GGGGCAGCTT
7561 GTCGGCGACG	TGGGGGTTG	CCCTCACCA	S GICGCIGAGO	CCGTGCTGCT	CGAGGGCCCA
7621 CTGCAAGCGC	TCCCGGTAC	P CACCCAACM	CECCCCC	AGATCCACGO	CCAGGGCGGT
7681 GCAGTAGAAG	GTGCGGGGG	r CCCCCTCCC	COCCMCCCAC	GCCATTTTT	CGGGGGTGAC
7741 GTGGGCGAGC	TCGACGAGC	# GCGGGTGCC	CCACACROMOR	TIGAGCIGGA	GGGCGAGGTC
7801 GAGCTGCTTG	CCGAAGGAC	CCDTCCACC	CMACCOMMOC	AIGACCAGCA	TGAAGGGGAC
7861 CCTTTCGGTG	CGAGGATGCG	ACCCCARCC	CAACAACHC	ACATCGTAGG	TGAGGAAGAG
7921 GGAATGGCTG	TTGATGTGAT	CCVVCMVCV	S GAAGAACTGG	ATCTCCTGCC	ACCAGTTGGA
7981 GTGTTTATAC	AAGCGTCCGC	. ACTICOTOCO	ATGUCGAUGU	CGCGCCGAGC	ACTCGTGCTT
8041 CTGTACCTGG	GTTCCTTTC	CCACCAAMM	ACGCTGCACG	GGATGCACGT	GCTGCACGAG
8101 CTGGTGCTGT	ACTACCTICA	CCCCAMCCCC	CAGTGGGCAG	TGGAGCGCTG	GCGGCTGCAT
8161 GCTGACGAGC	CCGCGCGCG	. GGCCAICGGC	GIGGCCATCG	TCTGCCTCGA	TGGTGGTCAT
8221 GACGAGGGCG	CGCAGGCCGG	ACCACGICCA	GACTTUGGUT	CGGACGGGTC	GGAGAGCGAG
8281 GGGCAGCGGC	GGCGCGCGCGC	TGDCTGTCCAC	GGTCCTGAGA	CGCTGCGGAG	TCAGGTCAGT
8341 ATGGTACTTG	ATCTCCACGG	CCCCCTTGCAG	GAGCTTTTCC	AGGGCGCGCG	GGAGGTCCAG
8401 CCCCTGGGGC	GCCACCACCG	TCCCCCTTGG1	COURTE	ACGGCTTGCA	GGGTCCCGTG
8461 AAGCGGCGGC	GAGGACGCGC	GCCCCCGITI	CTTCTTGGGC	GCTGCTTCCA	TGCCGGTCAG
8521 GGCAGGGGCA	CGTCGGCGC	GCCCGGGCGGGC	AGGGGGGGCT	CGGGACCCGG	AGGCAGGGGC
8581 GCGTGAGCGA	CGACGCGACG	CTTCACCTCC	. AGGTTCTGGT	ACTGCGCCCG	GAGAAGACTG
8641 GGACCCGTGA	GTTTGAACCT	GIIGACGICC	TGGATCTGAC	GCCTCTGGGT	GAAGGCCACG
8701 GCGGCCTGCC	GCAGGATCTC	TTCCACCTCC	TCGACAGAAT	CAATCTCGGT	ATCGTTGACG
8761 ATGAACTGCT	CGATCTCCTC	CTCCTCAACC	TCCCGAGTTGT	CCTGGTAGGC	GATCTCGGTC
8821 GCGAGGTCGT	TGGAGATGCG	GCCCATGAGG	TCTCCGCGGC	CGGCGCGCTC	GACGGTGGCC
8881 CAGACGCGGC	TGTAGACCAC	GGCTCCCTCC	CCCTCCCCCC	CGTTCATGCC	GGCCTCGTTC
8941 AGGTTGAGCT	CGACGTGGCG	CGTCAACACC	CCCMACMMCC	CGCGCATGAC	CACCTGGGCG
9001 TTGAGCGTGG	TGGCGATGTG	СТСССТСАСС	A A CA A CHIA CA	AGAGGCGCTG	GTAGAGGTAG
9061 ATCTCGCTGA	CGTCGCCCAG	GGCTTCCAAC	CCCMCCAMOO	TGATCCAGCG	GCGGAGCGGC
9121 AAGTTGAAAA	ACTGGGAGTT	GCGCGCCCAAG	ACCCTCCATGG	CCTCGTAGAA	GTCCACGGCG
9181 AGCTCAGCGA	TGGTGGCGCG	CACCTCGCGC	TCGAACCCCC	CCCCCCCCAG	AAGACGGATG
9241 ATCTCTTCCT	CCTCCACTAA	CATCTCTTCT	ACTOCCOCCO	Caccaccac	CTCTTCTTCC
9301 GGGGCCCTGC	GTCGCCGGCG	GCGCACGGGC	AGACGGTCCA	TICA A COCCUMO	CGGCGGGGA
7507 CCGCGCCGGC	GACGCATGGT	CTCGGTGACG	GCGCGCCCC	CCMCCCCCCC	0000000000
Jan Tarowcachec	CGCGCATCTC	CAGGTGGCCG	CCCCCCCCCC	CMCCCMmcccc	a
MOUNDIADO TOFC	TGCATCTTAT	CAATTCCCCC	COLD COCO COCO	00000033003	
JUST ICONOMICCA	CURRENTICE	$A \Delta \Delta C C C C C C C C C C C C C C C C C $	7 (	~~~~~~~	
SOUT COINGGCIGM	GCCCGGTTTC	T. L. C. S. L. L. C. S. L. L. L. C. S.	いこころかででしてい	030000000	~~~~~~
	ACTIGNAGIA	Catal (404) ( '11')		TO COTTO CONTRACT	A3 AA4 AA4 AA
3,52 1001100000	COCCITOCIC	GATT-CLECACA	CCCCCCCC	magaaaa aaa	
S.O. CINCEIGGGA	GGICCITGIA	(41)A(41)(1(1))/2(1	ATCACCCCC	002000000	~-~
200000000000000000000000000000000000000	COTOCHIC	CHANGAGGGGGGG	AACCCCCCCCC	AAAAAMAA A	
	しひしひしょしほほん	LAMPINATION IN .	יויין אייים אייין ביייי		~~~~~~
Prof. 16016GWG1	CUANDUNACCE	CFTC-CFT ACCCCTT	いいににかいかのかっ	TOO TO THE TOTAL THE TOTAL TO T	
TOTAL TITOMOGRACO	VGTT GWC PGT	Chicachicachicach	にに中にないれている	COMCOMCOM	
= 10 T10 T10 GCGC	GCGIGICGAA	CANTEST MENT CO	リッパスとくからる	00300300ms	
ZULLE HOOMGGMAGI	マンシンシンシンシンシ	CHAGGICALTICAL	ACCCCCCAMO	COMOCOMOCO	~~~~~~~
eccecondi	CCICGAGCAI	LEAGE CHEST CALL	リロスについていかんか	mama aamaa s	
	COGTOGTOGA	Catal Call Call Call Call	ΔΔΓΨΓΩΡΩΛΑ	CCCCCCCCCC	~~ ~~~~~~~
MAAAT TTOCGGCWGW	MGTAGTTCAT	GGTGGCCGCC	CTCTCCCCCC	man addadaa	
TOTAL MILOCICIAGA	CATACOCACA	AAAACTAAAAC	CCCTCACCCC		
TO THE OCTAMOCONY	-6661.1.666C	TGCGCGTGTA	CCCCCCTTTCC	እ አጥሮመርር እ አ m	ar acamaar a
	COICCIACIC	GUAUNT CUGN	じりじにないたいかん	CCCMAAmaaa	~
DADDJAIADD TOOL	3CGGGTCGTT	1"1"1"FGGCCTT	<b>ににかいにいかいといか</b>	Camcaaaaa	ma 000 a 0000
TANDOUTH COUNTRIES (	-GCCCGCGAT	GGCTCGCTGC	<b>CCTXCTCTC</b>	7/7777/777/7/	~~~~~~~
10681 CGTTGCGGTG	FGCCCCGGTT	CGAGCCTCAG	CGCTCGGCGC	CGGCCGGATT	CCCCGGGTIG
		_			CCGCGGCIAA

SEQ ID No: 4		6	3/15:	3		
1074	1 CGTGGGCGT	G GCTGCCCCG1	CGTTTCCAAC	ACCCCTTACC	י פאפפפפאפשת	CTCCAGTTAC
1080	1 GGAGCGAGC	C CCTCTTTTTC	TTGTGTTTT	CCCAGATGC	TOUCH TOUCH CONTRACT TO	CTCCAGTTAC CGGCAGATGC
1000	T GCCCCCACC	C TCCACCTCA	A CCGCCCCTAC	CGCCGCAGC	\	CCCCCCCCC
1092	1 TGCCCCCGC	C CCAGCAGCAG	CCAGCCACTA	A CCGCGGCGGC	CCCCCTCACAC	GGAGCCGCCTTC
1098	1 TTCAGTATG	A CCTGGCCTTG	GAAGAGGGC	AGGGGCTGGC	CCCCTCCCC	GCGTCGTCGC
TT04	I CGGAGCGGC	A CCCGCGCGTG	: CAGATGAAA	\ GGGACGCTCC	CCACCCCTAC	CECCCCANACC
TTTO	I AGAACCTGT"	I' CAGAGACAGO	AGCGGCGAGG	AGCCCGAGGZ	CATCCCCCCC	meceeemmaa
TTT0	T ACGCGGGGC	3 GGAGCTGCGG	CGCGGCCTGG	ACCGAAAGCG	COTTOTO	CACCACCAMO
TT44.	I TUGAGGUGG	A CGAGCTGACG	GGGATCAGCC	: CCGCGCGCGCGC	' GCACGTGGCC	CCCCCCAACC
1179	L TGGTCACGG	: GTACGAGCAG	ACCGTGAAGG	AGGAGAGC A A	ርጥጥርር አአአአአ	TO COMPONIA CA
1134	L ACCACGIGCO	3 CACGCTGATC	GCGCGCGAGG	AGGTGACCCT	CCCCCTCATC	CACCMCMCCC
1140	L ACCIGCIGGA	A GGCCATCGTG	CAGAACCCCA	CGAGCAAGCC	CCTCACCCCC	CACCMCMMMC
TT#0.	LTGGTGGTGCA	A GCACAGTCGG	GACAACGAGA	CGTTCAGGGA	CCCCCTCCTC	3 3 M 3 M 0 3 C C C
1134.	L AGCCCGAGG	# CCGCTGGCTC	CTGGACCTGG	TGAACATTCT	CCACACCATC	CINCCINCONOC
1130.	L AGCGCGGGC	r GCCGCTGTCC	GAGAAGCTGG	CCCCTATCAA	CONTRACTOR	CECACOCECO
1104	L GCAAGTACTA	A CGCTAGGAAG	ATCTACAAGA	CCCCGTACGT	CCCCATACAC	A A CC A CCMCA
11/0.	L AGATCGACG	GTTTTACATG	CGCATGACCC	TGAAAGTGCT	CACCCTCACC	CACCAMCMCC
TT \ 0 7	L GGGTGTACCG	: CAACGACAGG	ATGCACCGCG	CGGTGAGCGC	CACCCCCCCC	CCCCACCECA
1102	L GCGACCAGGA	A GCTGATGCAC	AGCCTGCAGC	GGGCCCTGAC	CCCCCCCCCCC	ACCCA CCCCC
TT887	LAGAGCTACTI	' TGACATGGGC	GCGGACCTGC	GCTGGCAGCC	CAGCCGCCGG	CCCMMCCAAA
エエンゼコ	- CIGCCGGCGG	TTCCCCCTAC	GTGGAGGAGG	TGGACGATGA	GGAGGAGGAC	CCCCACMACC
T7007	. TGGAAGACTC	ATGGCGCGAC	CGTATTTTTG	CTAGATGCAG	CAACACCCAC	CCCCTCCTCC
T7007	- TCCCGCGATG	CGGGCGCGC	TGCAGAGCCA	GCCGTCCGGC	<b>ልጥጥል ልሮጥሮሮጥ</b>	CCCACCAMMC
T7T71	. GACCCAGGCC	: ATGCAACGCA	TCATGGCGCT	GACGACCCCC	<u> እልጥሮሮሮሮ</u> አለር	CCMMMACACA
72727	. GCAGCCTCAG	GCCAACCGGC	TCTCGGCCAT	CCTGGAGGCC	CTCCTCCCCT	CCCCCCCCAA
17741	. CCCCACGCAC	GAGAAGGTGC	TGGCCATCGT	GAACGCGCTG	CTCCACAACA	ACCCCA MCCC
12301	. CGGCGACGAG	GCCGGGCTGG	TGTACAACGC	GCTGCTGGAG	CCCCTCCCCC	CCTACAACAC
T7301	. CACCAACGIG	CAGACGAACC	TGGACCGCAT	GGTGACCGAC	GTGCGCGAGG	CCCMCMCCCA
12421	GCGCGAGCGG	TTCCACCGCG	AGTCGAACCT	GGGCTCCATG	GTGGCGCTGA	7.CCCCmmccm
12401	GAGCACGCAG	CCCGCCAACG	TGCCCCGGGG	CCAGGAGGAC	ጥልሮልሮሮልልሮም	THE ATTE A COCCO
17241	GCTGCGGCTG	ATGGTGGCCG	AGGTGCCCCA	GAGCGAGGTG	TACCACTCCC	CCCCCCACMA
TOOUT	CTTCTTCCAG	ACCAGTCGCC	AGGGCTTGCA	GACCCTCAAC	CTCACCCACC	COMMONNON
17007	CTTGCAGGGA	CTGTGGGGCG	TGCAGGCCCC	GGTCGGGGAC	CCCCCCACCC	TOTAL COOK
72/27	GCTGACGCCG	AACTCGCGCC	TGCTGCTGCT	GCTGGTGGCG	CCCTTCACCC	707000070
T7/0T	CGTGAGCCGC	GACTCGTACC	TGGGCTACCで	GCTTA ACCTG	TACCCCCACC	CCAMCCCCC
14041	GGCGCACGTG	GACGAGCAGA	CCTACCAGGA	GATCACCCAC	CTCACCCCCC	CCCMCCCCC
TABOT	GGAGGACCCG	GGCAACCTGG	AGGCCACCCT	GAACTTCCTC	CTCACCAACC	CCTCCCACAA
TSAOT	GATCCCGCCC	CAGTACGCGC	TGAGCACCGA	GGAGGAGCCC	ATCCTCCCCT	A C C TT C C A C C A
T207T	GAGCGTGGGG	CTGTTCCTGA	TGCAGGAGGG	GGCCACGCCC	ACCCCCCCCC	TO CACAMOAG
TOCOT	CGCGCGCAAC	ATGGAGCCCA	GCATGTACGC	TCGCAACCGC	<b>CCC</b> 中中で 入中で 入	<b>እጥ</b> እ እ ር ር መር እ መ
エラエオエ	GGACTACTTG	CATCGGGCGG	CCCCCATGAA	CTCCCACTAC	TITTE A CONTROL	CC M M C M M C M M
13201	CCCGCACTGG	CTCCCGCCGC	CCGGGTTCTA	CACGGGCGAG	TACGACATGC	CCGACCCCAA
13201	CONCOGNIC	CIGIGGRACG	ACGTGGACAG	CACCGTGTTC	TCCCCCCCCCC	CCCCCACCAC
T227T	CGIGIGGAAG	AAAGAGGGCG	GGGACCGGCG	GCCGTCCTCC	CCCCTCTCCC	CTCCCCCCCC
TOOOT	TREATRECTRE	GCGGTGCCTG	AGGCCGCCAG	CCCCTTCCCC	ACCCTCCCC	TOTO COMO A A
13501	CAGCGTGCGC	AGCAGCGAGC	TGGGTCGGCT	GACGCGGCCG	CGCCTGCTGG	GCGAGGAGGA
13561	ACACACCCOMO	GACTCCTTGT	TGAGGCCCGA	GCGCGAGAAG	AACTTCCCCA	ATAACGGGAT
T220T	MONGAGCCIG	GIGGACAAGA	TGAGCCGCTC	GAAGACGTAC	CCCCACCACC	A C A C C C A A C C A
13601	TOTOCOTO	AGCAGCAGCG	CAGGCACCCG	TAGACGCCAG	CGACACGACA	GGCAGCGGGG
137/11	TCIGGIGIGG	GACGATGAGG	ATTCCGCCGA	CGACAGCAGC	GTGTTGGACT	TGGGTGGGAG
13801	TGGTGGTGGT	AACCCGTTCG	CTCACTTGCG	CCCCCGTATC	GGGCGCCTGA	TGTAAGAATC
13007	IGMMAMAATA	AAAAACGGTA	CTCACCAAGG	CCATGGCGAC	CACCCTCCCT	memamamam
13921	CCACTAGLWCL	AGTATGATGA	GGCGCGTGTA	CCCGGAGGGT	CCTCCTCCCT	CGTACGAGAG
13981	CCCGCGGWC	CAGGCGGTGG	CGGCGGCGAT	GCAGCCCCCG	CTGGAGGCGC	CTTACGTGCC
14041	CTTCTCTACCAM	CTGGCGCCTA	CGGAGGGGCG	GAACAGCATT	CGTTACTCGG	AGCTGGCACC
14101	GAACTACCAT	ACCACCOGT	TGTWCCTGGT	GGACAACAAG	TCGGCGGACA	TCGCCTCGCT
14161	CCCCACGGAC	AACGACCACA	GCAACTTCCT	GACCACCGTG	GTGCAGAACA	ACGATTTCAC
14221	GCTGAAAACC	GCCAGCACCC	CCAACCATCAA	CTTTGACGAG	CGCTCGCGGT	GGGCCGCCA
14281	GTTCAAGGCG	ATCATGCACA	TCHACATGCC	CAACGTGAAC	GAGTTCATGT .	ACAGCAACAA
		CGGGTGATGG	AMODODOLOL	GACCCCCAAT	GGGGTCGCGG '	TGGATGAGAA

	EQ ID No: 4	(	54	/15	3	3		
1434	1 TTATGATGO	T AGTCAGGAC	G AG	CTGACTT	ΓA	CGAGTGGGT	G GACTTTCAC	C TGCCCGAGGG
0	T CLEACHICE	O GIGACCATI	A UU	ATT CLATT	",	(2) አጥር እአለት አ	0 000×ma×ma	~ - ~
	1 000001000	O CGICAGAAC	(+ (+(+	Carreacyreac	ΙΔ	$C\Delta CCC\Delta C\Delta C\Delta C$	~ ~~~~~~~~~~~~~~	T
	T CHACLICE	G CIGGGCIGG	G AC	CCCGTGA	<b>λ(</b> !	CGACCTCCT	~ `````````````````````````````````````	7 mama as acces
	T COMOGCCII	. C CACCCGAC	A TC	GTCCCCC	777	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	~ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	T TO
1464	1 CCGCCTCAG	C AACCTGCTG	G GC	ATCCGC	7 7	GCGCGGCIG	GGCGTGGAC	F TCACCGAGAG G GCTTCCAGAT
1470	1 CCTGTACGA	G GACCTGGAG	G GG	CCCAACA	/ UL	CCCCCCCCCC	TTCCAGGAG	G GCTTCCAGAT  G AAGCCTATGA
1476	1 GAAAAGCAA	G GAGGAGGCC	G CC	CCACCC	יי	CACCCCCACCC	TIGGATGTC	G AAGCCTATGA G CCTCTACCGA
1482	1 GGTGCGGGG	С САТААТТТ	2 CT:	ACCCCCC	יכ	CCCACAGC	GIGGCCACC	G CCTCTACCGA G AAACCGAAAG
1488	1 TAAGATAGT	C ATCCAGCCG	2 TC/	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	אי	CACCAGTGGC	GAGGCGGCT	AAACCGAAAG ACGTGCTCGC
1494	1 GGACAAGAA	A AACACCGCC	ያ ነው።	3232223333 3222222		CAGCAAGGA	C AGGAGCTAC	A ACGTGCTCGC GCGACCCCGA
1500	1 GAAGGGCGT	G CGCTCCTGG	CCC	このころのこと	G	GIACCTGGC(	TACAACTAC	GCGACCCCGA GCGTGGAGCA
1506	1 AGTCTACTG	G TEGETGEECE	7 707		יא	ACCTCGGA(	GTCACCTGC	GCGTGGAGCA
1512	1 AGTTAGCAA	C TACCCCCCCCC	a AC	TOOCOO	A	AGACCCCGGTC	ACCTTCCGCT	GCGTGGAGCA CCACGCGTCA
1518	1 CAACGAGCA	C CCCCGGIG	2 1.GC	3000000	A	GCTCCTGCCC	GTCTACTCC	CCACGCGTCA AGAGCTTCTT
1524	CAACCGCTT	C CCCCACAAC	CGC	CAGCAGC	.T.	GCGCGCCTTC	: ACCTCGCTC	A AGAGCTTCTT A CGCACGTCTT
15301	CAGTGAAAA	C CTTCCTCCTC	AGE	ATCCTCG	T.	CCGCCCGCCC	: GCGCCCACC2	CGCACGTCTT TTACCACCGT
15361	GGGAGTCCA	C CCCCTCTACAC	TCF	ACAGATC	A	CGGGACCCTG	CCGCTGCGC2	TTACCACCGT GCAGTATCCG
15421	GGCCCTGGG	C CONCOCCO	TOP	ACTGACG	C	CAGACGCCGC	: ACCTGCCCCT	GCAGTATCCG ACGTCTACAA
15481		C CCCACMAAM	CGC	GCGTCC	T -	CTCGAGCCGC	: ACCTTCTAAZ	ACGTCTACAA AAATGTCCAT
15541	ACCCCCTCC	C CAACCOMCC	ACA	ACCGGTT	G ·	GGGCCTGCGC	GCGCCCAGCA	AGATGTACGG
15601	CTCCCCCCCC	CAACGCTCCA	CGC	AACACC	C	CGTGCGCGTG	CGCGGGCACT	TCCGCGCTCC
		- CICAAGGGCC	. (-((.(-	21/040/040/17/	וייו	にたにたりんたりんたん	CECONONNO	
15721	)	C GACGCGCGCA	ACT	ACACGC	C (	CGCCGCCGCG	CCCGCCTCCA	CCGTGGACGC
	· COTCHICGM	- MUCUIUGIG	CCG	ATGCCC	C (	<u> </u>	CCCCCCAAAA	0000000000
	. 0000111000	- CGGCGGCALL	( →( →A	L-C'ACTO		<b>っこっしょう かんしっしつ</b>	0000000000	~~~~~~~
~	· cradaaccy(	JAFIFIFICACION TO A COLOR OF THE COLOR OF TH	(-i('A	CCCCCA	T (	ごいかい かんしんしん	000303000	
	DETOCITOCE	- ひししひひしみほぼみ	. uau	(⊰( 'A(¿A('Y	2 (	ייבריבירית אירי	00000000000	
			(40)	רבו ים מורוביו	r 1	ごかり しかししんしかつ	00000000000	~~~~~~
	2000019000	- GIGCGCACCC	GCC	CCCCTC	3 (	<b>ገል</b> ርጥጥር እልር አ	ጥርረመርን ረመመረ	CCC3 mcmmcs
	TOTOTOCK	T CGGCGAGGAG	(ZA'I'	ל ביויניני בובו	~ /	ፕሮሮስ እ አ አጠአረነአ	2002202020	~~~~~~
	1110000000	AGATUTACEG	CCC	CGCGGTG	3 7	AACCACCAAA	CANACCCCCCC	03330000330
	COCCICIAN	AGGACAAAAA	GGA	GGAGGA	<b>A</b> (	#ATCTCC2CC	<u>で</u> れて中でで中でです。	COOMMONOO
-0-0-	Crack TCGCCC		-CGT	GCAGTGC	3 (	''CC'CCCCCC''	77/7/777777	COMOCMOCCO
~~~	CCCGGCACCA	L CGCIGGICIT	CAC	RCCCGGC	ם י	37 こうしゅうしんしょ	CCMCCCCCMC	
	THUGHUGHGG	TGTACGGGGA	CGA	GGACATC	י ר	" <b>ም</b> ሶር እር ር አርር	CCCTCCAACCC	mamagaaaa e
	GC - 174CG	CAAGCGCAG	C:C:G40	ccccc	2 6	ነሮሮጥጥሮአ አ አ ሶ	7 CC7 CCCCCC	OFFICE
	CIGGACCACG	GUMACCCCAC	GCC	GAGCCTC	: 2	ACCCCCTCA	CCCTCCACCA	COMOCHOCO
	*100000000		-CTTC	CAAGCCC	' ເ	BCCCCCCCC	እ <i>ሮሮ እ</i> መረመረመ አ	00000000000
	CITOCIONIG	TUCLCAAGCG	CCA	AAGCTG	േദ	BCCACCTCC	TOCACOACAM	03 3 00maas a
TO001	CCCGAGGIGC	AGCCCGAGGI	CAA	GTCCCC		'ሮሮልሞሮል አሮሮ	7 CCTCCCCCCC	OGGGGGGGGG
	OTOCAGACCG	TIGGAL ATCAA	1.24.17	יויררארכ	•	'X ~ ~ ~ ~ X m ~ ~ .	222000200	A A
	MONTOCCE	CCAGCACCAT	(+(+A(	SCTCC AC	. Δ	CCCAMCCCM	COMMODOCOC	~~~~~~
		MALUALITUMA	1-1 AI	12121 121 12		CCACCCMCC.	$m \cap m \cap m \cap m \rightarrow m$	A
	OTAT COL T COM	TONTOCCAC	14111	-1-1-1 "P'A('		CCCCCACCC		~~~~~
		GCAMBALLAL.	LACT	1 121 1 121		CCCMCCMC	777777777	~~ ~~ ~~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
			171711	- ( -   -   -   -   -   -   -   -   -	12	יוינייויא רירירית א	CCCCCCCCC	~~~~~~
		COCOCIACCA		- Δ( -)( 'Δ')'' '		ריריא החחחות אירוי	MAMAAAAAA	~~~~~~
	0011011117100	CCCTCMCMIG	1.1.33	7 717 7 726 1	(2)	サイプ・イング かんしょう	CCCCCCC CCC	~~~~~~~
	COCCCCIA	GAAGGLIGAL.	1717171.	: Δ Δ ( '('.)('.)('.)		mcccmcccc	3 MA3 AA3 AAA	
	CCCITTCUCK	C1C1C1C1C1 1 C1C1C1	1-1-1-4	112626 201019	771	mararara	MARMAAAA	
	AACITIC GGGG	CONTRACTOR	CATA	121 111111111		TOCOCOMO	3 0000momos	~~~~~
		GOWWWATTITE	TAAT	. ~ ~ ~ ~ ~ ~ ~ ~ ~	Α,	ヤククスクのぐるべ	AAMAAMAAMA .	AMARA
	- OTTITION	TOGAAGACAT	CAAT	", ", ", ", ", ", ", ", ", ", ", ", ", "	· •	~~~~~~~~~~	777777777A	~~~~~~~~~
		GOMGCGGGC	HAAL	$\Delta \Delta \gamma \gamma$	~~	ימתממאממיי	MAN * * * AA**	maaaa
T\QQT	CCCGACGCGG	AGGAGACGCT	GCTG.	ACGCAC	AC	CGGACGAGC	CGCCCCCGTA	CGAGGAGGCG

SI	EQ ID No: 4	6	5/153	3		
1794	1 GTGAAACTG	G GTCTGCCCAC			TGGCCACCGG	CCTCCTCNNN
1800	1 CCCAGCAGC	A GCAGCCAGCC	CGCGACCCTC	GACTTGCCTC	'	CCCCCCCCCCCCCCC
1806	1 ACAGTGGCT	A AGCCCCTGCC	GCCGGTGGCC	GTCGCGTCGC	. GCGCCGGCIIC	ACCCCCCCCC
1812	1 CAGGCGAAC	GGCAGAGCAC	TCTGAACAGO	ATCGTGGGTC	. TEEEDECEEE	CACTCTCAAC
1818:	1 CGCCGCCGC	GCTATTAAAA	GACACTGTAG	CGCTTAACTT	, CC##C#C#C#C#	CUCUNUNUCU
1824	1 ATGTCCGCC	G ACCAGAAGGA	GGAAGAGGCG	CGTCGCCGAG	TTCCDACATC	GIGIAIAIGI
1830	1 CGATGCTGC	CCAGTGGGCG	TACATGCACA	TCGCCGGAC	CCACCCTTCC	CACMACCCCAT
1836	l GTCCGGGTCT	GGTGCAGTTC	GCCCGCGCCA	CAGACACCTA	CONCOCITCO	CCCAACAACA
1842	l TTAGGAACCO	CACGGTGGCG	CCCACGCACG	ATGTGACCAC	CITCAGICIG	CACCCCCCCCCCCC
1848:	L CGCTGCGCTT	CGTGCCCGTG	GACCGCGAGG	ACAACACCTA	CTCCTACAAA	CMCCCCMACA
18541	L CGCTGGCCGT	GGGCGACAAC	CGCGTGCTGG	ACATGGCCAG	CICGIACAAA	CACAMCCCCC
18601	L GCGTGCTGG	TCGGGGGCCC	AGCTTCAAAC	ССТАСТСССС	CACCIACIII	AACAICCGCG
18661	LCTCCCAAGGG	AGCGCCCAAC	ACTTGCCAGT	GGACATATA	へんここうこう こうしょう しょうしょう しょうしゅう しゅうしゅう しゅうしゅう ひんしゅう しゅうしゅう しゅうしゃ しゅう	AMCAGCCIGG
18723	L AAAAAACCTA	TACATATGGA	AATGCACCTG	TGCAAGGCAT	. WGCIGGIGWI	ACTGATACAG
18781	LTTCAACTTGG	AACTGACAGC	GATGGTCAGG	СВАТСТВТСС	ACACCATIACA	MAGGAIGGIA
18841	AGCCTCAAGT	GGGTGATGCT	GAATGGCATG	ACATCACTCC	TORCORRECT	AAAMAMAGAA
18901	GCAGAGCTCT	TAAGCCTGAC	ACCAAAATGA	AGCCTTGCTA	TACIGAIGAA	CCCAACCCMA
18961	CCAATAAAGA	AGGAGGCCAG	GCAAATGTGA	AAACCGAAAC	ACCCCCTACC	A A A C A A M A M C
19021	ACATTGACAT	GGCATTCTTC	GATAATCGAA	GTGCAGCTGC	CCCCCCCCC	CCCCCACAAA
19081	. TTGTTTTGTA	TACTGAGAAT	GTGGATCTGG	AAACTCCAGA	ውያርር ያውርር 123 የልርርር አጥአጥጥ	CTATACAACC
19141	. CAGGTACAGA	TGACAGTAGC	TCTTCTATCA	ATTTCCCTCA	CCACTCCATAII	CCCAACACAC
19201	CCAACTACAT	TGGCTTCAGA	GACAACTTTA	TCGGTCTGAT	GTACTACA AC	ACCACTCCCA
19261	ATATGGGTGT	ACTGGCTGGA	CAGGCCTCCC	AGCTGAATGC	TGTGGTGGAC	TTCCACCACA
19321	. GAAACACCGA	ACTGTCCTAC	CAGCTCTTGC	TTGACTCTCT	GGGTGACAGA	ACC ACCORAGO
19381	TCAGTATGTG	GAATCAGGCG	GTGGACAGTT	ATGACCCCGA	TCTCCCCATT	ACCAGGIATT
19441	ACGGTGTGGA	GGATGAACTT	ССТААСТАТТ	CCTTCCCCCT	CCATCCTCTC	AT I GWAAATC
19501	ATACTTACCA	GGGAATTAAG	GCCAATGGTG	ATAATCAAAC	CACCTCCACC	AAACAMCAMA
19561	CTGTTAATGA	TGCTAATGAA	TTGGGCAAGG	CCAATCCTTT	CCCCATCCAC	AMAGAIGAIA
19621	AGGCCAACCT	GTGGCGGAAC	TTCCTCTACG	CGAACGTGGC	CCTCTACCTC	CCCCACMCCC
19681	ACAAGTACAC	GCCGGCCAAC	ATCACGCTGC	CCACCAACAC	CAACACCTAC	CCCGACICCI
19741	ACGGCCGCGT	GGTGGCGCCC	TCGCTGGTGG	ACGCCTACAT	CAACATCCCC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
19801	CGCTGGACCC	CATGGACAAC	GTCAACCCCT	TCAACCACCA	CCGCAACGCG	CCCCTCCCAM
19861	ACCGCTCCAT	GCTCCTGGGC	AACGGGCGCT	ACGTGCCCTT	CCACATCCAG	GTGCCCCAAA
19921	AGTTTTTCGC	CATCAAGAGC	CTCCTGCTCC	TGCCCGGGTC	CTACACCTAC	GAGTGGAACT
19981	TCCGCAAGGA	CGTCAACATG	ATCCTGCAGA	GCTCCCTCGG	CAACGACCTC	CCCACCCACC
20041	GGGCCTCCAT	CGCCTTCACC	AGCATCAACC	TCTACGCCAC	CTTCTTCCCC	ATECCECACA
20101	ACACCGCCTC	CACGCTCGAG	GCCATGCTGC	GCAACGACAC	CAACGACCAG	ጥሮሮጥጥሮ አልሮር
20161	ACTACCTCTC	GGCGGCCAAC	ATGCTCTACC	CCATCCCGGC	CAACGCCACC	AACCTCCCCA
20221	TCTCCATCCC	CTCGCGCAAC	TGGGCCGCCT	TCCGCGGCTG	GTCCTTCACG	CCCCTCAACA
20281	CCCGCGAGAC	GCCCTCGCTC	GGCTCCGGGT	TCGACCCCTA	CTTCGTCTAC	TCGGGCTCCA
20341	TCCCCTACCT	CGACGCCACC	TTCTACCTCA	ACCACACCTT	CAACAACCTC	TOCATOACOM
20401	TCGACTCCTC	CGTCAGCTGG	CCCGGCAACG	ACCGCCTCCT	GACGCCCAAC	GAGTTCGAAA
20401	TCAAGCGCAC	CGTCGACGGA	GAGGGGTACA	ACGTGGCCCA	GTGCAACATG	ACCAAGGACT
Z022T	GGTTCCTGGT	CCAGATGCTG	GCCCACTACA	ACATCGGCTA	CCAGGGCTTC	TACCTCCCCC
20281	AGGGCTACAA	GGACCGCATG	TACTCCTTCT	TCCGCAACTT	CCAGCCCATG	AGCCGCCAGG
2064I	TCGTGGACGA	GGTCAACTAC	AAGGACTACC	AGGCCGTCAC	CCTGGCCTAC	CACCACAACA
20/01	ACTCGGGCTT	CGTCGGCTAC	CTCGCGCCCA	CCATGCGCCA	GGGCCAGCCC	ጥልሮሮሮሮሮሮር
20/0T	ACTACCCCTA	CCCGCTCATC	GGCAAGAGCG	CCGTCGCCAG	CGTCACCCAG	<b>Δ Δ Δ Δ Δ С</b> ጥጥሮሮ
7087T	TCTGCGACCG	GGTCATGTGG	CGCATCCCCT	TCTCCAGCAA	CTTCATGTCC	ATGGGCGCGC
7088T	TCACCGACCT	CGGCCAGAAC	ATGCTCTACG	CCAACTCCGC	CCACGCGCTA	GACATGAATT
20941	TCGAAGTCGA	CCCCATGGAT	GAGTCCACCC	TTCTCTATGT	TGTCTTCGAA	GTCTTCGACG
~TOOT	TUGTUUGAGT	GCACCAGCCC	CACCGCGGCG	TCATCGAGGC	CGTCTACCTC	CGCACGCCCT
5T00T	TCTCGGCCGG	CAACGCCACC	ACCTAAGCCT	CTTCCTTCTT	GCAAGATGAC	GGCCTGCGCG
7TT7T	GGCTCCGGCG	AGCAGGAGCT	CAGGGCCATC	CTCCGCGACC	TEGECTECE	CCCCTCCTTC
STTRT	CTGGGCACCT	TCGACAAGCG	CTTCCCGGGA	TTCATGGCCC	CGCACAAGCT	GGCCTGCGCC
27747	ATCGTCAACA	CGGCCGGCCG	CGAGACCGGG	GGCGAGCACT	GGCTGGCCTT	<u>ሮሮሮሮምሮር</u> ክ አሮ
7720T	CCGCGCTCCC	ACACCTGCTA	CCTCTTCGAC	CCCTTCGGGT	TCTCGGACGA	<b>ር</b> ርርርርጥር እ አር
7120T	CAGATCTACC	AGTTCGAGTA -	CGAGGGCCTG	CTGCGTCGCA	GCGCCCCTGGC	CACCGAGGAC
7747T	CGCTGCGTCA	CCCTGGAAAA	GTCCACCCAG	ACCGTGCAGG	GTCCGCGCTC	GGCCGCCTGC
21481	GGGCTCTTCT	GCTGCATGTT	CCTGCACGCC	TTCGTGCACT	GGCCCGACCG	CCCCATGGAC

SEQ ID No: 4	6	6/15	3		
21541 AAGAACCCCA 21601 GTGGAACCCA	CCATGAACTT	CCTCACCC	C CMCCCCCxxx	~ ~~~~~	_
==	CUCUCUMITAIT	THAT CHAPTAC	A CCCCCMMAA:		
	CACALLLAIL	TTC (2 A 11' 12' 11' 17'	1 CCMCCMmam		
000110000110	C110CCC.11.17	140 1 714 122 2714 27	' <i>%~~~~~~~~~~~~</i>		
	CUGGICETI	THE CACTACTACTA	, <i>א</i> הכככההככאת	0100100000	
	ししれびほににいれる	ACTEMBER 12121 TA		Ammamma	
	CUCCUMMUTI.	AGGGGGGGGGGGGGG	- $        -$	AAMAMAA A A A	
COLCCITCIC (	GGIGAIGCGC	ACGGGGGGGAA	<b>みごごででいる かごごご</b>	030000000	
	T T C C T T C C . I T . I **	C -1.4 (2.1.4. 1. 1.1.4. 24.24.)	mc $m$ $m$ $m$ $m$ $m$ $m$	A * * * * * * * * * * * * * * * * * * *	
23281 CAGAGCCCCT 3	TATTCOCGITCG	CCCT CCCCT	CCTGGCGGCG	CTGCTCTGAC	TGACTTCCTC
23341 CGCGGCCGGC (23401 CATCGCCATC 1	recececeece	CCCCCCCCA	CAAGCATGGA	GACTCAGCCA	TCGTCGCCAA
23461 CCGCCCGCC G	CCCAGCCCC	ACCECCGACG ACCECCGACG	AGAACCAGCA	GCAGCAGAAT	GAAAGCTTAA
COLIGING CA		L-AL-1 'A'I (-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1	$\lambda C \cap \lambda C \cap \Delta \Delta \Delta$	0000000	And the second second
I GCCCCICAG C	-UTGGGGAI+	CUCARCCCCCC	CCMACCACCC	0330000000	
+OCCCCCAA G	CGCCAGCCC	AACGGCACCT	CCCACCCAA	000000000	
	GIGCLIIAI I	30 3 3 31 31 31 31 31 31 31	CCMXCCXCCX		
25081 GCGGCGAGGG CC	LOCICGAG T	GCCACTGCC (	CTGCAACCT (	TGCACGCCG (	CACCGCTCCC

SI	EQ ID No: 4	6	7/153	3		
2514	1 TGGCCTGCA				י רפפרא ככשיים	GAGTTGCAAG
2520.	r gcccccgccg	A GGGCAAGGGG	GGTCTGAAAC	TCACCCCGG	CCTCTCCACC	TO COCO CONTRACTOR
2526	L TGCGCAAGT	CGTGCCCGAG	GACTACCATO	ССТТССАСАТ	CACCUTCOACC	GAGGACCAAT
2532	1 CCCAGCCGC	CAAGGCCGAG	CTGTCGGCCT	GCGTCATCAC	CLOGITCIAC	ATCCTGGCCC
25383	L AATTGCAAG	CATCCAGAAA	TCCCGCCAAG	AATTTCTGCT	GAAAAAGGGCC	CACGGGGTCT
2544	L ACTTGGACC	CCAGACCGGA	GAGGAGCTCA	ACCCCAGCTT	CIMERIAGGGC	GCCCCGAGGA
2550:	L AGCAGCAAGA	AGCTGAAAGT	GGAGCTGCCG		ACCATTTCCA	GCCCCGAGGA
25563	L GAGAGCAGTO	AGGCAGAGGA	GGAGGAGATG	GAAGACTGGG	ACAGCACTCA	GGCAGAGGAG
25623	L GACAGCCTG	AAGACAGTCT	GGAGGAGGAA	GACGAGGTGG	AGGAGGCAGA	GGAAGAAGCA
<b>4568.</b>	L GCCGCCGCCZ	A GACCGTCGTC	CTCGGCGGAG	GAGGAGAAAG	CAAGCAGCAC	CCATACCATC
25741	L TCCGCTCCGC	GTCGGGGTCG	CGGCGGCCGG	GCCCACAGTA	GATGGGACGA	GACCCCCCCCC
2360.	L TTCCCGAACC	: CCACCACCCA	GACCGGTAAG	AAGGAGCGGC	AGGGATACAA	CTCCTCCCCC
4586.	L GGGCACAAA	ACGCCATCGT	CTCCTGCTTG	CAAGCCTGCG	GGGGCAACAT	ርጥሮርጥጥር አ ሮር
45943	CGGCGCTACC	: TGCTCTTCCA	CCGCGGGGTG	AACTTCCCCC	GCAACATCTT	ርሮልሞካልሮሞልሮ
Z598]	L CGTCACCTCC	: ACAGCCCCTA	CTACTGTTTC	CAAGAAGAGG	CAGAAACCCA	CCACCACCAC
20041	. CAGCAGCAGA	AAACCAGCGG	CAGCAGCTAG	AAAATCCACA	GCGGCGGCAG	GTGGACTGAG
<b>∇</b> ρΤ01	GATCGCGGCG	AACGAGCCGG	CGCAGACCCG	GGAGCTGAGG	AACCGGATCT	ጥጥሮሮሮልሮሮሮሞ
<b>50101</b>	- CTATGCCATC	TTCCAGCAGA	GTCGGGGGCA	AGAGCAGGAA	CTGAAAGTCA	ACA ACCCCTTC
20221	. TCTGCGCTCG	CTCACCCGCA	GTTGTCTGTA	TCACAAGAGC	GAAGACCAAC	<b>ምምሮ አርሮርር አ</b> ሮ
26281	. TCTCGAGGAC	GCCGAGGCTC	TCTTCAACAA	GTACTGCGCG	CTCACTCTTA	AACACTACCC
20341	. CGCGCCCGCC	CACACACGGA	AAAAGGCGGG	AATTACGTCA	CCACCTGCGC	CCTTCCCCCC
Z0401	ACCATCATCA	TGAGCAAAGA	GATTCCCACG	CCTTACATGT	GGAGCTACCA	CCCCCACATIC
20401	GGCCTGGCCG	CCGGCGCCGC	CCAGGACTAC	TCCACCCGCA	TGAACTCCCT	CAGTGCCCCC
20021	CCCGCGATGA	. TCTCACGGGT	GAATGACATC	CGCGCCCACC	GAAACCAGAT	<b>እርጥሮሮ</b> ጥ አርአ አ
7028T	CAGTCAGCGA	TCACCGCCAC	GCCCCGCCAT	CACCTTAATC	<b>CCCGTA A TTC</b>	CCCCCCCCCC
20041	CTGGTGTACC	AGGAAATTCC	CCAGCCCACG	ACCGTACTAC	TTCCCCCACA	CCCCCACCCC
20/01	GAAGTCCAGC	TGACTAACTC	AGGTGTCCAG	CTGGCCGGCG	GCGCCGCCCT	CTCTCCTCAC
70/0T	CGCCCCGCTC	AGGGTATAAA	GCGGCTGGTG	ATCCGAGGCA	GAGGCACACA	CCTCAACCAC
70971	GAGGTGGTGA	GCTCTTCGCT	GGGTCTGCGA	CCTGACGGAG	ጥርጥጥርር ል ል ረጥ	CCCCCCAMCC
7088T	GGGAGATCTT	CCTTCACGCC	TCGTCAGGCC	GTCCTGACTT	TCCACACTTC	CTCCTCCCAC
20941	CCCCGCTCGG	GTGGCATCGG	CACTCTCCAG	TTCGTGGAGG	<b>Δርጥጥሮ Δርጥሮሮ</b>	CTCCCTCTAC
2/00T	TTCAACCCCT	TCTCCGGCTC	CCCCGGCCAC	TACCCGGACG	<b>Δርጥጥሮ Δጥሮሮሮ</b>	CAACOTOCAC
Z 100T	GCCATCAGCG	AGTCGGTGGA	CGGCTACGAT	TGAATGTCCC	ATCCTCCCCC	CCCTCACCTA
2/121	GCTCGGCTTC	GACACCTGGA	CCACTGCCGC	CGCTTCCCCT	CCTTCCCTCC	CCAMCMCCCC
7 / T R T	GAGTTTGCCT	ACTTTGAGCT	GCCCGAGGAG	CACCCTCACC	CCCCCCCCC	CCCACMCCCC
4/247	ATCGTCGTCG	AAGGGGGTCT	CGACTCCCAC	$CTCCTTCCC\Delta$	ጥርጥጥር አርርር አ	CCCMCCCAMO
Z/301	CIGGCCGAGC	GCGAGCAAGG	ACAGACCCTT	CTGACCCTGT	<b>Δሮሞሮሮ Δሞሮሞሮ</b>	CAACCACCCC
2/301	GGCCTGCATG	AAAGTCTTTG	TTGTCTGCTG	TGTACTGAGT	<b>ልጥልልጥልልልል</b> ር	で中でみぐみ中でなぐ
2/421	CGACTACTCC	GGACTTCCGT	GTGTTCCTGC	TATCAACCAG	ጥሮሮሮሞርሞሞርሞ	TCACCCCAA
Z/40T	CGAGACCGAG	CTCCAGCTCC	AGTGTAAGCC	CCACAAGAAG	TACCTCACCT	CCCTCTTCCTT
27501	GGGCTCTCCG	ATCGCCGTTG	TCAACCACTG	CGACAACGAC	GGAGTCCTGC	TGAGCGGCCC
Z/001	IGCCAACCIT	ACTITITCCA	CCCGCAGAAG	CAAGCTCCAG	で中で中中でであるで	CCTTCCTCCC
2,00T	COGGACCIAI	CWGTGCGTCT	CGGGACCCTG	CCATCACACC	ጥጥርር እርርጥር እ	ጥሮሮሮሮስ አመአሮ
27701	UMCCOOCCO	CTCCCCGCTA	CTAACAACCA	AACTACCCAC	CAACGCCACC	GTCGCGACCT
27701	TTCCTCTGGG	TCTAATACCA	CTACCGGAGG	TGAGCTCCGA	GGTCGACCAA	CCTCTGGGAT
27041	TIACIACGGC	CCCTGGGAGG	TGGTAGGGTT	AATAGCGCTA	GGCCTAGTTG	CGGGTGGGCT
27901	COMMONACANA	TGCTACCTAT	ACCTCCCTTG	CTGTTCGTAC	TTAGTGGTGC	TGTGTTGCTG
2/201	GIIIMAGMAA	TGGGGAAGAT	CACCCTAGTG	AGCTGCGGTG	TROTTO CONTROL	CCTCCTCCTT
28021	TCGATIGIGG	GACTGGGCGG	CGCGGCTGTA	GTGAAGGAGA	AGGCCGATCC	CTGCTTGCAT
28141	ATCANCECCC	ACAAATGCCA	GCTGAGTTTT	CAGCCCGATG	GCAATCGGTG	CGCGGTGCTG
28201	A T CAAG I GCG	GATGGGAATG	CGAGAACGTG	AGAATCGAGT	ACAATAACAA	GACTCGGAAC
28261	CCTCCTCTCC	CGTCCGTGTG	GCAGCCCGGG	GACCCCGAGT	GGTACACCGT	CTCTGTCCCC
28321	ACCOMONMON	GCTCCCCGCG	CACCGTGAAT	AATACTTTCA	TTTTTGCGCA	CATGTGCGAC
28381	CTCTTCATGT	GGATGAGCAA	GCAGTACGAT	ATGTGGCCCC	CCACGAAGGA	GAACATCGTG
28441	ATTICICA	TCGCTTACAG	CGTGTGCACG	GCGCTAATCA	CCGCTATCGT	GTGCCTGAGC
28501	CACCTTOC	TCATCGCTAT	TOUCCUCAGA	AATAATGCCG	AAAAAGAAAA	ACAGCCATAA
28561	CCAGTCTCAT	CACACACCTT TGCCGTCATT	TICHGACCA '	TGGCCTCTGT	TAAATTTTTG	CTTTTATTTG
28621	CTAATCACAC	TGCCGTCATT ATTGAAAGGT	CCACACAAAAAC	GTAATGAGAA	AATTACTATT	TACACTGGCA
28681	ATGAATCAGA	TGTATCTACT		CACAGAAGT	TTCATGGTAT	TGTTATTTTA
				GUNANCHATAA	CAAAAAAAAT	GAGAGCATTA

SF	EQ ID No: 4	6	8/153	3		
	-					
28/4.	CTCTCATCAA	GTTTCAATGT	GGATCTGACT	TAACCCTAAT	TAACATCACT	AGAGACTATG
2880.	TAGGTATGTA	TTATGGAACT	ACAGCAGGCA	TTTCGGACAT	GGAATTTTAT	CAAGTTTCTG
2886.	TGTCTGAACC	CACCACGCCT	AGAATGACCA	CAACCACAAA	AACTACACCT	GTTACCACTA
28921	TACAGCTCAC	TACCAATGGC	TTTCTTGCCA	TGCTTCAAGT	GGCTGAAAAT	AGCACCAGCA
28981	TTCAACCCAC	CCCACCCAGT	GAGGAAATTC	CCAGATCCAT	GATTGGCATT	ATTGTTGCTG
2904	TAGTGGTGTG	CATGTTGATC	ATCGCCTTGT	GCATGGTGTA	CTATGCCTTC	TGCTACAGAA
2910	AGCACAGACT	GAACGACAAG	CTGGAACACT	TACTAAGTGT	TGAATTTTAA	TTTTTTAGAA
29161	CCATGAAGAT	CCTAGGCCTT	TTAGTTTTTT	CTATCATTAC	CTCTGCTCTA	TGCAATTCTG
2922	. ACAATGAGGA	CGTTACTGTC	GTTGTCGGAT	CAAATTATAC	ACTAAAAGGT	CCAGCAAAAG
29283	GTATGCTTTC	GTGGTATTGT	TGGTTCGGAA	CTGACGAGCA	ACAGACAGAA	CTTTGCAATG
2934	. CTCAAAAAGG	CAAAACCTCA	AATTCTAAAA	TCTCTAATTA	TCAATGCAAT	GGCACTGACT
29401	. TAGTATTGCT	CAATGTCACG	AAAGCATATG	CTGGCAGTTA	CACCTGCCCT	GGAGATGATG
29401	. CCGACAATAT	GATTTTTTAC	AAAGTGGAAG	TGGTTGATCC	CACTACTCCA	CCGCCCACCA
29321	. CCACAACTAC	TCATACCACA	CACACAGAAC	AAACACCAGA	GGCAGCAGAA	GCAGAGTTGG
29301	. CCTTCCAGGT	TCACGGAGAT	TCCTTTGCTG	TCAATACCCC	TACACCCGAT	CAGCGGTGTC
20701	. CGGGGCTGCT	CGTCAGCGGC	ATTGTCGGTG	TGCTTTCGGG	ATTAGCAGTC	ATAATCATCT
29701	. GCATGTTCAT	TTTTGCTTGC	TGCTATAGAA	GGCTTTACCG	ACAAAAATCA	GACCCACTGC
29701	. TGAACCTCTA	CCC ADDCOOM	TTTCCAGAGC	CATGAAGGCA	GTTAGCGCTC	TAGTTTTTTG
20021	TTCTTTGATT	GGCATTGTTT	TTAGTGCTGG	GTTTTTTGAAA	AATCTTACCA	TTTATGAAGG
29001	TGAGAATGCC AGATGGGTGG	ACTUTACTCC	GCATCAGTGG	TCAAAATGTC	AGCTGGCTAA	AATACCATCT
30001	CCTCACCATT	AMAGACATTT	GCGATTGGAA	TGTCACTGTG	TATACATGTA	ATGGAGTTAA
30001	CCTCACCATT TAGAAATAAT	CCCTATIGCCA	CCCAAGATCA	GAATGGTAGG	TTTAAGGGCC	AGAGTTTCAC
30101	TGAGACTGCC	ACCACCACAC	CCCATAACAT	GTTTATCTAT	GACGTCACTG	TCATCAGAAA
30121	AACCACACAG	ACCACCACAC	CAMCA ACMCA	TACACACAGT	TCTACCACTA	CTACCATGCA
30241	AAGTAGTGCA	CCCCCTCACC	CCCACCCOORD	CCCMMMCAAA	ACCACTACAG	CAGCAAAGCC
30301	TACTAGGACC	AATCACCACACA	CCCAGGCTTT	MMMCMCC3 CM	GUTGUACAAC	CTAGTACAAC
30361	TACCTCCAGT	CCCMMCMCMM	CIACIGAAII	TITGICCACT	GTCGAGAGCC	ACACCACAGC
30421	TCCCGCTACT	ACTCCCACCC	CACCTCTTCT	CCCCACTCCC	CTTTCCTCTA	CMCACCACAC
30481	CGGCATGCAA	TCCCACATCA	CCCTCCTCAT	TCTCATCCCC	CIGAAGCAAA	TOCCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCO
30541	GCTCTACTAC	ATCTTCTGCC	GCCGCATTCC	CANCECECNE	CCCAAACCCC	CCMACAACCC
30601	CATCGTTATC	GGGCAGCCGG	ACCCCCTTCA	CAACGCGCAC	CGCAAACCGG	ATCTTCTCTCTCT
30661	CTCTTTTACA	GTATGGTGAT	TGAACTATGA	TTCCTACACA	ATTCTTCATC	ACTICICIT
30721	TCTGCCTCCT	CCAAGTCTGT	GCCACCCTCG	CTCTGGTGGC	CAACGCCAGT	CCACACTCTA
30781	TTGGGCCCTT	CGCCTCCTAC	GTGCTCTTTG	CCTTCATCAC	CTGCATCTGC	ТССТВАСТВІА ТССТСТВССВ
30841	TAGTCTGCCT	GCTTATCACC	TTCTTCCAGT	TCATTGACTG	CATCTTTCTC	CCCATCCCCT
30901	ACCTGCGCCA	CCACCCCCAG	TACCGCGACC	AGCGAGTGGC	GCGGCTGCTC	AGGCTCCTCT
30961	GATAAGCATG	CGGGCTCTGC	TACTTCTCGC	GCTTCTGCTG	TTAGTGCTCC	CCCCCCCCCT
31021	CGACCCCCGG	TCCCCCACTC	AGTCCCCCGA	AGAGGTCCGC	AAATGCAAAT	TCCAAGAACC
31081	CTGGAAATTC	CTCAAATGCT	ACCGCCAAAA	ATCAGACATG	CTTCCCAGCT	GGATCATGAT
31141	CATTGGGATC	GTGAACATTC	TGGCCTGCAC	CCTCATCTCC	TTTGTGATTT	ACCCCTGCTT
31201	TGACTTTGGT	TGGAACTCGC	CAGAGGCGCT	CTATCTCCCG	CCTGAACCTG	ACACACCACC
31261	ACAGCAACCT	CAGGCACACG	CACTACCACC	ACCACAGCCT	AGGCCACAAT	ACATGCCCAT
31321	ATTAGACTAT	GAGGCCGAGC	CACAGCGACC	CATGCTCCCC	GCTATTAGTT	ACTTCAATCT
31381	AACCGGCGGA	GATGACTGAC	CCACTGGCCA	ACAACAACGT	CAACGACCTT	CTCCTGGACA
31441	TGGACGGCCG	CGCCTCGGAG	CAGCGACTCG	CCCAACTTCG	CATTCGCCAG	CAGCAGGAGA
31501	GAGCCGTCAA	GGAGCTGCAG	GACGGCATAG	CCATCCACCA	GTGCAAGAAA	GGCATCTTCT
31561	GCCTGGTGAA	ACAGGCCAAG	ATCTCCTACG	AGGTCACCCC	GACCGACCAT	CGCCTCTCCT
31621	ACGAGCTCCT	GCAGCAGCGC	CAGAAGTTCA	CCTGCCTGGT	CGGAGTCAAC	CCCATCGTCA
31681	TCACCCAGCA	GTCGGGCGAT	ACCAAGGGGT	GCATCCACTG	CTCCTGCGAC	TCCCCCGACT
31741	GCGTCCACAC	TCTGATCAAG	ACCCTCTGCG	GCCTCCGCGA	CCTCCTCCCC	ATGAACTAAT
31801	CACCCCCTTA	TCCAGTGAAA	TAAATATCAT	ATTGATGATG	ATTTAAATAA	AAAATAATCA
31861	TTTGATTTGA	AATAAAGATA	CAATCATATT	GATGATTTGA	GTTTTAAAAA	ATAAAGAATC
31921	ACTTACTTGA	AATCTGATAC	CAGGTCTCTG	TCCATGTTTT	CTGCCAACAC	CACCTCACTC
31981	CCCTCTTCCC	AGCTCTGGTA	CTGCAGACCC	CGGCGGGCTG	CAAACTTCCT	CCACACGCTG
32041	AAGGGGATGT	CAAATTCCTC	CTGTCCCTCA	ATCTTCATTT	TATCTTCTAT	CAGATGTCCA
32101	AAAAGCGCGT	CCGGGTGGAT	GATGACTTCG	ACCCCGTCTA	CCCCTACGAT	GCAGACAACG
32T0J	CACCGACCGT	GCCCTTCATC	AACCCCCCT	TCGTCTCTTC	AGATGGATTC	CAAGAGAAGC
32221	CCCTGGGGGT	GCTGTCCCTG	CGACTGGCTG	ACCCCGTCAC	CACCAAGAAC	GGGGAAATCA
2448I	CCCTCAAGCT	GGGAGAGGGG	GTGGACCTCG	ACTCCTCGGG	AAAACTCATC	TCCAACACGG

S	EQ ID No: 4	6	9/15	3		
3234	1 CCACCAAGG	c cecceccco	CTCAGTTTT	- CCAACAACA	~	AACATGGATA
3440	T CCCCICITI	A TACCAAAGA	L GGAAAATTA	י ככידידאר אוני	P	מות מות מות מות ל
3240	1 TAAAATCAA	C CATTCTGAA(	: ACATTAGCTO	፣ ጥAGCጥጥልጥር/	2 Amc Accmmm	CONCORCACIO
3232	T GIGGCACIG	C TCTTGCAGTA	L CAGTTGGCC1	የ ሮሞሮሮልሮሞሮል	$\sigma$ $\sigma$	777CC777M7
2230	T TIMAMATIA	A CCTAGCCAGT	' GGTCCATTAZ	\ CAGTTGATG	` <u>```````````````````````````````````</u>	አራመአመረካ አራመ
2204	T GCAAAAGAG	G GGTCACTGTC	: ACTACCTCAG	፤ GAGAጥርሮልል፣	የ ጥርልአልሮሮአልር	* 3m3300m000
3270	1 CTAAAGGTA	T AAGATTTGA	GGTAATGGC	TAGCTGCAA	CAMMAGCAMC	GGATTGGAAT
32/0	T TIGGAACCA	C TAGTACAGAC	ACTGATGTCA	CAGATGCATZ	\	COMPARAMOCO
3404	I GIACIGGCC	r TACCTTTGAC	AGTACAGGCC	CCATTGTTGC	' ጥጥርርልልርእእ	CACCAMCAMA
2200	T AACTTACAT	r ATGGACCACA	L GCCGACCCCT	' CGCCAAAጥጥ(	ያ ሮአአአአመአመአር	mamaxxxxx
3234	L ATGUCAAAC	r CACACTTTGC	TTGACAAAGT	' GTGGAAGTCZ	Δ ΔΨΨĊΨζζζζ	ACMOMOAOMO
3300	I TATTGGCAG	r gaataatgga	AGTCTCAACC	CAATCACAA	CACACTAACC	A CMCCA AMAC
3300.	L TUTUCUTUA	A GTTTGATGCA	<b>AGTGGAGTTT</b>	' TGCTAAGCAG	: <b>ር</b> ጥርር አር አጥጥአ	CACAAACAA
3312.	L ATTGGAACT	L CAGAAAGGGA	GATGTTACAC	CTGCTGAGCC	' ሮሞልሞልሮሞልልሞ	CCMAMACCMM
2270	L TTATGCCTA	* CATAAAGGCC	TATCCTAAAA	ACACAጥርጥርር	<u>እር</u> ርመመር አአአአ	3.000 3 m 3 mmo
JJ24.	L TUAGTUAAG	L TATCICAAT	' GGGGATGAGG	CCAAACCACT	CAMCCMCAMM	A MIMA CIMMA
3330.	L AIGAAACIGA	1 GGATGCAACT	TGCACCTACA	ርጥልጥሮልሮጥጥ፣	ጥሮልልጥሮሮአአአ	MCCCA Ma CMa
3330.	L CTAAGTACAC	: AGGTGAAACA	CTTGCTACCA	ርርጥሮሮጥጥሮልር		3.00000003.3.0
3342.	. MATGAACACT	GTATCCCACC	CTGCATGCCA	<b>ልሮሮሮሞጥሮሮሮ</b> ል	CCCCACTCTC	mama mada a a
. 2240	LAMACICIGA	I GCACAAAATA	<u> </u>	~ C X X C T C T T T T T T T T T T T T T T	A DECAMENTA	~~ ~~~~~ ~ ·
22247	- GGATICGAGC	AGTTATTT	CCTCCACCCT	СССАССАСАТ	CCNAMACACC	3 CCCMCmccc
20002	JUMUMUMUMUMUMUMUMUMUMUMUMUMUMUMUMUMUMUM	CITCAACATC	TGAATGCCAT	тсстсатсса	$C\Delta TCCTTTTTC$	CITCITICATACA
22007	. ICCACACAGI	TTCAGAGCGA	GCCAGTCTCG	$-$ GGTCGGTC $\Delta$ G	CCACAMCAAA	CCCMCCCCC
22/21	ACTUCUGUAT	· CTGCACCTCA	CAGCTCAACA	GCTGAGGATT	CTCCTCCCTC	CMCCCCAMOA
22/01	. CGGTTATCTG	GAAGAAGCAG	AAGAGCGGCG	GTGGGAATCA	TACTOCOCOA	3.00003.maga
22041	CCGGTGGTGT	CGCATCAGGC	CCCGCAGCAG	TCGCTGCCGC	CCCCCCCCCCC	max x aamaam
22201	GUTUAGGGGG	TCCGGGTCCA	GGGACTCCCT	CAGCATGATG	CCCACGCCCC	MC3 CC3 mc3 C
22301	TCGTCTGGTG	CGGCGGGCGC	AGCAGCGCAT	GCGGATCTCG	CTCACCTCCC	mcca cma com
24077	GCAACACAGG	ACCACCAGGT	TGTTCAACAG	ጥሮሮልጥልሮጥጥሮ	እ አ <i>ርአርርር</i> ርመርር	2000022200
24001	CATCGCGGGA	AGGATGCTAC	CCACGTGGCC	GTCGTACCAG	<b>ልጥሮርጥር አርርጥ</b>	77700777000
24747	GCGCICCCIC	CAGAACACGC	TGCCCACCTA	$C\Delta TC\Delta TCTC$	ጥጥር ርርርር አጠርጠ	CCCCCCCCCC
24707	CACCTCCCGG	TACCACATCA	CCCTCTGGTT	CAACATCCAC	CCCCCCAMCA	maamaaaa a
34201	CCACAGGGGCC	AGCACCGCCC	CGCCCGCCAT	GCAGCGAAGA	CACCCCCCCC	CCCCCCTTTCC
74727	GCAAIGGAGG	ACCCACCGCT	CGTACCCGTG	GATCATCTCC	CACCOCAACA	A COO COO COO COO COO COO COO COO COO CO
2420T	GGCACAGCAC	AGGCATATGC	TCATGCATCT	CTTCACCACT	CTCACCTCCT	OCCOCCEDON N
つけみみエ	AACCATATCC	CAGGGCACGG	GGAACTCTTG	CAGGACAGCG	<b>አአሮሮሮሮሮሮ</b> ል	2202000022
2420T	ICCICGCACA	TAACTTACAT	TGTGCATGGA	CAGGGTATCG	CAATCACCCA	CCACCCCCC
2420T	ATCCTCCACC	AGAGAAGCGC	GGGTCTCGGT	CTCCTCACAC	CCTCCTTAACC	aaaaaaaaa
2407T	ATACGGGTGA	TGGCGGGACG	CGGCTGATCG	TGTTCGCGAC	CCCCCCCAMCA	maaa ammaam
24001	1 1 CGGACATT	TTCGTACTTG	CTGTAGCAGA	ACCTCCTCCC	CCCCCCTCCA	A CCCCA MCCCCC
24/47	GGCGGCGGIC	CCGGCGCTTG	GAACGCTCCC	שמא א א שישיים א	000000000000000000000000000000000000000	~~ ~~~~~~
34861	TCATCACATC	CAGATCTAGG	GCCTCAGGAG	TGATGAAGAT	CCCATCATGC	CTGATAGCTC
0 1 0 0 1	T C117 C17C17 C	GWCCWCCGIG	GAATGGCCA	CACCCACCCA	<b>でかかぐみがぐぐみ</b> ス	mmmmanmaaa
34981	GCTCTCCCAC	GGCGGGGGAG	GGAAGAACAG	GAAGAACCAT	GATTAACTTT	TAATCCAAAC
35041	GGTGGAAAAT	CACTTCAAAA	TGAAGGTCGC	GGAGATGGCA	CCTCTCGCCC	CCGCTGTGTT
35101	CCAGCAAAGC	AACAGCCAGG	TCAAAGGTGA	TACGGTTCTC	GAGATGTTCC	ACGGTGGCTT
35161	СТААТТССТС	CTCCACGCGC	MCATCCAGAA	ACAAGACAAT	AGCGAAAGCG	GGAGGGTTCT
35221	AGCCTTGAAT	AATCATCATG	ACMMOCACTOCT	GCACCATCCC	CAGATAATTT	TCATTTTTCC
35281	CGCGCAGAGC	GATTCGAACT	CCCAMMOMMA	GTAAATCCAA	GCCAGCCATG	ATAAAGAGCT
35341	CTCCTGGTTC	GCCCTCCACC	CAUMCACAAC	AGCACACCCT	CATAATTCCA	AGATATTCTG
35401	AAGCTCCTCC	ACCTGCAGCA	ACTCUA ACTA	CGGAATATCA	AAATCTCTGC	CGCGATCCCT
35461	CATAGGACCA	CTCAGCAATA	CAMMACCCCA	CTCTTTCATA	TCCTCTCCGA	AATTTTTAGC
35521	CCAGTGAGCA	CCAGGAATAA	CVVCVCWCCW GWT TWGGGGCW	AGCCACAGTA	CAGATAAACC	GAAGTCCTCC
35581	TTCCAGATAA	TTGCCAAATG	A AMCACTGCT	ATAAGCATGC	TGGCTAGACC	CGGTGATATC
35641	ATCCTCCAGG	CTGGACAGAA . TGCACGTTTA	CACCCAC	A ACA A COSTO	AGAAAATCAA	CAAAAGAAAA
35701	TTCCAGCATC	GTTAGTTAGC	CATCTCGGG .	AAAACGATG	AAGTAAATGC	AAGCGGTGCG
35761	AGCCTGGCGA	ACAGGTGGGT	ANTOLGIAM .	CTCCACARAAA	ATAAAACATT .	AAACCATGCT
35821	GGCGCGACCC	TCGTAAAAAT	TGTCGCTATC	ATTCA A A A CC	AGGCAGGCCA	CGGGGTCTCC
35881	GTGGCCGGCG	TGAATGATTC (	GACAAGATGA	ATACACACACC	ATCACAGAGA (	GACGTTCCCG
				ALACACCCCC	GGAACATTGG (	CGTCCGCGAG

### ITR0048PV

SEQ ID	No: 4	. /	U/153			
35941 TG	AAAAAAAG	CGCCCGAGGA	AGCAATAAGG	CACTACAATG	CTCAGTCTCA	AGTCCAGCAA
					TACAAAATGT	
36061 CTC	CCTGCACA	GGCAGCGAAG	CCCCGATCC	CTCCAGATAC	ACATACAAAG	CCTCAGCGTC
					CAGAGAAAGG	
					TACACTGACG	
					CACGCCCAGA	
					TGCCGTCATT	
					CCGTTAAAAA	
					CCTCCCTCCC	
36481 CAC	CTCATTT	GCATATTAAC	GCGCACCAAA	AGTTTGAGGT	${\tt ATATTATTGA}$	TGATG

SEQ ID NO: 5 71/153

	catcatcaa	at aatatacct	c aaacttttg	g tgcgcgtta	a tatgcaaat	g aggtatttga
		~~ 9~99946	L Uall.Gorn	r namenaea	~ ~~~~	
	- 3	-s wegacataa	C CULUADOCO	0 20000000	~ ~~~~++~	
	3-1-3	~~ 949964644	L LLUMACACACO	T 22252660	~ ++++~~~~	
	22	egecectury	u cuuatucaa	u Lussasava	~ ~~~+++	
		-s cgaaaaccc	u autaaricc	O COFFFATOR	~ ~~~~~~~	
	555-5	'y woulded	u allacaran	7 77777777		
	3-35	· · · · · · · · · · · · · · · · · · ·	C CCLacerrai	T FM22MAAA	~ ++	
		~ ~~~~~~~~	a cucuucadad	T MTMAMAAA	. ~~+~~~~~	
		w couguating	. Latuadoaai	" ACETACATA	* ~~~~~~ <u>~</u>	
		· · · · · · · · · · · · · · · · · · ·	a ucuaaccam	1 (12(11(2)22)	* ^~~~~~~~~	
	-55-000	- Lactetique	: uuacacooct	, utaamtatta	. +~~~++	
		y yyaraacci	. LLUUACFFAT		200000000	
		y -yaa	L audiciaence	' AMEStetse	~~~~	
		. Ccccaagiq	uludeleato	actraggggg	acces of the	
			. Caulicadad	CAGGACTCAT	~~~~ + ~ + ~ - ~	
		* voawactawa	Caucincian	202204026		
			LLUMOAGAGE	OFCCT WALSE		
	3 ~ ug - c		Cadadrarre	TABABAAAA		
	5	- cacacaca	Latinicocce	じじつけんのせんべつ	~~~~~~	
	~ o o o o u g c u g	ggattactut	CLUGACTOCE	Taccactace.	+++	
		gggac caauc	uuuaaaaaaa	TUSUUSUS 4+		
	-99	a cyay couca	uucucccana	arconterator.		
2341	gggatagat	gaggtctcag	tgatgcatga	gaaatattgg	cygcacgagg	rgcagtcgca
2761 g	aggggatgc	agtttttcag	ccaactacat	grycarryag	gcctggggca	gtgtttcagt
2821 g	tcagtgaag	aaatgcctgt	tegagagata	gggggtegtg	ggcagaacca	agagcatggt
2881 c	aaaqtcaaa	cactgcgcct	ctaccaaca	ccacetgggg	gtgatgagcg	agggcgaagc
2941 c	aaaqtcaaq	cataatatoa	tetategagae	gggctgcttt	gtactgatca	agggcaatgc
3001 c	tacaccaat	cataatatga	atatectar-	cccggatgag	cgcggctacc	agatgctgac
y	-gggga	ctgggtggga	gcctgcatga	tgggcagaat	gactaaaatc i	tgtgttttc
						= -

Fig. 9A

3481	. tgcgcagcag	catgagcgga	agcgcctcct	ttgagggagg	ggtattcagc	ccttatctga
3541	. cggggcgtct	cccctcctgg	gcgggagtgc	gtcagaatgt	gatgggatcc	acqqtqqacq
3601	. gccggcccgt	gcagcccgcg	aactcttcaa	ccctgaccta	cgcgaccctg	agctcctcgt
3661	. ccgtggacgc	agctgccgcc	gcagctgctg	cttccgccgc	cagcgccgtg	cocogaatoo
3721	. ccctgggcgc	cggctactac	agctctctgg	tggccaactc	gagttccacc	aataatcccd
3781	. ccagcctgaa	cgaggagaag	ctactactac	tgatggccca	gctcgaggcc	ctgacccage
3841	gcctgggcga	gctgacccag	caggtggctc	agctgcaggc	adadacacaa	accacaatta
3901	ccacggtgaa	aaccaaataa	aaaatgaatc	aataaataaa	cadadacadt	tattasttt
3961	aacacagagt	cttgaatett	tatttgattt	ttcacacaca	ataggeeta	gecgaece
4021	ctcgatcatt	gagcacccgg	togatettt	ccaddacccd	gtagaggtag	acttaceggt
4081	tgaggtacat	gggcatgagc	ccatcccaaa	aataaaaata	actccattac	aggacge
4141	gctcgggggt	ggtgttgtaa	atcacccagt	cataggaggg	acacaaaaca	taataataa
4201	cgatgtcctt	gaggaggaga	ctgatggcca	cadacaacc	cttaatataa	atattascas
4261	acctgttgag	ctqqqaqqqa	tacatacaaa	gggagatgag	atocatctto	acctagatet
4321	tgagattggc	gatgttcccg	cccagatece	accagaaatt	catottotoc	aggaggagga
4381	gcacggtgta	tecaatacae	ttggggaatt	tatcatacaa	cttggegege	aggaccacca
4441	agaatttgga	gacgcccttg	taaccaccca	aattttccat	cceggaaggg	atastastas
4501	cgatgggccc	ataaacaaca	acttagacaa	agacatttca	gaaataaaa	acgacgacgg
4561	tgtggtcctg	ggtgaggtcg	tcataggcca	ttttaatgaa	tttaaaaaaa	acaccycayt
4621	actgggggac	gaaggtgccc	tcaatcccaa	aaacataatt	acceteacea	agggracecy
4681	cccaggcctt	gaggtcggag	agagggatca	tatecaceta	caaaacaata	accogcator
4741	tttccggggc	gagaaagata	agetagacca	aaarcaratt	cogggcgatg	tagasattag
4801	cgcagccggt	aggaccataa	atdaccccda	taaccaacta	caggagagaga	ttaaaaaaaa
4861	gacagctgcc	gtcctcgcgg	addaddddd	ccacctcatt	caggiggiag	ccgagggaga
4921	tgttctcgcg	caccacttcc	acceaaaaa	acteaccege	cattattttg	cycacatyca
4981	gcgaggcgaa	atttttcaac	aacttaaacc	catcagagast	aaycyayayy	agetettgea
5041	gttgcaagag	ttccaracor	teceagaget	cactastata	gggcactttg	gagagggtet
5101	gcagacctcc	tcatttcaca	aattaaaaca	agtagaagaa	tagggga	cetegateea
5161	gtccagcgag	accadantee	aatcettees	accgcgggag	atagggcacca	ggcgatgggc
5221	cgtcacggtg	aaaaaataca	caccacacta	ggggcgcagg	greegegrea	gegeggeeee
5281	ccggctggtc	aagaaccact	cccaatcaa	ggcgcccgcg	tagagagaga	reaggeteat
5341	catgagttcg	tagttgagcg	cctcaaccac	geeeegegeg	coggodaggt	togetheres
5401	agtgtgtccg	cadacdddac	agaggagga	cttgagggggg	tagaggt	tacctttgga
5461	gacggactcg	aggacataga	catccacaca	acaactaaca	cagagerrat	gggcgaggaa
5521	gagccaggtg	aggtetage	gatcagage	geagerggeg	tttaataat	cgcactccac
5581	gcgtttctta	cctctaatct	ccatgaggtc	atatacaaa	taggtgagaa	getttttgat
5641	cgtgtccccg	tagaccgact	ttatgggccc	gtgttttgt	cgggtgacaa	agaggetgte
5701	gtagaggaac	cccaccact	ccdadacdaa	gcccccgage	ggggtgeege	ggteetegte
5761	cacgtgggag	adataccact	cattatacaa	ggcccgggcc	cagyccagca	cgaaggagge
5821	gcacatgtcc	ccctcatcca	catccaccac	cagegggeee	ttatacatat	gggtatgcaa
5881	accgggggtc	ccaaccaaaa	aaccaggaa	ggcgaccggc	cigiaagigi	aggecaegeg
5941	ttccggatcg	ctatccagag	acaccaacta	ttagggtgggc	tattactet	ceteaetgte
6001	catgaceteg	gcactcaggt	tatcaattta	tagaaagg	TALLUCCCCCC	cgaaggcggg
6061	gccgttggag	acocctttca	tgagggggg	atacatataa	yayyatttga	cattgaeggt
6121	gttgtcgagc	ttaataacaa	aggagagaga	gcccacctgg	ccagaaaaga	tonner
6181	gcgcatggtc	taattettt	ccttataaaa	gagggegetg	gagageaget	tggcgatgga
6241	gtactcgcgc	accacacact	tccattoggc	gegeteettg	geggegatgt	rgagergeae
6301	tetgacecce	cadcadcadt	tatacacact	gaagacggtg	gryagerige	cyggcacgat
6361	tctgacccgc	tcattcatca	accacagggt	gatgaggtee	acgctggtgg	ccacctcgcc
6421	gcgcaggggc	atgaggtcc	caaaaaaaa	agataaa	cycgagcaga	aygggggcag
6481	cgggtccagc	aagtagetge	tacaaataaa	ggcgtccacg	grgaagatgc	cyggcaggag
6541	ctcggggtcg	acacactcat	addadatas=	cayaccgecc	agegeegett	gccagtcgcg
6601	cacggccagc	tacateceee	agaygeegag	gggcgtgccc	cagggcatgg	ggtgcgtgag
6661	cgcggaggcg	tacacyccyc	ccccccc	gacgtagagg	ggctcctcga	ggacgccgat
6721	gtaggtgggg	addadcccc	tacacacacat	gergegege	acgtagtcgt	acagetegtg
6781	cgagggcgcg	aagatgcccyg	agazatta	ggagegetge	ggcttttcgg	cycggtagac
6841	gatetggegg	aagacyycyt	aaaaraar	gyayatggtg	ygcctctgga	agatgttgaa
	gtgggcgtgg	ggcagcccga	Cogagicccc	yaryaagtgg	gegtaggagt	cergeagert

73/153

			· ·			
6901	ggcgacgag	c tcggcggtg	ra cgaggacgt	C Caddacaca	g tagtcgagg	~ +a+a++
9721 a	gcaccaggt	ccttggacgaa	gccyaaytag	gcggtcctga	gacggcggat	ggtggcgagg
9781 t	ggtcctgac	acctaacaaa	gtcctgctgg	argegeagae	gacggcggat ggtcggccat	gccccaggcg
9901 a	gcgccaggt	Caacaacaac	gegeatgege	grgageeega	acccgcgctg	cggctggacg
9961 g	tctggaagt	catcasaatc	gegeteggeg	aggatggcct	gctggatctg	ggtgagggtg
10141 t	ggtatccga (	caaaaaata	caacaacaaa	taggage	tgcaggtgcg (	cacgaggtac
10201 g	aaacaccaa o	acacaaaatc	ctccaccato	rggcggtaga	gcggccatcg (	ctcggtggcg
10261 at	tccaggtga t	taccaacaac	actactacca	aggeggtggt	agccgtagat (	gtacctggac
10381 ca	agtegtgga t	getetagae .	atacadace	arageegegg	tctggcccgt g ggtcagcggc t	Jaggegegeg
		S		aaacyaaagc	ggtcagcggc t	cgactccgt

Fig. 9C

1044	1 ggcctggag	g ctaagcgaa	c gggttgggc	t gcgcgtgta	c cccaattea	a gtccctgctc
		, - ggauctuca	u claacoroo	T actorcact	a aaatata.	
		· · · · · · · · · · · · · · · · · · ·	v uuauucuan	T COFFEEDOO	c	
		· · · · · · · · · · · · · · · · · · ·	a ucaaceme	C CCC3+~~~+	~ ~~+~~~	
		y yyttytytt	y caalaracc	C COOTTCCC	a atasassis	
		y yelaalulu	u ucalaacra	C CCCAtcatt	+ ~~~~~~~	
		u ucacaaaa	u dagereere	r	<del>~</del>	
		~ gatacacac	u daecerrera	C C2C22C0~~	a aakaa	
			u ccccancan	r arcaronae	~ ~~~ <del>~</del> ~~~~~	
		- www.gcadaa	C CLULICATIA	T ACAMMAMA	~ ~~~~~~~	
	-33	uccyquucci	- uauuucccari		· ~~+~~+~~	-11 .
		- gcaggaacat	- uuuccaa	' FAFCCGAGA	· ~~+~~~~~~	_ 4
		. gg-ggagalt	. uacuuurrri	. acatacacat	* ***	Andrew Co. 10
		· yyyyayau	: Lactemaca	TAMARCANA -		
12001	aggagggcga	gtacctggaa	gactgatggc	. cccacgtgga	ttttgctaga	gatgaggagg
	J-5-5-55-5	graceacace	ucuaucunii	CCACCCCCC	+	managed as a control of the control
		~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	Lucuumar	COTTOTOTOTO	~-~~~~~~	
			LULLCUARIAC	CACECCCCCC	~~~++~	
12781	cttcacggac	agcggcagcg	tgagccgcga	ctcgtgcctg	ggctacctgc	tggtggcgcc
	3	uugeegatuu	actactions	FARRARAAA	~~~~	
13801	tategggege	ctgatgtaag	aatctdaass	aataaaaaa	ffcgctcacc ( ggtactcacc (	rgcgcccccg
		- San Carra		aacaaaagac	ggtactcacc a	aaggccatgg

75/153

13861 cgaccagcgt gcgttcttct ctgttgtttg tagtagtatg atgaggcgcg tgtacccgga 13921 gggtcctcct ccctcgtacg agagcgtgat gcagcaggcg gtggcggcgg cgatgcagcc 13981 cccgctggag gcgccttacg tgccccgcg gtacctggcg cctacggagg ggcggaacag 14041 cattegttac teggagetgg caccettgta cgataccace eggttgtace tggtggacaa 14101 caagteggeg gacategeet egetgaacta eeagaaegae cacageaact teetgaceae 14161 cgtggtgcag aacaacgatt tcaccccac ggaggccagc acccagacca tcaactttga 14221 cgagcgctcg cggtggggcg gccagctgaa aaccatcatg cacaccaaca tgcccaacgt 14281 gaacgagttc atgtacagca acaagttcaa ggcgcgggtg atggtctcgc gcaagacccc 14341 caacggggte acagtaacag atggtagtca ggacgagctg acctacgagt gggtggagtt 14401 tgagctgccc gagggcaact tctcggtgac catgaccatc gatctgatga acaacgccat 14461 catcgacaac tacttggcgg tggggcggca gaacggggtg ctggàgagcg acatcggcgt 14521 gaagttcgac acgcgcaact tccggctggg ctgggacccc gtgaccgagc tggtgatgcc 14581 gggcgtgtac accaacgagg cettecacce cgacategte etgetgeeeg getgeggegt 14641 ggacttcace gagageegee teageaacet getgggeate egcaagegge agecetteea 14701 ggagggcttc cagatcctgt acgaggacct ggagggggc aacatccccg cgctgctgga 14761 cgtggacgcc tacgagaaaa gcaaggagga tagcgccgcc gcggcgaccg cagccgtggc 14821 caccgcctct accgaggtgc ggggcgataa ttttgctagc gccgcgacac tggcagcggc 14881 cgaggcggct gaaaccgaaa gtaagatagt gatccagccg gtggagaagg acagcaagga 14941 gaggagetac aacgtgeteg eggacaagaa aaacacegee tacegeaget ggtacetgge 15001 ctacaactac ggcgaccccg agaagggcgt gcgctcctgg acgctgctca ccacctcgga 15061 cgtcacctgc ggcgtggagc aagtctactg gtcgctgccc gacatgatgc aagacccggt 15121 caccttccgc tccacgcgtc aagttagcaa ctacccggtg gtgggcgccg agctcctgcc 15181 cgtctactcc aagagcttct tcaacgagca ggccgtctac tcgcagcagc tgcgcgcctt 15241 cacctegete aegeaegtet teaacegett ceeegagaae cagateeteg ttegeeegee 15301 egegeceace attaccaceg teagtgaaaa egtteetget etcacagate aegggaceet 15361 gccgctgcgc agcagtatcc ggggagtcca gcgcgtgacc gtcactgacg ccagacgccg 15421 cacctgcccc tacgtctaca aggccctggg cgtagtcgcg ccgcgcgtcc tctcgagccg 15481 caccttctaa aaaatgtcca ttctcatctc gcccagtaat aacaccggtt ggggcctgcg 15541 cgcgcccagc aagatgtacg gaggcgctcg ccaacgctcc acgcaacacc ccgtgcgcgt 15601 gegegggeae tteegegete eetggggege ceteaaggge egegtgeget egegeaceae 15661 cgtcgacgac gtgatcgacc aggtggtggc cgacgcgcgc aactacacgc ccgccgccgc 15721 gecegtetee accgtggacg cegteatega cagegtggtg geegacgege geeggtacge 15781 ccgcgccaag agccggcggc ggcgcatcgc ccggcggcac cggagcaccc ccgccatgcg 15841 cgcggcgcga gccttgctgc gcagggccag gcgcacggga cgcagggcca tgctcagggc 15901 ggccagacgc gcggcctccg gcagcagcag cgccggcagg acccgcagac gcgcggccac 15961 ggcggcggcg gcggccatcg ccagcatgtc ccgccgcgg cgcggcaacg tgtactgggt 16021 gegegacgee gecaceggtg tgegegtgee egtgegeace egeceeete geacttgaag 16081 atgctgactt cgcgatgttg atgtgtccca gcggcgagga ggatgtccaa gcgcaaattc 16141 aaggaagaga tgctccaggt catcgcgcct gagatctacg gcccggcggc ggtgaaggag 16201 gaaagaaagc cccgcaaact gaagcgggtc aaaaaggaca aaaaggagga ggaagatgtg 16261 gacggactgg tggagtttgt gcgcgagttc gcccccggc ggcgcgtgca gtggcgcggg 16321 cggaaagtga aaccggtgct gcgacccggc accacggtgg tettcacgcc cggcgagcgt 16381 teeggeteeg etteetaegae gaggtgtaeg gggaegagga eateetegag 16441 caggeggeeg aacgtetggg egagtttget taeggeaage geageegeee egegeeettg 16501 aaagaggagg cggtgtccat cccgctggac cacggcaacc ccacgccgag cctgaagccg 16621 ggcgaggatc tgtacccgac catgcagctg atggtgccca agcgccagaa gctggaggac 16681 gtgctggage acatgaaggt ggaccccgag gtgcagcccg aggtcaaggt gcggcccatc 16741 aagcaggtgg ccccgggcct gggcgtgcag accgtggaca tcaagatccc cacggagccc 16801 atggaaacgc agaccgagcc cgtgaagccc agcaccagca ccatggaggt gcagacggat 16861 ccctggatgc cggcaccggc ttccaccacc cgccgaagac gcaagtacgg cgcggccagc 16921 ctgctgatgc ccaactacgc gctgcatcct tccatcatcc ccacgccggg ctaccgcggc 16981 acgcgcttct accgcggcta caccagcagc cgccgccgca agaccaccac ccgccgccgc 17041 cgtcgtcgca cccgccgcag cagcaccgcg acttccgccg ccgccctggt gcggagagtg 17101 taccgcagcg ggcgcgagcc tctgaccctg ccgcgcgcgc gctaccaccc gagcatcgcc 17161 atttaactac cgcctcctac ttgcagatat ggccctcaca tgccgcctcc gcgtccccat 17221 tacgggctac cgaggaagaa agccgcgccg tagaaggctg acggggaacg ggctgcgtcg 17281 ccatcaccac eggeggegge gegecateag caageggttg gggggagget teetgeeege 17341 gctgatgccc atcatcgccg cggcgatcgg ggcgatcccc ggcatagctt ccgtggcggt

17401						
17401	geaggeetet	cagegeeact	gagacacagc	ttggaaaatt	tgtaataaaa	aatggactga
17501	cgctcctggt	cctgtgatgt	gtgtttttag	atggaagaca	tcaatttttc	gtccctggca
17521	ccgcgacacg	gcacgcggcc	gtttatgggc	acctggagcg	acatcggcaa	cagccaactg
T\287	. aacgggggc	, ccttcaattg	gagcagtctc	tggagcgggc	ttaagaattt	cagatecaca
T\041	. ctcaaaacct	: atggcaacaa	ggcgtggaac	agcagcacag	ggcaggcgct	gagggaaaag
T / / 01	. ctgaaagagd	: agaacttcca	gcagaaggtg	gtcgatggcc	taaceteaaa	catcaacggg
T1\07	. gtggtggacc	: tggccaacca	ggccgtgcag	aaacagatca	acagegget.	agacacaatc
T/877	. ccgcccgcgg	, ggtccgtgga	gatgccccag	gtggaggagg	agctgcctcc	cctggacaag
17881	cgcggcgaca	agcgaccgcg	tcccgacgcg	gaggágacgc	tactaacaca	cacqqacqaq
17941	ccgccccgt	acgaggaggc	ggtgaaactg	ggtctgccca	CCacacaaca	catageaeet
18001	. ctggccaccg	gggtgctgaa	acccagcagc	agcagcagcc	gacccacasc	cctagactta
18061	cctccgcctg	cttcccgccc	ctccacagtg	gctaagcccc	taccaccaat	aaccatcaca
18121	. tcgcgcgccc	cccgaggccg	CCCCGaaaca	aactggcaga	acactetasa	caccatcata
18181	gatetagaag	tgcagagtgt	daadcaccac	cactactatt	aaaaaaaat	ataggatta
18241	acttacttat	ctgtgtgtat	atgtatgtcc	accascaas	addagacact	gragegerea
18301	caccaaatta	caagatggcc	accccatcca	tactaccasa	aygaygayga	agaggegege
18361	CCGGGCGGG	cgcttcggag	tecctaecta	cacatatast	graggegrae	argeacateg
18421	acacctactt	cactotoggag	aaccegagee	cgggtetggt	gcagttegee	cgcgccacag
18481	taaccacca	cagtctgggg	aacaagttta	ggaaccccac	ggrggcgccc	acgcacgatg
18541	acacctacta	ccgcagccag	cygccyacyc	tgegettegt	gecegtggae	cgcgaggaca
18601	tagagagaga	gtacaaagtg	cyctacacge	rggccgrggg	cgacaaccgc	gtgctggaca
19661	agecageae	ctactttgac	accegeggeg	tgctggatcg	gggccctagc	ttcaaaccct
19721	acteeggeac	cgcttacaac	agcerggere	ccaagggagc	gcccaacact	tgccagtgga
10721	tacacaaage	tgatggtgat	actggtacag	aaaaaaccta	tacatatgga	aatgcgcctg
100/1	rgcaaygcar	tagtattaca	aaagatggta	ttcaacttgg	aactgacact	gatgatcagc
10041	ccatttatge	agataaaact	tatcaaccag	agcctcaagt	gggtgatgct	gaatggcatg
10061	acateactgg	tactgatgaa	aaatatggag	gcagagctct	caagcctgac	accaaaatga
10001 T030T	agecetgeta	tggttctttt	gccaagccta	ccaataaaga	aggaggtcag	gcaaatgtga
19021	aaaccgaaac	aggcggtacc	aaagaatatg	acattgacat	ggcattcttc	gataatcgaa
19081	grgcagerge	ggctggcctg	gccccagaaa	ttgttttgta	tactgagaat	gtggatctgg
19141	aaactccaga	tactcatatt	gtatacaagg	cgggcacaga	tgacagcagc	tcttctatca
19201	atttgggtca	gcagtccatg	cccaacagac	ccaactacat	tggctttaga	gacaacttta
T359T	tcgggctcat	gtactacaac	agcactggca	acatgggcgt	actaactaat	caggettee
19377	agctgaatgc	tgtggtggac	ttgcaggaca	gaaacactga	actotectae	cagetettge
19381	ttgactctct	gggcgacaga	accaggtatt	tcagtatgtg	gaatcaggcg	gtggacagct
19441	atgaccccga	tgtgcgcatt	attgaaaatc	acqqtqtqqa	ggatgaactc	cctaactatt
TADOT	getteeect	ggatgctgtg	ggtagaactg	atacttacca	gggaattaag	accaataata
TADAT	ctgatcaaac	cacctggacc	aaagatgata	ctattaataa	toctaatoaa	ttgggcaagg
TA95T	gcaatccttt	cgccatggag	atcaacatcc	aggccaacct	ataacaaaac	ttcctctacq
TAGRT	cgaacgtggc	gctgtacctg	cccgactcct	acaagtacac	gccggccaac	atcacactac
19/4T	cgaccaacac	caacacctac	gattacatga	acooccocot	aataacaccc	teactaataa
TARUT	acgcctacat	caacatcggg	gcgcgctggt	cactagaccc	catggacaac	gtcaacccct
TAGOT	tcaaccacca	ccgcaacgcg	ggcctgcact	accoctccat	actectagge	aacqqqqqct
13371	acgtgccctt	ccacatccag	gtgccccaaa	agttettege	catcaagage	ctcctactcc
TAART	rgcccgggrc	ctacacctac	gagtggaact	tccqcaaqqa	cotcaacato	atcctgcaga
2004I	getecetegg	caacgacctg	Cgcacggacg	gggcctccat	caccttcacc	agcatcaacc
SOTOT	tctacgccac	cttcttcccc	atggcgcaca	acaccocctc	cacactegag	accatactac
SOTPT	gcaacgacac	caacgaccag	tccttcaacq	actacctctc	aacaaccaac	atoctctacc
20221	ccatcccggc	caacgccacc	aacgtgccca	tetecatece	ctcccccac	tagaccacct
20281	tccgcggatg	gtccttcacg	cacctcaaga	Cccacaaaac	acceteacte	aactccaaat
20341	tcgaccccta	cttcgtctac	tcgggctcca	tcccctacct	cascaccacc	ttctacctca
20401	accacacctt	caagaaggtc	tccatcacct	tegactecte	catagacatag	cccaccica
20461	accgcctcct	gacgcccaac	gagttcgaaa	teaacccac	catacagaaga	anagage and
20521	acqtqqccca	gtgcaacatg	accaarract	arttactact	cyccyacyya	gaggggtaca
20581	acatcggcta	ccagggcttc	tacgtgccc	aggggtaggt	agacycty	tagtagttata
20641	tccccaactt	ccagcccatg	addddddadd	tcatacase=	ggaccgcarg	accectect
20701	aggccatcac	cctggcctac	Cadcacaaca	actoggacya	ggtcaactac	ataggactacc
20761	ccatgcacca	gggacagccc	taccccccca	actaccceta	coccatasta	gggaagaaga
				accepted	coogcicate	ggcaagagcg

2002						
2082.	l ccgtcgccaq	g cgtcacccag	aaaaagttcc	tctgcgaccg	ggtcatgtgg	cgcatcccct
2000.	Liciccagcaa	i cttcatgtcc	atgggcgcgc	tcaccgacct	COOCCAGAAC	atactetaca
2094.	L ccaactccg	: ccacgcgcta	gacatgaatt	tcqaaqtcqa	ccccatogat	gagtccaccc
2100.	Licietatgi	: tgtcttcgaa	gtcttcgacg	tcatccaaat	gcaccagccc	caccacaaca
21001	. ccategagge	c cgtctacctg	cgcacgccct	teteaaceaa	caacdccacc	acctaagece
2112	- cyclettget	: tcttgcaaga	tgacqqcctq	tacaaactcc	gacaaacaaa	ageteaggge
21101	. catecteege	: gacctgggct	gegggeeeta	cttcctaaac	accttccaca	agggetteec
21241	gggattcato	gccccgcaca	agetggeetg	caccatcatc	aacacoocco	accacaaaac
21301	cgggggcgag	cactggctgg	ccttcaccta	gaacccgcgc	tcccacacct	gccgcgagac
21361	. cgaccccttc	gggttctcgg	acgagegeet	caagcagatc	taccagttcg	actaccece
21421	cctgctgcgc	cgcagcgccc	taaccaccaa	ggaccgctgc	atcaccctaa	agracgaggg
21481	. ccagaccgto	cagggtccgc	actcaaccac	ctacagacte	ttctactace	tattaataa
21541	cgccttcgtc	cactggcccg	accoccccat	adacaadaac	cccaccatca	agttggtga
21601	gggggtgccc	aacggcatgc	tccagtcgcc	ccadatadaa	cccaccatga	accegacigac
21661	ggaggcgctc	taccgcttcc	tcaacgccca	ctccacctac	tttcactcac	aggggggggg
21721	. catcgagaac	gccaccgcct	tcgaccgcat	ceeegeeeac	atataaaaa	tetetete
21781	tgaatgettt	attcataata	aacaccacat	atttatagae	acgtataccy	cgtgtgtatg
21841	ttatttagaa	atcgaagggg	ttctgccgac	teteggeta	cccccccga	ggetetgaet
21901	tocogaacto	gtacttgggc	accecttca	actoggogast	ccccgcggge	agggatacgt
21961	gatcaaaaa	cgagtcgctc	cacaccttgc	acceggggae	cagcagette	ggcacgggga
22021	gcacaaaaat	cttgaaatcg	cacagerrac	gcgrgagrtg	cagggcgccc	agcaggtcgg
22081	caaaattaca	gcactggaac	agetgggac	cegegttetg	cgcgcgggag	ttgcggtaca
22141	catcaataat	gcactggaac	tacaattaat	cegggtgett	cacgetegee	agcaccgtcg
22201	tacaggtgta	gccctccacg	ataggacce	eggegeegge	catecegaag	ggggtcatct
22261	agaaggteeg	ccgccccatg	ccgggcacgc	agecgggett	grggrrgcaa	tcgcagtgca
22321	aagceteeag	catcatctgg	geetgetegg	ageteatgee	cgggtacatg	gccttcatga
22381	aggacttgct	ctggcggaag	tteeteeee	cettgeegee	ctcggtgaag	aagaccccgc
22441	cattattaac	agagaactgg	accatacas	ageeggegte	gtgcacgcag	cagcgcgcgt
22501	cacaattata	cagctgcacc	acgetgegee	cccagcggtt	ctgggtgatc	ttggcccggt
22561	actectteta	cttcagcgcg	cgctgcccgt	tetegetege	cacatccatc	tcgatcgtgt
22621	accontacta	gatcatcacg	greeegrgea	ggcatcgcag	cttgccctcg	gcctcggtgc
22681	accegegeag	ccacagegeg	cageeggtge	actcccagtt	cttgtgggcg	atctgggagt
227711	taaaaataa	gaagccctgc	aggaagegge	ccatcatcgt	ggtcagggtc	ttgttgctgg
22741	agaaggccag	cgggatgccg	eggtgeteet	cgttcacata	caggtggcag	atgcggcggt
22861	acacctegee	ctgctcgggc	atcagctgga	aggcggactt	caggtcgctc	tccacgcggt
22001	acceggeceae	cagcagcgtc	atgacttcca	tgcccttctc	ccaggccgag	acgatcggca
22321	ggcccagggg	gttcttcacc	gccgttgtca	tettagtege	cgccgctgag	gtcagggggt
22301	cgttetegte	cagggtctca	aacactcgct	tgccgtcctt	ctcggtgatg	cgcacggggg
23101	gaaagetgaa	gcccacggcc	gccagctcct	cctcggcctg	cctttcgtcc	tcgctgtcct
23161	ggergargre	ttgcaaaggc	acatgcttgg	tcttgcgggg	tttctttttg	ggcggcagag
73701	geggeggegg	agacgtgctg	ggcgagcgcg	agttctcgct	caccacgact	atttcttctt
22221	caragecate	gtccgagacc	acgcggcggt	aggcatgcct	cttctggggc	agaggcggag
22241	gegaeggget	ctcgcggttc	aacaaacaac	tggcagagcc	ccttccgcgt	tegggggtge
22341	geteetggeg	gcgctgctct	gactgacttc	ctccgcggcc	ggccattgtg	ttctcctagg
23401	gagcaacaag	catggagact	cagccatcgt	cgccaacatc	gccatctgcc	cccgccgccg
4340I	ccgacgagaa	ccagcagcag	aatgaaagct	taaccgcccc	accacccaac	cccacctcca
23321	acgeegeege	ggccccagac	atgcaagaga	tggaggaatc	catcgagatt	gacctgggct
7220T	acgigacgee	cgcggagcac	gaqqaqqaqc	tagcagcaca	Cttttcaccc	ccacaacaca
23041	accaccaaga	gcagccagag	caggaagcag	agagggagga	acaacaaact	agactcaaac
23/UI	arggegaeta	cctgagcggg	gcagaggacg	toctcatcaa	acatetaace	caccaataca
43/01	Lualugudaa	ggacgcgctg	ctcaaccaca	ccgaggtgcc	cctcaccata	acadadates
Z30ZI	geegegeeta	cgagcgcaac	ctcttctccc	cacacatacc	CCCCSSGCGC	Cancecaaca
7300T	gcaccugcga	gcccaaccca	CCCCCcaact	tetacecont	attacacata	~~~~~~~
<b>4334</b> 1	tuuccaccta	ccacccccc	EECaagaacc	aaaggatggg	~~+~+~~	~~~~~~~
22001	gcacccgcgc	cyacycucug	Cicaacctgg	arcccaacac	ccacchacch	matatement.
27001	CCLLygaaya	ggccccaag	atettegagg	atctaaacaa	caacaaact	COOOCCOCCO
74777	acgetetgea	ayyaagcgga	gaggagcatg	agcaccacag	caccetaata	manttmman
74101	gegacaaege	gcgcctggcg	gtactcaaac	gcacggtcga_	actasacasa	ttcccctacc
7474T	eggegeteaa	ccrgccccc	aaqqtcatqa	acaccatcat	agaccaggta	ctcatcaacc
24301	gcgcctcgcc	cctctcggat	gaggacatgc	aggaccccga	gageteggae	gagggcaagc
				_		

SEQ ID NO: 5 78/153

2436	1 ccgtggtca	g cgacgagcag	g ctggcgcgct	ggctgggag	gagtagcacc	. ccccagagct
2442	- cyyaayayc	y ycycaagct	: atgatggccc	r taateetaai	. daccatage	r ctccsatata
2440	i egegeeget	i citegeega	gcagagacco	: tacacaaaa	CCACCACACA	ctocactacc
2434	L ccccayye	a cyggtttgtg	i cgccaggcct	: gcaagatctd	: caacotooac	ctcaccaaca
2400	i tygteteet	a catgggcato	: ctgcacgaga	. accacctaa	I dcadaacdto	ctacecece
2400.	r cccracacaca	y yyaygcccgo	: cgcgactaca	i tecacaacta	, catchaccto	tacctctccc
2412	L acacetyge	a gacgggcatg	i gacatataac	agcagtgcct	. ddaddadcad	ascetassa.
24/0.	. agetetgea	a gctcctgcac	, aaqaacctga	aggedetata	r daccdddtto	andanaaa.
2404.	L ccaccgeet	. ggacetgge	gacctcatct	tececaaaca	r ectacaacta	accetacas
2470.	ı acyyacıycı	. cgactttatc	f agtcaaagca	. tattacaaaa	ctttcactct	ttastaataa
2490.	L aacyctccgg	y gateetgeed	gccacctact	ceaeactaca	' ctcaaactta	atacacatas
2302.	. cetteegega	* grgcccccc	r ccactctaga	. gccactgcta	cctactacaa	ctagggaagt
2000	. acceggeee	i ccacicggac	grgarcgagg	acatcaacaa	caaaaatcta	ctcaeataca
2014	ı acıyceyetç	, caacctctgc	acaccacaca	geteectaac	ctocaacccc	cacctcctcc
2320	. gcgagaccc	a gattategge	accttcgagt	tacaaaaacca	Caacasaaaa	aaccccccctc
2000	. egadactcat	, ceeggggerg	tggacctcgg	cctacttaca	caadttcata	caaaaaaaat.
23323	accatecett	. cyagatcagg	ttctacqaqq	accaatecca	accacccaaa	accassatat
23301	. eggeetgegt	. catcacccag	gaaaccatcc	tααcccaatt	gcaagccatc	cacaaataaa
27441	. yccaayaatt	. tetgetgaaa	aagggccacg	gaatetacet	ggacccccag	accadadada
2000	. agcicaaccc	: caycttccc	caggatgccc	CGaggaagga	gcaagaaget	naaantooan
2001	. ctgccgccgc	: cygaggattt	ggaggaaqac	taggagagca	atcadacada	nennennenn
23021	. aryyaayaci	. yyyacagcac	tcaggcagag	gaggagagg	tocaagacag	teterasarar
23001	. yayytyyayy	, ayyayycaga	ggaaqaaqca	accaccacca	gaccotcotc	ctcaacaaaa
27/41	. aaaycaayca	ı gcacggatac	catctccact	ccaaatcaaa	atcacaacaa	CCCCCCCCC
23001	. aytayytyyy	acgagaccgg	gcacttccca	aaccccacca	CCCSGSCCGG	taagaaggaag
25001	. cyycaygyai	. acaagteetg	gcgggggcac	aaaaacocca	teateteeta	cttaceeacc
2000	gcgggggca	acateteett	cacccqccqc	tacctoctct	tecacegegg	aatassatta
23301	Coccycaaca	. ccttgcatta	ctaccgtcac	ctccacagee	cctactacto	tttccsscss
20041	yayycayaaa	. cccagcagca	gcagaaaacc	agcggcagca	acaactaaaa	aatooagaaga
20101	ggcggcaggc	ggactgagga	tcacaacaa	casaccaaca	Cadacccddd	aggtgaggaa
20101	ccggatett	cccaccctct	argccatctt	ccagcagagt	Cadadacsaa	accaccaact
2022	gadagicaag	aaccyllete	tgcgctcact	caccccccact	tatatatata	acaacacaa
20201	agaccaaccc	cagcgcactc	tcgaggacgc	cgaggetete	ttcaacaagt	actocococt
20341	Cacicicada	gagtagcccg	cgcccgccca	cacacagaaa	aaggcgggaa	ttacatcaca
FOAOT	accugegeee	ttcgcccgac	catcatcato	agcaaagaga	ttcccacaca	ttagatataa
20407	agetaceage	cccagatggg	cctaaccacc	gacaccacca	aggactactc	Caccoggata
20321	uactyyctta	gegeeggee	cgcgatgatc	tcacoootoa	atgacatccg	CUCCCCCCCC
20301	aaccagatac	teetagaaca	gtcagcgatc	accoccacoc	cccaccatca	ccttaateee
20041	cgtaattggc	ccgccgccct	ggtgtaccag	gaaattcccc	adcccacdac	catactactt
20/01	ccycgagacg	cccaggccga	agtccagctg	actaactcag	atatecaact	aaccaaaaa
20/01	gccgccccgc	gregreaceg	ccccactcaa	ggtataaagc	aactaataat	CCGBGGGGGG
20021	ggcacacage	ccaacgacga	ggtggtgagc	tettegetag	atctacaacc	taecaaeata
Z0001	riccaacteg	ccggatcggg	gagatettee	ttcacccctc	atcagggggt	aataaattta
20347	gagagitegt	ccccgcagcc	ccactcaaat	ggcatcggca.	ctctccaatt	aataanaaa
Z/001	Licacideet	cggtctactt	caaccccttc	tecaacteee	ccaaccacta	CCCCCCCCC
2/001	cccaccccga	acticgacge	catcagcgag	tcaataaaca	actacaatta	aatotooost
2/121	ggrggcgcag	ctgacctage	tcaacttcaa	cacctggace.	actotogoot	ataataaaaa
2/101	Ciccigcage	agegeeagaa	gttcacctgc	Ctaatcaaaa	tcaaccccat	catestases
2/247	caycagicgg	gcgataccaa	ggggtgcatc	cactoctcct	acaactcccc	CCactacata
Z1301	cacactetga	tcaagaccct	ctacaacete	cacaacataa	teccestess	atsates
2/301	certatecag	tgaaataaag	atcatattga	tgatttgagt	ttaataaaaa	taaagaahaa
2/441	cctacttyaa	accegatacc	aggtctctat	ccatottttc	taccaacacc	acttonetes
2/401	CCCCCCC	gctctggtac	tgcaggcccc	agcagactac.	aaacttcctc	Cacacaca
2/341	aggggatgtc	aaattcctcc	tatccctcaa	tetteattt	atcttctatc	20210100
27661	adayegegee	cgggtggatg	atgacttcga	ccccgtctac	ccctacgatg	cagacaacgc
2,001	accgaccyty	cccttcatca	acccccctt	catatatha	astanattee	2202022000
~!!41	cccgggggtg	ctgtccctgc	gtctggccga	tcccgtcacc	accaagaacg	gggaaatcac

0==0						
2778	1 cctcaagct	g ggagatggg	g tggacctcga	a ctcctcggga	a aaactcatct	ccaacacggc
2704	i caccaagge	u geegeeet	: tcaqtttttc	: caacaacac	atttccctts	20210010
2/30	1 CCCCCCCCCC	c aacaacaat	i qaaaqttaq	i catqaaaqt	actortroar	tassastast
2,50	* agacacaga	- LLyCLadaaa	t cacttottot	. agcttatgga	, caadatttad	7 02202220
2002	ı cacıygıycı	cttgttgcc	: aactaqcato	: cccacttact	tttmatames	* *******
	- cyccccaa	- LLaggedaate	i daccattdaa	agtggatgca	a aatamamtma	303400044
2024	r caacagagg	<sup>2</sup> Cucuatgeta	i ctaccacaaa	agatgcactc	t daameen t	+==~++~~~
2020.	r caargerate	, acatttatag	r gaaatgccat	: gggtgtcaat	· attoatacac	* 22222444+
2020.	ı ycaacteyy	: accactagta	l ccqtcqcaqa	l tottaaaaac	' octtacccc	tagaaatgaa
2032.	ı acııyyaycı	- ggtctcacat	ttgacagcac	: aggtgcaatt	attacataca	acasaataa
2030.	Lugacaaycc	- acactatgga	ı ccacaqccqa	Licecetetee	aattotooos	· +>+>+++++
28441	l aaaggatgct	aagcttacac	tttgcttgac	: aaagtgtggg	actegetate	tgggcactgt
28501	l ttccctcata	gctgttgata	ctggcagttt	aaatcccata	. agccagactc	taaccactgc
28561	l tcttgtctca	cttaaattco	atgcaaatgc	anttttacas	acaggaacag	cactagactc
28623	l agactattgo	r aatttcagac	agggagatgt	tacacctcct	ageageteaa	cactagacte
28681	l aggtttcatc	cccaatctaa	. aagcataccc	taeacccgc	gaayeetata	caaaaagtca
28741	cattettee	r aaagtgtacc	tacatooco	tagagagaaa	agrggagerg	caaaaagtca tcattattac
28801	l tttcaatgaa	acaagtgatg	aatetteeae	ttacayycada	ccactggace	ggcagtgggg
28861	ggctgatcaa	tataaaaato	aaececttaa	cractytatt	aactttcaat	ggcagtgggg cctatattgc
28921	taaagaataa	accccactct	atacaccege	tatatatata	tteacettt	tgaaacacaa
28981	. aataaaataa	anttcaanto	ttttattat	tacate	gaaaaaactc	tgaaacacaa
29041	ttttcctcca	ccctcccaa	agatggac	ccaacagttt	tacaggattc	gagcagttat
29101	Catctgaatg	ccettcctagg	tagagatag	caccaccete	tccccccgca	cagccttgaa
29161	acasaccsat	ctccccgccga	tasaaaaa	tttggtctcc	acgttccaca	cagtttcaga
29221	ctcacacctc	eccyggicgg	ccaygyayat	gaaaccctcc	gggcactccc	gcatctgcac
29281	acadagaac acadaagaac	aacagctgag	garigieete	ggrggrcggg	atcacggtta	tctggaagaa
29341	annececae	ggcggcggga	accatagice	gcgaacggga	teggeeggtg	gtgtcgcatc
29401	tecaeeeset	geageegeeg	regeegeege	tccgtcaagc	tgctgctcag	ggggtcgcatc
29461	CCCCAGGGGCC	agatagaat	gatgeceaeg	gccctcagca	tcagtcgtct	ggtgcggcgg
~	gegeageage	gcatycygat	ctcactcaaa	Ecochocach	acatacaaca	G3GG3GGG
27523	aggingnica	acagiccata	gttcaacaco	ctccagccga	aactcatcac	aaaaaaaa aa
22301	cracecacge	ggccgccgca	ccagateete	aggtaaatca	antagegggg	aataanaan
	acguigecta	Lycacalgal	CECCETAGAC	atotoocoot	tasaasaata	~~~~~
20,01	accaccccc	ggulyaadal	acaaccccaa	atratretre	MM33000000	
,	geceegeeeg	CCatucaucu	aadadacccc	aaateeeaaa	33 + ~~~~~~ + h	
	-geregeace	- cy cygaccat	CLUGGAGGEG	aacaactcta	tattaaaaa	
	arguicatgu	acciccicad	Cactereage	TCCTCCCCCC	tassssss	
	~~gggguucc	Cttucaddac	aucuaacccc	Transarana	~~~~	
	would be a control of the control of	Lydacaddd	alcoraarca	MACCAMCAMA	~~+~~+~~	
	gegeggeee	Cadicion	academent	ADDUDUDEE	aaaaa baaaa	
	39-999	u cog cg cccq	Cuaccorarr	argargeagt.	taatttaaaa	
	- cogccgcag	cagaacctqq	LCCGGGGGGG	CCSCSCCCS+	^~~~~~~~~	
	ggaacgc	coggicatica	auttoraaaa	Carceacter	atasasas	
	uugggcctca	ggagtgatga	audecccarc	atacctasta	artatastas	
20007	cgcggaacgg	gccagaccca	gccagatgat.	ocaattttot	taratttara	+~~~~~~~
J J 12 1	ggugggaaga	acayyaayaa	CCargarraa	Cttttaatcc	22244444	
30404	uuaatyaaya	Legeggagae	uucacctctc	acceceacta	tattaataa	
00012	cuggicaaag	gigalacycl	LUCCGAGATG	ttccacacata	acttacae.	
0000	gegeacacee	ayaaacaaya	Caaranchaa	adcadaadaa	++~+~	
3000-	catgulacat	Lectiquatea	CCCccarara	attttcattt	ttaaaaaahh	
	wac tag t ttt	Lyayytaaat	CCdadccadc	Catrataaar	200teen	
00.01	ouccygcatt.	Citadycaca	CCCccaraar	trraaratat	totootooto	
00011	uguagattua	Caaucuuaat	atcaaaatet	Ctacacacat	~~~~~~~	
	aucuacigia	agtactctt	Catatectet	ccgaaatttt	tagggatagg	2002002002
	acaagactag	ggcaagccac	autacacara	aaccdaadta	ataaaaata	
J T O C T	aatycaayac	Lyctataage	atgetaacha	gacccggtga	tatattaaaa	ataaataaaa
31081	agaaaatcgc	ccaggcaatt	tttaagaaaa	tcaacaaaaa	aaaaatcctc	caggtgcacg
			**	- 3		

21145						
21141	tttagagcct	cgggaacaac	gatggagtaa	atgcaagcgg	tgcgttccag	catggttagt
31201	tagctgatct	gtagaaaaaa	acaaaaatga	acattaaacc	atgctagcct	ggcgaacagg
31261	tgggtaaatc	gttctctcca	gcaccaggca	ggccacgggg	tctccggcac	gaccctcgta
31321	aaaattgtcg	ctatgattga	aaaccatcac	agagagacgt	tecegatage	caacataaat
31381	gattcgacaa	gatgaataca	cccccggaac	attogcotco	acasatass	aaaaacaccc
31441	aaggaagcaa	taagggagta	caatootoao	tetessetee	2022222	taaastaaa
21505		caaggeaeea	caacgcccag	cccaagecc	aycaaaycga	Lgccatgcgg
31201	atgaagcaca	aaattctcag	gtgcgtacaa	aatgtaatta	ctccctcct	gcacaggcag
31561	caaagccccc	gatccctcca	ggtacacata	caaagcctca	gcgtccatag	cttaccgage
31621	agcagcacac	aacaggcgca	agagtcagag	aaaggctgag	ctctaacctg	tccaccccct
31681	ctctgctcaa	tatatagccc	agatctacac	tgacgtaaag	gccaaagtct	aaaaataccc
31741	gccaaataat	cacacacgcc	cagcacacgc	ccagaaaccg	gtgacacact	caaaaaaata
31801	cgcgcacttc	ctcaaacgcc	caaactocco	tratttrag	attacasaaa	taggtgatga
21061		<b>*</b>	daddegeeg	ccacceegg	geeceacge	tacgicatea
21001	aaattcgact	ttcaaattcc	gtcgaccgtt	aaaaacgtcg	cccgccccgc	ccctaacggt
31921	cgccgctccc	gcagccaatc	accgccccgc	atccccaaat	tcaaatacct	catttgcata
31981	ttaacgcgca	ccaaaagttt	gaggtatatt	attgatgatg		

- ${\tt 1} \quad {\tt ATGAAGCGCA} \quad {\tt CCAAAACGTC} \quad {\tt TGACGAGAGC} \quad {\tt TTCAACCCCG} \quad {\tt TGTACCCCTA} \\ {\tt TGACACGGAA}$
- 61 AGCGGCCCTC CCTCCGTCCC TTTCCTCACC CCTCCCTTCG TGTCTCCCGA
- 121 GAAAGTCCCC CCGGGGTCCT GTCTCTGAAC CTGGCCGAGC CCCTGGTCAC TTCCCACGGC
- 181 ATGCTCGCCC TGAAAATGGG AAGTGGCCTC TCCCTGGACG ACGCTGGCAA
- 241 CAAGATATCA CCACCGCTAG CCCTCCCCTC AAAAAAACCA AGACCAACCT
- 301 ACCTCATCCC CCCTAACTGT GAGCACCTCA GGCGCCCTCA CCGTAGCAGC
- 361 CTGGCGGTGG CCGGCACCTC CCTCACCATG CAATCAGAGG CCCCCTGAC AGTACAGGAT
- 421 GCAAAACTCA CCCTGGCCAC CAAAGGCCCC CTGACCGTGT CTGAAGGCAA
- $481\,$  CAAACATCGG CCCGCTGAC GGCCGCTGAC AGCAGCACCC TCACAGTCAG TGCCACACCA
- 541 CCCCTTAGCA CAAGCAATGG CAGCTTGGGT ATTGACATGC AAGCCCCCAT TTACACCACC
- 601 AATGGAAAAC TAGGACTTAA CTTTGGCGCT CCCCTGCATG TGGTAGACAG CCTAAATGCA
- 661 CTGACTGTAG TTACTGGCCA AGGTCTTACG ATAAACGGAA CAGCCCTACA
- 721 TCAGGTGCCC TCAACTATGA CACATCAGGA AACCTAGAAT TGAGAGCTGC AGGGGGTATG
- 781 CGAGTTGATG CAAATGGTCA ACTTATCCTT GATGTAGCTT ACCCATTTGA
- 841 AATCTCAGCC TTAGGCTTGG ACAGGGACCC CTGTTTGTTA ACTCTGCCCA CAACTTGGAT
- 901 GTTAACTACA ACAGAGGCCT CTACCTGTTC ACATCTGGAA ATACCAAAAA GCTAGAAGTT
- 961 AATATCAAAA CAGCCAAGGG TCTCATTTAT GATGACACTG CTATAGCAAT
- 1021 GATGGGCTAC AGTTTGACTC AGGCTCAGAT ACAAATCCAT TAAAAACTAA
- 1081 GGACTGGATT ATGACTCCAG CAGAGCCATA ATTGCTAAAC TGGGAACTGG

#### SEQ ID NO: 6

- 1141 GACAACACAG GTGCCATCAC AGTAGGCAAC AAAAATGATG ACAAGCTCAC CTTGTGGACC
- 1201 ACACCAGACC CATCTCCTAA CTGTAGAATC TATTCAGAGA AAGATGCTAA ATTCACACTT
- 1261 GTTTTGACTA AATGCGGCAG TCAGGTGTTG GCCAGCGTTT CTGTTTATC TGTAAAAGGT
- 1321 AGCCTTGCGC CCATCAGTGG CACAGTAACT AGTGCTCAGA TTGTCCTCAG ATTTGATGAA
- 1381 AATGGAGTTC TACTAAGCAA TTCTTCCCTT GACCCTCAAT ACTGGAACTA CAGAAAAGGT
- $1441\,$  GACCTTACAG AGGGCACTGC ATATACCAAC GCAGTGGGAT TTATGCCCAA CCTCACAGCA
- 1501 TACCCAAAAA CACAGAGCCA AACTGCTAAA AGCAACATTG TAAGTCAGGT TTACTTGAAT
- 1561 GGGGACAAAT CCAAACCCAT GACCCTCACC ATTACCCTCA ATGGAACTAA : TGAAACAGGA
- $1621\,$  GATGCCACAG TAAGCACTTA CTCCATGTCA TTCTCATGGA ACTGGAATGG AAGTAATTAC
- 1681 ATTAATGAAA CGTTCCAAAC CAACTCCTTC ACCTTCTCCT ACATCGCCCA AGAATAA

- $1\,$  ATGTCCAAAA AGCGCGTCCG GGTGGATGAT GACTTCGACC CCGTCTACCC CTACGATGCA
- $61\,$  GACAACGCAC CGACCGTGCC CTTCATCAAC CCCCCCTTCG TCTCTTCAGA TGGATTCCAA
- 121 GAGAAGCCCC TGGGGGTGTT GTCCCTGCGA CTGGCCGACC CCGTCACCAC CAAGAACGGG
- $181\,$  GAAATCACCC TCAAGCTGGG AGAGGGGGTG GACCTCGATT CCTCGGGAAA ACTCATCTCC
- $241\,$  AACACGGCCA CCAAGGCCGC CGCCCCTCTC AGTTTTTCCA ACAACACCAT TTCCCTTAAC
- 301 ATGGATCACC CCTTTTACAC TAAAGATGGA AAATTATCCT TACAAGTTTC TCCACCATTA
- 361 AATATACTGA GAACAAGCAT TCTAAACACA CTAGCTTTAG GTTTTGGATC
- 421 CTCCGTGGCT CTGCCTTGGC AGTACAGTTA GTCTCTCCAC TTACATTTGATACTGATGGA
- 481 AACATAAAGC TTACCTTAGA CAGAGGTTTG CATGTTACAA CAGGAGATGC AATTGAAAGC
- 541 AACATAAGCT GGGCTAAAGG TTTAAAATTT GAAGATGGAG CCATAGCAAC CAACATTGGA
- 601 AATGGGTTAG AGTTTGGAAG CAGTAGTACA GAAACAGGTG TTGATGATGC TTACCCAATC
- 661 CAAGTTAAAC TTGGATCTGG CCTTAGCTTT GACAGTACAG GAGCCATAAT GGCTGGTAAC
- 721 AAAGAAGACG ATAAACTCAC TTTGTGGACA ACACCTGATC CATCACCAAA CTGTCAAAATA
- 781 CTCGCAGAAA ATGATGCAAA ACTAACACTT TGCTTGACTA AATGTGGTAG TCAAATACTG
- 841 GCCACTGTGT CAGTCTTAGT TGTAGGAAGT GGAAACCTAA ACCCCATTAC TGGCACCGTA
- 901 AGCAGTGCTC AGGTGTTTCT ACGTTTTGAT GCAAACGGTG TTCTTTTAAC AGAACATTCT
- 961 ACACTAAAAA AATACTGGGG GTATAGGCAG GGAGATAGCA TAGATGGCAC TCCATATACC
- 1021 AATGCTGTAG GATTCATGCC CAATTTAAAA GCTTATCCAA AGTCACAAAG
- 1081 AAAAATAATA TAGTAGGGCA AGTATACATG AATGGAGATG TTTCAAAACC

SEQ ID NO: 7

84/153

1141 ACTATAACCC TCAATGGTAC TGATGACAGC AACAGTACAT ATTCAATGTC ATTTCATAC

1201 ACCTGGACTA ATGGAAGCTA TGTTGGAGCA ACATTTGGGG CTAACTCTTA TACCTTCTCA

1261 TACATCGCCC AAGAATGA

- 1 ATGTCCAAAA AGCGCGTCCG GGTGGATGAT GACTTCGACC CCGTCTACCC CTACGATGCA
- 61 GACAACGCAC CGACCGTGCC CTTCATCAAC CCCCCCTTCG TCTCTTCAGA TGGATTCCAA
- 121 GAGAAGCCCC TGGGGGTGCT GTCCCTGCGT CTGGCCGATC CCGTCACCAC CAAGAACGGG
- $181 \quad {\tt GAAATCACCC} \quad {\tt TCAAGCTGGG} \quad {\tt AGATGGGGTG} \quad {\tt GACCTCGACG} \quad {\tt ACTCGGGAAA} \\ {\tt ACTCATCTCC} \quad$
- 241 AACACGGCCA CCAAGGCCGC CGCCCCTCTC AGTTTTTCCA ACAACACCAT TTCCCTTAAC
- 301 ATGGATACCC CTCTTTACAA CAACAATGGA AAGCTAGGTA TGAAGGTAAC CGCACCATTA
- 361 AAGATATTAG ACACAGATCT ACTAAAAACA CTTGTTGTTG CTTATGGGCA
- 421 ACAAACACCA ATGGTGCTCT TGTTGCCCAA CTAGCATACC CACTTGTTTT TAATACCGCT
- 481 AGCAAAATTG CCCTTAATTT AGGCAATGGA CCATTAAAAG TGGATGCAAA TAGACTGAAC
- 541 ATTAATTGCA AAAGAGGTAT CTATGTCACT ACCACAAAAG ATGCACTGGA GATTAATATC
- . 601 AGTTGGGCAA ATGCTATGAC ATTTATAGGA AATGCCATTG GTGTCAATAT
- 661 AAAGGCCTAC AGTTCGGCAC TTCAAGCACT GAAACAGATG TTAAAAAATGC TTTTTCACTC
- 721 CAAGTAAAAC TTGGAGCTGG TCTTACATTT GACAGCACAG GTGCCATTGT TGCTTGGAAC
- 781 AAAGAAGATG ACAAACTTAC ACTGTGGACC ACAGCCGATC CATCTCCAAA CTGTCACATA
- 841 TATTCTGCAA AGGATGCTAA GCTTACACTC TGCTTGACAA AGTGTGGTAG TCAAATCCTA
- 901 GGCACTGTCT CCCTATTAGC AGTCAGTGGC AGCTTGGCTC CTATCACAGG GGCTGTTAGA
- 961 ACTGCACTTG TATCACTCAA ATTCAATGCT AATGGAGCCC TTTTGGACAA ATCAACTCTG
- 1021 AACAAAGAAT ACTGGAACTA CAGACAAGGA GATCTAATTC CAGGTACACC
- 1081 GCTGTGGGTT TCATGCCTAA CAAAAAGCC TACCCTAAAA ACACAACTGC AGCTTCCAAG

#### SEQ ID NO: 8

- 1141 AGCCACATTG TGGGTGATGT GTATTTAGAT GGAGATGCAG ATAAACCTTT
- 1201 ATCACTTTCA ATGAAACTGA TGATGAAACC TGTGATTACT GCATCAACTT TCAATGGAAA
- 1261 TGGGGAGCTG ATCAATATAA GGATAAGACA CTCGCAACCA GTTCATTCAC
  - 1321 ATCGCCCAAG AATAA

- $61\,$  GACAACGCAC CGACCGTGCC CTTCATCAAC CCCCCCTTCG TCTCTTCAGA TGGATTCCAA
- $121\,$  GAGAAGCCCC TGGGGGTGCT GTCCCTGCGA CTGGCCGACC CCGTCACCAC CAAGAACGGG
- 181 GAAATCACCC TCAAGCTGGG AGAGGGGGTG GACCTCGACT CCTCGGGAAA
- 241 AACACGGCCA CCAAGGCCGC CGCCCCTCTC AGTTTTTCCA ACAACACCAT
- 301 ATGGATACCC CTTTTTACAA CAATAATGGA AAGTTAGGCA TGAAAGTCAC TGCTCCACTG
- 361 AAGATACTCG ACACAGACTT GCTAAAAACA CTTGTTGTAG CTTATGGACA AGGTTTAGGA
- $421\,$  ACAAACACCA CTGGTGCCCT TGTTGCCCAA CTAGCAGCCC CACTTGCTTT TGATAGCAAT
- 481 AGCAAAATTG CCCTTAATTT AGGCAATGGA CCATTGAAAG TGGATGCAAA TAGACTGAAC
- 541 ATCAATTGCA ATAGAGGACT CTATGTTACT ACCACAAAAG ATGCACTGGA AACCAACATA
- $601\,$  AGTTGGGCTA ATGCTATGAC ATTTATAGGA AATGCCATGG GTGTCAATAT TGATACACAA
- 661 AAAGGCTTGC AATTTGGCAC CACTAGTACC GTCGCAGATG TTAAAAAACGC
- 721 CAAGTCAAAC TGGGAGCTGG TCTCACATTT GACAGCACAG GTGCAATTGT
- 781 AAAGAAGATG ACAAACTTAC ACTGTGGACC ACAGCCGATC CATCTCCAAA
- 841 TATTCTGACA AGGATGCTAA GCTTACACTC TGCTTGACAA AGTGTGGCAG TCAGATACTG .
- 901 GGCACTGTTT CTCTCATAGC TGTTGATACT GGTAGCTTAA ATCCAATAAC AGGACAAGTA
- 961 ACCACTGCTC TTGTTTCACT TAAATTCGAT GCCAATGGAG TTTTGCAAAC CAGTTCAACA
- 1021 TTGGACAAAG AATATTGGAA TTTTAGAAAA GGAGATGTGA CACCTGCTGA GCCATATACT
- 1081 AATGCTATAG GTTTCATGCC CAATCTAAAG GCATACCCTA AAAACACAAG TGGAGCTGCA

## Fig. 13A

#### SEQ ID NO: 9

- 1141 AAAAGTCACA TTGTTGGGAA AGTGTACCTA CATGGGGATA CAGACAAACC ACTGGACCTG
- 1201 ATTATTACTT TCAATGAAAC AAGTGATGAA TCTTGCACTT ACTGTATTAA CTTTCAATGG
- 1261 AAATGGGATA GTACTAAGTA CACAGGTGAA ACACTTGCTA CAAGCTCCTT CACCTTCTCC
  - 1321 TACATTGCCC AAGAATGA

- 1 ATGTCCAAAA AGCGCGTCCG GGTGGATGAT GACTTCGACC CCGTCTACCC CTACGATGCA
- 61 GACAACGCAC CGACCGTGCC CTTCATCAAC CCCCCCTTCG TCTCTTCAGA
- 121 GAGAAGCCCC TGGGGGTGTT GTCCCTGCGA CTGGCCGACC CCGTCACCAC CAAGAACGGG
- 181 GAAATCACCC TCAAGCTGGG AGAGGGGGTG GACCTCGACT CCTCGGGAAA
- 241 AACACGGCCA CCAAGGCCGC TGCCCCTCTC AGTTTTTCCA ACAACACCAT TTCCCTTAAC
- 301 ATGGATCACC CCTTTTACAC TAAAGATGGA AAATTAGCCT TACAAGTTTC TCCACCATTA
- 361 AATATACTGA GAACAAGCAT TCTAAACACA CTAGCTTTAG GTTTTGGATC AGGTTTAGGA
- 421 CTCCGTGGCT CTGCCTTGGC AGTACAGTTA GTCTCTCCAC TTACATTTGA TACTGATGGA
- 481 AACATAAAGC TTACCTTAGA CAGAGGTTTG CATGTTACAA CAGGAGATGC AATTGAAAGC
- 541 AACATAAGCT GGGCTAAAGG TTTAAAATTT GAAGATGGAG CCATAGCAAC
- 601 AATGGGTTAG AGTTTGGAAG CAGTAGTACA GAAACAGGTG TCGATGATGC TTACCCAATC
- 661 CAAGTTAAAC TTGGATCTGG CCTTAGCTTT GACAGTACAG GAGCCATAAT GGCTGGTAAC
- 721 AAAGAAGACG ATAAACTCAC TTTGTGGACA ACACCTGATC CATCACCAAA
- 781 CTCGCAGAAA ATGATGCAAA ACTAACACTT TGCTTGACTA AATGTGGTAG TCAAATACTG
- 841 GCCACTGTGT CAGTCTTAGT TGTAGGAAGT GGAGACCTAA ACCCCATTAC TGGCACCGTA
- 901 AGCAGTGCTC AGGTGTTTCT ACGTTTTGAT GCAAACGGTG TTCTTTTAAC AGAACATTCT
- 961 ACACTAAAAA AATACTGGGG GTATAGGCAG GGAGATAGCA TAGATGGCAC TCCATATGCC
- $1021\,$  AATGCTGTAG GATTCATGCC CAATTTAAAA GCTTATCCAA AGTCACAAAG TTCTACTACT
- 1081 AAAAATAATA TAGTAGGGCA AGTATACATG AATGGAGATG TTTCAAAACC TATGCTTCTC
- 1141 ACTATAACCC TCAATGGTAC TGATGACAGC AACAGTACAT ATTCAATGTC

## Fig. 14A

SEQ ID NO: 10

90/153

1201 ACCTGGACTA ATGGAAGCTA TGTTGGAGCA ACATTTGGAG CTAACTCTTA TACCTTCTCC

1261 TACATCGCCC AAGAATGA

- ${\bf 1}$  ATGTCCAAAA AGCGCGTCCG GGTGGATGAT GACTTCGACC CCGTCTACCC CTACGATGCA
- 61 GACAACGCAC CGACCGTGCC CTTCATCAAC CCCCCCTTCG TCTCTTCAGA
- 121 GAGAAGCCCC TGGGGGTGCT GTCCCTGCGA CTGGCCGACC CCGTCACCAC CAAGAACGGG
- ${\footnotesize 181 \quad GAAATCACCC \quad TCAAGCTGGG \quad AGAGGGGGTG \quad GACCTCGACT \quad CCTCGGGAAA \quad ACTCATCTCC \quad }$
- 241 AACACGGCCA CCAAGGCCGC CGCCCCTCTC AGTTTTTCCA ACAACACCAT
- 301 ATGGATCACC CCTTTTACAC TAAAGATGGA AAATTATCCT TACAAGTTTC
- 361 AATATACTGA GAACAAGCAT TCTAAACACA CTAGCTTTAG GTTTTGGATC AGGTTTAGGA
- 421 CTCCGTGGCT CTGCCTTGGC AGTACAGTTA GTCTCTCCAC TTACATTTGA TACTGATGGA
- $481\,$  AACATAAAGC TTACCTTAGA CAGAGGTTTG CATGTTACAA CAGGAGATGC AATTGAAAGC
- 541 AACATAAGCT GGGCTAAAGG TTTAAAATTT GAAGATGGAG CCATAGCAAC CAACATTGGA
- 601 AATGGGTTAG AGTTTGGAAG CAGTAGTACA GAAACAGGTG TTGATGATGC TTACCCAATC
- 661 CAAGTTAAAC TTGGATCTGG CCTTAGCTTT GACAGTACAG GAGCCATAAT GGCTGGTAAC
- 721 AAAGAAGACG ATAAACTCAC TTTGTGGACA ACACCTGATC CATCGCCAAA
- 781 CTCGCAGAAA ATGATGCAAA ACTAACACTT TGCTTGACTA AATGTGGTAG
- 841 GCCACTGTGT CAGTCTTAGT TGTAGGAAGT GGAAACCTAA ACCCCATTAC TGGCACCGTA
- 901 AGCAGTGCTC AGGTGTTTCT ACGTTTTGAT GCAAACGGTG TTCTTTTAAC AGAACATTCT
- 961 ACACTAAAAA AATACTGGGG GTATAGGCAG GGAGATAGCA TAGATGGCAC TCCATATACC
- 1021 AATGCTGTAG GATTCATGCC CAATTTAAAA GCTTATCCAA AGTCACAAAG
- 1081 AAAAATAATA TAGTAGGGCA AGTATACATG AATGGAGATG TTTCAAAACC TATGCTTCTC

# Fig. 15A

SEQ ID NO: 11

92/153

1141 ACTATAACCC TCAATGGTAC TGATGACAGC AACAGTACAT ATTCAATGTC ATTTTCATAC

1201 ACCTGGACTA ATGGAAGCTA TGTTGGAGCA ACATTTGGGG CTAACTCTTA TACCTTCTCA

1261 TACATCGCCC AAGAATGA

- 61 AACGGTCCTC CCTCCGTCCC TTTCCTCACC CCTCCCTTCG TGTCTCCCGA
- 121 GAGAGCCCCC CCGGGGTCCT GTCTCTGAAC CTGGCCGAGC CCCTGGTCAC TTCCCACGGC
- 181 ATGCTCGCCC TGAAAATGGG AAGTGGCCTC TCCCTGGACG ACGCCGGCAA
- 241 CAAGATGTCA CCACCACTAC CCCTCCCCTG AAAAAAACCA AGACCAACCT CAGCCTAGAA
- 301 ACCTCAGCCC CCCTGACTGT GAGCACCTCA GGCGCCCTCA CCCTAGCAGC CGCCGTTCCC  $^{\circ}$
- 361 CTGGCGGTGG CCGGCACCTC CCTCACCATG CAATCAGAGG CCCCCCTGAC
- $421\,$  GCAAAACTCA CCCTGGCCAC CAAGGGCCCC CTGACCGTGT CTGAAGGCAA ACTAGCCTTG
- 481 CAGACCTCGG CCCCGCTGAC GGCCGCTGAC AGCAGCACCC TCACAATCAG
- 541 CCCCTTAGCA CAAGCAATGG CAGCTTGGGT ATTGACATGC AAGCCCCCAT
- 601 AACGGAAAAC TGGGACTTAA CTTTGGTGCT CCCCTGCATG TGGTAGACAG CCTAAATGCA
- 661 CTGACTGTAG TGACTGGCCA AGGTCTTACG ATAAACGGTA CAGCCCTACA
- 721 TCAGGTGCCC TCAACTATGA CTCATCAGGA AACCTAGAAT TGAGAGCTGC AGGGGGTATG
- 781 CGAGTTGATG CAAATGGCAA ACTTATCCTT GACGTAGCTT ACCCATTTGA
- 841 AACCTCAGCC TTAGACTTGG ACAGGGACCC CTGTTTGTTA ACTCTGCCCA
- 901 GTTAACTACA ACAGAGGCCT CTACCTGTTC ACATCTGGAA ATACCAAAAA GCTAGAAGTT
- 961 AATATCAAAA CAGCCAAAGG CCTCATTTAT GATGACACTG CTATAGCAAT CAATCCAGGC
- 1021 GATGGGCTAG AGTTTGGCTC AGGCTCAGAT ACAAATCCAT TAAAAACTAA
- 1081 GGACTAGAGT ATGACTCCAG CAGAGCCATA ATTGCTAAGC TGGGAACCGG

#### SEQ ID NO: 12

- 1141 GACAACACAG GTGCCATCAC AGTGGGCAAC AAAAATGATG ACAAGCTTAC CTTGTGGACC
- 1201 ACACCAGACC CCTCTCCCAA CTGTAGAATT TATTCAGAAA AAGATGCTAA ATTTACACTA
- 1261 GTTTTAACTA AATGCGGCAG TCAGGTGTTG GCCAGCGTTT CTGTTTATC TGTAAAAGGC
- 1321 AGCCTTGCGC CCATCAGTGG CACAGTAACT AGCGCTCAGA TTATTCTCAG ATTTGATGAA
- 1381 AATGGAGTTC TACTAAGCAA TTCTTCTCTT GACCCCCAAT ACTGGAACTA CAGAAAAGGT
- 1441 GACCTTACAG AGGGCACTGC ATATACCAAC GCAGTGGGAT TTATGCCCAA CCTCACAGCA
- 1501 TACCCAAAAA CACAGAGTCA AACTGCTAAA AGCAACATTG TAAGCCAGGT TTACTTGAAT
- 1561 GGGGACAAAT CCAAACCCAT GATCCTCACC ATTACCCTCA ATGGAACTAA TGAAACAGGG
- 1621 GATGCTACAG TTAGCACTTA CTCCATGTCA TTCTCATGGA ATTGGAATGG AAGTAATTAC
- 1681 ATTAATGAAA CGTTCCAAAC CAACTCTTTC ACCTTCTCCT ACATCGCCCA AGAATAA

#### SEQ ID NO: 13

- 1 ATGTCCAAAA AGCGCGTCCG GGTGGATGAT GACTTCGACC CCGTCTACCC CTACGATGCA
- 61 GACAACGCAC CGACCGTGCC CTTCATCAAC CCCCCCTTCG TCTCTTCAGA
- 121 GAGAAGCCCC TGGGGGTGCT GTCCCTGCGA CTGGCTGACC CCGTCACCAC CAAGAACGGG
- $181\,$  GAAATCACCC TCAAGCTGGG AGAGGGGGTG GACCTCGACT CCTCGGGAAA ACTCATCTCC
- $241\,$  AACACGGCCA CCAAGGCCGC CGCCCCTCTC AGTTTTTCCA ACAACACCAT TTCCCTTAAC
- 301 ATGGATACCC CTTTTTACAC CAAAGATGGA AAATTAACCA TGCAGGTCAC TGCACCACTA
- 361 AAGTTAGCAA ACACAGCCAT ATTGAACACA CTAGCTATGG CATATGGAAA TGGATTAGGT
- 421 CTAAGCAACA ACGCTCTTAC CGTTCAGTTA CAATCTCCAC TCACCTTTAA CAACAGCAAG
- 481 GTTGCAATCA ACCTGGGAAA TGGACCACTA AATGTAACAT CAAACAGACT TAGCATTAAT
- 541 TGCAAGAGG GTGTCTATGT CACCACCACA GGAGATGCAA TTGAAACCAA CATAAGTTGG
- 601 TCAAATGCTA TTAAATTTAT AGGAAATGCC ATGGGTGTCA ACATTGATAC AAACAAAGGC
- 661 TTGCAATTTG GCACCACCAG CACTGTCACA GATGTGACCA ATGCTTTCCC CATACAAGTC
- 721 AAACTTGGGG CTGGTCTTGC ATTTGATAGC ACTGGAGCTA TTGTTGCATG
- 781 GATGACAGTC TCACTTTGTG GACTACACCA GATCCATCTC CAAATTGCAA GATAGCATCT
- 841 GACAAAGATG CTAAACTCAC ACTTTGCTTG ACAAAATGTG GTAGTCAGAT ACTGGGCACT
- 901 GTCTCCTTGT TAGCTGTGAG TGGCAGTTTA GCTCCTATCA CTGGAGCTGT GAGCACTGCA
- 961 CTTGTATCAC TTAAATTCGA TGCCAATGGA GCACTCTTGG AAAAATCAAC CCTAAACAGA
- 1021 GAATATTGGA ACTATAGACA AGGAGATCTT ATTCCAGGTA CGCCATATAC TCACGCAGTA
- 1081 GGTTTCATGC CCAACAAGAA AGCCTACCCT AAAAACACAA CTGCAGCTTC CAAAAGCCAC

SEQ ID NO: 13

- 1141 ATTGTGGGAG AAGTCTATCT AGACGGAGAT GCAGATAAGC CCCTATCTCT CATAATCACT
- 1201 TTTAATGAAA CTGATGATGA ATCATGTGAC TATTGCATGA ACTTTCAATG
- 1261 GCTGATCAAT ACAAGGACAA AACACTCGCT ACCAGCTCCT TCACCTTCTC CTACATTGCC
  - 1321 CAAGAATGA

#### SEQ ID NO: 14

- 1 ATGAAGCGCA CCAAAACGTC TGACGAGAGC TTCAACCCCG TGTACCCCTA TGACACGGAA
- 61 AGCGGCCCTC CCTCCGTCCC TTTCCTCACC CCTCCCTTCG TGTCTCCCGA TGGATTCCAA
- 121 GAAAGCCCCC CCGGGGTCCT GTCTCTGAAC CTGGCCGAGC CCCTGGTCAC TTCCCACGGC
- 181 ATGCTTGCCC TGAAAATGGG AAGTGGCCTC TCCCTGGACG ACGCTGGCAA CCTTACCTCT
- 241 CAAGATATTA CCTCCACTAC CCCTCCCCTC AAAAAAACCA AGACCAACCT CAGCCTAGAA
- 301 ACCTCATCCC CCCTAACTGT AAGCACCTCA GGCGCCCTCA CCGTAGCAGC CGCCGCTCCC
- 361 CTGGCGTGG CCGCACCTC CCTCACCATG CAATCAGAGG CCCCCTGGC AGTACAGGAT
- 421 GCAAAACTCA CCCTGGCCAC CAAAGGCCCC CTGACCGTGT CTGAAGGCAA ACTGGCCTTG
- 541 CCAATTAGTG TAAGCAGTGG AAGTTTGGGC TTGGACATGG AAGACCCCAT GTATACTCAC
- 601 GATGGAAAAC TGGGAATAAG AATTGGGGGT CCACTAAGAG TAGTAGACAG CTTGCACACA
- 661 CTCACTGTAG TTACCGGAAA TGGACTAACT GTAGATAACA ATGCCCTCCA AACTAGAGTT
- 721 ACGGGCGCC TAGGTTATGA CACATCAGGA AATCTACAAC TGAGAGCCGC AGGGGGTATG
- 781 CGAATTGATG CAAATGGCCA ACTTATCCTT GATGTGGCAT ACCCATTTGA TGCTCAAAAC
- 841 AATCTCAGCC TTAGACTTGG TCAGGGACCC CTGTATGTAA ATACAGACCA CAACCTGGAT
- 901 TTAAATTGCA ACAGAGGTCT AACCACAACT ACCACCAACA ACACAAAAAA ACTTGAGACT
- 961 AAAATTAGCT CAGGCTTAGA CTATGACACC AATGGTGCTG TCATTATTAA ACTTGGCACT
- 1021 GGTCTAAGCT TCGACAACAC AGGCGCCCTA ACTGTGGGAA ACACTGGTGA TGATAAACTG
- 1081 ACTCTGTGGA CGACCCCAGA CCCATCTCCA AATTGCAGAA TTCACTCAGA CAAAGACTGC

#### SEQ ID NO: 14

- 1141 AAGTTTACTC TCGTCCTAAC TAAGTGTGGA AGCCAAATCC TGGCCTCTGT CGCCGCCCTA
- 1201 GCGGTATCAG GAAATCTGGC TTCGATAACA GGCACCGTTG CCAGCGTTAC CATCTTTCTT
- 1261 AGATTTGATC AGAATGGAGT GCTTATGGAA AACTCCTCAC TAGACAAGCA GTACTGGAAC
- $1321\,$  TTCAGAAATG GCAATTCAAC TAATGCTGCC CCCTACACCA ACGCAGTTGG GTTCATGCCA
- 1381 AACCTCGCAG CGTACCCCAA AACGCAAAGC CAGACTGCTA AAAACAACAT TGTAAGTCAG
- 1441 GTTTACTTGA ATGGAGACAA ATCCAAACCC ATGACCCTTA CCATCACCCT CAATGGAACT
- 1501 AATGAATCCA GTGAAACTAG TCAGGTGAGT CACTACTCCA TGTCATTTAC ATGGGCTTGG
- 1561 GAAAGCGGGC AATATGCCAC TGAAACCTTT GCCACCAACT CCTTCACCTT TTCTTACATT
  - 1621 GCTGAACAAT AA

- 1 ATGAAGCGCA CCAAAACGTC TGACAAGAGC TTCAACCCCG TGTACCCCTA TGACACGGAA
- 61 AACGGTCCTC CCTCCGTCCC TTTCCTCACC CCTCCCTTCG TGTCTCCCGA TGGATTCCAA
- 121 GAGAGCCCCC CCGGGGTCCT GTCTCTGAAC CTGGCCGAGC CCCTGGTCAC TTCCCACGGC
- 181 ATGCTCGCCC TGAAAATGGG AAGTGGCCTC TCCCTGGACG ACGCCGGCAA
- 241 CAAGATGTCA CCACCACTAC CCCTCCCCTG AAAAAAACCA AGACCAACCT CAGCCTAGAA
- 301 ACCTCAGCCC CCCTGACTGT GAGCACCTCA GGCGCCCTCA CCCTAGCAGC CGCCGCCCCC
- 361 CTGGCGGTGG CCGGCACCTC CCTCACCATG CAATCAGAGG CCCCCTGAC AGTCCAAGAT
- 421 GCAAAACTCA CCCTGGCCAC CAAGGGCCCC CTGACCGTGT CTGAAGGCAA ACTGGCCTTG
- 481 CAGACCTCGG CCCCGCTGAC GGCCGCTGAC AGCAGCACCC TCACCGTTAG CGCCACACCA
- 541 CCCATCAGTG TAAGCAGTGG AAGTTTGGGC TTAGACATGG AAGACCCAAT GTATACTCAT
- $601\,$  GATGGAAAAC TGGGAATAAG AATTGGGGGC CCACTGAGAG TAGTAGACAG CCTGCACACA
- 661 CTGACTGTAG TTACCGGAAA TGGAATAGCT GTAGATAACA ATGCCCTCCA AACTAGAGTT
- 721 ACGGGCGCCC TGGGTTATGA CACATCAGGA AACCTACAAC TGAGAGCCGC GGGGGGTATG
- 781 CGAATTGATG CAAATGGCCA ACTTATCCTT GATGTGGCAT ACCCATTTGA TGCTCAAAAC
- 841 AATCTCAGCC TTAGACTTGG TCAGGGACCC CTGTATGTAA ACACAGACCA CAACCTAGAT
- 901 TTGAATTGCA ACAGAGGTCT GACCACAACT ACCACCAACA ACACAAAAAA ACTTGAAACT  $\cdot$
- 961 AAAATTGGCT CAGGCTTAGA CTATGATACC AATGGTGCTG TTATTATTAA ACTTGGCACT
- 1021 GGTGTCAGCT TTGACAGCAC AGGTGCCCTA AGTGTGGGAA ACACTGGCGA TGATAAACTG
- 1081 ACTCTGTGGA CAACCCCAGA CCCATCTCCA AATTGCAGAA TTCACTCAGA

#### SEQ ID NO: 15

- 1141 AAGTTTACTC TAGTCCTAAC TAAGTGTGGA AGTCAAATCC TGGCTTCTGT CGCCGCCCTA
- 1201 GCGGTGTCAG GAAATCTGGC TTCAATAACA GGCACCGTTT CCAGCGTTAC
- 1261 AGATTTGATC AGAATGGAGT GCTTATGGAA AACTCCTCGC TAGACAAGCA GTACTGGAAC
- $1321\,$  TTCAGAAATG GTAATTCAAC CAATGCCACC CCCTACACCA ATGCAGTTGG GTTTATGCCA
- 1381 AACCTCGCAG CATACCCCAA GACACAGAGC CAGACTGCAA AAAACAACAT TGTAAGTCAG
- 1441 GTTTACTTGA ATGGGGACAA ATCCAAACCC ATGACCCTTA CCATTACCCT CAATGGAACT
- 1501 AATGAATCCA GTGAAACTAG CCAGGTGAGT CACTACTCCA TGTCATTTAC GTGGGCTTGG
- 1561 GAGAGTGGGC AATATGCCAC CGAAACCTTT GCCACCAATT CCTTTACCTT
  - 1621 GCTGAACAAT AA

LKUNSTDGFL EENIN	DSSTLTISAT PPLSTSNGSL GIDMQAPIYT DSSTLTVSAT PPLSTSNGSL GIDMQAPIYT DSSTLTVSAT PPLSVSGSL GIDMEDPMYT DSSTLTVSAT PPINVSGSL GIDMEDPMYT DSSTLTVSAT PPISVSGSL GIDMEDPMYT C. KAA APLSISNNTI SLWRDAPFYN C. KAA APLSFSNNTI SLNMDTPLYN C. KAA APLSFSNNTI SLNMDTPLYN C. KAA APLSFSNNTI SLNMDTPFYT C. KAA APLSFSNNTI SLNMDTPFYT C. KAA APLSFSNNTI SLNMDHPFYT
GALDIKVGGG GMLALKMGSG GMLALKMGSG GMLALKMGSG GMLALKMGSG GMLALKMGSG GEITLKLGEG GEITLKLGEG GEITLKLGEG GEITLKLGEG GEITLKLGEG GEITLKLGEG GEITLKLGEG GEITLKLGEG GEITLKLGEG GEITLKLGEG GEITLKLGEG GEITLKLGEG GEITLKLGEG GEITLKLGEG	LQTSAPLTAA DSS' LQTSAPLTAA DSS' LQTSAPLTAA DSS' LQTSAPLTAA DSS' LQTSAPLTAA DSS'
GE TQSPDGVLTL NCVAPLITTAN  GE ÇESPEGVLSL NLAEPLVTSH  GE ÇERPLGVLSL RLADPVTTKN  GE ÇERPLGVLSL RLA	IVQ DAKLTLATKG PLTVSEGKLA
EN SSHPFI NPGFISPNGF ENGPSYPFI TPPFVSPDGF ESGPPSVPFI TPPFVSPDGF ESGPPSVPFI TPPFVSPDGF ESGPPSVPFI TPPFVSPDGF DN. APTVPFI NPPFVSSDGF	PLAVAGTSLT MOSEAPLTVO PLAVAGTSLT MOSEAPLTVO PLAVAGTSLT MOSEAPLAVO PLAVAGTSLT MOSEAPLTVO PLAVAGTSLT MOSEAPLTVO
MAKRTRISSS .ENPVYPYED MKRTKTSDES .ENPVYPYDT MKKTKTSDE .ENPVYPYDT MSKKRVRVDD DEDPVYPYDA MSKKRARVDD DEDPVYPYDA MSKKRVRVDD DEDPVYPYDA	ETSABLIVST SGALTLAAAV ETSSPLTVST SGALTVAAAA ETSSPLTVST SGALTVAAAA ETSSPLTVST SGALTLAAAA ETSABLTVST SGALTLAAAA
Ci Chad11 Chad20 Chad3 Chad3 Chad3 Chad5 Chad5 Chad5 Chad7 PAN5 PAN5 PAN5 Chad4 Chad10 Chad4 Chad10 Chad4	C1 Chad11 ETS Chad20 ETS Chad3 ETS Chad3 ETS Chad3 ETS Chad4 ETS Chad5 Pan6 Pan7 Chad5 Pan7 Chad9 Chad4

Fig. 20A

300 LSLRLGGGPL SNISWARGLK TNISWSNAIR	400 SSSAIAMEN. NTGAITVGNK NTGAITVGNT NTGALTVGNT STGALSVGNT STGALSVGNT STGAIVAWNK STGAIVAWNK STGAIVAWNK STGAIVAWNK STGAIVAWNK STGAIVAWNK STGAIMAGNK STGAIMAGNK STGAIMAGNK
LSIRI LSIRI LSIRI LSIRI LSIRI LSIRI NISK TNISK TNISK SNISK SNISK SNISK SNISK SNISK	
AQNN AQNN AQNN AQNN AQNN AQNN IRGLE DALE DALE DALE DALE DALE DALE	LYED LISED LISED LISED LISED LITED LISED LISED LISED LISED LISED
VAYPEDAQNN VAYPEDAQNN VAYPEDAQNN VAYPEDAQNN VAYPEDAQNN INSSENGLE YVTTKDALE YVTTKDALE YVTTKDALE TVTTKDALE LHVTTGDALE	VKLGKGLVFD AKLGTGLSFD AKLGTGLSFD IKLGTGLSFD IKLGTGLSFD IKLGTGLSFD IKLGTGLSFD VKLGTGLFD VKLGAGLTFD VKLGAGLSFD VKLGAGLSFD VKLGAGLSFD VKLGAGLSFD
KLILD QLILD QLILD QLILD QLILD QLILD RLNINCRGI	GLOTNEAKLC LEYDSSRAII LDYDSSRAII LDYDTNGAVI LDYDTNGAVI LDYDTNGAVI LDYDTNGAVI LDYDTNGAVI TOVKNAFELO ADVKNAYFIO ADVKNAYFIO TOVTDAYFIO TOVTDAYFIO TOVTDAYFIO TOVTDAYFIO TOVTDAYFIO TOVTDAYFIO TOVDAYFIO TGVDDAYFIO TGVDDAYFIO
AGGMRVDANG AGGMRVDANG AGGMRIDANG AGGMRIDANG AGGMRIDANG BKG GNGPLKVDAN GNGG DRG	NHSIGLEWSD NPLKTKLGLG NPLKTKLGLG KISSG KISSG TKIGSG TKIGSG TC
JELRA JELRA JOLRA JOLRA JOLRA JOLRA JALNI JALNI JALNI JALNI JALNI KLTI KLTI KLTI KLTI KLTI	
DSSGNLELRA DTSGNLELRA DTSGNLELRA DTSGNLOLRA DTSGNLOLRA SSNS.ITVKT NTASKIALNI NTASKIALNI NTASKIALNI DTSKNIKLTL DTDGNIKLTL DTDGNIKLTL DTDGNIKLTL DTDGNIKLTL DTDGNIKLTL NTSKIALNI NTSKIKLTL DTDGNIKLTL DTDGNIKLTL NTSKIKLTL	TISPLIKS GLEFGSGSDT GLQFDSGSDT
SALNY SALNY SALGY SALGY SALGY SALGY SPLTE SPLTE SPLTE SPLTE	NAGD
CTRVSGALNY OTRVSGALNY OTRVJGALGY OTRVJGALGY OTRVJGALGY TVOLTHPLTE VAQLAYPLVF VAQLAYPLTF AVQLASPLTF AVQLVSPLTF AVQLVSPLTF AVQLVSPLTF AVQLVSPLTF TVQLQSPLTF TVQLQSPLTF	DTAIAINPGD DTAIAINAGD
GITING. TAL GITING. TAL GITING. TAL GITVDN. NAL GIGAVDN. NAL GIGTNYNGAL GIGTNYNGAL GIGTNYTGAL GLGTNYTGAL GLGTNYTGAL GLGINGTAR GLGINGT SAL GLGING SAL GLGING SAL GLGING SAL GLGING SAL GLGING SAL	IKTAKGLIYD IKTAKGLIYD I
_	EEVN.
INALTAVYGO INALTAVYGO LHTLTAVTGO LHTLTAVYGO LHTLTAVYGO LKTLVVAYGO LKTLVVAYGO LKTLVVAYGO LKTLVVAYGO LKTLVVAYGO LKTLVVAYGO LNTLAVGGS LNTLALGEGS LNTLALGEGS LNTLALGEGS	SGNTKKLEVN SGNTKKLEVN TNNTKKLET TNNTKLET TNNTKKLET TNNTKKKLET TNNTKKKLET TNNTKKKLET TNNTKKKLET TNNTKKKLET TNNTKKKLET TNNTKKKLET TNNTKKKKLET TNNTKKKKET TNNTKKKKKET TNNTKKKKKET TNNTKKKKKET TNNTKKKKKET TNNTKKKKKET TNNTKKKKKKET TNNTKKKKKKET TNNTKKKKKKKET TNNTKKKKKKKKKK
APLHVVDS APLHVVDS GPLRVVDS GPLRVVDS GPLRVDS TPLAVFPT APLKILDTDL APLKILDTDL APLKILDTDL PPLNILKSTI PPLNILKTSI PPLNILKTSI PPLNILKTSI PPLNILKTSI APLKILDTDL APLKILDTDL APLKILDTDL APLKILDTDL APLKILDTDL APLKILDTDL APLKILDTSI APLKILTTSI APLKILTTSI APLKILTTSI APLKILTTSI APLKILTTSI APLKILTTSI	NYNRGLYLFT NYNRGLYLFT NCNRGLTTTT NCNRGLTTTT NCNRGLTTTTT NCNRGLOFGT DTKKGLOFGT DTKKGLOFGT DTKKGLOFGT G.NGLEFGS G.NGLEFGS G.NGLEFGS G.NGLEFGS G.NGLEFGS
+ (1) (1) (1) (1) (1) (2) (4) (4) (4) (4) (4) (4) (4) (4) (4)	- на
201 TUGKIGINE TUGKIGINE HDGKLGINE HDGKLGIRI HDGKLGIRI HDGKLGIRI NNGTLSINV NNGKLGMKV NNGKLGMKV NNGKLGMKV KDGKLSIQV	301  FEVSAHNLDV  YVNTDHNLDL  YVNTDHNLDL  YVNTDHNLDL  YVNTDHNLDL  FEGNAIATYI  FIGNAIGVNI  FIGNAIGVNI  FIGNAIGVNI  FIGNAIGVNI  FEGNAIGVNI  FEGNAIGVNI  FEGNAIGVNI  FEGNAIGVNI  FEGNAIGVNI  FEGNAIGVNI  FEGNAIGVNI  FEGNAIGVNI
111 20 111 111 111 111 111 111 111 111 1	20 0 0 701
C1 Chad11 Chad37 Chad37 Chad19 PAN6 Chad5 Chad6 Chad6 Chad7 PAN7 Chad10 Chad10	CI Chad11 Chad20 Chad3 Chad3 Chad19 Pan6 Chad5 Chad7 Chad9 Chad9 Chad4 Chad4 Chad4

Fig. 20B

SOO NYRK, GDLTE NYRK, GDLTE NYRK, GDLTE NYRN, GNSTN NFRN, GNSTN NFR, GDVTP NYRQ, GDLIP NYRQ, GDVTP NYRQ, GDVTP NYRQ, GDVTP OYRQ, GDVTP OYRQ, GDSID GYRQ, GDSID GYRQ, GDSID GYRQ, GDSID	600 LITSPEFESY EQTWSFTESY FATWSFTESY FATWSFTESY FATWSFTESY LATSSFTESY LATSSFTESY LAVSSFTESY LAVSSFTESY LAVSSFTESY LAVSSFTESY LAVSSFTESY FCANSYTESY FCANSYTESY FCANSYTESY FCANSYTESY FCANSYTESY FCANSYTESY
YLSSLKS.NL N.SSLDPQYW N.SSLDPQYW N.SSLDRQYW N.SSLDRQYW N.SSLDRQYW N.SSLDRQYW S.STLDREYW S.STLDKEYW S.STLDKEYW S.STLDKEYW E.HSTLKKYW E.HSTLKKYW E.HSTLKKYW E.HSTLKKYW E.HSTLKKYW E.HSTLKKYW	EEAPETTEVT SNYINET SNYINET GQYATET GQYATET DYKDKNIT DQYKDET TKYTGET DQYKDET TKYTGET GSYKGAT GSYVGAT GSYVGAT GSYVGAT
AFDNTGQIIT RFDENGVLLS RFDENGVLLS RFDQNGVLME RFDQNGVLME RFDQNGVLME RFDANGVLME KFDANGVLQA KFDANGVLQA KFDANGVLQT KFDANGVLGT KFDANGVLGT RFDANGVLLT RFDANGVLLT RFDANGVLLT RFDANGVLLT RFDANGVLLT RFDANGVLLT RFDANGVLLT RFDANGVLLT	AMNESWSLNA SMSFSWNWNG SMSFSWNWNG SMSFTWAWES SMSFTWAWES SMSFTWAWES SMSFTWAWES CINFOWOWGA CINFOWKWGA CINFOWKWDS CINFOWKWDS SMSFSYTWTN SMSFSYTWTN SMSFSYTWTN SMSFSYTWTN
NKQVTIDVNL GTVTSAQIII GTVTSAQIVL GTVSAVTIFL GTVSSVTIFL GTVSSAIVEL GAVRTALVSL GAVTTALVSL GTVTTALVSL GTVTTALVSL GTVTTALVSL GTVTTALVSL GTVTTALVSL GTVTTALVSL GTVSSAQVFL GTVSSAQVFL GTVSSAQVFL GTVSSAQVFL GTVSSAQVFL GTVSSAQVFL	ASGMAY TGD.ATVSTY TGD.ATVSTY SSETSQUSHY SSETSQUSHY SSETSQUSHY SSETSQUSHY ETCDY ESCTY ESCTY ESCTY SNSTY SNSTY SNSTY
SE. YTNTLEK K. GSLAPIS K. GSLAPIS S. GNLASIT S. GNLASIT VGSALNPIN DT. GSLNPIT DT. GSLNPIT GS. GDLNPIT GS. GNLNPIT	VTVTLNRRMS LTITLNGTNE LTITLNGTNE LTITLNGTNE LTITLNGTNE LTITLNGTNE LTITLNGTNE LTITLNGTNE LITTRNETSD LITTRNETSD LITTRNETSD LITTRNETSD LITTRNETSD LITTRNETSD LITTRNETSD LTITRNETSD LTITRNETSD LTITRNETSD LTITRNETSD LTITRNGTDD LTITLNGTDD LTITLNGTDD LTITLNGTDD LTITLNGTDD LTITLNGTDD LTITLNGTDD
VNGYITIMGD VLASVSVLSV VLASVSALAV ILASVAALAV ILGTSVAALAV ILGTVSLLAV ILGTVSLIAV ILGTVSLIAV ILGTVSLIAV ILGTVSLIAV ILGTVSLIAV ILGTVSLIAV ILGTVSVLVV ILATVSVLVV ILATVSVLVV ILATVSVLVV	STNGTLFPLK GD. KSKPWI GD. KSKPWI GD. KSKPWT GD. KSKPWT GD. ANKFPMT GD. ADKPLN GD. ADKPLN GD. TGKPLD GD. TGKPLD GD. TGKPLD GD. VSKPWI
TLVLVKNGGL TLVLTKCGSQ TLVLTKCGSQ TLVLTKCGSQ TLCTTKCGSQ	DYIYGECYYK SNIVSQYIN SNIVSQYIN NNIVSQYIN NNIVSQYYL SHIVGEYYL SHIVGEYYL SHIVGEYYL SHIVGEYYL SHIVGEYYL SHIVGEYYL SHIVGEYYL SHIVGEYYL SHIVGEYYL SHIVGEYYL SHIVGEYYL NNIVGQYYN NNIVGYYN NNIVGY NNIV NNIV NNIV NNIV NNIV N
EGEDSPDCKI. SEKDAKE SEKDAKE SDKDCKE SDKDCKE SDKDCKE SDKDCKE SDKDAKI SDKDAKI SAKDAKI SAKDAKI SEKDAKI SEKDAKI AENDAKI AENDAKI AENDAKI AENDAKI	TYATOSIN.EKTOSOTAKKTOSOTAKKTOSOTAKKTOSOTAKKTOSOTAKKTOSOTAKKTOSOTAKKNTSAASKKNTSGAAKKNTSGAAKKNTSGAAKKNTSGAAKKNTSGAAKKNTSGAAKKNTSGAAKKNTSGAAKKNTSGATKKNTSGAAKKNTSGAAKKNTSGAAKKNTSGAAKKNTSGAAKKNTSGAAKKNTSGAAKKNTSGAAKKNTSGAAKKNTSGATKKSOSSTTKKSOSSTTKKSOSSTTKKSOSSTTK
AKPSANCVIK PDPSPNCRIY PDPSPNCRIY PDPSPNCRIH PDPSPNCRIH PDPSPNCRIH ADPSPNCHIX ADPSPNCHIX ADPSPNCHIX ADPSPNCHIX PDPSPNCHIX PDPSPNCHIX PDPSPNCKIX PDPSPNCQIL PDPSPNCQIL PDPSPNCQIL PDPSPNCQIL	MPSTTAYPEI MPNLTAYP MPNLTAYP MPNLAAYP MPNLAAYP MPNLAAYP MPNLAAYP MPNLAAYP MPNLKAYP
401NILWTG NDDKLTLWTT GDDKLTLWTT GDDKLTLWTT GDDKLTLWTT GDDKLTLWTT EDDKLTLWTT	501 GTIT.SAKGE GTAYTNAVGE AAPYTNAVGE AAPYTNAVGE SVAYTNAVGE GTEYTNAIGE AEPYTNAIGE AEPYTNAIGE AEPYTNAIGE GTEYZNAIGE GTEYZNAYGE GTEYZNAVGE GTEYTNAVGE
C1 Chad11 Chad20 Chad3 Chad3 Chad3 Chad4 Chad5 Chad6 Chad6 Chad7 Pan5 Pan5 Pan7 Chad9 Chad4 Chad4 Chad4	C1 Chad11 Chad20 Chad17 Chad3 Chad19 PAN6 Chad5 Chad7 PAN5 PAN7 Chad4 Chad4 Chad4 Chad4

Fig. 20C

```
C1 IREDD
Chad11 IAQE.
Chad20 IAQE.
Chad17 IAEQ.
Chad19 IAEQ.
Chad3 IAQE.
Chad5 IAQE.
Chad6 IACE.
Chad7 IAQE.
Chad7 IAQE.
PAN7 IAQE.
PAN7 IAQE.
Chad4 IAQE.
```

Fig. 20D

#### 105/153

- 1 ATGGCGACCC CATCGATGAT GCCGCAGTGG TCGTACATGC ACATCTCGGG CCAGGACGCC
- 61 TCGGAGTACC TGAGCCCCGG GCTGGTGCAG TTCGCCCGCG CCACCGAGAG CTACTTCAGC
- 121 CTGAGTAACA AGTTTAGGAA CCCCACGGTG GCGCCCACGC ACGATGTGAC CACCGACCGG
- 181 TCTCAGCGCC TGACGCTGCG GTTCATTCCC GTGGACCGCG AGGACACCGC GTACTCGTAC
- 241 AAGGCGCGGT TCACCCTGGC CGTGGGCGAC AACCGCGTGC TGGACATGGC CTCCACCTAC
- 301 TTTGACATCC GCGGGGTGCT GGACCGGGT CCCACTTTCA AGCCCTACTC TGGCACCGCC
- 361 TACAACTCCC TGGCCCCCAA GGGCGCTCCC AACCCATGCG AGTGGGATGA
- 421 GCCCTTGACA TTGATTTGAA CGCAGAAGAC GATGAAGAAA GCGACGAAGC TCAAGGGGAA
- 481 GCAGATCAGC AGAAAACTCA TGTATTTGGC CAGGCGCCCT ACTCCGGACA GAACATTACA
- 541 AAAGAAGGCA TACAGATAGG CATAGATGCT GCCAGTCAAG CCCAGACACC TGTATATGCC
- 601 GATAAAACAT TCCAACCAGA ACCTCAAGTT GGAGAATCAC AGTGGAATGA GACAGAGATT
- 661 AGTTATGGAG CGGGACGGGT GCTTAAAAAA ACCACTCTCA TGAAACCTTG
- 721 TATGCAAGGC CTACTAATGA GAACGGAGGT CAGGGCATCC TCTTGGAACA AGATGGAAAG
- 781 AAAGAAAGTC AAGTGGAAAT GCAATTTTTC TCTACTACTC AGGCAGCCGC GGGTAATTCA
- 841 GATAATCCTA CCCCAAAGGT TGTTTTGTAC AGCGAGGATG TTAACCTGGA AACACCAGAT
- 901 ACACACATTT CATACATGCC CACCAACAAC GAGACAAATT CAAGAGAGCT
- 961 CAGGCCATGC CCAACAGGCC TAATTACATT GGCTTCAGAG ACAACTTTAT CGGTCTCATG
- 1021 TATTACAACA GCACTGGCAA CATGGGAGTG CTTGCAGGTC AGGCCTCTCA GTTGAACGCA
- 1081 GTGGTGGACT TGCAAGACAG AAACACAGAA CTGTCATACC AGCTCTTGCT TGATTCCATG

Fig. 21A

- 1141 GGTGACAGAA CCAGATACTT TTCCATGTGG AATCAGGCAG TGGACAGTTA TGACCCAGAT
- 1201 GTCAGAATTA TTGAAAATCA TGGAACTGAA GACGAGCTCC CCAACTATTG
- 1261 GGCGGCGTAA TCAATACGGA AACTTTCACA AAAGTAAAAC CTAAAGCTGC ACAGGACGCT
- 1321 CAGTGGGAAA AAGATTCAGA ATTTTCAGAT AAAAATGAAA TAAGGGTGGGAAACAACTTC
- 1381 GCCATGGAAA TTAACCTCAA TGCCAATCTG TGGAGGAACT TTTTGTACTC CAACGTAGCC
- 1441 CTCTACTTGC CTGACAAGCT TAAGTATACT CCATCCAATG TGCAAATTTC CAACAATCCC
- 1501 AACTCCTACG ATTACATGAA CAAGCGAGTG GTGGCCCCGG GGCTGGTGGA
- 1561 AACCTGGGCG CGCGCTGGTC GCTGGACTAC ATGGACAACG TCAACCCCTT CAACCACCAC
- 1621 CGCAATGCGG GCCTGCGCTA CCGCTCCATG CTCCTGGGCA ACGGGCGCTA CGTGCCCTTC
- 1681 CACATCCAGG TGCCCCAGAA GTTCTTTGCC ATCAAGAACC TCCTCCTCCT GCCGGGCTCC
- 1741 TACACCTACG AGTGGAACTT CAGGAAGGAT GTCAACATGG TCCTCCAGAGCTCTCTGGGT
- 1801 AACGATCTCA GGGTGGACGG GGCCAGCATC AAGTTCGAGA GCATCTGCCT CTACGCCACC
- 1861 TTCTTCCCCA TGGCCCACAA CACGGCCTCC ACGCTCGAGG CCATGCTCAG GAACGACACC
- 1921 AACGACCAGT CCTTCAATGA CTACCTTTCC GCCGCCAACA TGCTCTACCC CATACCCGCC
- 1981 AACGCCACCA ACGTCCCCAT CTCCATCCCC TCGCGCAACT GGGCGGCCTT CCGCGGCTGG
- 2041 GCCTTCACCC GCCTCAAGAC CAAGGAGACC CCCTCCCTGG GCTCGGGATT CGACCCCTAC
- 2101 TACACCTACT CGGGCTCCAT TCCCTACCTG GACGGCACCT TCTACCTCAA
- 2161 AAGAAGGTCT CGGTCACCTT CGACTCCTCG GTCAGCTGGC CGGGCAACGA

- 2221 ACCCCCAACG AGTTCGAGAT CAAGCGCTCG GTCGACGGGG AGGGCTACAA
- 2281 TGCAACATGA CCAAGGACTG GTTCCTGGTC CAGATGCTGG CCAACTACAA CATCGGCTAC .
- $2341\,$  CAGGGCTTCT ACATCCCAGA GAGCTACAAG GACAGGATGT ACTCCTTCTT CAGGAACTTC
- 2401 CAGCCCATGA GCCGGCAGGT GGTGGACCAG ACCAAGTACA AGGACTACCA GGAGGTGGGC
- 2461 ATCATCCACC AGCACAACAA CTCGGGCTTC GTGGGCTACC TCGCCCCCAC CATGCGCGAG
- 2521 GGACAGGCCT ACCCCGCCAA CTTCCCCTAC CCGCTCATAG GCAAGACCGC GGTCGACAGC
- 2581 ATCACCCAGA AAAAGTTCCT CTGCGACCGC ACCCTCTGGC GCATCCCCTT CTCCAGCAAC
- 2641 TTCATGTCCA TGGGTGCGCT CTCGGACCTG GGCCAGAACT TGCTCTACGC CAACTCCGCC
- 2701 CACGCCTCG ACATGACCTT CGAGGTCGAC CCCATGGACG AGCCCACCCT TCTCTATGTT
- 2761 CTGTTCGAAG TCTTTGACGT GGTCCGGGTC CACCAGCCGC ACCGCGGCGT CATCGAGACC
  - 2821 GTGTACCTGC GTACGCCCTT CTCGGCCGGC AACGCCACCA CCTAA

- 1 ATGGCCACCC CATCGATGCT GCCCCAGTGG GCGTACATGC ACATCGCCGG ACAGGACGCT
- 61 TCGGAGTACC TGAGTCCGGG TCTGGTGCAG TTCGCCCGCG CCACAGACAC
- 121 CTGGGGAACA AGTTTAGGAA CCCCACGGTG GCGCCCACGC ACGATGTGAC CACCGACCGC
- 181 AGCCAGCGGC TGACGCTGCG CTTCGTGCCC GTGGACCGCG AGGACAACAC CTACTCGTAC
- 241 AAAGTGCGCT ACACGCTGGC CGTGGGCGAC AACCGCGTGC TGGACATGGC
- 301 TTTGACATCC GCGGCGTGCT GGATCGGGGC CCTAGCTTCA AACCCTACTC CGGCACCGCC
- 361 TACAACAGCC TGGCTCCCAA GGGAGCGCCC AATTCCAGCC AGTGGGAGCA AAAAAAGACT
- 421 GGCAATAATG CCAATGGAGA TACGGAGAAT GTCACTTATG GTGTAGCTGC CATGGGAGGA
- 481 ATTGACATCG ATAAAAATGG CCTTCAAATT GGAACCGATG ACACCAAAGA
- 541 GAAATTTATG CAGACAAAAC ATATCAGCCT GAGCCGCAAA TAGGAGAGGA AAACTGGCAA
- 601 GAAACATATT CCTACTATGG AGGTAGAGCT CTTAAAAAAG ATACCAAAAT GAAGCCATGC
- 661 TATGGCTCAT TTGCCAGACC TACCAATGTG AAAGGAGGAC AGGCAAAAAT AAAAACAGAT
- 721 GGAGATGTTA AGTCATTTGA CATAGACCTA GCCTTCTTTG ATATTCCCAA
- 781 GGAAATGCA CAAATGTTAA CGATGATCCA GATATGCTTA TGTATACAGA AAATGTAAAT
- 841 CTGGAAACCC CAGATACTCA TATTGTGTAC AAACCAGGAA CTTCAGATGA CAGCTCAAAG
- 901 GTCAACTTGT GTCAGCAATC CATGCCTAAC AGACCCAATT ATATTGGCTT CAGAGACAAT
- 961 TTTATTGGGC TTATGTACTA CAACAGCACT GGCAATATGG GTGTGCTGGC TGGTCAGGCC
- 1021 TCTCAACTGA ATGCCGTGGT GGACTTGCAA GACAGAAACA CAGAGCTGTC
- 1081 TTGCTTGACT CTCTGGGTGA CAGAACCAGG TATTTCAGTA TGTGGAATCA GGCGGTGGAC

- 1141 AGTTATGATC CTGATGTGCG CATTATTGAA AACCATGGTG TGGAGGATGA
- 1201 TATTGCTTCC CCTTGGATGG AGCAGGCACC AATTCGGTTT ACCAAGGTGT TAAACCAAAA
- 1261 ACTGACAATG GCAACGATCA GTGGGAAACA GATTCCACAG TTTCAAGTCA CAATCAGATA
- 1321 TGCAAAGGCA ATATCTATGC CATGGAGATC AACCTCCAGG CCAACCTGTG GAGAAGTTTT
- 1381 CTCTACTCGA ACGTGGCCCT GTACCTGCCC GATTCTTACA AGTACACGCC GGCCAACATC
- 1441 ACCCTGCCCA CCAACACCAA CACCTACGAT TACATGAACG GGAGAGTGGT GCCTCCCTCG
- 1501 CTGGTGGACG CCTACATCAA CATCGGGGCG CGCTGGTCGC TGGACCCCAT GGACAACGTG
- 1561 AATCCCTTCA ACCACCACCG CAACGCGGGC CTGCGCTACC GCTCCATGCT CCTGGGCAAC
- 1621 GGGCGCTACG TGCCCTTCCA CATCCAGGTG CCCCAGAAAT TTTTCGCCAT CAAGAGCCTC
- 1681 CTGCTCCTGC CCGGGTCCTA CACCTACGAG TGGAACTTCC GCAAGGACGT CAACATGATC
- 1741 CTGCAGAGCT CCCTCGGCAA CGACCTGCGC ACGGACGGGG CCTCCATCTC
- 1801 ATCAACCTCT ACGCCACCTT CTTCCCCATG GCGCACAACA CGGCCTCCACGCTCGAGGCC
- 1861 ATGCTGCGCA ACGACACCAA CGACCAGTCC TTCAACGACT ACCTCTCGGC GGCCAACATG
- 1921 CTCTACCCCA TCCCGGCCAA CGCCACCAAC GTGCCCATCT CCATCCCCTC GCGCAACTGG
- 1981 GCCGCCTTCC GCGGCTGGTC CTTCACGCGC CTCAAGACCC GCGAGACGCC CTCGCTGGGC
- 2041 TCCGGGTTCG ACCCCTACTT CGTCTACTCG GGCTCCATCC CCTACCTCGA CGGCACCTTC
- 2101 TACCTCAACC ACACCTTCAA GAAGGTCTCC ATCACCTTCG ACTCCTCCGT CAGCTGGCCC
- 2161 GGCAACGAC GCCTCCTGAC GCCCAACGAG TTCGAAATCA AGCGCACCGT CGACGGAGAG
- $2221\,$  GGATACAACG TGGCCCAGTG CAACATGACC AAGGACTGGT TCCTGGTCCA GATGCTGGCC

### 110/153

- 2281 CACTACAACA TCGGCTACCA GGGCTTCTAC GTGCCCGAGG GCTACAAGGA CCGCATGTAC
- 2341 TCCTTCTCC GCAACTTCCA GCCCATGAGC CGCCAGGTGG TGGACGAGGT CAACTACAAG
- 2401 GACTACCAGG CCGTCACCCT GGCCTACCAG CACAACAACT CGGGCTTCGT CGGCTACCTC
- 2461 GCGCCCACCA TGCGCCAGGG CCAGCCCTAC CCCGCCAACT ACCCGTACCC GCTCATCGGA
- 2521 AAGAGCGCCG TCACCAGCGT CACCCAGAAA AAGTTCCTCT GCGACAGGGT CATGTGGCGC
- 2581 ATCCCCTTCT CCAGCAACTT CATGTCCATG GGCGCGCTCA CCGACCTCGG
- 2641 CTCTATGCCA ACTCCGCCCA CGCGCTAGAC ATGAATTTCG AAGTCGACCC CATGGATGAG
- 2701 TCCACCCTTC TCTATGTTGT CTTCGAAGTC TTCGACGTCG TCCGAGTGCA CCAGCCCCAC
- 2761 CGCGGCGTCA TCGAGGCCGT CTACCTGCGC ACCCCCTTCT CGGCCGGTAA CGCCACCACC

2821 TAA

#### 111/153

- 1 ATGGCCACCC CATCGATGCT GCCCCAGTGG GCGTACATGC ACATCGCCGG ACAGGACGCT
- 61 TCGGAGTACC TGAGTCCGGG TCTGGTGCAG TTCGCCCGCG CCACAGACAC CTACTTCAGT
- $121\,$  CTGGGGAACA AGTTTAGGAA CCCCACGGTG GCGCCCACGC ACGATGTGAC CACCGACCGC
- 181 AGCCAGCGGC TGACGCTGCG CTTCGTGCCC GTGGACCGCG AGGACAACAC CTACTCGTAC
- 241 AAAGTGCGCT ACACGCTGGC CGTGGGCGAC AACCGCGTGC TGGACATGGC CAGCACCTAC
- 301 TTTGACATCC GCGGCGTGCT GGATCGGGGC CCTAGCTTCA AACCCTACTC CGGCACCGCC
- 361 TACAACAGCC TGGCTCCCAA GGGAGCGCCC AATTCCAGCC AGTGGGAGCA AAAAAAAGACT
- 421 GGCAATAATG CCAATGGAGA TACGGAGAAT GTCACTTATG GTGTAGCTGC CATGGGAGGA
- 481 ATTGACATCG ATAAAAATGG CCTTCAAATT GGAACCGATG ACACCAAAGA TGACGATAAT
- 541 GAAATTTATG CAGACAAAAC ATATCAGCCT GAGCCGCAAA TAGGAGAGGA AAACTGGCAA
- 601 GAAACATATT CCTACTATGG AGGTAGAGCT CTTAAAAAAG ATACCAAAAT GAAGCCATGC
- 661 TATGGCTCAT TTGCCAGACC TACCAATGTG AAAGGAGGAC AGGCAAAAAT AAAAACAGAT
- 721 GGAGATGTTA AGTCATTTGA CATAGACCTA GCCTTCTTTG ATATTCCCAA TTCTGGCGCG
- 781 GGAAATGCA CAAATGTTAA CGATGATCCA GATATGGTTA TGTATACAGA AAATGTAAAT
- 841 CTGGAAACCC CAGATACTCA TATTGTGTAC AAACCAGGAA CTTCAGATGA CAGCTCAAAG
- 901 GTCAACTTGT GTCAGCAATC CATGCCTAAC AGACCCAATT ATATTGGCTT CAGAGACAAT
- 961 TTTATTGGGC TTATGTACTA CAACAGCACT GGCAATATGG GTGTGCTGGC TGGTCAGGCC
- 1021 TCTCAACTGA ATGCCGTGGT GGACTTGCAA GACAGAAACA CAGAGCTGTC CTACCAGCTC
- 1081 TTGCTTGACT CTCTGGGTGA CAGAACCAGG TATTTCAGTA TGTGGAATCA GGCGGTGGAC

### Fig. 23A

<b>SEQ</b>	m	NO:	18
	w	INO.	Lυ

- 1141 AGTTATGATC CTGATGTGCG CATTATTGAA AACCATGGTG TGGAGGATGA ATTGCCAAAC
- 1201 TATTGCTTCC CCTTGGATGG AGCAGGCACC AATTCGGTTT ACCAAGGTGT TAAACCAAAA
- 1261 ACTGACAATG GCAACGATCA GTGGGAAACA GATTCCACAG TTTCAAGTCA CAATCAGATA
- 1321 TGCAAAGGCA ATATCTATGC CATGGAGATC AACCTCCAGG CCAACCTGTG GAGAAGTTTT
- 1381 CTCTACTCGA ACGTGGCCCT GTACCTGCCC GATTCTTACA AGTACACGCC GGCCAACATC
- 1441 ACCCTGCCCA CCAACACCAA CACCTACGAT TACATGAACG GGAGAGTGGT GCCTCCCTCG
- 1501 CTGGTGGACG CCTACATCAA CATCGGGGCG CGCTGGTCGC TGGACCCCAT GGACAACGTG
- 1561 AATCCCTTCA ACCACCACCG CAACGCGGGC CTGCGCTACC GCTCCATGCT CCTGGGCAAC
- 1621 GGGCGCTACG TGCCCTTCCA CATCCAGGTG CCCCAGAAAT TTTTTGCCAT CAAGAGCCTC
- 1681 CTGCTCCTGC CCGGGTCCTA CACCTACGAG TGGAACTTCC GCAAGGACGT CAACATGATC
- 1741 CTGCAGAGCT CCCTCGGCAA CGACCTGCGC ACGGACGGGG CCTCCATCTC CTTCACCAGC
- 1801 ATCAACCTCT ACGCCACCTT CTTCCCCATG GCGCACAACA CGGCCTCCAC GCTCGAGGCC
- 1861 ATGCTGCGCA ACGACACCAA CGACCAGTCC TTCAACGACT ACCTCTCGGC GGCCAACATG
- 1921 CTCTACCCCA TCCCGGCCAA CGCCACCAAC GTGCCCATCT CCATCCCCTC GCGCAACTGG
- 1981 GCCGCCTTCC GCGGCTGGTC CTTCACGCGC CTCAAGACCC GCGAGACGCC CTCGCTGGGC
- 2041 TCCGGGTTCG ACCCCTACTT CGTCTACTCG GGCTCCATCC CCTACCTCGA CGGCACCTTC
- 2101 TACCTCAACC ACACCTTCAA GAAGGTCTCC ATCACCTTCG ACTCCTCCGT CAGCTGGCCC
- 2161 GGCAACGACC GCCTCCTGAC GCCCAACGAG TTCGAAATCA AGCGCACCGT CGACGGAGAG
- 2221 GGATACAACG TGGCCCAGTG CAACATGACC AAGGACTGGT.TCCTGGTCCAGATGCTGGCC

Fig. 23B

### 113/153

- 2281 CACTACAÁCA TCGGCTACCA GGGCTTCTAC GTGCCCGAGG GCTACAAGGA
- 2341 TCCTTCTTCC GCAACTTCCA GCCCATGAGC CGCCAGGTCG TGGACGAGGT CAACTACAAG
- 2401 GACTACCAGG CCGTCACCCT GGCCTACCAG CACAACAACT CGGGCTTCGT CGGCTACCTC
- 2461 GCGCCCACCA TGCGCCAGGG CCAGCCCTAC CCCGCCAACT ACCCCTACCC GCTCATCGGC
- 2521 AAGAGCGCCG TCGCCAGCGT CACCCAGAAA AAGTTCCTCT GCGACCGGGT CATGTGGCGC
- 2581 ATCCCCTTCT CCAGCAACTT CATGTCCATG GGCGCGCTCA CCGACCTCGG CCAGAACATG
- 2641 CTCTACGCCA ACTCCGCCCA CGCGCTAGAC ATGAATTTCG AAGTCGACCC CATGGATGAG
- 2701 TCCACCCTTC TCTATGTTGT CTTCGAAGTC TTCGACGTCG TCCGAGTGCA
- 2761 CGCGGCGTCA TCGAGGCCGT CTACCTGCGC ACCCCCTTCT CGGCCGGTAA AGCCACCACC

2821 TAA

### 114/153

- ${\tt 1}$  ATGGCCACCC CATCGATGCT GCCCCAGTGG GCGTACATGC ACATCGCCGG ACAGGACGCT
- 61 TCGGAGTACC TGAGTCCGGG TCTGGTGCAG TTCGCCCGCG CCACAGACAC
- 121 CTGGGGAACA AGTTTAGGAA CCCCACGGTG GCGCCCACGC ACGATGTGAC CACCGACCGC
- 181 AGCCAGCGGC TGACGCTGCG CTTCGTGCCC GTGGACCGCG AGGACAACAC CTACTCGTAC
- 241 AAAGTGCGCT ACACGCTGGC CGTGGGCGAC AACCGCGTGC TGGACATGGC
- 301 TTTGACATCC GCGGCGTGCT GGACCGGGGC CCTAGCTTCA AACCTTACTC CGGCACCGCT
- 361 TACAACAGCC TGGCCCCCAA GGGAGCACCC AATTCCAGCC AGTGGGAGCA
- 421 GGCAAAAATG CCAATGGAGA TACGGAGAAT GTCACTTATG GTGTAGCTGC CATGGGAGGA
- 481 ATTGACATCG ATAAAAATGG CCTTCAAATT GGAACCGATG ACACCAAAGA TGGCGATAAT
- 541 GAAATTTATG CAGACAAAAC ATATCAGCCT GAGCCGCAAA TAGGAGAGGA AAACTGGCAA
- 601 GAAACATATT CCTACTATGG AGGTAGAGCT CTTAAAAAAG ATACCAAAAT GAAGCCATGC
- 661 TATGGCTCAT TTGCTAGACC TACCAATGTG AAAGGAGGAC AGGCAAAAAT AAAAACAGAT
- 721 GGAGATGTTA AGTCATTTGA CATAGACCTA GCCTTCTTTG ATATTCCAAA
- 781 GGAAATGCA CAAATGTTAA CGATGATCCA GATATGGTTA TGTATACAGA AAATGTAAAT
- 841 CTGGAAACCC CAGATACTCA TATTGTGTAC AAACCAGGAA CTTCAGATGA CAGCTCCGAG
- 901 GTCAACTTGT GTCAGCAATC CATGCCTAAC AGACCCAATT ATATTGGCTT CAGAGACAAT
- 961 TTTATTGGGC TTATGTACTA CAACAGCACT GGCAATATGG GTGTGCTGGC TGGTCAGGCC
- 1021 TCTCAACTGA ATGCCGTGGT GGACTTGCAA GACAGAAACA CAGAGCTGTC CTACCAGCTC
- 1081 TTGCTTGACT CTCTGGGTGA CAGAACCAGG TATTTCAGTA TGTGGAATCA

# Fig. 24A

- 1141 AGTTATGATC CTGATGTGCG CATTATTGAA AACCÁTGGTG TGGAGGATGA ATTGCCAAAC
- 1201 TATTGCTTCC CCTTGGATGG AGCAGGCACC AATTCGGTTT ACCAAGGTGT TAAACCAAAA
- 1261 ACTGACAATG GCAACGATCA GTGGGAAACA GATTCCACAG TTTCAAGTCA CAATCAGATA
- 1321 TGCAAAGGCA ATATCTATGC CATGGAGATC AATCTCCAGG CCAACCTGTG GAGAAGTTTC
- 1381 CTCTACTCGA ACGTGGCCCT GTACCTGCCC GATTCTTACA AGTACACGCC GGCCAACATC
- 1441. ACCCTGCCCA CCAACACCAA CACCTACGAT TACATGAACG GGAGAGTGGT GCCTCCCTCG
- 1501 CTGGTGGATG CCTACATCAA CATCGGAGCG CGCTGGTCGC TGGACCCCAT GGACAACGTC
- 1561 AATCCCTTCA ACCACCACCG CAATGCGGGG CTGCGCTACC GCTCCATGCT CCTGGGCAAC
- 1621 GGGCGCTACG TGCCCTTCCA CATCCAGGTG CCCCAGAAAT TTTTCGCCAT CAAGAGCCTT
- 1681 CTGCTCCTGC CCGGGTCCTA CACCTACGAG TGGAACTTCC GCAAGGACGT CAACATGATC
- 1741 CTGCAGAGCT CCCTCGGCAA CGACCTGCGC ACGGACGGGG CCTCCATCTC
- 1801 ATCAACCTCT ACGCCACCTT CTTCCCCATG GCGCACAACA CGGCCTCCAC GCTCGAGGCC
- 1861 ATGCTGCGCA ACGACACCAA CGACCAGTCC TTCAACGACT ACCTCTCGGC GGCCAACATG
- 1921 CTCTACCCCA TCCCGGCCAA CGCCACCAAC GTGCCCATCT CCATCCCCTC GCGCAACTGG
- 1981 GCCGCCTTCC GCGGCTGGTC CTTCACGCGC CTCAAGACCA AGGAGACGCC CTCGCTGGGC
- 2041 TCCGGGTTCG ACCCATACTT CGTCTACTCG GGCTCCATCC CCTACCTCGA CGGCACCTTC
- 2101 TACCTCAACC ACACCTTCAA GAAGGTCTCC ATCACCTTCG ATTCCTCCGT CAGCTGGCCC
- 2161 GGCAACGACC GGCTCCTGAC GCCCAACGAG TTCGAAATCA AGCGCACCGT
- 2221 GGATACAACG TGGCCCAGTG CAACATGACC AAGGACTGGT TCCTGGTCCA

# 116/153

- 2281 CACTACAACA TCGGCTACCA GGGCTTCTAC GTGCCCGAGG GCTACAAGGA
- 2341 TCCTTCTCC GCAACTTCCA GCCCATGAGC CGCCAGGTGG TGGACGAGGT CAACTACAAG
- 2401 GACTACCAGG CCGTCACCCT GGCCTACCAG CACAACAACT CGGGCTTCGT
- 2461 GCGCCCACCA TGCGCCAGGG CCAGCCCTAC CCCGCCAACT ACCCGTACCC GCTCATCGGC
- 2521 AAGAGCGCCG TCACCAGCGT CACCCAGAAA AAGTTCCTCT GCGACAGGGT CATGTGGCGC
- 2581 ATCCCCTTCT CCAGCAACTT CATGTCCATG GGCGCGCTCA CCGACCTCGG GCAGAACATG
- 2641 CTCTATGCCA ACTCCGCCCA CGCGCTAGAC ATGAATTTCG AAGTCGACCC CATGGATGAG
- 2701 TCCACCCTTC TCTATGTTGT CTTCGAAGTC TTCGACGTCG TCCGAGTGCA
- 2761 CGCGGCGTCA TCGAGGCCGT CTACCTGCGC ACCCCCTTCT CGGCCGGTAA CGCCACCACC

2821 TAA

- 1 ATGGCCACCC CATCGATGCT GCCCCAGTGG GCGTACATGC ACATCGCCGG ACAGGACGCT
- 61 TCGGAGTACC TGAGTCCGGG TCTGGTGCAG TTCGCCCGCG CCACAGACAC CTACTTCAGT
  - 121 CTGGGGAACA AGTTTAGGAA CCCCACGGTG GCACCCACGC ACGATGTGAC CACCGACCGC
  - 181 AGCCAGCGGC TGACGCTGCG CTTCGTGCCC GTGGACCGCG AGGACAACAC
  - 241 AAAGTGCGCT ACACGCTGGC CGTGGGCGAC AACCGCGTGC TGGACATGGC CAGCACCTAC
  - 301 TTTGACATCC GCGGCGTGCT GGATCGGGGC CCTAGCTTCA AACCCTACTC CGGCACCGCT
  - 361 TACAACAGCC TGGCTCCCAA GGGAGCGCCC AACACTTGCC AGTGGACATA TACTGATAAC
  - 421 CAAACTGAGA AAACAGCCAC ATATGGAAAT GCACCCGTAG AGGGCATTAA CATTACAAAA
  - 481 GATGGCATTC AACTTGGAAC TGACAGCGAT GGTCAGGCAA TCTATGCAGA
  - 541 CAGCCCGAAC CTCAGGTGGG AGATCCTGAA TGGCATGATA CCACAGGTAC AGAAGAAAAA
  - 601 TATGGAGGCA GAGCGCTTAA ACCTGCCACC GACATGAAAC CTTGCTATGG CTCTTTTGCC
  - 661 AAGCCAACTA ATGTTAAGGG AGGTCAGGCC AAAAGCAGAA CAAAAACTGA TGGAACAACT
  - 721 GAGCCTGATA TTGACATGGC CTTTTTTGAT GGCAGAAATG CAACAACAGC TGGTTTGACT
  - 781 CCAGAAATTG TTTTGTATAC TGAAAATGTG GATCTGGAAA CTCCAGATAC CCATATTGTA
  - 841 TACAAGGCAG GCACAGATGA CAGCAGCTCT TCTATCAATT TGGGTCAGCA GTCCATGCCC
  - 901 AACAGACCCA ACTACATTGG CTTCAGAGAC AACTTTATCG GGCTCATGTA
  - 961 ACTGGCAATA TGGGTGTACT GGCTGGACAG GCCTCCCAGC TGAATGCTGT GGTGGACTTG
  - $1021 \quad {\tt CAGGACAGAA} \quad {\tt ACACTGAACT} \quad {\tt GTCCTACCAG} \quad {\tt CTCTTGCTTG} \quad {\tt ACTCTCTGGG} \\ \quad {\tt TGACAGAACC} \quad$
  - 1081 AGGTATTTCA GTATGTGGAA TCAGGCGGTG GACAGTTATG ACCCCGATGT GCGCATTATT

SEQ	$\mathbf{m}$	NO:	20
-----	--------------	-----	----

- 1141 GAAAATCACG GTGTGGAGGA TGAACTCCCC AACTATTGCT TCCCCCTGAA
- 1201 AGAACAAATA GTTATCAGGG AATTAAACCC AATGGAGGCG ATCCAGCTAC ATGGGCCAAA
- 1261 GATGAAAGCG TCAATGATTC TAATGAATTG GGCAAGGGCA ATCCTTTCGC CATGGAGATC
- 1321 AACATCCAGG CCAACCTGTG GCGGAACTTC CTCTACGCGA ACGTGGCGCT GTACCTGCCC
- 1381 GACTCCTACA AGTACACGCC GGCCAACATC ACGCTGCCCG CCAACACCAA
- 1441 TACATGAACG GCCGCGTGGT GGCGCCCTCG CTGGTGGACG CCTACATCAA CATCGGGGCG
- 1501 CGCTGGTCGC TGGACCCCAT GGACAACGTC AACCCCTTCA ACCACCACCG CAACGCGGGC
- 1561 CTGCGCTACC GCTCCATGCT CCTGGGCAAC GGGCGCTACG TGCCCTTCCA CATCCAGGTG
- 1621 CCCCAAAAGT TTTTCGCCAT CAAGAGCCTC CTGCTCCTGC CCGGGTCCTA CACCTACGAG
- 1681 TGGAACTTCC GCAAGGACGT CAACATGATC CTGCAGAGCT CCCTCGGCAA
- 1741 ACGGACGGG CCTCCATCGC CTTCACCAGC ATCAACCTCT ACGCCACCTT CTTCCCCATG
- 1801 GCGCACAACA CCGCCTCCAC GCTCGAGGCC ATGCTGCGCA ACGACACCAA CGACCAGTCC
- 1861 TTCAACGACT ACCTCTCGGC GGCCAACATG CTCTACCCCA TCCCGGCCAA
- 1921 GTGCCCATCT CCATCCCCTC GCGCAACTGG GCCGCCTTCC GCGGATGGTC CTTCACGCGC
- 1981 CTCAAGACCC GCGAGACGCC CTCGCTAGGC TCCGGGTTCG ACCCCTACTT CGTCTACTCG
- 2041 GGCTCCATCC CCTACCTCGA CGGCACCTTC TACCTCAACC ACACCTTCAA GAAGGTCTCC
- 2101 ATCACCTTCG ACTCCTCCGT CAGCTGGCCC GGCAACGACC GCCTCCTGAC GCCCAACGAG
- 2161 TTCGAAATCA AGCGCACCGT CGACGGAGAG GGATACAACG TGGCCCAGTG CAACATGACC
- 2221 AAGGACTGGT TCCTGGTCCA GATGCTGGCC CACTACAACA TCGGCTACCA
  GGGCTTCTAC

- 2281 GTGCCCGAGG GCTACAAGGA CCGCATGTAC TCCTTCTTCC GCAACTTCCA GCCCATGAGC
- 2341 CGCCAGGTCG TGGACGAGĠT CAACTACAAG GACTACCAGG CCGTCACCCT GGCCTACCAG
- 2401 CACAACAACT CGGGCTTCGT CGGCTACCTC GCGCCCACCA TGCGCCAGGG CCAGCCCTAC
- 2461 CCCGCCAACT ACCCCTACCC GCTCATCGGC AAGAGCGCCG TCGCCAGCGT CACCCAGAAA
- 2521 AAGTTCCTCT GCGACCGGGT CATGTGGCGC ATCCCCTTCT CCAGCAACTT CATGTCCATG
- 2581 GGCGCGCTCA CCGACCTCGG CCAGAACATG CTCTACGCCA ACTCCGCCCA CGCGCTAGAC
- 2641 ATGAATTTCG AAGTCGACCC CATGGATGAG TCCACCCTTC TCTATGTTGT CTTCGAAGTC
- 2701 TTCGACGTCG TCCGAGTGCA CCAGCCCCAC CGCGGCGTCA TCGAGGCCGT CTACCTGCGC
  - 2761 ACGCCCTTCT CGGCCGGCAA CGCCACCACC TAA

### 120/153

- ${\tt 1} \quad {\tt ATGGCCACCC} \quad {\tt CATCGATGCT} \quad {\tt GCCCCAGTGG} \quad {\tt GCGTACATGC} \quad {\tt ACATCGCCGG} \\ {\tt ACAGGACGCT} \quad {\tt CATCGATGCT} \quad {\tt GCCCCAGTGG} \quad {\tt GCGTACATGC} \quad {\tt ACATCGCCGG} \\ {\tt ACAGGACGCT} \quad {\tt CATCGATGCT} \quad {\tt GCCCCAGTGG} \quad {\tt GCGTACATGC} \quad {\tt ACATCGCCGG} \\ {\tt ACAGGACGCT} \quad {\tt CATCGATGCT} \quad {\tt GCCCCAGTGG} \quad {\tt GCGTACATGC} \quad {\tt ACATCGCCGG} \\ {\tt ACAGGACGCT} \quad {\tt CATCGATGCT} \quad {\tt GCCCCAGTGG} \quad {\tt GCGTACATGC} \quad {\tt ACATCGCCGGG} \\ {\tt ACAGGACGCT} \quad {\tt CATCGATGCT} \quad {\tt GCCCCAGTGG} \quad {\tt GCGTACATGC} \quad {\tt ACATCGCCGGG} \\ {\tt ACAGGACGCT} \quad {\tt CATCGATGCT} \quad {\tt GCCCCAGTGG} \quad {\tt GCGTACATGC} \quad {\tt ACATCGCCGGG} \\ {\tt ACAGGACGCT} \quad {\tt CATCGATGCT} \quad {\tt GCCCCAGTGG} \quad {\tt GCGTACATGC} \quad {\tt ACATCGCCGGG} \\ {\tt ACAGGACGCT} \quad {\tt CATCGATGCT} \quad {\tt ACATCGCCGGG} \quad {\tt ACATCGCGCGGG} \quad {\tt ACATCGGCGGG} \quad {\tt ACATCGGCGGG} \quad {\tt ACATCGGCGGG} \quad$
- 61 TCGGAGTACC TGAGTCCGGG TCTGGTGCAG TTCGCCCGCG CCACAGACAC CTACTTCAGT
- 121 CTGGGGAACA AGTTTAGGAA CCCCACGGTG GCGCCCACGC ACGATGTGAC CACCGACCGC
- 181 AGCCAGCGGC TGACGCTGCG CTTCGTGCCC GTGGACCGCG AGGACAACAC CTACTCGTAC
- 241 AAAGTGCGCT ACACGCTGGC CGTGGGCGAC AACCGCGTGC TGGACATGGC CAGCACCTAC
- 301 TTTGACATCC GCGGCGTGCT GGATCGGGGC CCTAGCTTCA AACCCTACTC CGGCACCGCC
- 361 TACAACAGCC TGGCTCCCAA GGGAGCGCCC AACACTTGCC AGTGGACATA TACTGATAAC
- 421 CAAACTGAGA AAACAGCCAC ATATGGAAAT GCGCCTGTGC AAGGCATTAG
  TATTACAAAA
- 481 GATGGTATTC AACTTGGAAC TGACACTGAT GATCAGCCCA TTTATGCAGA TAAAACTTAT
- 541 Caaccagage ctcaagtggg tgatgctgaa tggcatgaca tcactggtac tgatgaaaaa
- 601 TATGGAGGCA GAGCTCTCAA GCCTGACACC AAAATGAAGC CCTGCTATGG TTCTTTTGCC
- 661 AAGCCTACCA ATAAAGAAGG AGGTCAGGCA AATGTGAAAA CCGAAACAGG CGGTACCAAA
- 781 CCAGAAATTG TTTTGTATAC TGAGAATGTG GATCTGGAAA CTCCAGATAC TCATATTGTA
- 841 TACAAGGCAG GCACAGATGA CAGCAGCTCT TCTATCAATT TGGGTCAGCA
- 901 AACAGACCCA ACTACATTGG CTTCAGAGAC AACTTTATCG GTCTCATGTA
- 961 ACTGGCAATA TGGGTGTACT GGCTGGTCAG GCCTCCCAGC TGAATGCTGT GGTGGACTTG
- 1021 CAGGACAGAA ACACTGAACT GTCCTACCAG CTCTTGCTTG ACTCTCTGGG
- 1081 AGGTATTTTA GTATGTGGAA TCAGGCGGTG GACAGTTATG ACCCCGATGT GCGCATTATT

## Fig. 26A

### 121/153

- · 1141 GAAAATCACG GTGTGGAGGA TGAACTCCCT AATTATTGCT TCCCCCTTAA
- 1201 AGAACTGATA CTTACCAGGG AATTAAGGCC AATGGTGCTG ATCAAACCAC
- 1261 GATGATACTG TTAATGATGC TAATGAATTG GGCAAGGGCA ATCCTTTCGC CATGGAGATC
- 1321 AACATCCAGG CCAACCTGTG GCGGAACTTC CTCTACGCGA ACGTGGCCCT
- 1381 GACTCCTACA AGTACACGCC GGCCAACATC ACGCTGCCCA CCAACACCAA CACCTACGAT
- 1441 TACATGAACG GCCGCGTGGT GGCGCCCTCG CTGGTGGACG CCTACATCAA CATCGGGGCG
- 1501 CGCTGGTCGC TGGACCCCAT GGACAACGTC AACCCCTTCA ACCACCACCG CAACGCGGGC
- 1561 CTGCGCTACC GCTCCATGCT CCTGGGCAAC GGGCGCTACG TGCCCTTCCA CATCCAGGTG
- 1621 CCCCAAAAGT TCTTCGCCAT CAAGAGCCTC CTGCTCCTGC CCGGGTCCTA CACCTACGAG
- 1681 TGGAACTTCC GCAAGGACGT CAACATGATC CTGCAGAGCT CCCTCGGCAA CGACCTGCGC
- 1741 ACGGACGGG CCTCCATCGC CTTCACCAGC ATCAACCTCT ACGCCACCTT CTTCCCCATG
- 1801 GCGCACAACA CCGCCTCCAC GCTCGAGGCC ATGCTGCGCA ACGACACCAA CGACCAGTCC
- 1861 TTCAACGACT ACCTCTCGGC GGCCAACATG CTCTACCCCA TCCCGGCCAA TGCCACCAAC
- 1921 GTGCCCATCT CCATCCCCTC GCGCAACTGG GCCGCCTTCC GCGGATGGTC CTTCACGCGC
- 1981 CTCAAGACCC GCGAGACGCC CTCGCTAGGC TCCGGGTTCG ACCCCTACTT CGTCTACTCG
- 2041 GGCTCCATCC CCTACCTCGA CGGCACCTTC TACCTCAACC ACACCTTCAA GAAGGTCTCC
- 2101 ATCACCTTCG ACTCCTCCGT CAGCTGGCCC GGCAACGACC GCCTCCTGAC GCCCAACGAG
- 2161 TTCGAAATCA AGCGCACCGT CGACGGAGAG GGGTACAACG TGGCCCAGTG CAACATGACC
- 2221 AAGGACTGGT TCCTGGTCCA GATGCTGGCC CACTACAACA TCGGCTACCA GGGCTTCTAC

# Fig. 26B

- 2281 GTGCCCGAGG GCTACAAGGA CCGCATGTAC TCCTTCTTCC GCAACTTCCA GCCCATGAGC
- 2341 CGCCAGGTCG TGGACGAGGT CAACTACAAG GACTACCAGG CCGTCACCCT GGCCTACCAG
- 2401 CACAACAACT CGGGCTTCGT CGGCTACCTC GCGCCCACCA TGCGCCAGGG CCAGCCCTAC
- 2461 CCCGCCAACT ACCCCTACCC GCTCATCGGC AAGAGCGCCG TCGCCAGCGT CACCCAGAAA
- 2521 AAGTTCCTCT GCGACCGGGT CATGTGGCGC ATCCCCTTCT CCAGCAACTT CATGTCCATG
- 2581 GGCGCGCTCA CCGACCTCGG CCAGAACATG CTCTACGCCA ACTCCGCCCA CGCGCTAGAC
- 2641 ATGAATTTCG AAGTCGACCC CATGGATGAG TCCACCCTTC TCTATGTTGT CTTCGAAGTC
- 2701 TTCGACGTCG TCCGAGTGCA CCAGCCCCAC CGCGGCGTCA TCGAGGCCGT CTACCTGCGC
  - 2761 ACGCCCTTCT CGGCCGGCAA CGCCACCACC TAA

- 1 ATGGCGACCC CATCGATGAT GCCGCAGTGG TCGTACATGC ACATCTCGGG CCAGGACGCC
- 61 TCGGAGTACC TGAGTCCCGG GCTGGTGCAG TTCGCTCGCG CCACCGAGAG CTACTTCAGT
- 121 CTGAGTAACA AGTTTAGGAA CCCCACGGTG GCGCCCACGC ACGATGTGAC CACCGACCGG
- 181 TCCCAGCGCC TGACGCTGCG GTTCATCCCC GTGGACCGCG AGGACACCGC GTACTCGTAC
- 241 AAGGCGCGGT TCACCCTGGC CGTGGGCGAC AACCGCGTGC TGGACATGGC
- 301 TTTGACATCC GCGGCGTGCT GGACCGCGGC CCCACCTTCA AGCCCTACTC
- 361 TACAACTCCC TGGCCCCCAA GGGCGCTCCC AACTCCTGCG AGTGGGAGCA AGAGGAAACT
- 421 CAGGCAGTTG AAGAAGCAGC AGAAGAGGAG GAAGAAGATG CTGACGGTCA AGCTGAGGAA
- 481 GAGCAAGCAG CTACCAAAAA GACTCATGTA TATGCTCAGG CTCCCCTTTC CGGCGAAAAA
- 541 ATTAGCAAAG ACGGTCTGCA GATAGGAACG GACGCTACAG CAACCGAACA
- 601 TATGCAGACC CTACATTCCA GCCCGAACCC CAAATCGGGG AGTCCCAGTG GAATGAGGCA
- 661 GATGCTACAG TCGCTGGTGG TAGAGTGCTC AAGAAAACCA CTCCCATGAA ACCATGCTAT
- 721 GGTTCCTATG CAAGACCCAC GAATGCTAAT GGAGGTCAGG GTGTACTAGC GGCAAATGCC
- 781 CAAGGACAGC TAGAATCTCA GGTTGAAATG CAATTCTTTT CAACTTCTGA AAACGCCCGT
- 841 AACGAGGCTA ACAACATTCA GCCCAAATTG GTGCTGTATA GCGAGGATGT GCACATGGAG
- 901 ACCCCGGATA CACACCTCTC TTACAAGCCC ACAAAAAGCG ATGACAATTC TAAAGTTATG
- 961 CTGGGCCAAC AGGCCATGCC CAACAGGCCT AATTACATTG GCTTCAGAGA CAACTTTATC
- 1021 GGTCTCATGT ACTACAACAG CACTGGCAAC ATGGGAGTGC TTGCAGGTCA GGCCTCTCAG
- 1081 TTGAATGCAG TGGTGGACTT GCAAGACAGA AACACAGAAC TGTCCTACCA GCTCTTGCTT

### 124/153

- 1141 GATTCCATGG GTGACAGAAC CAGATATTTC TCCATGTGGA ATCAGGCAGT GGACAGTTAT
- 1201 GACCCAGATG TCAGAATTAT TGAAAATCAT GGAACTGAAG ACGAGCTCCC CAACTATTGT
- 1261 TTCCCTCTGG GCGGCATAGG GGTAACTGAC ACTTACCAGG CTGTTAAGAC CAACAATGGC
- 1321 AATAATGGGG GTCAGGTGAC TTGGACAAAA GATGAAACTT TTGCAGAGCG
- 1381 GGGGTGGGAA ACAATTTCGC CATGGAGATC AACCTCAATG CCAACCTGTG
- 1441 CTGTACTCCA ACGTGGCCCT GTACCTGCCA GACAAGCTTA AGTACAACCC CTCCAACGTG
- 1501 GACATCTCTG ACAACCCCAA CACCTACGAT TACATGAACA AGCGAGTGGT
- 1561 CTGGTGGACT GCTACATCAA CCTGGGCGCG CGCTGGTCGC TGGACTACAT GGACAACGTC
- 1621 AACCCTTTCA ACCACCACCG CAACGCGGGC CTGCGCTACC GCTCCATGCT CCTGGGCAAC
- 1681 GGGCGCTACG TGCCCTTCCA CATCCAGGTG CCCCAGAAGT TCTTTGCCAT CAAGAACCTC
- 1741 CTCCTCCTGC CGGGCTCCTA CACCTACGAG TGGAACTTCA GGAAGGATGT CAACATGGTC
- 1801 CTCCAGAGCT CTCTGGGCAA CGATCTCAGG GTGGACGGGG CCAGCATCAA GTTCGAGAGC
- 1861 ATCTGCCTCT ACGCCACCTT CTTCCCCATG GCCCACAACA CCGCCTCCAC GCTCGAGGCC
- 1921 ATGCTCAGGA ACGACACCAA CGACCAGTCC TTCAATGACT ACCTCTCCGC CGCCAACATG
- 1981 CTCTACCCCA TCCCCGCCAA CGCCACCAAC GTCCCCATCT CCATCCCCTC GCGCAACTGG
- 2041 GCGGCCTTCC GCGGCTGGGC CTCACCCGC CTCAAGACCA AGGAGACCCC CTCCCTGGGC
- 2101 TCGGGATTCG ACCCCTACTA CACCTACTCG GGATCCATTC CCTACCTGGA
- 2161 TACCTCAACC ACACTTTCAA GAAGGTCTCG GTCACCTTCG ACTCCTCGGT CAGCTGGCCG
- 2221 GGCAACGACC GCCTGCTCAC CCCCAACGAG TTCGAGATCA AGCGCTCGGTCGACGGGGAG

Fig. 27B

# 125/153

- 2281 GGCTACAACG TGGCCCAGTG CAACATGACC AAGGACTGGT TCCTGGTCCA GATGCTGGCC
- 2341 AACTACAACA TCGGCTACCA GGGCTTCTAC ATCCCAGAGA GCTACAAGGA CAGGATGTAC
- 2401 TCCTTCTTCA GGAACTTCCA GCCCATGAGC CGGCAGGTGG TGGACCAGAC CAAGTACAAG
- 2461 GACTACCAGG AGGTGGGCAT CATCCACCAG CACAACAACT CGGGCTTCGT GGGCTACCTC
- 2521 GCCCCCACCA TGCGCGAGGG ACAGGCCTAC CCCGCCAACT TCCCCTACCC GCTCATAGGC
- 2581 AAGACCGCGG TCGACAGCAT CACCCAGAAA AAGTTCCTCT GCGACCGCAC CCTCTGGCGC
- 2641 ATCCCCTTCT CCAGCAACTT CATGTCCATG GGTGCGCTCA CGGACCTGGG CCAGAACCTG
- 2701 CTCTATGCCA ACTCCGCCCA CGCGCTCGAC ATGACCTTCG AGGTCGACCC CATGGACGAG
- 2761 CCCACCCTTC TCTATGTTCT GTTCGAAGTC TTTGACGTGG TCCGGGTCCA
- 2821 CGCGGCGTCA TCGAGACCGT GTACCTGCGC ACGCCCTTCT CGGCCGGCAACCCCACCACC

2881 TAA

- 1 ATGGCCACCC CATCGATGCT GCCCCAGTGG GCGTACATGC ACATCGCCGG ACAGGACGCT
- 61 TCGGAGTACC TGAGTCCGGG TCTGGTGCAG TTCGCCCGCG CCACAGACAC CTACTTCAGT
- 121 CTGGGGAACA AGTTTAGGAA CCCCACGGTG GCGCCCACGC ACGATGTGAC CACCGACCGC
- 181 AGCCAGCGGC TGACGCTGCG CTTCGTGCCC GTGGACCGCG AGGACAACAC
- 241 AAAGTGCGCT ACACGCTGGC CGTGGGCGAC AACCGCGTGC TGGACATGGC CAGCACCTAC
- 301 TTTGACATCC GCGGCGTGCT GGACCGGGGC CCTAGCTTCA AACCCTACTC CGGCACCGCC
- 361 TACAACAGCC TGGCCCCCAA GGGAGCTCCC AATTCCAGTC AGTGGGAGCA GACGGAGAAC
- 421 GGGGGGGAC AGGCTACGAC TAAAACACAC ACCTATGGAG TTGCCCCAAT GGGTGGAACT
- 481 AATATTACAG TCGACGGACT ACAAATTGGA ACTGACGCTA CAGCTGATAC GGAAAAACCA
- 541 ATTTATGCTG ATAAAACATT CCAACCTGAG CCTCAGATAG GAGAGGAAAA CTGGCAAGAA
- 601 ACTGAAAGCT TTTATGGCGG TAGGGCTCTT AAGAAAGACA CAAACATGAA GCCTTGTTAT
- 661 GGCTCATTTG CCAGACCTAC CAATGAAAAG GGAGGTCAAG CTAAACTTAA AGTTGGAGCT
- 721 GATGGGCTGC CGACCAAAGA ATTTGACATA GACCTAGCAT TCTTTGATAC TCCTGGTGGC
- 781 ACTGTGACCG GAGGTACAGA GGAGTATAAA GCAGATATTG TTATGTATAC CGAAAACACG
- 841 TATCTGGAAA CTCCAGACAC ACATGTGGTG TATAAACCAG GCAAGGATAA
- 901 AAAATTAACC TGGTCCAGCA GTCTATGCCC AACAGGCCCA ACTACATTGG
- 961 AACTTTATTG GGCTCATGTA TTACAACAGC ACTGGCAATA TGGGTGTGCT GGCCGGTCAG
- 1021 GCTTCTCAGT TGAATGCTGT GGTTGACTTG CAAGACAGAA ACACTGAACT GTCTTACCAG
- 1081 CTCTTGCTTG ACTCTTTGGG TGACAGAACC AGGTATTTCA GTATGTGGAA TCAGGCGGTG

11K004	48PV					
SEQ II				27/15		
TGAACI	TCCC		AICCIGAIGI	GCGCATTATT	GAAAACCATG	GTGTGGAAGA
12 TGTGAA	01 AGTA	AACTATTGCT	TCCCCCTGGA	TGGGTCTGGC	ACTAACGCCG	CTTACCAAGG
12 TGTCGC	61 AGCT	AAAAATGGTC	AAGATGGTGA	TGTTGAGAGC	GAATGGGAAA	AAGATGATAC
13	21	ርርል እ ልጥሮ ል ልጥ	<b>ም</b> ስጥሮር እ አ <i>ርርር</i>	C > > C > mmmmm	GGG1 C	

- 1321 CGAAATCAAT TATGCAAGGG CAACATTTTT GCCATGGAGA TCAATCTCCA GGCCAACCTG
- 1381 TGGAGAAGTT TTCTCTACTC GAACGTGGCC CTGTACCTGC CCGATTCTTA
- 1441 CCGGCCAACA TCACCCTGCC CACCAACACC AACACCTACG ATTACATGAA CGGGAGAGTG
- 1501 GTGCCTCCCT CGCTGGTGGA CGCCTACATC AACATCGGGG CGCGCTGGTC
- 1561 ATGGACAACG TCAATCCCTT CAACCACCAT CGCAACGCGG GGCTGCGCTA
- 1621 CTCCTGGGCA ACGGGCGCTA CGTGCCCTTC CACATCCAGG TGCCCCAGAA ATTTTTCGCC
- 1681 ATTAAGAGCC TCCTGCTCCT GCCCGGGTCC TACACCTACG AGTGGAACTT CCGCAAGGAC
- 1741 GTCAACATGA TCCTGCAGAG CTCCCTCGGC AACGACCTGC GCACGGACGG
- 1801 TCCTTCACCA GCATCAACCT CTACGCCACC TTCTTCCCCA TGGCGCACAA
- 1861 ACGCTCGAGG CCATGCTGCG CAACGACACC AACGACCAGT CCTTCAACGA
- 1921 GCGGCCAACA TGCTCTACCC CATCCCGGCC AACGCCACCA ACGTGCCCAT
- 1981 TCGCGCAACT GGGCCGCCTT CCGCGGCTGG TCCTTCACGC GCCTCAAGAC CAAGGAGACG
- 2041 CCCTCGCTGG GCTCCGGGTT CGACCCCTAC TTCGTCTACT CGGGCTCCAT CCCCTACCTC
- 2101 GACGGCACCT TCTACCTCAA CCACACCTTC AAGAAGGTCT CCATCACCTT
- 2161 GTCAGCTGGC CCGGCAACGA CCGGCTCCTG ACGCCCAACG AGTTCGAAAT CAAGCGCACC
- 2221 GTCGACGGCG AGGGCTACAA CGTGGCCCAG TGCAACATGA CCAAGGACTG
- 2281 CAGATGCTGG CCCACTACAA CATCGGCTAC CAGGGCTTCT ACGTGCCCGA

#### ITR0048PV

#### SEQ ID NO: 23

## 128/153

- 2341 GACCGCATGT ACTCCTTCTT CCGCAACTTC CAGCCCATGA GCCGCCAGGT CGTGGACGAG
- 2401 GTCAACTACA AGGACTACCA GGCCGTCACC CTGGCCTACC AGCACAACAA CTCGGGCTTC
- 2461 GTCGGCTACC TCGCGCCCAC CATGCGCCAG GGCCAGCCCT ACCCCGCCAA
- 2521 CCGCTCATCG GCAAGAGCGC CGTCGCCAGC GTCACCCAGA AAAAGTTCCT CTGCGACCGG
- 2581 GTCATGTGGC GCATCCCCTT CTCCAGCAAC TTCATGTCCA TGGGCGCGCT CACCGACCTC
- 2641 GGCCAGAACA TGCTCTACGC CAACTCCGCC CACGCGCTAG ACATGAATTT CGAAGTCGAC
- 2701 CCCATGGATG AGTCCACCCT TCTCTATGTT GTCTTCGAAG TCTTCGACGT CGTCCGAGTG
- 2761 CACCAGCCC ACCGCGGCGT CATCGAGGCC GTCTACCTGC GCACCCCCTT CTCGGCCGGT

2821 AACGCCACCA CCTAA

- 1 ATGGCGACCC CATCGATGAT GCCGCAGTGG TCGTACATGC ACATCTCGGG CCAGGACGCC
- 61 TCNGAGTACC TGAGCCCCGG GCTGGTGCAG TTCGCCCGCG CCACCGAGAG CTACTTCAGC
- 121 · CTGAGTAACA AGTTTAGGAA CCCCACGGTG GCGCCCACGC ACGATGTGAC CACCGACCGG
- 181 TCTCAGCGCC TGACGCTGCG GTTCATTCCC GTGGACCGCG AGGACACCGC GTACTCGTAC
- 241 AAGGCGCGGT TCACCCTGGC CGTGGGCGAC AACCGCGTGC TGGACATGGC CTCCACCTAC
- 301 TTTGACATCC GCGGGGTGCT GGACCGGGGT CCCACTTCA AGCCCTACTC TGGCACCGCC
- 361 TACAACTCCC TGGCCCCCAA GGGCGCTCCC AACTCCTGCG AGTGGGAGCA AGAGGAAACT
- 421 CAGGCAGTTG AAGAAGCAGC AGAAGAGGAA GAAGAAGATG CTGACGGTCA AGCTGAGGAA
- 481 GAGCAAGÇAG CTACCAAAAA GACTCATGTA TATGCTCAGG CTCCCCTTTC TGGCGAAAAA
- 541 ATTAGTAAAG ATGGTCTGCA AATAGGAACG GACGCTACAG CTACAGAACA AAAACCTATT
- 601 TATGCAGACC CTACATTCCA GCCCGAACCC CAAATCGGGG AGTCACAGTG GAATGAGGCA .
- 661 GATGCTACAG TCGCCGGCGG TAGAGTGCTA AAGAAATCTA CTCCCATGAA
- 721 GGTTCCTATG CAAGACCCAC AAATGCTAAT GGAGGTCAGG GTGTACTAAC GGCAAATGCC
- 781 CAGGGACAGC TAGAATCTCA GGTTGAAATG CAATTCTTTT CAACTTCTGA
- 841 AACGAGACTA ACAACATTCA GCCCAAATTG GTGCTGTATA GTGAGGATGT GCACATGGAG
- 901 ACCCCGGATA CGCACCTTTC TTACAAGCCC GCAAAAAGCG ATGACAATTC AAAAATCATG
- 961 CTGGGTCAGC AGTCCATGCC CAACAGACCT AATTACATCG GCTTCAGAGA TAACTTTATC
- 1021 GGCCTCATGT ATTACAATAG CACTGGCAAC ATGGGAGTGC TTGCAGGTCA GGCCTCTCAG
- 1081 TTGAATGCAG TGGTGGACTT GCAAGACAGA AACACAGAAC TGTCCTACCA

- 1141 GATTCCATGG GTGACAGAAC CAGATACTTT TCCATGTGGA ATCAGGCAGT GGACAGTTAT
- 1201 GACCCAGATG TTAGAATTAT TGAAAATCAT GGAACTGAAG ACGAGCTCCC CAACTATTGT
- 1261 TTCCCTCTGG GTGGCATAGG GGTAACTGAC ACTTACCAGG CTGTTAAAAC CAACAATGGC
- 1321 AATAACGGGG GCCAGGTGAC TTGGACAAAA GATGAAACTT TTGCAGATCG CAATGAAATA
- 1381 GGGGTGGGAA ACAATTTCGC TATGGAGATA AACCTCAGTG CCAACCTGTG GAGAAACTTC
- 1441 CTGTACTCCA ACGTGGCGCT GTACCTACCA GACAAGCTTA AGTACAACCC CTCCAATGTG
- 1501 GACATCTCTG ACAACCCCAA CACCTACGAT TACATGAACA AGCGAGTGGT GGCCCCGGGG
- 1561 CTGGTGGACT GCTACATCAA CCTGGGCGCG CGCTGGTCGC TGGACTACAT GGACAACGTC
- 1621 AACCCCTTCA ACCACCACCG CAATGCGGGC CTGCGCTACC GCTCCATGCT CCTGGGCAAC
- 1681 GGGCGCTACG TGCCCTTCCA CAȚCCAGGTG CCCCAGAAGT TCTTTGCCAT CAAGAACCTC
- 1741 CTCCTCCTGC CGGGCTCCTA CACCTACGAG TGGAACTTCA GGAAGGATGT CAACATGGTC
- 1801 CTCCAGAGCT CTCTGGGTAA CGATCTCAGG GTGGACGGGG CCAGCATCAA GTTCGAGAGC
- 1861 ATCTGCCTCT ACGCCACCTT CTTCCCCATG GCCCACAACA CGGCCTCCAC GCTCGAGGCC
- 1921 ATGCTCAGGA ACGACACCAA CGACCAGTCC TTCAATGACT ACCTCTCCGC CGCCAACATG
- 1981 CTCTACCCCA TACCCGCCAA CGCCACCAAC GTCCCCATCT CCATCCCCTC GCGCAACTGG
- 2041 GCGGCCTTCC GCGGCTGGGC CTCACCCGC CTCAAGACCA AGGAGACCCC CTCCCTGGGC
- 2101 TCGGGATTCG ACCCCTACTA CACCTACTCG GGCTCCATTC CCTACCTGGA CGGCACCTTC
- 2161 TACCTCAACC ACACTTTCAA GAAGGTCTCG GTCACCTTCG ACTCCTCGGT CAGCTGGCCG
- 2221 GGCAACGACC GTCTGCTCAC CCCCAACGAG TTCGAGATCA AGCGCTCGGT CGACGGGGAG

## 131/153

- 2281 GGCTACAACG TGGCCCAGTG CAACATGACC AAGGACTGGT TCCTGGTCCA
- 2341 AACTACAACA TCGGCTACCA GGGCTTCTAC ATCCCAGAGA GCTACAAGGA CAGGATGTAC
- 2401 TCCTTCTA GGAACTTCCA GCCCATGAGC CGGCAGGTGG TGGACCAGAC CAAGTACAAG
- 2461 GACTACCAGG AGGTGGGCAT CATCCACCAG CACAACAACT CGGGCTTCGT GGGCTACCTC
- 2521 GCCCCCACCA TGCGCGAGGG ACAGGCCTAC CCCGCCAACT TCCCCTATCC GCTCATAGGC
- 2581 AAGACCGCGG TCGACAGCAT CACCCAGAAA AAGTTCCTCT GCGACCGCAC CCTCTGGCGC
- 2641 ATCCCCTTCT CCAGCAACTT CATGTCCATG GGTGCGCTCT CGGACCTGGG CCAGAACTTG
- 2701 CTCTACGCCA ACTCCGCCCA CGCCCTCGAC ATGACCTTCG AGGTCGACCC CATGGACGAG
- 2761 CCCACCCTTC TCTATGTTCT GTTCGAAGTC TTTGACGTGG TCCGGGTCCA
- 2821 CGCGGCGTCA TCGAGACCGT GTACCTGCGT ACGCCCTTCT CGGCCGGCAA

2881 TAA

- 1 ATGGCGACCC CATCGATGAT GCCGCAGTGG TCGTACATGC ACATCTCGGG CCAGGACGCC
- 61 TCGGAGTACC TGAGCCCCGG GCTGGTGCAG TTCGCCCGCG CCACCGAGAG CTACTTCAGT
- 121 CTGAGTAACA AGTTTAGGAA CCCCACGGTG GCGCCCACGC ACGATGTGAC CACCGACCGG
- 181 TCCCAGCGCC TGACGCTGCG GTTCATCCCC GTGGACCGCG AGGACACCGC GTACTCGTAC
- 241 AAGGCGCGGT TCACCCTGGC CGTGGGCGAC AACCGCGTGC TGGACATGGC
- 301 TTTGACATCC GCGGCGTGCT GGACCGCGGC CCCACCTTCA AGCCCTACTC CGGCACCGCC
- 361 TACAACTCCC TGGCCCCCAA GGGCGCTCCC AACTCTTGTG AGTGGGAGCA
- 421 GCCCAGGCCG CTTTGGAAGA CGAAGAATTA GAAGATGAAG ACGAGGAACC ACAGGATGAG
- 481 GCGCCTGTGA AAAAGACCCA TGTATACGCT CAGGCTCCCC TTTCTGGAGA AGAAATTACT
- 541 AAAGACGGTT TGCAAATAGG GTCAGATAAC ACAGAAGCTC AGTCTAAGCC
  TATATATGCA
- 601 GACCCTACAT TCCAGCCCGA ACCCCAAATC GGGGAGTCCC AGTGGAACGA GGCAGATGCT
- 661 ACAGTCGCTG GTGGTAGAGT GCTCAAGAAA ACCACTCCCA TGAAACCATG
- 721 TATGCAAGAC CCACGAATGC TAATGGAGGT CAGGGTGTGC TGGTGGCTGA TGATAAGGGG
- 781 GTCCTTCAAT CTAAAGTTGA ATTGCAATTT TTTTCAAATA CTACTACTCT TAATCAGCGG
- 841 GAGGGTAATG ATACAAAACC AAAAGTAGTG CTGTATAGCG AGGATGTGCA CATGGAAACA
- 901 CCAGACACCC ACATTTCTTA CAAGCCCACA AAAAGCGATG ACAATTCTAA AGTTATGCTG
- 961 GGCCAACAGT CCATGCCCAA CAGGCCTAAT TACATCGGCT TCAGAGACAA
- 1021 CTCATGTACT ACAACAGCAC TGGCAACATG GGAGTGCTTG CAGGTCAGGC
- 1081 AATGCAGTGG TGGACTTGCA AGACAGAAAC ACAGAACTGT CCTACCAGCT

# 133/153

- 1141 TCCATGGGTG ACAGAACCAG ATATTTCTCC ATGTGGAATC AGGCAGTGGA CAGTTATGAC
- 1201 CCGGATGTCA GAATTATTGA AAATCATGGA ACCGAAGACG AGCTCCCCAA
- 1261 CCTCTGGGTG GCATAGGGGT AACTGACACT TACCAGGTCA TTAAAACTAA TGGCAATGGT
- 1321 CAAGCAGACC CAACCTGGGA AAAAGATACA GAGTTTGCAG ACCGCAATGA AATAGGGGTG
- 1381 GGAAACAATT TCGCCATGGA GATCAACCTC AATGCCAACC TGTGGAGGAA
- 1441 TCCAACGTGG CCCTGTACCT GCCAGACAAG CTTAAGTACA ACCCCTCCAA CGTGGACATC
- 1501 TCTGACAACC CCAACACCTA CGATTACATG AACAAGCGAG TGGTGGCCCC GGGGCTGGTG
- 1561 GACTGCTACA TCAACCTGGG CGCGCGCTGG TCGCTGGACT ACATGGACAA
- 1621 TTCAACCACC ACCGCAACGC GGGCCTGCGC TACCGCTCCA TGCTCCTGGG CAACGGGCGC
- 1681 TACGTGCCCT TCCACATCCA GGTGCCCCAG AAGTTCTTTG CCATCAAGAA
- 1741 CTGCCGGGCT CCTACACCTA CGAGTGGAAC TTCAGGAAGG ATGTCAACAT GGTCCTCCAG
- 1801 AGCTCTTTGG GCAACGATCT CAGGGTGGAC GGGGCCAGCA TCAAGTTCGA GAGCATCTGC
- 1861 CTCTACGCCA CCTTCTTCCC CATGGCCCAC AACACCGCCT CCACGCTCGA GGCCATGCTC
- 1921 AGGAACGACA CCAACGACCA GTCCTTCAAT GACTACCTCT CCGCCGCCAA CATGCTCTAC
- 1981 CCCATCCCG CCAACGCCAC CAACGTCCCT ATCTCCATCC CCTCGCGCAA CTGGGCGGCC
- 2041 TTCCGCGGCT GGGCCTTCAC CCGCCTCAAG ACCAAGGAGA CACCCTCCCT GGGCTCGGGA
- 2101 TTCGACCCT ACTACACCTA CTCGGGATCC ATTCCCTACC TGGACGGCAC CTTCTACCTC
- 2161 AACCACACTT TCAAGAAGGT CTCGGTCACC TTCGACTCCT CGGTCAGCTG
- 2221 GACCGCCTGC TCACCCCCAA CGAGTTCGAG ATCAAGCGCT CGGTCGACGG

Fig. 30B

- 2281 AACGTGGCCC AGTGCAACAT GACCAAGGAC TGGTTCCTGG TCCAGATGCT
- 2341 AACATCGGCT ACCAGGGCTT CTACATCCCA GAGAGCTACA AGGACAGGAT GTACTCCTTC
- 2401 TTCAGGAACT TCCAGCCCAT GAGCCGGCAG GTGGTGGACC AAACCAAGTA CAAGGACTAC
- 2461 CAGGAGGTGG GCATCATCCA CCAGCACAAC AACTCGGGCT TCGTGGGCTA
- 2521 ACCATGCGCG AGGGACAGGC CTACCCCGCC AACTTCCCCT ACCCGCTCAT AGGCAAGACC
- 2581 GCGGTCGACA GCATCACCCA GAAAAAGTTC CTCTGCGACC GCACCCTCTG
- 2641 TTCTCCAGCA ACTTCATGTC CATGGGTGCG CTCACGGACC TGGGCCAGAA
- 2701 GCCAACTCCG CCCACGCGCT CGACATGACC TTCGAGGTCG ACCCCATGGA CGAGCCCACC
- 2761 CTTCTCTATG TTCTGTTCGA AGTCTTTGAC GTGGTCCGGG TCCACCAGCC GCACCGCGC
- 2821 GTCATCGAGA CCGTGTACCT GCGCACGCCC TTCTCGGCCG GCAACGCCAC CACCTAA

	1				50
hAd12		SYMHIAGQDA	SEYLSPGLVO	FARATDTYFT	
hAd3		AYMHIAGQDA		FARATDTYFS	MGNKFRNPTV
hAd7	MATPSMMPOW	AYMHIAGODA		FARATDTYFS	MGNKFRNPTV
hAd11	MATPSMLPQW	AYMHIAGODA		FARATDTYFN	LGNKFRNPTV
hAd21	MATPSMLPOW	AYMHIAGODA		FARATDTYFN	LGNKFRNPTV
hAd34	MATPSMLPQW	AYMHIAGODA		FARATDTYFN	LGNKFRNPTV
hAd35	MATPSMLPQW	AYMHIAGODA		FARATDTYFN	LGNKFRNPTV
C1	MATPSMLPOW	AYMHIAGODA		FARATDTYFN	LGNKFRNPTV
hAd1	MATPSMMPQW	SYMHISGODA		FARATETYFS	LNNKFRNPTV
hAd2	MATPSMMPOW	SYMHISGODA		FARATETYFS	LNNKFRNPTV
hAd5	MATPSMMPQW	SYMHISGODA		FARATETYFS	LNNKFRNPTV
ChAd3	MATPSMMPOW	SYMHISGQDA	SEYLSPGLVQ	FARATESYFS	LSNKFRNPTV
ChAd11	MATPSMMPOW	SYMHISGODA		FARATESYFS	LSNKFRNPTV
ChAd17	MATPSMMPOW	SYMHISGODA	SEYLSPGLVO	FARATESYFS	LSNKFRNPTV
ChAd19	MATPSMMPQW	-		FARATESYFS	LSNKFRNPTV
ChAd20	MATPSMMPOW			FARATESYFS	LSNKFRNPTV
hAd48		AYMHIAGQDA		FARATDTYFS	LGNKFRNPTV
ChAd4		AYMHIAGQDA		FARATDTYFS	LGNKFRNPTV
ChAd5		AYMHIAGQDA		FARATDTYFS	LGNKFRNPTV
ChAd7		AYMHIAGODA		FARATDTYFS	LGNKFRNPTV
ChAd16		AYMHIAGQDA		FARATDTYFS	LGNKFRNPTV
Pan6	-	AYMHIAGODA		FARATDTYFS	LGNKFRNPTV
hAd4	~	AYMHIAGQDA		FARATDTYFS	LGNKFRNPTV
hAd16		AYMHIAGQDA		FARATDTYFS	MGNKFRNPTV
ChAd6		AYMHIAGQDA		FARATDTYFS	LGNKFRNPTV
ChAd9		AYMHIAGQDA		FARATDTYFS	LGNKFRNPTV
ChAd10	-	AYMHIAGODA			LGNKFRNPTV
C68		AYMHIAGODA			LGNKFRNPTV
Pan5		AYMHIAGQDA			LGNKFRNPTV
Pan7	-	AYMHIAGODA			LGNKFRNPTV
hAd41	MATPSMMPOW	-			LGNKFRNPTV
hAd40	MATPSMMPOW	-		FARATDTYFS	LGNKFRNPTV
	<b>~</b>	. ~	-		
	51				100
hAd12	APTHDVTTDR	SQRLTLRFVP	VDREDTTYSY	KARFTLAVGD	NRVLDMASSY
hAd3	APTHDVTTDR		VDREDNTYSY		
hAd7	APTHDVTTDR		VDREDNTYSY		
hAd11	APTHDVTTDR		VDREDNTYSY		
hAd21	APTHDVTTDR	SQRLMLRFVP			
hAd34	APTHDVTTDR		VDREDNTYSY		
hAd35		SQRLMLRFVP			
C1	APTHDVTTDR	. SQRLMLRFVP	VDREDNTYSY	KVRYTLAVGE	NRVLDMASTF
hAd1	APTHDVTTDR	SQRLTLRFIP	VDREDTAYSY	KARFTLAVGE	NRVLDMASTY
hAd2	APTHDVTTDR	SQRLTLRFIP	VDREDTAYSY	KARFTLAVGE	NRVLDMASTY
hAd5	APTHDVTTDR	SQRLTLRFIP	VDREDTAYSY	KARFTLAVGI	NRVLDMASTY
ChAd3	APTHDVTTDR	SQRLTLRFIP	VDREDTAYSY	KARFTLAVGI	NRVLDMASTY
ChAd11	APTHDVTTDR	SQRLTLRFIP	VDREDTAYSY	KARFTLAVGI	NRVLDMASTY
ChAd17	APTHDVTTDR	SQRLTLRFIP	VDREDTAYSY	KARFTLAVGI	NRVLDMASTY
ChAd19	APTHDVTTDR	SQRLTLRFIP	VDREDTAYSY	KARFTLAVGI	NRVLDMASTY
ChAd20	APTHDVTTDR	SQRLTLRFIP	VDREDTAYSY	KARFTLAVGI	NRVLDMASTY
hAd48	APTHDVTTDR	SQRLTLRFVF	VDREDTTYSY	KARFTLAVGI	NRVLDMASTY
ChAd4	APTHOVTTOR	SQRLTLRFVF	VDREDNTYSY	KVRYTLAVGI	) NRVLDMASTY
ChAd5	APTHDVTTDF	SQRLTLRFVF	VDREDNTYSY	KVRYTLAVGI	NRVLDMASTY
ChAd7	APTHDVTTDF	SQRLTLRFVF	VDREDNTYSY	KVRYTLAVGI	NRVLDMASTY
ChAd16	APTHDVTTDF	SQRLTLRFVF	VDREDNTYSY	KVRYTLAVGI	NRVLDMASTY

Pan6	APTHDVTTDR	SQRLTLRFVP	VDREDNTYSY	KVRYTLAVGD	NRVLDMASTY
hAd4	APTHDVTTDR	SORLTLRFVP	VDREDNTYSY	KVRYTLAVGD	NRVLDMASTY
hAd16	APTHDVTTDR	SORLMLRFVP	VDREDNTYSY	KVRYTLAVGD	NRVLDMASTF
ChAd6	APTHDVTTDR	SORLTLRFVP	VDREDNTYSY	KVRYTLAVGD	NRVLDMASTY
ChAd9	APTHDVTTDR	SQRLTLRFVP	VDREDNTYSY	KVRYTLAVGD	NRVLDMASTY
ChAd10	APTHDVTTDR	SQRLTLRFVP	VDREDNTYSY	KVRYTLAVGD	NRVLDMASTY
C68	APTHOUTTOR	SORLTLRFVP	VDREDNTYSY	KVRYTLAVGD	NRVLDMASTY
Pan5	APTHDVTTDR	SORLTLRFVP	VDREDNTYSY	KVRYTLAVGD	NRVLDMASTY
Pan7	APTHDVTTDR	SQRLTLRFVP	VDREDNTYSY	KVRYTLAVGD	NRVLDMASTY
hAd41	APTHOVTTOR	SQRLTLRFVP	VDREDTAYSY	KVRFTLAVGD	NRVLDMASTY
hAd40	APTHOUTTOR	SORLTLREVP	VDREETAYSY	KVRFTLAVGD	
	101		1		150
hAd12	FDIRGVLDRG	PSFKPYSGTA	YNSLAPKGAP	NASQWSD	
hAd3		PSFKPYSGTA	YNSLAPKGAP	NTSQWIVTTN	GDNA
hAd7	FDIRGVLDRG	PSFKPYSGTA	YNSLAPKGAP	NTSQWIVTAG	EERA
hAd11	FDIRGVLDRG	PSFKPYSGTA	YNSLAPKGAP	NTSQWIAEGV	KNTTGEEHVT
hAd21	FDIRGVLDRG	PSFKPYSGTA	YNSLAPKGAP	NTSQWIAEGV	KKEDGGSDEE
hAd34	FDIRGVLDRG	PSFKPYSGTA	YNSLAPKGAP	NASQWLDKGV	TSTGLVDDGN
hAd35	FDIRGVLDRG	PSFKPYSGTA	YNSLAPKGAP	NASQWIAKGV	PTAAAAGNGE
C1	FDIRGVLDRG		YNSLAPKGAP	NTSQWLDKGV	TTTDNNTENG
hAd1	FDIRGVLDRG			NSCEWEGEEP	TQEMAEELED
hAd2	FDIRGVLDRG	PTFKPYSGTA	YNALAPKGAP	NSCEWEQTED	SGRAVAEDEE
hAd5	FDIRGVLDRG		The second secon		ALEINLEEED
ChAd3	FDIRGVLDRG				
ChAd11	FDIRGVLDRG			NSCEWEQ.EE	-
ChAd17	FDIRGVLDRG			NSCEWEQ.EE	
ChAd19	FDIRGVLDRG			NSCEWEQLEE	
ChAd20	FDIRGVLDRG			NPCEWDEAAT	
hAd48	FDIRGVLDRG			NPSQWEEKKN	
ChAd4	FDIRGVLDRG		YNSLAPKGAP		
	FDIRGVLDRG		YNSLAPKGAF		
ChAd5 ChAd7	FDIRGVLDRG		YNSLAPKGAF	~ ~	
	FDIRGVLDRG			NSSQWEQTEN	
ChAd16	FDIRGVLDRG			NSSQWEQAKT	
Pan6				NTCQWKD	
hAd4	FDIRGVLDRG			NTCQWKD	
hAd16	FDIRGVLDRG			NTSQWITKDN	
ChAd6	FDIRGVLDRG			NTCQWTYTDN	
ChAd9	FDIRGVLDRG		VNCT V DKCAL	NTCQWTYTDN	I
ChAd10	FDIRGVLDRG FDIRGVLDRG	LOCKDACCAN LOCKADACCAN	VAIGT. A DECAL	NTCQWITIDI	GE
C68		. DOEKDAGGUY	VNICT A DECAI	NTCOWITCE NTCOWTVKAT	G
Pan5	FDIRGVLDRG	, POEKEIOGIA	VNICT. A DECA 1	NTCQWITTER	D
Pan7	FDIKGATDKG	. POEKEISGIA	VATOT A DEMAIL	P NPCEWKD	
hAd41	FDIKGATOKG	, POLKEIOGIE	VMCINDERIA	TATEMATOR	
hAd40	FDIKGATDKG	Forkersdie	I INDUMENOIS	. INLUQUELING	
	151				200
hAd12	202		. NAKLNTFA	APYLSD	r itaadgikvg
hAd3			VTTTTNTFG	I ASMKGGI	ITKE.GLQIG
hAd7			VTTTTNTFG	I ASMKGDI	ITKE.GLEIG
hAd11	EEE -		TNTTTYTFG	N APVKAEAI	E ITKE.GLPVG
hAd21	EEK		NLTTYTFG	N APVKAEG.GI	O ITKDKGLPIG
hAd34	מממ	GEF	AKKATYTFG	N APVKAEA	E ITKD.GLPVG
hAd35	EEH	rra	E EKTATYTFA	N APVKAEA.	Q ITKE.GLPIG
C1	DE	EDEVARECE	EKOATYTEG	N APVKAEA	E ITKE.GLPIG
hAd1	PP	EEFENDUALU	) KAKKAHAAA	O APLAGE	K ITAN.GLQIV
IMUL	DEBABBBBAI	- BRURKE AUD		×	

<b>ITR004</b>	8	P	V	7
---------------	---	---	---	---

hAd2				APLSGET	
hAd5				APYSGIN	
ChAd3				APLSGEK	
ChAd11				APLSGEK	
ChAd17	EEED			APLSGEK	
ChAd19	ED		PVKKTHVYAQ		ITKD.GLQIG
ChAd20	DE		DQQKTHVFGQ NQMQTHTFGV		ITAK.GLOIG
hAd48	• • • • • • • • • •		GDTENVTYGV		IDKN.GLQIG
ChAd4	• • • • • • • • • •		GDTENVTYGV		IDKN.GLQIG
ChAd5 ChAd7	• • • • • • • • • •		GDTENVTYGV		IDKN.GLQIG
ChAd16			ATTKTHTYGV		ITVD.GLQIG
Pan6			GTMETHTYGV		ITKD.GLQIG
hAd4				AAMPGVTGKK	IEAD.GLPIR
hAd16				AAMPGVTGKK	IEAD.GLPIG
ChAd6				APVRGLD	ITEE.GLQIG
ChAd9				APVEGIN	ITKD.GIQLG
ChAd10				APVQGIS	ITKD.GIOLG
CIACIO C68			ATEKTYTYGN		ITKD.GIOLG
Pan5		DT		APVQGIS	ITKD.GIQLG
Pan7			DTEKTYTYGN		ITKD.GIQLG
hAd41				APFIGTN	
hAd40				APYIGQK	
1111111	• • • • • • • • •	• • • • • • • • • • • • • • • • • • • •	. 2.11.1.1.0.02		
	201				250
hAd12		AAVYANKTYO	PEPOVGPSEW	NTSIE.NVKA	GGRALKOTTA
hAd3		KPIYADKTYO			
hAd7		KPIYADKTYO		TDTDGTNEKF	GGRALKPATK
hAd11		KPIYADKTYO	~	TDLDGKTEKY	GGRALKPDTK
hAd21		KPIYADKLYO		TDTDGTTEKY	
hAd34		KPIYADKLYO	PEPOVGDETW		GGRVLKPETK
hAd35		KPIYADKLYQ	PEPOVGDETW		GGRALKPDTK
C1		KPIYADKLYO	PEPOVGEESW		GGRALKPETK
hAd1		NPVFADPTYQ	~		GGRVLKKTTP
hAd2	~	KPVYADPSYQ		NEADANAA	GGRVLKKTTP
hAd5	VEGO		•-	YETEINHA	AGRVLKKTTP
ChAd3	~	KPIYADPTFQ		NEADATVA	GGRVLKKSTP
ChAd11		KPIYADPTFQ	· · · · · · · · · · · · · · · · · · ·	NEADATVA	GGRVLKKTTP
ChAd17	TDATAT. EQ	KPIYADPTFQ	PEPQIGESQW	NEADATVA	GGRVLKKSTP
ChAd19	SDNTEAQS	KPIYADPTFQ	PEPQIGESQW		GGRVLKKTTP
ChAd20	IDAASQAQ	TPVYADKTFQ	PEPQVGESQW		AGRVLKKTTL
hAd48	IDATKEEDNG	KEIYADKTFQ			GGRAIKKETK
ChAd4	TDDTKDDD	NEIYADKTYQ	PEPQIGEENW	QETYSYY	GGRALKKDTK
ChAd5					GGRALKKDTK
ChAd7	TDDTKDGD	NEIYADKTYQ	PEPQIGEENW	QETYSYY	GGRALKKDTK
ChAd16	TDATADTE	KPIYADKTFQ	PEPQIGEENW	QETESFY	GGRALKKDTN
Pan6					GGRALKKDTN
hAd4	IDSTSGTD	TVIYADKTFQ	PEPQVGNDSW	VDTNDAEEKY	GGRALKDTTN
hAd16					GGRALKDTTK
ChAd6	PDESGGES	KKIFADKTYQ	PEPQLGDEEW	HDTIGAEDKY	GGRALKPATN
ChAd9					GGRALKPATD
ChAd10	TDTDD	QPIYADKTYQ	PEPQVGDAEW	HDITGTDEKY	GGRALKPDTK
C68					GGRALKPDTK
Pan5					GGRALKPDTK
Pan7					GGRALKPDTK
hAd41	TDTTN	QPIYADKTYQ	PEPQVGQTQW	NSEVGAAQKV	AGRVLKDTTP
hAd40	SDSNN	RDVFADKTYQ	PEPQVGQTQW	NINPMQNA	AGRILKQTTP

	251				300
hAd12	MQPCYGSYAR	PTNEHGGOS.		KDDNIE	LKFFDSANNA
hAd3	MKPCYGSFAR	PTNIKGGOAK	NRKVKPTTEG	GVETEEPDID	MEFFDGRDAV
hAd7	MKPCYGSFAR	PTNIKGGOAK	NRKVKP.TEG	DVETEEPDID	MEFFDGREAA
hAd11	MKPCYGSFAK			QKVEYDID	MEFFDAASQK
hAd21	MKPCYGSFAK				MNFFDEASQK
hAd34	MKPCYGSFAK				MNFFDLRSQR
hAd35	MKPCYGSFAK			.NQKVEYDID	MEFFDAASQR
C1			VKKVEEG	KVEYDID	MNFFDLRSQK
hAd1	MKPCYGSYAR	PTNKNGGQGI	LVANNQG	ALESKVE	MQFFAPSGTA
hAd2			LVPDEKG	VPLPKVD	LQFFSNTTSL
hAd5			LVKQQNG	KLESQVE	MQFFSTTEAT
ChAd3			LTANAQG	QLESQVE	MQFFSTSENA
ChAd11			LAANAQG	QLESQVE	MQFFSTSENA
ChAd17			LTANAQG	QLESQVE	MOFFSTSENA
ChAd19			LVADDKG	VLQSKVE	LQFFSNTTTL
ChAd20			LLEQDG	KKESQVE	MQFFSTTQAA
hAd48			FKTPEKEGE.	EPKELDID	LNFFDIPSTG
ChAd4			IKTDGD	VKSFDID	LAFFDIPNSG
ChAd5	MKPCYGSFAR	PTNVKGGQAK	IKTDGD		LAFFDIPNSG
ChAd7	MKPCYGSFAR	PTNVKGGQAK	IKTDGD	VKSFDID	LAFFDIPNSG
ChAd16			LKVGADG	.LPTKEFDID	LAFFDTPGGT
Pan6	MKPCYGSYAR	PTNEKGGQAK	LKVGDDG		LAFFDTPGGT
hAd4			LKDSETA	.ATTPNYDID	LAFFDGKNIV
hAd16			LKDSETA	.ATTPNYDID	LAFFDNKNIA
ChAd6	MKPCYGSFAK	PTNAKGGQAK	SRTKDDG		MAFFDDRSQQ
ChAd9	MKPCYGSFAK	PTNVKGGQAK	SRTKTDG	TTEPDID	MAFFDGRNAT
ChAd10	MKPCYGSFAK	PTNKEGGQAN	VKTETGG		MAFFDNRSAA
Ç68	MKPCYGSFAK	PTNKEGGQAN	VKTGTGT		MAFFDNRSAA
. Pan5	MKPCYGSFAK	PTNKEGGQAN	VKTETGG	TKEYDID	MAFFDNRSAA
Pan7	MKPCYGSFAK	PTNKEGGQAN	VKTETGG	TKEYDID	MAFFDNRSAA
hAd41	MLPCYGSYAK	PTNEKGGQAS	LITNGTD	QTLTSDVN	LQFFALPST.
hAd40	MQPCYGSYAR	PTNEKGGQAK	LVKNDDN	QTTTTNVG	LNFFTTATET
					350
	301				-
hAd12	AN	TAQVVFYTED	VNLEMPDTHL	VEKETVINGI	
hAd3	AGAL	APEIVLYTEN	VNLETPDSHV	VXKPETSNN.	SHANLGQQ ISHANLGOO
hAd7	DAF	SPEIVLYTEN	VNLETPDSHV	VXKPGTSDDN	SSEANLGQQ
hAd11	TNL	SPKIVMYAEN	VNLETPDTHV	VIKEGIEDIS	
hAd21	ANF	SPKIVMYAEN	VDLETPDTHV	VINEGISEES	SSETNLGOO
hAd34	SEL	KPKIVMYAEN	VDLESPDTHV	OTUTONOUSVIIV	SSEANLGQQ
hAd35	TNF	SPKIVMYAEN	VGLETPDTHV VDLETPDTHV	VINEGIEDIS	SSHANLGQQ
C1		KPKIVMYAEN	ADPELADIUA	AIVEGUODU	T CKVMI'GOO
hAd1	MNERNAV	Obstantager	ONWELLDILL	SINESKIDEL	SKAMLGQQ
hAd2	NDRQGNAT	KPKVVLYSEL	) AMTELBOLUT	SINEGRADEL	1SKAMLGQQ
hAd5	AGNGDNL	TPKVVLYSEL	) ADTELLEDIUM	SIMPLIABLE	1SRELMGQQ
ChAd3	RNEANNI	OBKTATA SET	AUMETEDIAL	. GAKDURGDAN SIVEWVONN	1skimlgQQ 1skvmlgQQ
ChAd11	RNEANNI	OPKTATESET	AUMENTADIUT	GARDYRGUD, PIVEIVONNI	T CKIMICOO
ChAd17	RNETNNI	QPKLVLYSEL	AUMELEDING:	. GAMBUMGDDA 1 DIVENVONN	NSKIMLGQQ
ChAd19	NQREGNDT	KPKVVLYSEL	· AUST EMPONITA	. GAMDUNINGU.	1SKVMLGQQ
ChAd20	AGNSDNF	TEKAATISEL	· AMPETENTAL	. INKDUREDA: . PIMEIMMEII	NSRELLGQQ SSESNLTQQ
hAd48	TGGNGTNVNF	KEDMIMANE	AMPETANTHI	. VINEGREDA:	S CKINIT'LOU
ChAd4	AGNG . TNVNE	DEDMANATER	A AMPETEDIUM.	. VINEGIOUD	SSKVNLCQQ SSKVNLCQQ
ChAd5	AGNG.TNVNI	DEDWAMA.T.ET	VNLETPDTHI	. AIVEGIOND	2 PKAMTICAA

Fig. 31D

01- x 40	TOTAL CONTRACTOR	אים יישעייים איז	VNLETPDTHI	SUUSTESTES AND	SEVNLCQQ
ChAd7	AGNG. INVIO	DEDMANTIEN	TYLETPOTHV	VIKTOIDDD	SKINLVQQ
ChAd16	VIG. GIEEY	KADIVMITEN	TYLETPDIHV	AIKEGKDMID	SEINLVQQ
Pan6			VDLQTPDTHI		SESNLGQQ
hAd4				VYKPGTEDTS	SESNLGQQ
hAd16		DPDIVMYTEN			SSFNLGQQ
ChAd6		SPELVLYTEN		IYKPGTDETS	SSINLGOO
ChAd9		TPEIVLYTEN		VYKAGTDDSS	
ChAd10		APEIVLYTEN		VYKAGTDDSS	SSINLGQQ
C68		APEIVLYTEN		VYKAGTDDSS	SSINLGQQ
Pan5		APEIVLYTEN		VYKAGTDDSS	SSINLGQQ
Pan7		APEIVLYTEN		VYKAGTDDSS	SSINLGQQ
hAd41	PN	EPKAVLYAEN	VSIEAPDTHL	VYKPDVAQGT	ISSADLLTQQ
hAd40	ANF	SPKVVLYSED	VNLEAPDTHL	VFKPDVNGTS	AELLLGQQ
	351				400
hAd12	AAPNRANYIA	FRDNFIGLMY	YNSTGNMGVL	AGQASQLNAV	VDLQDRNTEL
hAd3	AMPNRPNYIG	FRDNFVGLMY	YNSTGNMGVL	AGQASQLNAV	VDLQDRNTEL
hAd7	AMPNRPNYIG	FRDNFVGLMY	YNSTGNMGVL	AGQASQLNAV	VDLQDRNTEL
hAd11		FRDNFIGLMY	YNSTGNMGVL	AGQASQLNAV	VDLQDRNTEL
hAd21		FRDNFIGLMY	YNSTGNMGVL	AGQASQLNAV	VDLQDRNTEL
hAd34		FRDNFIGLMY	YNSTGNMGVL	AGQASQLNAV	VDLQDRNTEL
hAd35		FRDNFIGLMY	YNSTGNMGVL	AGQASQLNAV	VDLQDRNTEL
C1		FRDNFIGLMY	YNSTGNMGVL	AGQASQLNAV	VDLQDRNTEL
hAd1		FRDNFIGLMY	YNSTGNMGVL	AGQASQLNAV	VDLODRNTEL
hAd2		FRDNFIGLMY	YNSTGNMGVL	AGQASQLNAV	VDLODRNTEL
hAd5		FRDNFIGLMY	YNSTGNMGVL	AGQASQLNAV	VDLODRNTEL
ChAd3		FRONFIGLMY		AGQASQLNAV	VDLODRNTEL
ChAd11		FRDNFIGLMY		AGQASQLNAV	VDLODRNTEL
		FRONFIGLMY		AGQASQLNAV	VDLODRNTEL
ChAd17		FRONFIGLMY		AGQASQLNAV	VDI ODRNTEI.
ChAd19		FRONFIGLMY		AGQASQLNAV	
ChAd20				AGQASQLNAV	
hAd48		FRDNFVGLMY		AGQASQLNAV	VDIQDIAVEI.
ChAd4		FRDNFIGLMY		AGQASQLNAV	ADIODIMIEI
ChAd5		FRDNFIGLMY		AGQASQLNAV	ADPODME
ChAd7		FRDNFIGLMY		AGQASQLNAV	ADPÓDENTED
ChAd16		FRDNFIGLMY	YNSTGNMGVL	AGQASQLNAV	ADPODEMLEP
Pan6	SMPNRPNYIG		YNSTGNMGVL	AGQASQLNAV	ADPODRIMED
hAd4	AMPNRPNYIG		i i	AGQASQLNAV	ADPODKALEP
hAd16		FRDNFIGLMY	YNSTGNMGVL	AGQASQLNAV	ADPODKMLEP
ChAd6	SMPNRPNYIG	FRDNFIGLMY		AGQASQLNAV	ADPODKULEP
ChAd9	SMPNRPNYIG		YNSTGNMGVL	AGQASQLNAV	VDLQDRNTEL
ChAd10	SMPNRPNYIC	FRDNFIGLMY	YNSTGNMGVL	agqasqlnav	VDLQDRNTEL
C68	AMPNRPNYIC	FRDNFIGLMY	YNSTGNMGVL	AGQASQLNAV	VDLQDRNTEL
Pan5	SMPNRPNYIC	FRDNFIGLMY	YNSTGNMGVL	. AGQASQLNAV	VDLQDRNTEL
Pan7	SMPNRPNYIO	FRDNFIGLMY	YNSTGNMGVI	. AGQASQLNAV	VDLQDRNTEL
hAd41	AAPNRPNYIC	FRDNFIGLMY	YNSTGNMGVI	. AGQASQLNAV	VDLQDRNTEL
hAd40	AAPNRPNYIC	FRDNFIGLMY	YNSTGNMGVI	. AGQASQLNAV	VDLQDRNTEL
	401				450
hAd12	SYQLMLDALO	DRTRYFSLW	I SAVDSYDPDV	RVIENHGVED	ELPNYCFPLS
hAd3	SYOLLLDSLO	DRTRYFSMW	I QAVDSYDPDV	RITENHGIED	ELPNYCFPLN
hAd7	SYOLLLDSLO	DRTRYFSMW	I QAVDSYDPDV	RITENHGIED	ELPNYCFPLD
hAd11	SYOLLLDSLO	DRTRYFSMW	I QAVDSYDPDV	RVIENHGVED	ELPNYCFPLD
hAd21	SYOLLLDSLO	DRTRYFSMW	OAVDSYDPD	RIIENHGVED	ELPNYCFPLD
hAd34	SYOLLIDSIC	DRTRYFSMW	OAVDSYDPD	RVIENHGVED	ELPNYCFPLD
hAd35	SYOLITOSIC	DRTRYFSMW	OAVDSYDPD	RVIENHGVED	ELPNYCFPLN
	~ - ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~				

Fig. 31E

```
SYOLLLDSLG DRTRYFSMWN QAVDSYDPDV RVIENHGVED ELPNYCFPLD
    C1
       SYQLLLDSIG DRTRYFSMWN QAVDSYDPDV RIIENHGTED ELPNYCFPLG
  hAd1
       SYOLLLDSIG DRTRYFSMWN OAVDSYDPDV RIIENHGTED ELPNYCFPLG
  hAd2
       SYOLLLDSIG DRTRYFSMWN OAVDSYDPDV RIIENHGTED ELPNYCFPLG
 hAd5
        SYQLLLDSMG DRTRYFSMWN QAVDSYDPDV RIIENHGTED ELPNYCFPLG
 ChAd3
        SYQLLLDSMG DRTRYFSMWN QAVDSYDPDV RIIENHGTED ELPNYCFPLG
ChAd11
        SYQLLLDSMG DRTRYFSMWN QAVDSYDPDV RIIENHGTED ELPNYCFPLG
ChAd17
        SYQLLLDSMG DRTRYFSMWN QAVDSYDPDV RIIENHGTED ELPNYCFPLG
ChAd19
        SYQLLLDSMG DRTRYFSMWN QAVDSYDPDV RIIENHGTED ELPNYCFPLG
ChAd20
        SYQLLLDSLG DRTRYFSMWN SAVDSYDPDV RIIENHGVED ELPNYCFPLD
 hAd48
        SYQLLLDSLG DRTRYFSMWN QAVDSYDPDV RIIENHGVED ELPNYCFPLD
 ChAd4
        SYQLLLDSLG DRTRYFSMWN QAVDSYDPDV RIIENHGVED ELPNYCFPLD
 ChAd5
        SYQLLLDSLG DRTRYFSMWN QAVDSYDPDV RIIENHGVED ELPNYCFPLD
 ChAd7
        SYOLLLDSLG DRTRYFSMWN QAVDSYDPDV RIIENHGVED ELPNYCFPLD
ChAd16
        SYOLLLDSLG DRTRYFSMWN QAVDSYDPDV RIIENHGVED ELPNYCFPLD
  Pan6
        SYQLLLDSLG DRTRYFSMWN QAVDSYDPDV RIIENHGVED ELPNYCFPLN
        SYQLLLDSLG DRTRYFSMWN QAVDSYDPDV RIIENHGVED ELPNYCFPLN
 hAd16
        SYQLLLDSLG DRTRYFSMWN QAVDSYDPDV RIIENHGVED ELPNYCFPLN
 ChAd6
        SYQLLLDSLG DRTRYFSMWN QAVDSYDPDV RIIENHGVED ELPNYCFPLN
 ChAd9
       SYQLLLDSLG DRTRYFSMWN QAVDSYDPDV RIIENHGVED ELPNYCFPLN
ChAd10
       SYQLLLDSLG DRTRYFSMWN QAVDSYDPDV RIIENHGVED ELPNYCFPLD
   C68
       SYQLLLDSLG DRTRYFSMWN QAVDSYDPDV RIIENHGVED ELPNYCFPLD
  Pan5
       SYQLLLDSLG DRTRYFSMWN QAVDSYDPDV RIIENHGVED ELPNYCFPLD
  Pan7
 hAd41
       SYOLMLDALG DRSRYFSMWN QAVDSYDPDV RIIENHGVED ELPNYCFPLG
        SYQLMLDALG DRSRYFSMWN QAVDSYDPDV RIIENHGVED ELPNYCFPLN
 hAd40
        AVG.EIKNYK GIKPDNG.....GGGGWTAD N.TVSEANHI GIGNIAAMEI
 hAd12
        GIG.PGHTYQ GIKVKTD... ..DTNGWEKD A.NVAPANEI TIGNNLAMEI
  hAd3
 · hAd7 GIG.PAKTYQ GIKSK..... ...DNGWEKD D.NVSKSNEI AIGNNQAMEI
 hAd11 GIGVPTTSYK SIVPNGD....NAPNWKEP ..EVNGTSEI GQGNLFAMEI
had21 GVGVPISSYK IIEPNG.....QGADWKEP ..DINGTSEI GQGNLFAMEI
had34 GVGPQTDSYK EIKPNG.....DQSTWTNV ..DPNGSSQL AKGNPFAMEI
 hAd35 GIGVPTTSYK SIVPNGE.....DNNNWKEP ..EVNGTSEI GQGNLSAMEI
    C1 GVGPRTDSYK GIETNGD....ENTTWKD L.DPNGISEL AKGNPFAMEI
        GIG.VTDTYQ GIKSNGNG.. .. NPQNWTKN D.DFAARNEI GVGNNFALEI
  hAd1
        GIG.VTDTYQ AIKANGNGAG DNGNTTWTKD E.TFATRNEI GVGNNFAMEI
        GVI.NTETLT KVKPKTG.....QENGWEKD ATEFSDKNEI RVGNNFAMEI
GIG.VTDTYQ AVKTNNGNNG ..GQVTWTKD E.TFADRNEI GVGNNFAMEI
 ChAd3
        GIG.VTDTYQ AVKTNNGNNG ...GQVTWTKD E.TFAERNEI GVGNNFAMEI
ChAd11
        GIG. VTDTYQ AVKTNNGNNG ... GQVTWTKD E. TFADRNEI GVGNNFAMEI
ChAd17
        GIG.VTDTYQ VIKT.NGNGQ ..ADPTWEKD T.EFADRNEI GVGNNFAMEI
ChAd19
        GVI.NTETFT KVKPKAAQ.. ...DAQWEKD S.EFSDKNEI RVGNNFAMEI
ChAd20
        GAG.TNAVYQ GVKVKTT....NNTEWEKD T.AVSEHNQI CKGNVYAMEI
 hAd48
        GAG.TNSVYQ GVKPKTDN....GNDQWETD S.TVSSHNQI CKGNIYAMEI
 ChAd4
        GAG.TNSVYQ GVKPKTDN....GNDQWETD S.TVSSHNQI CKGNIYAMEI
 ChAd5
ChAd7 GAG.TNSVYQ GVKPKTDN....GNDQWETD S.TVSSHNQI CKGNIYAMEI
ChAd16 GSG.TNAAYQ GVKVKNGQDG .DVESEWEKD D.TVAARNQL CKGNIFAMEI
  Pan6 GSG.TNAAYQ GVKVKDGQDG .DVESEWEND D.TVAARNQL CKGNIFAMEI
        GVG.LTDTYQ GVKVKTDA.. ..GSEKWDKD DTTVSTANEI HVGNPFAMEI
  hAd4
 hAd16 GVG.FTDTYQ GVKVKTDAVA GTSGTQWDKD DTTVSTANEI HGGNPFAMEI
 Chad6 GVG.FTDTFQ GIKVKTTNNG TANATEWESD T.SVNNANEI AKGNPFAMEI
        AVG.RTNSYQ GIKPNGG... ..DPATWAKD E.SVNDSNEL GKGNPFAMEI
 ChAd9
ChAdlo AVG.RTDTYQ GIKANGA.....DQTTWTKD D.TVNDANEL GKGNPFAMEI
        AVG.RTDTYQ GIKANGT.....DQTTWTKD D.SVNDANEI GKGNPFAMEI
   C68
        AVG.RTDTYQ GIKANGA... ..DQTTWTKD D.TVNDANEL GKGNPFAMEI
```

Pan7	AVG.RTDTYQ	GIKANGD	NQTTWTKD	D.TVNDANEL	GKGNPFAMEI
hAd41	GSA.ATDTYS	GIKAN	GQTWTAD	DNYADRGAEI	ESGNIFAMEI
hAd40	GQG.ISNSYQ	GVKTDN	GTNWSQN	NTDVSSNNEI	SIGNVFAMEI
	~ -				
	501				550
hAd12	NLQANLWRSF	LYSNVGLYLP	DDLKYTPGNI	KLPDNKNTYE	YMNGRVTAPG
hAd3	NIQANLWRSF	LYSNVALYLP	DVYKYTPPNI	TLPTNTNTYE	YMNGRVVSPS
hAd7	NIQANLWRSF	LYSNVALYLP	DVYKYTPTNI	TLPANTNTYE	YMNGRVVSPS
hAd11	NLQANLWRSF	LYSNVALYLP	DSYKYTPSNV	TLPENKNTYD	YMNGRVVPPS
hAd21	NLQANLWRSF	LYSNVALYLP	DSYKYTPANV	TLPTNNNTYD	YMNGRVVPPS
hAd34	NLQANLWRSF	LYSNVALYLP	DSYKYTPSNV	TLPENKNTYD	YMNGRVVPPS
hAd35	NLQANLWRSF	LYSNVALYLP	DSYKYTPSNV	TLPENKNTYD	YMNGRVVPPS
C1	NIQANLWRSF	LYSNVALYLP	DSYKYTPTNV	TLPENKNTYD	YMNGRVVPPS
hAd1	NLNANLWRNF	LYSNIALYLP	DKLKYTPTNV	EISPNPNSYD	YMNKRVVAPG
hAd2	NLNANLWRNF	LYSNIALYLP	DKLKYNPTNV	EISDNPNTYD	YMNKRVVAPG
hAd5	NLNANLWRNF	LYSNIALYLP	DKLKYSPSNV	KISDNPNTYD	YMNKRVVAPG
ChAd3	NLSANLWRNF	LYSNVALYLP	DKLKYNPSNV	DISDNPNTYD	YMNKRVVAPG
ChAd11	NLNANLWRNF	LYSNVALYLP	DKLKYNPSNV	DISDNPNTYD	YMNKRVVAPG
ChAd17	NLSANLWRNF	LYSNVALYLP	DKLKYNPSNV	DISDNPNTYD	YMNKRVVAPG
ChAd19	NLNANLWRNF	LYSNVALYLP	DKLKYNPSNV	DISDNPNTYD	YMNKRVVAPG
ChAd20	NLNANLWRNF	LYSNVALYLP	DKLKYTPSNV	QISNNPNSYD	YMNKRVVAPG
hAd48	NLQANLWKSF	LYSNVALYLP	DSYKYTPANV	TLPTNTNTYE	YMNGRVVAPS
ChAd4	NLQANLWRSF	LYSNVALYLP	DSYKYTPANI	TLPTNTNTYD	YMNGRVVPPS
ChAd5	NLQANLWRSF	LYSNVALYLP	DSYKYTPANI	TLPTNTNTYD	YMNGRVVPPS
ChAd7	NLQANLWRSF	LYSNVALYLP	DSYKYTPANI	TLPTNTNTYD	
ChAd16	NLQANLWRSF	LYSNVALYLP	DSYKYTPANI	TLPTNTNTYD	
Pan6	NLQANLWRSF	LYSNVALYLP	DSYKYTPTNV	TLPTNTNTYD	
hAd4	NIQANLWRNF	LYANVALYLP	DKYKYTPANI		
hAd16	NIQANLWRSF	LYSNVALYLP	DSYKYTPSNV		
ChAd6	NIQANLWRNF	LYANVALYLP	DSYKYTPANI		
ChAd9	NIQANLWRNF	LYANVALYLP	DSYKYTPANI		
ChAd10	NIQANLWRNF	LYANVALYLP	DSYKYTPANI		
C68	NIQANLWRNF	LYANVALYLP	DSYKYTPANV		
Pan5	NIQANLWRNF	LYANVALYLP	DSYKYTPANI		
Pan7	NIQANLWRNF	LYANVALYLP	DSYKYTPANI		
hAd41	NLAANLWRSF	LYSNVALYLP	DSYKITPDNI		
hAd40	NLAANLWRSF	LYSNVALYLP	DSYKITPDNI	TLPDNKNTYA	YMNGRVAVPS
					600
	551				
hAd12		RWSPDVMDNV			GREVPEHIQV
hAd3	LVDSYINIGA				GRYVPFHIQV GRYVPFHIQV
hAd7		RWSLDPMDNV			GRYVPFHIQV
hAd11		RWSLDAMDNV			
hAd21	LVDTYVNIGA	RWSLDAMDNV	NPFNHHRNAG	TEATROMPTON	GRYVPFHIQV
hAd34	LVDTYVNIGA	RWSLDAMDNV	NPFNHHRNAG	T DYDCMIICN	GRYVPFHIQV
hAd35	LVDTYVNIGA	RWSLDAMDNV	NPFNHHRNAG	T DVD CMI I CN	GRYVPFHIQV
C1	LVDTYVNIGA	RWSLDAMDNV	NPFNHHRNAG	T DVDCMIICN	GRYVPFHIQV
hAd1	LVDCYINLGA	RWSLDYMDNV	NPFNHHRNAG	THIRDMILLON	GRYVPFHIQV
hAd2	LVDCYINLGA	KWSLDYMDNV	NPFNHHRNAC	TOADSMILLS,	GRYVPFHIQV
hAd5	LVDCYINLGA	. KWSLDYMDNV	NEFNHHRNAU	TOTALISMAN TOTAL	GRYVPFHIQV
ChAd3	LVDCYINLGA	KWSLDYMDNV	NPFNHHRNAC	TOUDONT TON	GRYVPFHIQV
ChAd11	LVDCYINLGA	. RWSLDYMDNV	NPFNHHRNAC	TEXECUTAL C	GRYVPFHIQV
ChAd17	LVDCYINLGA	RWSLDYMDNV	NPFNHHRNA	S TRYRONITON	GRYVPFHIQV
ChAd19	LVDCYINLGA	RWSLDYMDNV	NPFNHHRNA	T DAD CALLOR	GRYVPFHIQV
ChAd20	LVDCYINLGA	RWSLDYMDNV	NPFNHHRNA	TEMPONITOR	GRYVPFHIQV
hAd48	LVDAYINIGA	7 KMSTDLWDWA	MPFMHHKNAC	PUIVDUUDU	N GRYVPFHIQV

					<b></b>
ChAd4	LVDAYINIGA	RWSLDPMDNV	NPFNHHRNAG	LRYRSMLLGN	GRYVPFHIQV
ChAd5	LVDAYINIGA	RWSLDPMDNV	NPFNHHRNAG	LRYRSMLLGN	
ChAd7	LVDAYINIGA	RWSLDPMDNV	NPFNHHRNAG	LRYRSMLLGN	GRYVPFHIQV
ChAd16	LVDAYINIGA	RWSLDPMDNV	NPFNHHRNAG	LRYRSMLLGN	GRYVPFHIQV
Pan6	LVDAYLNIGA		NPFNHHRNAG		GRYVPFHIQV
hAd4	LVDAYINIGA		NPFNHHRNAG		GRYVPFHIQV
hAd16	LVDTYVNIGA	RWSLDAMDNV	NPFNHHRNAG		GRYVPFHIQV
ChAd6	LVDAYINIGA	RWSLDPMDNV	NPFNHHRNAG		GRYVPFHIQV
ChAd9	LVDAYINIGA	RWSLDPMDNV	NPFNHHRNAG	LRYRSMLLGN	GRYVPFHIQV
ChAd10	LVDAYINIGA	RWSLDPMDNV	NPFNHHRNAG	LRYRSMLLGN	GRYVPFHIQV
C68	LVDSYINIGA	RWSLDPMDNV	NPFNHHRNAG	LRYRSMLLGN	GRYVPFHIQV
Pan5	LVDAYINIGA	RWSLDPMDNV	NPFNHHRNAG	LRYRSMLLGN	GRYVPFHIQV
Pan7	LVDAYINIGA	RWSLDPMDNV	NPFNHHRNAG	LRYRSMLLGN	GRYVPFHIQV
hAd41	ALDTYVNIGA	RWSPDPMDNV	NPFNHHRNAG	LRYRSMLLGN	GRYVPFHIQV
hAd40	ALDTYVNIGA	RWSPDPMDNV	NPFNHHRNAG	LRYRSMLLGN	GRYVPFHIQV
	601				650
hAd12	PQKFFAIRNL	LLLPGSYTYE	WNFRKDVNMI	LQSTLGNDLR	VDGASVRFDN
hAd3	PQKFFAVKNL	LLLPGSYTYE	WNFRKDVNMV	LQSSLGNDLR	TDGATISFTS
hAd7	PQKFFAVKNL	LLLPGSYTYE	WNFRKDVNMV	LQSSLGNDLR	TDGATISFTS
hAd11			WNFRKDVNMV	LQSSLGNDLR	VDGASISFTS
hAd21	PQKFFAVKNL	LLLPGSYTYE	WNFRKDVNMV	LQSSLGNDLR	VDGASISFTS
hAd34	PQKFFAVKNL	LLLPGSYTYE	WNFRKDVNMV	LQSSLGNDLR	VDGASISFTS
hAd35	PQKFFAVKNL	LLLPGSYTYE	WNFRKDVNMV	LQSSLGNDLR	VDGASISFTS
\ C1	PQKFFAVKNL	LLLPGSYTYE	WNFRKDVNMV	LQSSLGNDLR	VDGASISFTS
hAd1	PQKFFAIKNL	LLLPGSYTYE	WNFRKDVNMV	LQSSLGNDLR	VDGASIKFDS
hAd2	PQKFFAIKNL	LLLPGSYTYE	WNFRKDVNMV	LQSSLGNDLR	VDGASIKFDS
hAd5	PQKFFAIKNL	LLLPGSYTYE	WNFRKDVNMV	LQSSLGNDLR	VDGASIKFDS
ChAd3		LLLPGSYTYE		LQSSLGNDLR	VDGASIKFES
ChAd11		LLLPGSYTYE		LQSSLGNDLR	VDGASIKFES
ChAd17		LLLPGSYTYE		LQSSLGNDLR	VDGASIKFES
ChAd19		LLLPGSYTYE		LQSSLGNDLR	VDGASIKFES
ChAd20		LLLPGSYTYE		LQSSLGNDLR	VDGASIKFES
hAd48		LLLPGSYTYE		LQSSLGNDLR	VDGASVRFDS
ChAd4		LLLPGSYTYE		LQSSLGNDLR	TDGASISFTS
ChAd5		LLLPGSYTYE		LQSSLGNDLR	TDGASISFTS
ChAd7		LLLPGSYTYE		LQSSLGNDLR	TDGASISFTS
ChAd16		LLLPGSYTYE			TDGASISFTS
Pan6		LLLPGSYTYE			TDGASIAFTS
hAd4		LLLPGSYTYE		LQSSLGNDLR	TDGASITFTS
hAd16		LLLPGSYTYV		LQSSLGNDLR	VDGATISFTS
ChAd6	PQKFFAIKSL	LLLPGSYTYE	: WNFRKDVNMI		TDGASIAFTS
ChAd9	PQKFFAIKSI	LLLPGSYTYE	: WNFRKDVNMI	LQSSLGNDLF	TDGASIAFTS
ChAd10	PQKFFAIKSI	LLLPGSYTYE	WNFRKDVNMI	LQSSLGNDLF	TDGASIAFTS
C68	PQKFFAIKSI	, LLLPGSYTYE	E WNFRKDVNMI	LQSSLGNDLF	TDGASISFTS
Pan5	PQKFFAIKSI	LLLPGSYTYE	E WNFRKDVNMI	LQSSLGNDLF	TDGASIAFTS
Pan7	PQKFFAĻKSI	. LLLPGSYTYE	E WNFRKDVNMI	LQSSLGNDLF	TDGASIAFTS
hAd41	PQKFFAIKNI	, LLLPGSYTYE	E WNFRKDVNMI	LQSSLGNDLF	VDGASVRFDS
hAd40	PQKFFAIKNI	. LLLPGSYTYE	E WNFRKDVNMI	LQSSLGNDLF	VDGASVRFDS
					= -
	651				700
hAd12	IALYANFFPN	1 AHNTASTLE?	A MLRNDTNDQS	FNDYLCAANN	LYPIPANATS
hAd3	INLYATFFPN	1 AHNTASTLE	A MLRNDTNDQS	FNDYLSAAN	LYPIPANATN
hAd7	INLYATFFPN	1 AHNTASTLE	A MLRNDTNDQS	FNDYLSAAN	LYPIPANATN
hAd11	INLYATFFP	AHNTASTLE	A MLRNDTNDQS	FNDYLSAAN	1 LYPIPANATN
hAd21	INLYATFFP	AHNTASTLE	A MLRNDTNDQS	FNDYLSAAN	1 LYPIPANATN

Fig. 31H

hAd34	INLYATFFPM	AHNTASTLEA	MLRNDTNDQS	FNDYLSAANM	
hAd35		AHNTASTLEA		FNDYLSAANM	
C1	INLYATFFPM	AHNTASTLEA	MLRNDTNDQS	FNDYLSAANM	LYPIPANATN
hAd1		AHNTASTLEA		FNDYLSAANM	
hAd2		AHNTASTLEA		FNDYLSAANM	
hAd5		AHNTASTLEA		FNDYLSAANM	
ChAd3	ICLYATFFPM	AHNTASTLEA	MLRNDTNDQS	FNDYLSAANM	
ChAd11	ICLYATFFPM	AHNTASTLEA	MLRNDTNDQS	FNDYLSAANM	
ChAd17	ICLYATFFPM	AHNTASTLEA	MLRNDTNDQS	FNDYLSAANM	
ChAd19	ICLYATFFPM	AHNTASTLEA	MLRNDTNDQS	FNDYLSAANM	
ChAd20	ICLYATFFPM	AHNTASTLEA	MLRNDTNDQS	FNDYLSAANM	
hAd48	VNLYATFFPM	AHNTASTLEA	MLRNDTNDQS	FNDYLSAANM	
ChAd4	INLYATFFPM	AHNTASTLEA	MLRNDTNDQS		LYPIPANATN
ChAd5	INLYATFFPM	AHNTASTLEA	MLRNDTNDQS		LYPIPANATN
ChAd7	INLYATFFPM	AHNTASTLEA	MLRNDTNDQS		LYPIPANATN
ChAd16	INLYATFFPM	AHNTASTLEA	MLRNDTNDQS		LYPIPANATN
Pan6	INLYATFFPM	AHNTASTLEA	MLRNDTNDQS		LYPIPANATN
hAd4		AHNTASTLEA			LYPIPANATN
hAd16	INLYATFFPM	AHNTASTLEA	MLRNDTNDQS		LYPIPANATN
ChAd6		AHNTASTLEA			LYPIPANATN
ChAd9	INLYATFFPM	AHNTASTLEA	MLRNDTNDQS		LYPIPANATN
ChAd10	INLYATFFPM	AHNTASTLEA	MLRNDTNDQS		LYPIPANATN
C68	INLYATFFPM	AHNTASTLEA	MLRNDTNDQS		LYPIPANATN
Pan5	INLYATFFPM	AHNTASTLEA	MLRNDTNDQS		LYPIPANATN
Pan7		AHNTASTLEA			LYPIPANATN
hAd41		AHNTASTLEA			LYPIPSNATS
hAd40	INLYANFFPM	AHNTASTLEA	MLRNDTNDQS	FNDYLCAANM	LYPIPANATS
				•	
	701	'			750
hAd12	VPISIPSRNW		LKTKETPSLG		
hAd3	IPISIPSRNW	AAFRGWSFTR	LKTKETPSLG		
hAd7	IPISIPSRNW				
hAd11	IPISIPSRNW	AAFRGWSFTR	LKTKETPSLG	SGFDPYFVYS	
hAd21	VPISIPSRNW				
hAd34	IPISIPSRNW	AAFRGWSFTR	LKTKETPSLG		
hAd35	IPISIPSRNW		. LKTKETPSL <sub>(</sub> G		
C1	VPISIPSRNW		LKTKETPSLG		
hAd1	VPISIPSRNW	AAFRGWAFTR	LKTKETPSLG		
hAd2	VPISIPSRNW		LKTKETPSLG		
hAd5	VPISIPSRNW		LKTKETPSLO		
ChAd3	VPISIPSRNW	AAFRGWAFTR	LKTKETPSLO	S SGFDPYYTYS	
ChAd11	VPISIPSRNW		LKTKETPSLO		
ChAd17		AAFRGWAFTR			
ChAd19	VPISIPSRNW	AAFRGWAFTR	LKTKETPSLO	G SGFDPYYTYS	GSIPYLDGTF
ChAd20	VPISIPSRNW	AAFRGWAFTR	LKTKETPSLO	S SGFDPYYTYS	GSIPYLDGTF
hAd48	VPISIPSRNW	AAFRGWSFTR	LKTKETPSLO	S SGFDPYFVYS	GSIPYLDGTF
ChAd4	VPISIPSRNW	AAFRGWSFTR	LKTRETPSLO	SGFDPYFVYS	GSIPYLDGTF
ChAd5	VPISIPSRNW	AAFRGWSFTR	LKTRETPSLO	SGFDPYFVYS	GSIPYLDGTF
ChAd7	VPISIPSRNW	I AAFRGWSFTR	LKTKETPSLO	S SGFDPYFVYS	GSIPYLDGTF
ChAd16	VPISIPSRNW	I AAFRGWSFTF	LKTKETPSLO	S SGFDPYFVYS	GSIPYLDGTF
Pan6	VPISIPSRNW	AAFRGWSFTF	LKTRETPSLO	SGFDPYFVYS	GSIPYLDGTF
hAd4	VPISIPSRNW	AAFRGWSFTF	LKTKETPSLO	SGFDPYFVYS	GSIPYLDGTF
hAd16	IPISIPSRNW	AAFRGWSFTF	LKTKETPSLO	S SGFDPYFVYS	GSIPYLDGTF
ChAd6	VPISIPSRNW	AAFRGWSFTF	LKTRETPSLO	G SGFDPYFVYS	GSIPYLDGTF
ChAd9	VPISIPSRNW	AAFRGWSFTF	LKTRETPSLO	G SGFDPYFVYS	GSIPYLDGTF
ChAd10	VPISIPSRNV	V AAFRGWSFTF	LKTRETPSLO	G SGFDPYFVYS	GSIPYLDGTF

Fig. 31I

C68	VPISIPSRNW	AAFRGWSFTR			GSIPYLDGTF
Pan5	VPISIPSRNW	AAFRGWSFTR	LKTRETPSLG	SGFDPYFVYS	GSIPYLDGTF
Pan7	VPISIPSRNW	AAFRGWSFTR	LKTRETPSLG	SGFDPYFVYS	GSIPYLDGTF
hAd41	VPISIPSRNW	AAFRGWSFTR	LKTKETPSLG	SGFDPYFTYS	GSVPYLDGTF
hAd40	VPISIPSRNW	AAFRGWSFTR	LKTKETPSLG	SGFDPYFTYS	GSVPYLDGTF
maio	V 1 2.021 D.C.				
	751				800
hAd12		IMFDSSVSWP	GNDRLLTPNE	FEIKRSVDGE	GYNVAQCNMT
	YLNHTFKKVS	IMFDSSVSWP	GNDRLLSPNE	FEIKRTVDGE	GYNVAQCNMT
hAd3	YLNHTFKKVA				GYNVAQCNMT
hAd7	YLNHTFKKVS	IMFDSSVSWP	GNDRLLSPNE	FEIKRTVDGE	
hAd11	YLNHTFKKVS	IMFDSSVSWP	GNDRLLSPNE	FEIKRTVDGE	GYNVAQCNMT
hAd21	YLNHTFKKVŞ	IMFDSSVSWP	GNDRLLSPNE	FEIKRTVDGE	GYNVAQCNMT
hAd34	YLNHTFKKVS	IMFDSSVSWP	GNDRLLSPNE	FEIKRTVDGE	GYNVNQCNMT
hAd35	YLNHTFKKVS	IMFDSSVSWP	GNDRLLSPNE	FEIKRTVDGE	GYNVAQCNMT
C1	YLNHTFKKVS	IMFDSSVSWP	GNDRLLTPNE	FEIKRTVDGE	GYNVAQCNMT
hAd1	YLNHTFKKVA	ITFDSSVSWP	GNDRLLTPNE	FEIKRSVDGE	GYNVAQCNMT
hAd2	YLNHTFKKVA	ITFDSSVSWP	GNDRLLTPNE	FEIKRSVDGE	GYNVAQCNMT
hAd5	YLNHTFKKVA	ITFDSSVSWP	GNDRLLTPNE	FEIKRSVDGE	GYNVAQCNMT
ChAd3	YLNHTFKKVS	VTFDSSVSWP	GNDRLLTPNE	FEIKRSVDGE	GYNVAQCNMT
ChAd11	YLNHTFKKVS	VTFDSSVSWP	GNDRLLTPNE	FEIKRSVDGE	GYNVAQCNMT
ChAd17	YLNHTFKKVS	VTFDSSVSWP	GNDRLLTPNE	FEIKRSVDGE	GYNVAQCNMT
ChAd19	YLNHTFKKVS	VTFDSSVSWP	GNDRLLTPNE	FEIKRSVDGE	GYNVAQCNMT
ChAd20	YLNHTFKKVS	VTFDSSVSWP	GNDRLLTPNE	FEIKRSVDGE	GYNVAQCNMT
hAd48	YLNHTFKKVS	IMFDSSVSWP	GNDRLLTPNE	FEIKRSVDGE	GYNVAOCNMT
ChAd4	YLNHTFKKVS	ITFDSSVSWP	GNDRLLTPNE	FEIKRTVDGE	GYNVAQCNMT
ChAd5	YLNHTFKKVS	ITFDSSVSWP	GNDRLLTPNE	FEIKRTVDGE	GYNVAQCNMT
ChAd7	YLNHTFKKVS	ITFDSSVSWP	GNDRLLTPNE	FEIKRTVDGE	GYNVAQCNMT
ChAd16	YLNHTFKKVS	ITFDSSVSWP	GNDRLLTPNE	FEIKRTVDGE	GYNVAQCNMT
Pan6	YLNHTFKKVS	ITFDSSVSWP	GNDRLLTPNE	FEIKRTVDGE	GYNVAQCNMT
hAd4	YLNHTFKKVS	ITFDSSVSWP	GNDRLLTPNE	FEIKRTVDGE	GYNVAQCNMT
hAd16	YLNHTFKKVS	IMFDSSVSWP	GNDRLLSPNE	FEIKRTVDGE	
		ITFDSSVSWP	GNDRLLTPNE	FEIKRTVDGE	-
ChAd6	YLNHTFKKVS	ITFDSSVSWP	GNDRLLTPNE	FEIKRTVDGE	
ChAd9	YLNHTFKKVS		GNDRLLTPNE	FEIKRTVDGE	<del></del>
ChAd10	YLNHTFKKVS	ITFDSSVSWP		FEIKRTVDGE	-
C68	YLNHTFKKVS	ITFDSSVSWP	GNDRLLTPNE		-
Pan5	YLNHTFKKVS	ITFDSSVSWP	GNDRLLTPNE		
Pan7	YLNHTFKKVS	ITFDSSVSWP	GNDRLLTPNE	FEIKRTVDGE	-
hAd41	YLNHTFKKVS	IMFDSSVSWP	= :		~
hAd40	YLNHTFKKVS	VMFDSSVSWP	GNDRLLTPNE	FEIKRTVDGE	GYNVAQCNMT
					0.50
	801				850
hAd12			IPESYKDRMY		
hAd3				SFFRNFQPMS	
hAd7		NYNIGYQGFY		SFFRNFQPMS	
hAd11		NYNIGYQGFY		SFFRNFQPMS	
hAd21	KDWFLVQMLA	NYNIGYQGFY	VPEGYKDRMY	SFFRNFQPMS	
hAd34	KDWFLVQMLA	NYNIGYQGFY			
hAd35		NYNIGYQGFY		SFFRNFQPMS	RQVVDEVNYK
C1	KDWFLVQMLA	NYNIGYQGFY	VPEGYKDRMY	SFFRNFQPMS	RQVVDEINYK
hAd1		NYNIGYQGFY		SFFRNFQPMS	
hAd2	KDWFLVQMLA	NYNIGYQGFY	IPESYKDRMY		
hAd5	KDWFLVQMLA	NYNIGYQGFY	IPESYKDRMY	SFFRNFQPMS	RQVVDDTKYK
ChAd3	KDWFLVQMLA	NYNIGYQGFY	IPESYKDRMY	SFFRNFQPMS	RQVVDQTKYK
ChAd11	KDWFLVQMLA	NYNIGYQGFY	I PESYKDRMY	SFFRNFQPMS	RQVVDQTKYK
ChAd17	KDWFLVQMLA	NYNIGYQGFY	IPESYKDRMY	SFFRNFQPMS	RQVVDQTKYK
ChAd19		NYNIGYQGFY		SFFRNFQPMS	ROVVDQTKYK
		*			

Fig. 31J

					<b>_</b>
ChAd20	KDWFLVQMLA				RQVVDQTKYK
hAd48	KDWFLVQMLS				RQVVDEINYK
ChAd4	KDWFLVQMLA			-	RQVVDEVNYK
ChAd5	KDWFLVQMLA			SFFRNFQPMS	RQVVDEVNYK
ChAd7	KDWFLVQMLA			SFFRNFQPMS	RQVVDEVNYK
ChAd16	KDWFLVQMLA			SFFRNFQPMS	RQVVDEVNYK
Pan6	KDWFLVQMLA	HYNIGYQGFY	VPEGYKDRMY	SFFRNFQPMS	RQVVDEVNYK
hAd4	KDWFLVQMLA	HYNIGYQGFY	VPEGYKDRMY	SFFRNFQPMS	RQVVDEVNYK
hAd16	KDWFLVQMLA	NYNIGYQGFY	IPEGYKDRMY	SFFRNFQPMS	RQVVDEVNYT
ChAd6	KDWFLVQMLA	HYNIGYQGFY	VPEGYKDRMY	SFFRNFQPMS	RQVVDEVNYK
ChAd9	KDWFLVQMLA			SFFRNFQPMS	RQVVDEVNYK
ChAd10	KDWFLVQMLA			SFFRNFQPMS	RQVVDEVNYK
C68	KDWFLVQMLA			SFFRNFQPMS	RQVVDEVNYK
Pan5	KDWFLVQMLA			SFFRNFQPMS	RQVVDEVNYK
Pan7	KDWFLVQMLA			SFFRNFQPMS	RQVVDEVNYK
hAd41	KDWFLIQMLS			SFFRNFQPMS	RQVVNTTTYK
hAd40	KDWFLIQMLS			SFFRNFQPMS	RQVVDTTTYT
11110110	10112 20 2		•		
	851				900
hAd12	NYKKVTVEFQ	HNNSGFVGYL	GPTMREGOAY	PANYPYPLIG	QTAVESITQK
hAd3	DYKAVTLPYQ			PANYPYPLIG	
hAd7	DYKAVTLPYQ	HNINSGEVGYT	APTMROGERY	PANYPYPLIG	
hAd11	DFKAVAIPYQ	HNNISGEVGVM	APTMROGOPY		TTAVNSVTQK
hAd21	DYKAVAVPYQ	HNINGGEVGVM	APTMROGOAY	PANYPYPLIG	
hAd34	DIKWAWALIQ	HNNSGFVGYM	A PTMROGOPY	PANYPYPLIG	TTAVNSVTOK
hAd35		HNNSGFVGYM			TTAVNSVTQK
		HNNSGFVGYM			TTAVTSVTQK
C1 hAd1		HNNSGFVGYL			KTAVDSITQK
			APTMREGQAY		KTAVDSITQK
hAd2	DAGGAGTTHG	INNISGE VGID	APTRAEGQAI		KTAVDSITQK
hAd5	DAGGAGTPHG	HNNSGFVGYL	APTMREGQAY		KTAVDSITQK
ChAd3	DAGEAGITHG	HNNSGFVGYL	APTMREGQAY		KTAVDSITQK
ChAd11	DYQEVGITHQ	HNNSGFVGYL	APTMREGQAY		KTAVDSITQK
ChAd17	DYQEVGITHQ	HNNSGFVGYL	APTMREGQAY		KTAVDSITQK
ChAd19	DYQEVGIIHQ	HNNSGFVGYL	APTMREGQAY		KTAVDSITQK
ChAd20			APTMREGQAY		
hAd48			APTMRQGQPY		QTAVPSVTQK
ChAd4	DYQAVTLAYQ	HNNSGFVGYL	APTMRQGQPY		KSAVTSVTQK
ChAd5	DYQAVTLAYQ	HNNSGFVGYL	APTMRQGQPY		KSAVASVTQK
ChAd7	DYQAVTLAYQ	HNNSGFVGYL	APTMRQGQPY	PANYPYPLIG	KSAVTSVTQK
ChAd16	DYQAVTLAYQ	HNNSGFVGYL	APTMRQGQPY		KSAVASVTQK
Pan6			APTMRQGQPY		KSAVASVTQK
hAd4	DYQAVTLPYQ	HNNSGFVGYL	APTMRRGQPY		KSAVTSVTQK
hAd16			APTMRQGEPY		TTAVKSVTQK
ChAd6	DYQAVTLAYQ	HNNSGFVGYL	APTMRQGQPY	PANYPYPLIC	KSAVASVTQK
ChAd9	DYQAVTLAYQ	HNNSGFVGYL	APTMRQGQPY	PANYPYPLIC	KSAVASVTQK
ChAd10	DYQAVTLAYQ	HNNSGFVGYL	APTMRQGQPY	PANYPYPLIG	KSAVASVTQK
C68	DYQAVTLAYQ	HNNSGFVGYL	ARTMRQGQPY	PANYPYPLIC	KSAVTSVTQK
Pan5	DYQAVTLAYQ	HNNSGFVGYL	APTMRQGQPY	PANYPYPLIC	KSAVASVTQK
Pan7	DYQAVTLAYQ	HNNSGFVGYL	APTMRQGQPY	PANYPYPLIC	KSAVASVTQK
hAd41	EYQNVTLPFQ	HNNSGFVGYM	GPTMREGQA'	PANYPYPLIC	QTAVPSLTQK
hAd40	EYQNVTLPFQ	HNNSGFVGYM	GPAIREGQA'	PANYPYPLIC	QTAVPSLTQK
	901				950
hAd12	KFLCDRVMWR	IPFSSNFMSM	GALTDLGQN	1 LYANSAHALI	MTFEVDPMDE
hAd3	KFLCDRTMWR	IPFSSNFMSM	GALTDLGQN	I LYANSAHALI	MTFEVDPMDE
hAd7	KFLCDRTMWR	IPFSSNFMSM	GALTDLGQN	1 LYANSAHALI	MTFEVDPMDE

```
KFLCDRTMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MTFEVDPMDE
       KFLCDRTMWR IPFSSNFMSM GALTDLGQNL LYANSAHALD MTFEVDPMDE
       KFLCDRTMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MTFEVDPMDE
had35 KFLCDRTMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MTFEVDPMDE
   C1 KFLCDRTMWR IPFSSNFMSM GALTDLGQNL LYANSAHALD MTFEVDPMDE
 hAd1 KFLCDRTLWR IPFSSNFMSM GALTDLGQNL LYANSAHALD MTFEVDPMDE
       KFLCDRTLWR IPFSSNFMSM GALTDLGQNL LYANSAHALD MTFEVDPMDE
 hAd2
 hAd5
       KFLCDRTLWR IPFSSNFMSM GALTDLGQNL LYANSAHALD MTFEVDPMDE
ChAd3
       KFLCDRTLWR IPFSSNFMSM GALSDLGQNL LYANSAHALD MTFEVDPMDE
       KFLCDRTLWR IPFSSNFMSM GALTDLGQNL LYANSAHALD MTFEVDPMDE
ChAd11
       KFLCDRTLWR IPFSSNFMSM GALSDLGQNL LYANSAHALD MTFEVDPMDE
ChAd17
Chad19 · KFLCDRTLWR IPFSSNFMSM GALTDLGQNL LYANSAHALD MTFEVDPMDE
       KFLCDRTLWR IPFSSNFMSM GALSDLGQNL LYANSAHALD MTFEVDPMDE
ChAd20
       KFLCDRVMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MTFEVDPMDE
hAd48
       KFLCDRVMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MNFEVDPMDE
 ChAd4
       KFLCDRVMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MNFEVDPMDE
ChAd5
ChAd7
       KFLCDRVMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MNFEVDPMDE
       KFLCDRVMWR IPFSSNFMSM GALTDLGONM LYANSAHALD MNFEVDPMDE
ChAd16
       KFLCDRVMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MNFEVDPMDE
  Pan6
       KFICDRVMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MNFEVDPMDE
        KFLCDRTMWR IPFSSNFMSM GALTDLGQNL LYANSAHALD MTFEVDPMDE
        KFLCDRVMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MNFEVDPMDE
 ChAd6
       KFLCDRVMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MNFEVDPMDE
 ChAd9
       KFLCDRVMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MNFEVDPMDE
ChAd10
        KFLCDRVMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MNFEVDPMDE
   C68
        KFLCDRVMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MNFEVDPMDE
  Pan5
        KFLCDRVMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MNFEVDPMDE
  Pan7
 hAd41
        KFLCDRTMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MTFEVDPMDE
        KFLCDRTMWR IPFSSNFMSM GALTDLGQNM LYANSAHALD MTFEVDPMDE
 hAd40
 hAd12
        PTLLYVLFEV FDVVRIHQPH RGVIEAVYLR TPFSAGNATT
        PTLLYLLFEV FDVVRVHQPH RGVIEAVYLR TPFSAGNATT
  hAd3
        PTLLYLLFEV FDVVRVHQPH RGVIEAVYLR TPFSAGNATT
  hAd7
 hAd11
        PTLLYLLFEV FDVVRVHQPH RGIIEAVYLR TPFSAGNATT
        PTLLYLLFEV FDVVRVHQPH RGVIEAVYLR TPFSAGNATT
 hAd21
 hAd34 PTLLYLLFEV FDVVRVHQPH RGIIEAVYLR TPFSAGNATT
 hAd35 PTLLYLLFEV FDVVRVHQPH RGIIEAVYLR TPFSAGNATT
    C1 PTLLYLLFEV FDVVRVHQPH RGVIEAVYLR TPFSAGNATT
        PTLLYVLFEV FDVVRVHQPH RGVIETVYLR TPFSAGNATT
        PTLLYVLFEV FDVVRVHQPH RGVIETVYLR TPFSAGNATT
        PTLLYVLFEV FDVVRVHRPH RGVIETVYLR TPFSAGNATT
        PTLLYVLFEV FDVVRVHQPH RGVIETVYLR TPFSAGNATT
        PTLLYVLFEV FDVVRVHQPH RGVIETVYLR TPFSAGNATT
ChAd11
        PTLLYVLFEV FDVVRVHQPH RGVIETVYLR TPFSAGNATT
ChAd17
        PTLLYVLFEV FDVVRVHQPH RGVIETVYLR TPFSAGNATT
ChAd19
        PTLLYVLFEV FDVVRVHQPH RGVIETVYLR TPFSAGNATT
ChAd20
 hAd48
        PTLLYLLFEV FDVVRVHQPH RGVIEAVYLR TPFSAGNATT
        STLLYVVFEV FDVVRVHQPH RGVIEAVYLR TPFSAGNATT
 ChAd4
        STLLYVVFEV FDVVRVHQPH RGVIEAVYLR TPFSAGKATT
 ChAd5
        STLLYVVFEV FDVVRVHQPH RGVIEAVYLR TPFSAGNATT
 ChAd7
ChAd16
        STLLYVVFEV FDVVRVHQPH RGVIEAVYLR TPFSAGNATT
        STLLYVVFEV FDVVRVHQPH RGVIEAVYLR TPFSAGNATT
  Pan6
        STLLYVVFEV FDVVRVHQPH RGVIEAVYLR TPFSAGNATT
  hAd4
        PTLLSLVFEV FDVVRVHQPH RGVIEAVYLR TPFSAGNATT
 hAd16
        STLLYVVFEV FDVVRVHQPH RGVIEAVYLR TPFSAGNATT
```

Fig. 31L

מידיז	$\Delta \Delta A$	8PV
11 K	1 11 14	ארע.

ChAd9	STLLYVVFEV	FDVVRVHQPH	RGVIEAVYLR	TPFSAGNATT
ChAd10	STLLYVVFEV	FDVVRVHQPH	RGVIEAVYLR	TPFSAGNATT
C68	STLLYVVFEV	FDVVRVHQPH	RGVIEAVYLR	TPFSAGNATT
Pan5		FDVVRVHQPH		
Pan7		FDVVRVHQPH		
hAd41	PTLLYVLFEV	FDVVRIHQPH	RGVIEAVYLR	TPFSAGNATT
hAd40	PTLLYVLFEV	FDVVRIHOPH	RGVIEAVYLR	TPFSAGNATT

ITR0048PV

SEQ ID NO: 26

SEQ ID NO: 27

ATGGAATTCGTTTAAACCATCATCAATAATATACCTC

SEQ ID NO: 28

CGCTGGCACTCAAGAGTGGCCTC

SEQ ID NO: 29

ATGAAGCTTGTTTAAACCCAT CATCAATAATATACCT

SEQ ID NO: 30

**ATCTAGACAGCGTCCATAGCTTACCG** 

SEQ ID NO: 31

SEQ ID NO: 32

TAGGCGCGCCGCTTCTCCTCGTTCAGGCTGGCG

SEQ ID NO: 33

GATCTAGTTAGTTTAAACGAATTCGGATCTGCGACGCG

SEO ID NO: 34

TTCGATCATGTTTAAACGAAATTAAGAATTCGGATCC

SEO ID NO: 35)

TATTCTGCGATCGCTGAGGTGGGTGAGTGGGCG

SEQ ID NO: 36

TAGGCGCGCCCTTAAACGGCATTTGTGGGAG

SEQ ID NO: 37

CGTCTAGAAGACCCGAGTCTTACCAGT

SEO ID NO: 38

CGGGATCCGTTTAAACCATCATCAATAATATACCTTATT

SEO ID NO: 39

ATGGAATTCGTTTAAACCATCATCAATAATATACCTT

**SEO ID NO: 40** 

ATGACGCGATCGCTGATATCCTATAATAATAAAACGCAGACTTTG

SEQ ID NO: 45

**TGTCCTACCARCTCTTGCTTGA** 

SEQ ID NO: 46

**GTGGAARGGCACGTAGCG** 




Fig. 33




Fig. 34




Fig. 35




Fig. 36

